2019 annual report Dear Shareholders, Catalent performed strongly in fiscal 2019, led by Catalent Biologics. We also continued to implement our growth strategy, expanding our biologics capacity and capabilities, building our early development network to bring more molecules into our oral delivery and clinical businesses, and evolving our organizational structure to enhance our performance. We shipped first commercial supplies for almost 200 new products in fiscal 2019, including important new treatments for Parkinson’s and other nerve-related disorders, cancer, and several rare diseases. We also provided first-in-market over-the-counter line extensions and novel nutritional supplement products for customers around the world. As of June 30, we have approximately 1,100 customer projects in our pipeline for future launch, up 10% from last year. Our fiscal 2019 growth investments included the $1.2 billion acquisition of a leading, Maryland-based gene and cell therapy development and manufacturing partner, as well as the $127 million purchase of a well-established, early-phase drug development services provider with primary operations in Nottingham, United Kingdom. We also continued to reinvest in our current network, with a new biomanufacturing line coming on-stream at our Madison, Wisconsin facility as we entered the year. We also began significant new capacity expansions at our biologics facility in Bloomington, Indiana and our orally dissolving tablet facility in Swindon, United Kingdom and opened a second clinical supply services facility in China. The industry’s focus on biologic therapeutics continues to drive dynamic R&D and commercial activity, with biologics now comprising 40% of the active pipeline and almost one-third of global prescription revenues. Our focused strategy to build a differentiated biologics business has enabled us to triple our revenue share from biologics over the last five years, reaching 32% in fiscal 2019. We are confident that our ongoing investments in biomanufacturing and sterile fill/ finish, combined with our newly added gene and cell therapy expertise, will enable us to fully participate in this robust growth for years to come. FISCAL 2019 IN REVIEW Financial Performance Strategic Growth Drivers The Company delivered revenue growth of 5% in fiscal 2019 at constant exchange rates,1 with our consolidated revenues reaching $2,518.0 million. Delivering on our long-term growth strategy, including our organic and inorganic investments, once again enabled us to drive growth and profitability in fiscal 2019. We delivered $599.6 million in Adjusted EBITDA2 in fiscal 2019, an increase of 11% against the prior year at constant exchange rates. Adjusted EBITDA margin was 24.3% at constant exchange rates in the current year, and adjusted net income per diluted share3 was $1.81. As a result of our performance, we generated cash from operating activities of $247.7 million, which we actively redeployed in growth-generating capital expenditures and in strategic acquisitions. We also took advantage of favorable conditions in the capital markets to raise $950 million in new term debt, $500 million in new 5.00% notes, and $650 million in a new issue of preferred stock, which allowed us to complete our acquisitions, fund our capital expenditures, pay off nearly $800 million in existing debt, and extend the maturity profile of our debt. Biologics and Specialty Drug Delivery remained our fastest-growing business unit in fiscal 2019. Expanding sterile fill/finish revenues from a growing pipeline of commercially approved biologics, combined with scaling up of new biomanufacturing capacity and the mid-May addition of our new, fast-growth gene therapy business, drove a 24% growth at constant exchange rates in both revenue and Adjusted EBITDA. Our Clinical Supply Services segment contributed strongly to fiscal 2019’s Adjusted EBITDA performance, up 14% at constant exchange rates. Reported revenues were down by 24% due to the adoption of a new accounting standard, which caused certain business to be recorded at a net rather than gross basis.4 1 Comparisons “at constant exchange rates” exclude the effects of foreign currency fluctuations against the U.S. dollar during the year. For a reconciliation of constant currency results to our reported results, please see page 50 of the Annual Report on Form 10-K. 2 For an explanation of how we determine Adjusted EBITDA, a non-GAAP measure, and how this financial measure reconciles to our reported results, please see pages 60-61 of the Annual Report on Form 10-K. 3 For an explanation of how we determine adjusted net income per diluted share, a non-GAAP measure, and how this financial measure reconciles to our reported results, please see pages 62-63 of the Annual Report on Form 10-K. 4 For further discussion of this accounting change, see pages 83-84 of the Annual Report on Form 10-K. Our Follow the Molecule® strategy contributed significantly to the fiscal 2019 results of our Oral Drug Delivery segment, which were up 10% in both revenue and Adjusted EBITDA versus the prior year at constant exchange rates. With the fiscal 2017 addition of the San Diego site, the fiscal 2019 addition of the Nottingham site, and the refocus of our Somerset, New Jersey development site, we now have a comprehensive early- development network supporting pre-clinical and early- stage clinical work for oral compounds across dose forms and formulation types. As these projects advance, we expect our customers to seek later-stage capacity from our network of commercial oral manufacturing sites. In fiscal 2019, Catalent continued to invest in growth- driving assets, including $218.1 million in property, plants, and equipment, in addition to our acquisitions. Major capital projects included the beginning construction on our fourth and fifth biomanufacturing suites in Wisconsin, and the start of the next phase of expansion at that site; capability and capacity expansions in Indiana; and the installation of spray-dry capabilities in our Winchester, Kentucky facility. We also continued to invest in the development and scale-up of proprietary technologies, like Zydis Ultra®, a next-generation orally dissolving tablet. We continue to invest in technology and process innovation across the business, and, in fiscal 2019, we received 126 new patents. ® LOOKING AHEAD Looking to fiscal 2020 and beyond, Catalent is positioned increasingly well in an attractive, robust market. We have important leadership, scale, and diversification, which have been enhanced by our ongoing biologics expansion and the fiscal 2019 addition of gene therapy capabilities. With our proven Follow the Molecule strategy, our “patient first” focus, our operational excellence, and our ongoing growth investments, we are well placed to deliver future organic revenue and earnings growth. We continue to evolve Catalent’s organization to enable ongoing performance and growth. In February, Alessandroo Maselli, who was then head of our global operations, was named President and Chief Operating Officer, to focus on the growth and operational performance of our existing businesses. We also reintegrated the site operational functions back into our business units, to further enhance our operational effectiveness. We remain focused on building a culture that inspires our workforce and enables us to serve patients most effectively. Our emerging corporate responsibility and diversity and inclusion initiatives demonstrate our values in action and orient our decision-making. Given the rapidly evolving therapeutics market, particularly in biologics, we believe there are substantial opportunities for inorganic investments in areas that align well with the evolving needs of our customers and our overall strategic goals. We actively review these areas for potential targets, assessing them using our rigorous, value-oriented approach. Late in fiscal 2019, we announced two additional acquisitions to further these goals—a biologics fill/finish, oral solids, and packaging facility in Anagni, Italy and two early-development facilities in southern Maryland for our rapidly expanding gene therapy platform. We closed the purchase of the Maryland facilities in July and expect to close the Anagni purchase before the end of the second quarter of fiscal 2020. I recently celebrated my tenth anniversary as CEO of Catalent. As I reflect on Catalent’s transformation journey, I am proud of what our team has achieved. I am convinced we have the right growth strategy in place. And I am excited by what the future holds – for us, for , our customers, and for patients around the world. y Recognizing the curative potential of some gene therapies, our Maryland team refers to what they do as “manufacturing miracles.” For patients around the world, all of our more than 12,000 employees manufacture miracles and otherwise improve patient lives every day. On behalf of these employees and our board of directors, I would like to express our appreciation for your confidence in Catalent. John R. Chiminski Corporate Responsibility our values in action A sense of responsibility to our communities, our people, and our environment and a commitment to sustainability are essential parts of our business, and we strive at all times to act with integrity in everything we do. We put our people and patients first. In addition to developing, delivering, and supplying reliable, high-quality treatments, our team of more than 12,000 talented employees is supporting our corporate responsibility (CR) commitment and helping people around the world live better, healthier lives by: people environment community Putting patients first and investing in our people to help them and our business grow. Minimizing our impact on the environment in the areas of CO2 emissions, waste, water use, and wastewater disposal in order to secure a healthy and sustainable future. Dedicating time, STEM talent, and resources to serve patients and communities. 5 s t h g i l h g h r c 9 1 y f i Significant growth of employee-driven community initiatives, such as Catalent Month of Service, our 2019 “Catalent Unplugged” Earth Month celebration, and grants that we make in support of our communities. Implemented inclusive leadership and unconscious bias training at the leadership level and established a network of employee resource groups, as part of our emerging diversity & inclusion commitment. Obtained global accreditation under the international management standards for environment (ISO14001:2015) and occupational safety (OHSAS18001:2007). Accelerated our site-based CO2-reduction initiative, initially focusing on energy management within our operations. In fiscal 2020, we intend to build on our CR work by publishing our first CR report, which will include important information concerning our social and environmental impact commitments and targets for the medium and long term. 55 Please see “Corporate Responsibility” on page 17 of the Annual Report on 10-K for further information. Please see “Corporate Responsibility” on page 17 of the Annual Report on 10-K for further information. Looking to fiscal 2020 and beyond, Catalent is positioned increasingly well in an attractive, robust market. We have important leadership, scale, and diversification, which have been enhanced by our ongoing biologics expansion and the fiscal 2019 addition of gene therapy capabilities. Global Investment in Capabilities & Technologies Driving Long-Term Growth madison, wi bloomington, in Began $200 million capacity expansion for biomanufacturing and injectables nottingham, uk Added deeply experienced early development team, small-scale manufacturing haverhill, uk Accessed first commercial- scale spray-dried dispersion line shanghai, ch Opened second Clinical Supply Services facility to meet expected demand baltimore, md Acquired gene therapy development and supply capabilities across 4 facilities anagni, it Agreed to acquire a world- class oral, sterile and packaging facility continuous investment We have invested more than $3 billion over the last 5 fiscal years on new businesses, as well as new property, plants, and equipment in order to grow our business and lay the foundation for further growth. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-K ______________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 ___________________________ CATALENT, INC. (Exact name of registrant as specified in its charter) ______________________________ (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Delaware 20-8737688 14 Schoolhouse Road Somerset, New Jersey (Address of principal executive offices) 08873 (Zip Code) Registrant’s telephone number, including area code: (732) 537-6200 ______________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class ( ) Trading Symbol(s) g y g Name of each exchange on which registered g Common Stock, $0.01 par value per share CTLT New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None ______________________________ Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, ff smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Non-accelerated filer ff x o Accelerated filer Smaller reporting company Emerging growth company o o o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x As of December 31, 2018, the aggregate market value of the registrant’s voting and non-voting common equity held by non-affiliates was $5.5 billion. On August 22, 2019 there were 146,024,108 shares of the Registrant’s Common Stock, par value $0.01 per share, issued and outstanding. Portions of the Registrant's Proxy Statement relating to the 2019 Annual Meeting of Shareholders are incorporated by reference into Part DOCUMENTS INCORPORATED BY REFERENCE III of this report. 1 CATALENT, INC. INDEX TO ANNUAL REPORT ON FORM 10-K For the Year Ended June 30, 2019 Item Special Note Regarding Forward-Looking Statements PART I Item 1. Business Item 1A. Risk Factors Item 1B. Unresolved Staff Comments Item 2. Properties Item 3. Legal Proceedings Item 4. Mine Safety Disclosures Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity PART II Securities 6. Selected Financial Data Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 7A. Quantitative and Qualitative Disclosures About Market Risk Item 8. Financial Statements and Supplementary Data Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure Item 9A. Controls and Procedures Item 9B. Other Information Item 10. Directors, Executive Officers and Corporate Governance Item 11. Executive Compensation PART III Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters Item 13. Certain Relationships and Related Transactions, and Director Independence Item 14. Principal Accounting Fees and Services PART IV Item 15. Exhibits, Financial Statement Schedules Item 16. Form 10-K Summary Signatures Page 3 6 20 34 35 37 37 38 40 42 65 66 119 119 120 121 121 121 121 121 122 127 128 2 Special Note Regarding Forward-Looking Statements PART I In addition to historical information, this Annual Report on Form 10-K of Catalent, Inc. (“Catalent “ “ o” r the Company ”)” ard-looking statements w” ithin the meaning of Section 27A of the Securities Act of 1933, as amended (the Act”),” which are contains “forw“ S“ ecurities Act”),” and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange subject to the s“ afe harbor c” reated by those sections. All statements, other than statements of historical facts, included in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify these forward-looking statements “ “b by the use of words such as “outlook, “p “ s“ eeks,” “predicts, ” “anticipates, “ ” “plans, “ ” “intends, “p these words or other comparable words. ” “continues, “ ” “forw“ ” “future, ard,” s“ ustain o” r the negative version of ” “believes, ” “estimates, ” ” w“ ill,” s“ hould,” “could, ” “potential, “ ” expects, ” may, “p “ “ “ “ These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Any forward-looking statement is subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Some of the factors that may cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements include, but are not limited to, those described under the section entitled Factors” i” n this Annual Report on Form 10-K for the fiscal year ended June 30, 2019 (this A“ nnual Report”)” and the “ “Risk following: • • • • • • • • • • • • • We participate in a highly competitive market, and increased competition may adversely affect our business. The demand for our offerings depends in part on our customers’ research and development and the clinical and market success of their products. Our business, financial condition, and results of operations may be harmed if our customers spend less on, or are less successful in, these activities. We are subject to product and other liability risks that could exceed our anticipated costs or adversely affect our results of operations, financial condition, liquidity, and cash flows. Failure to comply with existing and future regulatory requirements could adversely affect our results of operations and financial condition or result in claims from customers. Failure to provide quality offerings to our customers could have an adverse effect on our business and subject us to regulatory actions or costly litigation. The services and offerings we provide are highly exacting and complex, and, if we encounter problems providing the services or support required, our business could suffer. Our global operations are subject to economic, political and regulatory risks, including the risks of changing regulatory standards or changing interpretations of existing standards, that could affect the profitability of our operations or require costly changes to our procedures. The exit of the United Kingdom (the U“ .K.”)” from the European Union could have future adverse effects on our operations, revenues, and costs, and therefore our profitability. If we do not enhance our existing or introduce new technology or service offerings in a timely manner, our offerings may become obsolete over time, customers may not buy our offerings, and our revenue and profitability may decline. We and our customers depend on patents, copyrights, trademarks, know-how, trade secrets, and other forms of intellectual property protections, but these protections may not be adequate. Our offering or our customers’ products may infringe on the intellectual property rights of third parties. Our future results of operations are subject to fluctuations in the costs, availability, and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients, purchased components, and raw materials. Changes in market access or healthcare reimbursement for our customers’ products in the United States ( U“ .S.”)” or internationally, including possible changes to the U.S. Affordable Care Act, could adversely affect our results of operations and financial condition by affecting demand for our offerings or the financial health of our customers. 3 • • • • • • • • • • • As a global enterprise, fluctuations in the exchange rate of the U.S. dollar, our reporting currency, against other currencies could have a material adverse effect on our financial performance and results of operations. Tax legislative or regulatory initiatives, new interpretations or developments concerning existing tax laws, or challenges to our tax positions could adversely affect our results of operations and financial condition. Our ability to use our net operating loss carryforwards, foreign tax credit carryforwards and certain other tax attributes may be limited. Changes to the estimated future profitability of the business may require that we establish an additional valuation allowance against all or some portion of our net U.S. deferred tax assets. We depend on key personnel whose continued employment and engagement at current levels cannot be assured. We use advanced information and communication systems to run our operations, compile and analyze financial and operational data, and communicate among our employees, customers, and counter-parties, and the risks generally associated with information and communications systems could adversely affect our results of operations. We are continuously working to install new, and upgrade existing, systems and provide employee awareness training around phishing, malware, and other cyber security risks to enhance the protections available to us, but such protections may be inadequate to address malicious attacks or inadvertent compromises of data security. We engage, from time to time, in acquisitions and other transactions that may complement or expand our business or divest of non-strategic businesses or assets. We may not be able to complete such transactions, and such transactions, if executed, pose significant risks, including risks relating to our ability to successfully and efficiently integrate acquisitions or execute on dispositions and realize anticipated benefits therefrom. The failure to execute or realize the full benefits from any such transaction could have a negative effect on our operations. We are subject to environmental, health, and safety laws and regulations, which could increase our costs and restrict our operations in the future. We are subject to labor and employment laws and regulations, which could increase our costs and restrict our operations in the future. Certain of our pension plans are underfunded, and additional cash contributions we may make to increase the funding level will reduce the cash available for our business, or to discharge other financial obligations. Our substantial leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or in our industry, expose us to interest-rate risk to the extent of our variable-rate debt, and prevent us from meeting our obligations under our indebtedness. We caution you that the risks, uncertainties, and other factors referenced above may not contain all of the risks, uncertainties, and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits, or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this report apply only as of the date of this report or as of the date they were made and we undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. 4 We file annual, quarterly, and current reports and other information with and furnish additional information to the U.S. s” ection as soon as reasonably practicable after we file such material, or furnish Securities and Exchange Commission (the SEC“ ”).” Our filings with the SEC are available to the public on the SEC’s website at www.sec.gov. Those filings are also available to the public on, or accessible through, our website (www.catalent.com) for free it to, the SEC. We also use “ via the Investors our website, corporate Facebook page (https://www.facebook.com/CatalentPharmaSolutions), corporate LinkedIn page (https:// www.linkedin.com/company/catalent-pharma-solutions/) and corporate Twitter account (@catalentpharma) as channels of distribution of information concerning our activities, our offerings, our various businesses, and other related matters. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, SEC filings, and public conference calls and webcasts. The information we file with or furnish to the SEC (other than the information set forth in this Annual Report) or contained on or accessible through our website, our social media channels, or any other website that we may maintain is not a part of this Annual Report. ff Catalent References and Fiscal Year Unless the context otherwise requires, in this Annual Report, the terms “Catalent,” “the company,” “we,” “us,” and “our” refer to Catalent, Inc. and its subsidiaries. All references to years in this Annual Report, unless otherwise stated, refer to fiscal years beginning July 1 and ending June 30. All references to quarters, unless otherwise stated, refer to fiscal quarters. Fiscal years are referred to by the calendar year in which they end. For example, “fiscal 2019” refers to the fiscal year ended June 30, 2019. Trademarks and Service Marks We have U.S. or foreign registration in the following marks, among others: Catalent®tt , Clinicopia®, CosmoPod® ,Easyburst®, FastChain®, Follow the Molecule®, Galacorin®, GPEx®, Liqui-Gels®, OmegaZero®, OptiDose®, OptiForm®, OptiGel®, OptiGel® Bio, OptiMelt®, OptiShell®, Paragon Bioservices®, Pharmatek®, RP Scherer®, SMARTag®, SupplyFlex®, Vegicaps®, and Zydis®. This Annual Report also includes trademarks and trade names owned by other parties, and these trademarks and trade names are the property of their respective owners. We use certain other trademarks and service marks, including FlexDose™, Manufacturing Miracles™, OneBioSM, OneBio SuiteSM, OptiPact™, PEEL-ID™, Savorgel™, Softdrop™, and Zydis Ultra™ on an unregistered basis in the United States and abroad. Solely for convenience, the trademarks, service marks, and trade names identified in this Annual Report may appear without the ®, SM, and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks, and trade names. 5 ITEM 1. BUSINESS Overview We are the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. Our oral, injectable, gene therapy, and respiratory delivery technologies address the full diversity of the pharmaceutical industry, including small molecules, protein and gene therapy biologics, and consumer health products. Through our extensive capabilities and deep expertise in product development, we help our customers take products to market faster, including nearly half of new drug products approved by the U.S. Food and Drug Administration (the F“ DA”)” in the last decade. Our advanced delivery technology platforms, which include those in our Softgel Technologies, Biologics and Specialty Drug Delivery, and Oral Drug Delivery segments, our proven formulation, manufacturing, and regulatory expertise, and our broad and deep intellectual property enable our customers to develop more products and better treatments forff consumers. Across both development and delivery, our commitment to reliably supply our customers’ and their patients’ needs is the foundation for the value we provide; annually, we produce approximately 73 billion doses for nearly 7,000 customer products, or approximately 1 in every 20 doses of such products taken each year by patients and consumers around the world. We believe that through our investments in growth-enabling capacity and capabilities, our ongoing focus on operational and quality excellence, the sales of existing customer products, the introduction of new customer products, our innovation activities and patents, and our entry into new markets, we will continue to benefit from attractive and differentiated margins and realize the growth potential from these areas. patients and We continue to invest in our sales and marketing activities, leading to growth in the number of active development programs for our customers. This has further enhanced our extensive, long-duration relationships and long-term contracts with a broad and diverse range of industry-leading customers. In fiscal 2019, we conducted business with 83 of the top 100 branded drug marketers, 21 of the top 25 generics marketers, 23 of the top 25 biologics marketers, and 21 of the top 25 consumer health marketers globally. Selected key customers include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, Roche, and Teva. We have many long-standing relationships with our customers, particularly in advanced delivery technologies, where we tend to follow a prescription molecule through its lifecycle, fromff the development and launch of the original brand prescription, to generics or over-the-counter switch. A prescription pharmaceutical product relationship with an innovator will often last many years, in several cases, nearly two decades or more, extending from pre-clinical development through the end of the product’s life cycle. We serve customers who require innovative product development, superior quality, advanced manufacturing, and skilled technical services to support their development and marketed product needs. Our broad and diverse range of technologies closely integrates with our customers’ molecules and other active ingredients to yield final formulations and dose forms, and this generally results in the inclusion of Catalent in our customers’ prescription product regulatory filings. Both of these factors frequently translate to long-duration supply relationships at an individual product level. We believe our customers value us because our depth of development solutions and advanced delivery technologies, intellectual property, consistent and reliable supply, geographic reach, and substantial expertise enable us to create a broad range of business and product solutions that can be customized to fit their individual needs. Today we employ approximately 2,400 scientists and technicians and hold more than 1,300 patents and patent applications in advanced delivery, drug and biologics formulation, and manufacturing. The aim of our offerings is to allow our customers to bring more products to market faster, and to develop and market differentiated new products that improve patient outcomes. We believe our leading market position and diversity of customers, offerings, regulatory categories, products, and geographies reduce our exposure to potential strategic and product shifts within the industry. i h We dand dproducts, i development l capsules, our l differentiat ded l diZydis i proprietary, diff fof bumber provide a n id i dand d h technologies l d our d advanced d lidelivery softgel l f include l d i fplatform i technologies l l h (“AAV”) vectors, associated ivirus ( i d ) offerings dand i hiwithin our d i service ff i iOptiForm l i Product Expression (“GPEx”) and SMARTag platforms for development of biologics and antibody-drug conjugates (ADCs), to analyticall s i f l l formulation, i d d l d clinical l demand-led li i dproducts across a n formulate l f offerings to our customers across i l technologies, advanced d lidelivery d i i hiwithin our d fplatforms. hThe core i solutions l adeno- liquids, adeno- unit-dose li i d tablets, bl dissolving bl l i orally di ll l i respiratory d lidelivery loral, i j technologies l h h injectable a dnd bl l fplatform span hthe ddrug d ranging ffrom our development process, istics fof characteri i hother h i service ff technologies l h id blow-fill-seal l fill technologies. hThe FastChain l di iunique difficult-to- manufacturing fof difficult-to- i learly-stage li i l i bumber l trials dand li i supply, i l i l clinical development l dneed iin hthe d hother solutions l i bioavailabilility il bi l offerings serve a c i i ff i i molecules, dand a range fof l i dproduct types. including our dand development, ritical l iervices, supply l solution. Our henhancement development learly-stage dand Gene clinical d iSuite ffor Solution fof bi dand h i fof f l i l l l We hhave d i in-licensing, h advanced our d i strategic llialliances, i dand hhave continued to i i OptiMelt, solution. i technologies l service ff i i li acquisitions. We i i i ll i i i iy i initiall d h h technologicalllly i l Solution iOptiPact, hthe diZydis i iOptiForm l approval ffor hthe fi l obtained iSince hthen, our customers hhave b i d dand grown our i expand our range fof new, iBio, offerings over more hthan 85 years h d d ntroduced our i offerings. dand our first-to-market internal l through i h l capsule technology iin hthe l softgel f fiscal 2013, we hhave l l iSince fi d l d h i demand-led li i iusing our dproduct d enhanced ff iSuite, d development, l 1930s i h ll OptiShell, l supply l launched h d l clinical OptiShell i h ll diZydis Nano, FastChain d regulatory l dand h d k l l 6 i i i l l i b h i i i “Catalent acquisition fof i i i acquisition fof i i i Bioscience iin i Technologies. In fi l technology iinto our ddrug f dand fiscal 2017, we formulation l dand we d Industries i dorder to extended our d d expanded our d d dand d lidelivery d d expanded our Limited ( i d i henhance our bi l addition fof spray d idrying i Laboratories, Inc. ( h network ivia hthe k i kCook h Pharmica LLC ((now Juniper h i acquired i d capabilitiies we bili development d Redwood i d iMicron h l (“Pharmatek”) iin k ) September 2016, b bFebruary 2017 acquisition fof Accucaps l Indiana, named d LLC”) iin di (“Juniper”), hi hwhich i Pharmaceutic lals, Inc. ( i Pharmatek k bili technology. We have also augmented our portfolio through acquisitions. In fiscal 2015, we added an ADC business through the bOctober 2014; completion fof our i November 2014 our l b including hthe ddi i l di i fof h Pharmatek k manufacturing f acquired i d 2019, we development d l htherapy d l biopharmaceut biopharmaceuti contributions ffrom our bi l ib i i acquire agreed to d Anagni, f ili i facility iin d dand development l 2020. We b libelieve our own i continue to i health h l h capabilitiies ivia bili i engineering i l particle bili capabilitiies, learly d development acquisition i i i through hthe h technologies, h l h dand softgel d development l f fiscal 2018, we ) (“Accucaps”). In fi l bili biologics i fiscal l capabilitiies. In fi learly reach fof hthe h geographic hi advanced gene ) adding d d (“Paragon”), ddi d integrated d end-to-end i d dand Paragon, revenue l dand d ) extends to hthe U.K. hthe Bioservices, Inc. ( i h enhancing our i biologics b ibusiness lCatalent Indiana di fiscal 2014 to 29% iin fi l manufacturing dproduct dand i l biologics b ibusiness hhave grown ffrom Bristol-Myers l Italy, a t l manufacturing isites iin i f dand acquisitions fof i i i approximately 10% iin fi l i il sterile biologics, lid calendar 2019, l d Maryland ffrom Novavax, Inc., hi hwhich l packaging k i l biologics li i clinical i l closed d iduring hthe fifirst quarter fiscal fof fi illwill acquisitions, i i i dand consumer i solutions ffor customers. In llarge part ddue to our solid, bi l Company’s o lral y ransaction hthat we expect to lclose bby hthe supplemented bby current d positions iin hthe d lidelivery gained h i d through h manufacturing i f southern h innovation, i leadership hi d partnerships fof ddrugs, bi l internal i l extend our l d external l development l dand hi biologics, i dand ffuture dand d capabilitiies to our bi l fiscal 2019. We lalso dand Paragon i advanced bi l i dend fof dand two d strengthen dproducts. Squibb ibb l i i l d dand dand ical l d h h d f ) i i i i l i History dand i fof our affiliates off Thhe (“PTS”) segment ) hScherer beginning i hwith R.P. We were f Pharmaceutic lal h i h h through a s ieries fof lCatalent hPharma owns b idi subsidiaries. context f facilities, i ili i Australia, li dand f facilities. In ili i “Common i i iits d ilApril 2007, hwhen ffili formed iin i Services ( h l Technologies i i i i i acquisitions b i (“Operating Solutions, Inc. ( i l acquisition fof PTS, we hhave i i i esult, we hhave l dand, as a r growth lplan, h remaining f network. In fi k facility ili i i transaction iin hthe fifirst h lfhalf i offering ( h(the completed hthe i i i l i initial d hExchange ( h(the kYork l kBlackstone Group L.P. ( fof l hHealth, Inc. ( Cardinal l di Corporation iin 1998. We are ha h ldiolding company hthat i di Company”), hi hwhich owns, di operating ) l i reviewed our regularly l ldsold seven b ibusinesses fiscal 2018, we l fof fi “IPO”) ) “NYSE”) ) secondary ff d iSince hthe 2007 strategic i integrating hthem iinto hthe i dand we expect to lclose hthat l lJuly 2014, we d listed on hthe New Stock”), hi hwhich iis li fof hthe fof our indirectly, l llall dand offerings ff i operations at fifive d lid i consolidated ili llsell our f Braeside, facility iin acquired new b ibusinesses actively i l i d lvalue $$0.01 ( h(the k stock, par l kBlackstone b l ) i d (“Blackstone”) l k acquired hthe core fof hthe Cardinal h dhad l (“Cardinal”). l ) di created PTS d indirectly l i operations iin hthe directly or i di f li portfolio fof dand agreed to d fof our common dunder hthe di offerings i stock hthey h ldheld iin us iin a s ieries fof fiscal 2020. We hhave lalso bli public ff Stock k minority partners symbol “CTLT.” September 2016. b ending iin ldsold llall k ) di id d k dand i l i l i Our Competitive Strengths Leading Provider of Advanced Delivery Technologies and Development Solutions We are the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer and animal health products. In the last decade, we have earned revenue with respect to nearly half of the drugs based on new molecular entities ( N“NMEs”)” approved by the FDA, and over the past three years with respect to more than 80% of the top 200 largest-selling compounds globally. With approximately 2,400 scientists and technicians worldwide and more than 1,300 patents and patent applications, our expertise is in providing differentiated technologies and solutions that help our customers bring more products and better treatments to market faster. For example, in the high-value area of new chemical entities ( N“NCEs”),” approximately 90% of NCE softgel approvals by the FDA over the last 25 years have been developed and supplied by us. Diversified Operating Platform We are diversified by virtue of our geographic scope, our large customer base, the extensive range of products we produce, our broad service offerings, and our ability to provide solutions at nearly every stage of a product’s lifecycle. In fiscal 2019, we produced nearly 7,000 distinct items across multiple categories; our fiscal 2019 regulatory-based classification of revenues demonstrates this: branded drugs (34%), generic prescription drugs (7%), protein and gene therapy biologics (32%), over-the-counter drugs (13%), and consumer health, veterinary products, medical devices, and diagnostics (14% combined). In fiscal 2019, our top 20 products represented approximately 20% of total revenue, with no single customer accounting for greater than 10% of revenue and with no individual product greater than 4%. We serve more than 1,000 customers in approximately 80 countries, with nearly half of our fiscal 2019 revenues coming from outside the United States. This diversity, combined with long product lifecycles and close customer relationships, has contributed to the stability of our business. It has also allowed us to reduce our exposure to potential strategic, customer, and product shifts as well as to payer-driven pricing pressures experienced by our drug and biologic customers. 7 Longstanding, Extensive Relationships with Blue Chip Customers We have longstanding, extensive relationships with leading pharmaceutical and biotechnology customers. In fiscal 2019, we did business with 83 of the top 100 branded drug marketers, 21 of the top 25 generics marketers, 23 of the top 25 biologics marketers, and 21 of the top 25 consumer health marketers globally, as well as with more than 1,000 other customers, including emerging and specialty companies, which are often more reliant on outside partners as a result of their more virtual business models. Regardless of size, our customers seek innovative product development, superior quality, advanced manufacturing, and skilled technical services to support their development and marketed product needs. We believe our customers value us because our depth of development solutions and advanced delivery technologies, consistent and reliable supply, geographic reach, and substantial expertise enable us to create a broad range of tailored solutions, many of which are unavailable from other individual providers. Deep, Broad and Growing Technology Foundation l i i i i i d dand l di dand our dand llong conjugate j breadth fof d h proprietary i including i l di iOptiPact lrelease lsolve dand bi l biologics ivia i syringes. We lalso participants. Our l di h l d technologies patented h fplatforms, i l softgel l f leading family il diZydis f including hthe ophthalmic, h h l advanced bi l dand AAV vectors ffor gene h inhalers challenges ffor our customers. We ffoffer d i dand i j biologics f i i i technologies, i l complex d lidelivery h ll l i respiratory, provide d id l technologies, h metered ddose d including l di advanced d lidelivery d position iin d applications, i i henhancement program ffor Our b ffrom hother i dindustry modified difi d expertise to i l molecules l prefilled fill d dand antibody-drug ib d d respiratory d lidelivery, i i hi our l d i i leadership technology l fplatforms l h bioavailabilility bioavailabi fplatform, our bi l biologics l i advanced d lidelivery grounded iin our d d d d i innovation iis i h l b l throughout our manufacturing processes h global l b l global i f opportunities ffor b hboth new customer i i priority i resources to our hi hhighest development development. As of June 30, 2019, we had approximately 1,100 product development programs in active development across our businesses. i ll b substantially diff innovation i k record fof i d track iVegicaps dand OptiShell, i h ll Liqui-Gels, i technologies, h OptiMelt dand i provide f id l i l h i advanced technologies ffor d lidelivery fof l d l iunit ddose blow-fill-seal fill including hthe bl l di cell-line ll li ioptions, i i leadership hi intra-nasal fforms. We hhave dand h d iSuite, da dose f di lculture fof dand our patents l biologics b ibusiness iinto gene htherapy. Our d technologies, our l network. Our k bl injectable routes, i including “GPEx” formulation l therapies. We hhave a m karket l d l differentiate us capsules, l formulation l ll small technology, h l dand SMARTag i i reinforced d launched more hthan da dozen new form-agnostic i i expands d lCatalent creativity a dnd i i proprietary i dand d application fof li fff fa f ocused technology l dand ddry technologies over hthe llast fifive years, as we hhave l l h dand development team d idrives introductions d l fiscal 2016 l molecules, i extends our bi l i h l di including hthe fi learly-stage i i dproduct d dproduct i position i hiwithin i f iOptiForm l acquisitions fof i i i launch fof our h dand hthe recent engineers, i l dand Paragon, hi hwhich Indiana, hi hwhich fplatform h powder i h l nebulized b li d scientists Solution dand l dand i l di dand li d i i i l i i dand our i Long-Duration Relationships Provide Sustainability Our broad and diverse range of technologies closely integrates with our customers’ molecules to yield final formulations and dose forms, and this generally results in the inclusion of Catalent in our customers’ prescription product regulatory filings. Both of these factors translate to long-duration supply relationships at an individual product level, to which we apply our expertise in contracting to produce long-duration commercial supply agreements. These agreements typically have initial terms of three to seven years with regular renewals of one to three years (see “—Contractual Arrangements” f” orff more detail). Approximately two-thirds of our fiscal 2019 advanced delivery technology platform revenues (comprised of our Softgel Technologies, Biologics and Specialty Drug Delivery, and Oral Drug Delivery reporting segments) were covered by such long- term contractual arrangements. We believe this base provides us with a sustainable competitive advantage. “— Significant Recent Growth Investments We have made significant investments over time to establish a manufacturing network, capable of serving customers and patients worldwide and today employ 6.4 million square feet of manufacturing and laboratory space across five continents. We have deployed approximately $815.0 million in the last five fiscal years in gross capital expenditures. Growth-related investments in facilities, capacity, and capabilities across our businesses have positioned us for future growth in areas aligned with anticipated future demand. Through our focus on operational, quality, and regulatory excellence, we drive ongoing and continuous improvements in safety, productivity, and reliable supply to customer expectations, which we believe further differentiate us. Our manufacturing network and capabilities allow us the flexibility to reliably supply the changing needs of our customers while consistently meeting their quality, delivery, and regulatory compliance expectations. High Standards of Regulatory Compliance and Operational and Quality Excellence We operate our plants in accordance with current good manufacturing practices ( cGM“ P”)” or other applicable requirements, following our own high standards that are consistent with those of many of our large global pharmaceutical and biotechnology customers. We have more than 1,900 employees around the globe focused on quality and regulatory compliance. All of our facilities are registered with the FDA or other applicable regulatory agencies, such as the European Medicines 8 “ Agency (the EMA ”).” In some cases, facilities are registered with multiple regulatory agencies. In fiscal 2019, we were subject to 75 regulatory audits, and, over the last five fiscal years, we successfully completed approximately 300 regulatory audits. We also undergo more than 400 customer and internal audits annually. We believe our quality and regulatory track record to be a favorable competitive differentiator. Strong and Experienced Management Team Our pharmaceuti pharmaceuti ddeep k lcal knowledge l d hi executive l d i dand h l h dand a widide leadership team ll industries. healthcare i d k collecti i i network fof i dindustry relationships. hi l i lvely hhas more hthan 200 years fof combined bi d i hWith an average fof more hthan 29 years fof f dand didiverse functional i l experience i i experience, hithis team possesses i hiwithin hthe Our Strategy We are pursuing the following key growth initiatives: ““Follow the Molecule””® Providing Solutions to our Customers across all Phases of the Product Lifecyclell We intend to use our advanced delivery technologies and development solutions across the entire lifecycle of our customers’ products to drive future growth. Our development solutions span the drug development process, starting with our platforms for early pre-clinical development of small molecules, biologics, and antibody-drug conjugates, to formulation and analytical services, through clinical development and manufacturing of clinical trial supplies, to regulatory consulting. Once a molecule is ready for therapeutic trials and subsequent commercialization, we provide our customers with a range of advanced delivery technologies and manufacturing expertise that allow them to deliver their molecules to the end-users in appropriate dosage forms. The relationship between a molecule and our advanced delivery technologies typically starts with developing and manufacturing the innovator product, then extends throughout the molecule’s commercial life, including with additional customers through potential generic launches or over-the-counter conversion. For prescription products, we are typically the sole and/or exclusive provider, and are reflected in customers’ new drug applications. Our revenues from our advanced delivery technologies are primarily driven by volumes and, as a result, the loss of an innovator drug’s market exclusivity may be mitigated if we supply both branded and generic customers. An example of this can be found in a leading over-the-counter respiratory brand, which today uses both our Zydis fast dissolve and our Liqui-Gels softgel technologies. We originally began development of the prescription format of this product for our multinational pharmaceutical company partner in 1992 to address specific patient sub-segment needs. After four years of development, we then commercially supplied the prescription Zydis product for six years, and we have continued to provide the Zydis form since the switch to over-the-counter status in the United States and other markets in the early 2000s. Subsequently, we proactively brought a softgel product concept for the brand to the customer, which the customer elected to develop and launch as well. By following this molecule, we have built a strong, 27-year-long relationship across multiple formats and markets. Customer Product Pipeline — Continuing to Grow Through New Projects and Product Launches We intend to grow by supplementing our existing diverse base of commercialized advanced delivery technology products with new development programs. As of June 30, 2019, our product development teams were working on approximately 1,100 new customer programs. Our base of active development programs has expanded in recent years from growing market demand, as well as from our expanded capabilities and technologies. Although there are many complex factors that affect the development and commercialization of pharmaceutical, biological, and consumer and animal health products, we expect that a portion of these programs will reach full development and market approval in the future and thereby add to our long-duration commercial revenues under long-term contracts and grow our existing product base. In fiscal 2019, we introduced 193 new products for our customers. Catalent continues to be the global leader in providing chemistry, manufacturing, and controls-based product development services to the global pharmaceutical, biotechnology, and consumer health industry, driven by thousands of projects annually. In fiscal 2019, we recognized approximately $653.0 million of revenue related to the development of products on behalf of customers, included in our Softgel Technologies, Biologics and Specialty Drug Delivery, and Oral Drug Delivery reporting segments, up 27% from the prior year. In addition, substantially all of the revenues associated with the Clinical Supply Services segment relate to our support of customer products in development. Capabilities & Capacity CC — Expanding in Biologics and Other Attractive Markets i i i Recognizing hthe fplatform iin 2002. l development d l strategic iimportance fof bi l iSince hthen, we hhave i biologics, we bbegan to b ild d i invested over $$2.2 billibillion iin our bi l i biologics ifferentiat ded bi l biologics b ibusiness, i i build da diff ll li dand f cell-line including l di formulation l capital l i i i 9 acquisition fof Paragon ffor an aggregate purchase h i nominal l iprice fof $$950.0 h purchase illimillion. iprice fof $$1.2 billibillion, dAnd we hhave i iinvestments, hthe fi i i i fiscal 2019 l acquisition fof i i i l Indiana ffor an aggregate nominal i lCatalent di capital iinvestment at our isites iin l illimillion dand Bloomington i l i projected d j capacity ddue to fill/finish product fill/fi i h product l di i iin bi l biologics, i i lvials, i fill d syringes, filled bioanalytic lal i l trials i l dand bi commerciall s i taking us to ki l llcell develop d d advanced d i iin a s econd-generation d d SMARTag including AAV vectors ffor gene h id cartridges; i l supply ffor bi l lcale expression ffor i antibody-drug ib d d product-development i increasingly iin production biologics ddrug i nearly 700 l conjugate j activities. i i i dand i third analysis. hThe hi d growth among our i therapies; d l dand d d h l l i expand ddrug bsubstance d dand ffuture customers. development, f l anufacturing fof bi l i diMadison to existing i i d cell-line d ll li advanced specializedd m f diMadison, bsubstance. We hhave i li isuite iin our formulation, l i biologic ddrug i facility came i Wisconsin f ili partnered i hwith customers ffrom i d f manufacturing dToday, we are a r dand hthe fi fiscal 2018 l commenced $a $200.0 d dand ddrug capacity i i ecognized l dleader i d -pre- fill-finish iinto bsubstance ffor use iin li i clinical l on-line iin fi dand fill fi i h fiscal 2018 l li around hthe d dAnd we hhave i ldworld to invested d llcell lilines, many technology, SMARTag, h l iusing our d d advanced GPEx continued progress iin our customers’ dand we see technology. l d h i In ddi i addition to our expand iin d capacity iin i iin dorder to production production dand our commencement h ) ( (ODT) Juniper h fof i Pharmaceutic lals i softgel l f capacity ivia our fi diZydis i technology, l attractive i i hWinchester, fof $a $27.0 i expansion iin bi l kmarkets, i biologics, we hhave i including a r i ecently l l di k Kentucky, hthe scaling-up fof li capital iinvestment to l illimillion i added kkey new lUltra. We hhave lalso dd d acquisition fof h i i i capital iin i l invested ddi i additional l d completed i significant ifi d l commerciall m f i commercialilize our i learly d capabilitiies iin bili Pharmatek, k fiscal 2017 l dand i several existing i l expansion fof our i anufacturing i next-generation i non-biological f ili i facilities l bi l ll d solid controlled lrelease lid loral inhalers, metered-dose i h l d d capacity ffor i tablet orally di i ll i disintegrating bl i i i ivia our fi acquisition fiscal 2019 l health American consumer h l h i hNorth i development l expanded our d d dand our fi l fiscal 2017 Accucaps acquisition. i i i Advanced Technologies — Capitalize on Our Substantial Platforms We have broad and diverse technology platforms that are supported by extensive know-how and more than 1,300 patents and patent applications in approximately 125 families across advanced delivery technologies, drug and biologics formulation, and manufacturing. For example, we have significant softgel fill and formulation know-how, databases of formulated products, and substantial softgel regulatory approval expertise, and, as a result, approximately 90% of NCE softgel approvals by the FDA over the last 25 years have been developed and supplied by us. In addition to resolving delivery challenges for our customers’ products, for more than two decades we have applied our technology platforms and development expertise to proactively develop proof-of-concept products, whether improved versions of existing drugs, new generic formulations or innovative consumer health products. In the consumer health area, we file product dossiers with regulators in relevant jurisdictions for self-created products, which help contribute sustainable growth to our consumer health business. We expect to continue to seek proactive development opportunities and other non-traditional relationships to increase demand for and value realized from our technology platforms. These activities have provided us with opportunities to capture an increased share of end-market value through out-licensing, profit-sharing and other arrangements. Operational Leverage — Deploy Existing Infrastructure and Operational Discipline to Drive Profitable Growth Through our existing infrastructure, including our global network of operating locations and programs, we promote operational discipline and drive margin expansion. With our Lean Manufacturing and Lean Six Sigma programs, a global procurement function and conversion cost productivity metrics in place, we have created a culture of functional excellence and cost accountability. We intend to continue to apply this discipline to leverage further our operational network for profitable growth. Since fiscal 2009, we have expanded gross margin by over 400 basis points and Adjusted EBITDA margin by over 400 basis points. Note that A“ djusted EBITDA” i” s a financial metric that is not prepared in accordance with the accounting principles generally accepted in the United States ( U“ .S. GAAP”),” and that further explanations of this metric and comparisons to the most nearly comparable U.S. GAAP metrics are set forth below at M“ anagement’s Discussion and Analysis of Financial Condition and Results of Operations—Historical and Adjusted EBITDA.” Strategic Acquisitions and Licensing — Build on our Existing Platform We operate in highly fragmented markets in both our advanced delivery technologies and development solutions businesses. Within those markets, the five top players represent approximately 35% and 10% of the total market share, respectively, by revenue. Our broad platform, global infrastructure and diversified customer base provide us with a strong foundation from which to consolidate within these markets and to generate operating leverage through such acquisitions. Since fiscal 2013, we have executed ten transactions, investing approximately $2.7 billion, and have demonstrated an ability to efficiently and effectively integrate these acquisitions. While we are rigorously focused on driving Catalent’s organic growth, we intend to continue to opportunistically source and execute bolt-on strategic acquisitions within our existing business areas, as well as to undertake transactions that provide us with expansion opportunities within new geographic markets or adjacent market segments. We have a dedicated corporate 10 development team in place to identify these opportunities and have a rigorous and financially disciplined process for evaluating, executing, and integrating such acquisitions. Our Reportable Segments We Technologies, h l below. below. currently operate iin ffour i i Biologics l i l operating segments, hi hwhich lalso liDelivery, i l lOral Drug Specialty Drug dand constitute our ffour dand li i reporting segments: Clinical l f l Softgel further d h Services, as f i Supply l liDelivery, i i i described ib d Softgel Technologies Through our Softgel Technologies segment, we provide formulation, development, and manufacturing services for soft capsules, or s“ oftgels, w” hich our predecessor first commercialized in the 1930s and which we have continually enhanced. We are the market leader in overall softgel development and manufacturing and hold the leading market position in the prescription arena. Our principal softgel technologies include traditional softgel capsules, in which the shell is made of animal-derived gelatin, and Vegicaps and OptiShell capsules, in which the shell is made from plant-derived materials. Softgel capsules are used in a broad range of customer products, including prescription drugs, over-the-counter medications, dietary supplements, unit- dose cosmetics, and animal health medicinal preparations. Softgel capsules encapsulate liquid, paste, or oil-based active compounds in solution or suspension within an outer shell. In the manufacturing process, the capsules are formed, filled, and sealed simultaneously. We typically perform encapsulation for a product within one of our softgel facilities, with active ingredients provided by customers or sourced directly by us. Softgels have historically been used to solve formulation challenges or technical issues for a specific drug, to help improve the clinical performance of compounds, to provide important market differentiation, particularly forff over-the-counter medications, and to provide safe handling of hormonal, potent, and cytotoxic drugs. We also participate in the softgel vitamin, mineral and supplement business in selected regions around the world. With the 2001 introduction of our plant-derived softgel shell, Vegicaps capsules, consumer health customers have been able to extend the softgel dose form to a broader range of active ingredients and serve patient/consumer populations that were previously inaccessible due to religious, dietary, or cultural preferences. In recent years, we have extended this platform to pharmaceutical products via our OptiShell capsule offering. Our Vegicaps and OptiShell capsules are protected by patents in most major global markets. Physician and patient studies we have conducted have demonstrated a preference for softgels versus traditional tablet and hard capsule dose forms in terms of ease of swallowing, real or perceived speed of delivery, ability to remove or eliminate unpleasant odor or taste and, for physicians, perceived improved patient adherence with dosing regimens. Representative customers of Softgel Technologies include Pfizer, Novartis, Bayer, GlaxoSmithKline, Teva, Johnson & Johnson, Procter & Gamble, and Allergan. Our Softgel Technologies segment represents 34%, 36%, and 40% of our aggregate revenue before inter-segment eliminations for fiscal 2019, 2018, and 2017, respectively. Biologics and Specialty Drug Delivery Our Biologics and Specialty Drug Delivery segment provides drug substance development and manufacturing, drug product clinical and commercial manufacturing, integrated clinical and commercial supply solutions for protein and gene therapy biologics and specialty small molecules administered via injection, inhalation, and ophthalmic routes, using both traditional and advanced delivery technologies. The business has extensive expertise in development, scale up and commercial manufacturing. Representative customers of Biologics and Specialty Drug Delivery include Eli Lilly, Teva, Mylan, Roche, Novartis, Sarepta, and Genentech, along with multiple innovative small and mid-tier pharmaceutical and biologics customers. Our growing biologics offering includes cell-line development based on our advanced and patented GPEx technology, which is used to develop stable, high-yielding mammalian cell lines for both innovator and biosimilar biologic compounds. GPEx technology can provide rapid cell-line development, high biologics production yields, flexibility, and versatility. Our development and manufacturing facility in Madison, Wisconsin has the capability and capacity to produce cGMP quality biologics drug substance from 250L to 4000L scale using single-use technology to provide maximum efficiency and flexibility. Our fiscal 2018 acquisition of Catalent Indiana added a biologics-focused contract development and manufacturing organization with capabilities across biologics development, clinical, and commercial drug substance manufacturing, formulation, finished-dose drug product manufacturing, and packaging. In fiscal 2019, we continued to expand production capacity in both Madison and Bloomington, starting construction on a fourth product manufacturing and packaging capacity in Bloomington. Our SMARTag next-generation antibody-drug conjugate technology enables development of antibody-drug conjugates and other protein conjugates with improved efficacy, safety, and manufacturability. In fiscal 2019, we launched our OneBio Suite, which provides customers the potential to seamlessly integrate drug substance, drug product, and clinical supply management for products in development, and for integrated commercial supply across both drug substance and product. We provide the broadest range of technologies and services drug substance suite in Madison, and new drug ff 11 supporting the development and launch of new biologic entities, biosimilars, and biobetters to bring a product from gene to commercialization, faster. acquired Paragon, hi hwhich iis f viral vectors biotech h therapies b i dand CAR-T llcell h i d On May 17, 2019, we l di l including i icals, i l biopharmaceut biopharmaceuti dand hpharma ldworld’s l di leading bi based on AAV dand d i including gene h l di therapies), h ) i iviruses AAV vectors, hthe most commonly l iusing cGMP, hi hwhich vectors manufactured f d Paragon lalso b ibrings to lCatalent iits diff fundamentally e hnhance our bi l f 2019, Paragon NNovavax, Inc. hThe Novavax i i differentiat ded i i acquire two ddi i acquisition l i i i biologics b ibusiness agreed to ll d d development l focused on hthe d d i therapies. For over 25 years, Paragon hhas fmanufacture next-generation i based on d oncology i l dand fmanufacture fof dused iin gene h develop l i dand companies to d d li i hother modalities, dand therapeutic i dused d lidelivery system ffor gene htherapy, as dproducts b vaccines, i i llwell as hother proteins, i complex bi l l capitalize on strong i dindustry il biologics. Paragon b ibrings capabilitiies iin l tailwinds iin hthe i d i position us to bili i manufacturing dand development, i scientific, d ifi i i ical l biopharmaceuti h integrated bi d end-to-end i d d dand located iin facilities l ili i manufacturing f i f lJuly 2019. dand l additional l blaboratory closed iin llate d li l l d bili f i d cutting-edge partnered i hwith some fof hthe f d l technologies, h transformative i i immunotherapies ( h (oncolytic i l i xpertise iin i specializedd e i li lentivirus i i dand l plasmids id kmarket ffor gene h i therapies. capabilitiies, hi hwhich illwill solutions ffor customers. In June southern h Maryland ffrom l d Our range of injectable manufacturing offerings includes filling small molecules or biologics into pre-filled syringes, cartridges, and vials, with flexibility to accommodate other formats within our existing network, increasingly focused on complex pharmaceuticals and biologics. With our range of technologies, we are able to meet a wide range of specifications, timelines, and budgets. We believe that the complexity of the manufacturing process, the importance of experience and know- how, regulatory compliance, and high start-up capital requirements provide us with a substantial competitive advantage in the market. For example, blow-fill-seal is an advanced aseptic processing technology, which uses a continuous process to form, fill with drug or biologic, and seal a plastic container in a sterile environment. Blow-fill-seal units are currently used for a variety of pharmaceuticals in liquid form, such as respiratory, ophthalmic, and otic products. Our sterile blow-fill-seal manufacturing has significant capacity and flexibility in manufacturing configurations. This business provides flexible and scalable solutions for unit-dose delivery of complex formulations such as suspensions and emulsions. Further, the business provides engineering and manufacturing solutions related to complex containers. Our regulatory expertise can lead to decreased time to commercialization, and our dedicated development production lines support feasibility, stability, and clinical runs. We plan to continue to expand our product line in existing and new markets, and in higher margin specialty products with additional respiratory, ophthalmic, injectable, and nasal applications. We also offer bioanalytical development and testing services for large molecules, including cGMP release and stability testing. Our respiratory product capabilities include development and manufacturing services for inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. Across multiple complex dosage forms, the segment provides drug and biologic solutions from early-stage development and clinical support all the way through to scale up and commercialization. Our Biologics and Specialty Drug Delivery segment represents 29%, 24% and 17% of our aggregate revenue before inter- segment eliminations for fiscal 2019, 2018, and 2017, respectively. Oral Drug Delivery Our Oral Drug Delivery segment provides various advanced formulation development and manufacturing technologies, and related integrated solutions including: clinical development and commercial manufacturing of a broad range of oral dose forms, including our proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled-release tablets, capsules, and sachet products. Representative customers of Oral Drug Delivery include Pfizer, Johnson & Johnson, Bayer, Novartis, and Perrigo. We provide comprehensive pre-formulation, development, and cGMP manufacturing at both clinical and commercial scales for traditional and advanced complex oral solid-dose formats, including coated and uncoated tablets, pellet/bead/powder- filled two-piece hard capsules, granulated powders, and other forms of immediate and modified release branded prescription, generic, and consumer products. We have substantial experience developing and scaling up products requiring accelerated development timelines, solubility enhancement, specialized handling (e.g., potent or DEA-regulated materials), complex technology transfers, and specialized manufacturing processes. We also provide micronization and particle engineering services, which may enhance a drug’s manufacturability or clinical performance. We offer comprehensive analytical testing and scientific services and stability testing for small molecules, both to support integrated development programs and on a fee-for- service basis. We provide global regulatory and support services for our customers’ clinical strategies during all stages of development. In recent years, we have expanded our network of development sites focused on earlier phase compounds, to engage with more customer molecules, earlier, with the intent to provide later stage manufacturing and supporting services as those molecules progress towards commercial approval and beyond. Demand for our offerings is driven by the need for a ff 12 scientific expertise and depth and breadth of services offered, as well as by the reliability of our supply, including quality, execution, and performance. We launched our orally dissolving tablet business in 1986 with the introduction of Zydis tablets, a unique proprietary freeze-dried tablet that typically dissolves in the mouth, without water, in less than three seconds. Most often used for drugs and patient groups that can benefit from rapid oral disintegration, we can adapt the Zydis technology to a wide range of products and indications, including treatments forff disease, and schizophrenia, and consumer healthcare products targeting indications such as pain and allergy relief. We continue to develop Zydis tablets in different ways with our customers as we extend the application of the technology to new therapeutic categories, including immunotherapy, vaccines, and biologic molecule delivery and improve its drug load capacity and taste- masking properties. a variety of central nervous system-related conditions such as migraines, Parkinson’s Our Oral Drug Delivery segment represents 24%, 23%, and 27% of our aggregate revenue before inter-segment eliminations for fiscal 2019, 2018, and 2017, respectively. Clinical Supply Services Our Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics in clinical trials. We offer customers flexible solutions for clinical supplies production and provide distribution and inventory management support for both simple and complex clinical trials. This includes over- encapsulation where needed; supplying placebos, comparator drug procurement, and clinical packages and kits for physicians and patients; inventory management; investigator kit ordering and fulfillment; and return supply reconciliation and reporting. We support trials in all regions of the world through our facilities and distribution network. In fiscal 2018, we completed the second phase of our expansion program in our Kansas City, Missouri facility. Further, in fiscal 2016 and again in fiscal 2018, we expanded our Singapore facility by building additional flexible cGMP space, and we introduced clinical supply services at our existing 100,000 square foot facility in Japan, expanding our Asia Pacific capabilities. Additionally, in fiscal 2013, we established our first clinical supply services facility in China as a joint venture, assumed full ownership in fiscal 2015, and opened a second facility in China in fiscal 2019. We are the leading provider of integrated development solutions and one of the leading providers of clinical trial supplies. Representative customers of Clinical Supply Services include Merck KGaA, IQVIA, Eli Lilly, AbbVie, and Incyte Corporation. Our Clinical Supply Services segment represents 13%, 17%, and 16% of our aggregate revenue before inter-segment eliminations for fiscal 2019, 2018, and 2017, respectively. Integrated Development and Product Supply Chain Solutions In addition to our proprietary offerings, we are also differentiated in the market by our ability to bring together our development solutions and advanced delivery technologies to offer innovative development and product supply solutions that can be combined or tailored in many ways to enable our customers to take their drugs, biologics, and consumer health products from laboratory to market. Once a product is on the market, we can provide comprehensive integrated product supply, from the sourcing of the bulk active ingredient to comprehensive manufacturing and packaging to the testing required for release to distribution. The customer- and product-specific solutions we develop are flexible, scalable and creative, so that they meet the unique needs of both large and emerging companies and are appropriate for products of all sizes. We believe that our development and product supply solutions such as OptiForm Solutions Suite and OneBioSuite will continue to contribute to our future growth. 13 Sales and Marketing Our target customers include large pharmaceutical and biotechnology companies, mid-size, emerging and specialty pharmaceutical and biotechnology companies, and consumer health companies, along with companies in other selected healthcare market segments such as animal health and medical devices and companies in adjacent industries, such as cosmetics. We have longstanding, extensive relationships with leading pharmaceutical and biotechnology customers. In fiscal 2019, we did business with 83 of the top 100 branded drug marketers, 21 of the top 25 generics marketers, 23 of the top 25 biologics marketers, and 21 of the top 25 consumer health marketers globally, as well as with more than 1,000 other customers. Faced with access, pricing, and reimbursement pressures as well as other market challenges, large pharmaceutical and biotechnology companies have increasingly sought partners to enhance the clinical competitiveness of their drugs and biologics and improve the productivity of their research and development activities, while reducing their fixed cost base. Many mid-size, emerging, and specialty pharmaceutical and biotechnology companies, while facing the same pricing and market pressures, have chosen not to build a full infrastructure, but rather to partner with other companies through licensing agreements or outsourcing to access the critical skills, technologies, and services required to bring their products to market. Consumer health companies require rapidly developed, innovative dose forms and formulations to keep up with the fast-paced over-the-counter medication, vitamins, and personal care markets. These market segments are all important to our growth, but require distinct solutions, marketing and sales approaches, and market strategy. ff We f ll follow ha h b id ybrid d l dand solutions, i individual heach i di id l d supported bby i kmarket dtrade hshows lCatalent’s essential ffor i l professionals, professionals, strategic i providing providing ie in m jajor participat participat iprint omprehensive h through a c h hi hhigh overall awareness iin our ll dadvantage ffor us. h i lsales specialist teams demand-generatiion d h i i li technical l offering. Our i ff id lsales inside dproduct dand lsales dand planning i l lrelevant to our on-line d li dand established bli h d kmarkets d lmodel, knowledge organization i i technical k h i i full b i breadth fof d h strategic account teams ff i hwith offering hthe f ll i i organization providing hthe i d idi experience i practical l i dand in-depth h experienced d i full-time, i currently l i consists fof more hthan 150 f ll i marketing team, strategic operations. We lalso hhave b ilbuilt da d di marketing ffefforts, we k i dand management ffor our fof our l globally offerings l b ll ff solutions i dand offerings i ff visibility to our i brand i hwith d lCatalent iis a strong b bli i dand advertising i i i i identity iis a c iuniverse fof target customers, dand i dand ensure dadequate i ibili publicity program. We b libelieve hthat edicated d offerings. As part ff dand hthat our b brand id d lsales k i l d ompetitive i l i Global Accounts We manage selected accounts globally due to their substantial current business and growth potential. We recorded approximately 20% of our total revenue in fiscal 2019 from these global accounts. Each global account is assigned a lead business development professional with substantial industry experience. These account leaders, along with other members of the sales and executive leadership teams, are responsible for managing and extending the overall account relationship. Account leaders work closely with the rest of the sales organization to ensure alignment around critical priorities for the accounts. Emerging, Specialty, and Virtual Accounts Emerging, specialty, and virtual pharmaceutical and biotechnology companies are expected to be critical drivers of industry growth globally. Historically, many of these companies have chosen not to build a full with other companies to produce their products. We expect them to continue to do so in the future, providing a critical source for future integrated solutions demand. We expect to continue to increase our penetration of geographic clusters of emerging companies in North America, Europe, South America, and Asia. We regularly use active pipeline and product screening and customer targeting to identify the optimal candidates for partnering based on product profiles, funding status, and relationships, to ensure that our technical sales specialists and field sales representatives develop custom solutions designed to address the specific needs of these customers. infrastructure, but rather partner ff Seasonality; Fluctuations in Operation Results Our annual financial reporting periods end on June 30. Our revenue and net earnings are generally higher in the third and fourth quarters of each fiscal year, with our first fiscal quarter typically generating our lowest revenue of any quarter, and our last fiscal quarter typically generating our highest revenue. These fluctuations are primarily the result of the timing of our, and our customers’, annual operational maintenance periods at locations in continental Europe and the U.K., the seasonality associated with pharmaceutical and biotechnology budgetary spending decisions, clinical trial and research and development schedules, the timing of new product launches and length of time needed to obtain full market penetration, and, to a lesser extent, the time of the year some of our customers’ products are in higher demand. Contractual Arrangements We generally enter into a broad range of contractual arrangements with our customers, including agreements with respect to feasibility, development, supply, licenses, and quality. The terms of these contracts vary significantly depending on the 14 offering and customer requirements. Some of our agreements may include a variety of revenue arrangements such as fee-for- service, minimum volume commitments, royalties, profit-sharing and fixed fees. We employ a range of capacity access approaches, from standard to completely dedicated capacity models, based on customer and product needs. We generally secure pricing and other contract mechanisms in our supply agreements to allow for periodic resetting of pricing terms, and, in some cases, these agreements permit us to renegotiate pricing in the event of certain price increases for the raw materials we use to make products. Our typical supply agreements include indemnification from our customers for product liability and intellectual property matters and caps on our contractual liabilities, subject in each case to negotiated exclusions. The terms of our manufacturing supply agreements range from three to seven years with regular renewals of one to three years, although some of our agreements are terminable upon much shorter notice periods, such as 30 or 90 days. For our development solutions offerings, we may enter into master service agreements, which provide for standardized terms and conditions and make it easier and faster for customers with multiple development needs to access our offerings. Backlog While we generally have long-term supply agreements that provide for a revenue stream over a period of years, our backlog represents, as of a point in time, future service revenues from work not yet completed. For our Softgel Technologies, Biologics and Specialty Drug Delivery, and Oral Drug Delivery segments, backlog represents firm orders for manufacturing services and includes minimum volumes, where applicable. For our Clinical Supply Services segment, backlog represents estimated future service revenues from work not yet completed under signed contracts. Using these methods of reporting backlog, as of June 30, 2019, our backlog was $1,349.8 million compared to $1,112.3 million as of June 30, 2018, including $366.3 million and $273.2 million, respectively, related to our Clinical Supply Services segment. We expect to recognize approximately 85% of revenue from the backlog in existence as of June 30, 2019 by the completion of fiscal year ending 2020. To the extent projects are delayed, the timing of our revenue could be affected. If a customer cancels an order, we may be reimbursed for the costs we have incurred. For orders that are placed inside a contractual firm period, we generally have a contractual right to payment in the event of cancellation. Fluctuations in our reported backlog levels also result from the timing and order pattern of our customers who often seek to manage their level of inventory on hand. Because of customer ordering patterns, our backlog reported for certain periods may fluctuate and may not be indicative of future results. Manufacturing Capabilities We operate manufacturing facilities, development centers and sales offices throughout the world. As of June 30, 2019, we had thirty-nine facilities (four geographical locations operate as multiple facilities because they support more than one reporting segment) on five continents with 6.4 million square feet of manufacturing, laboratory, and related space. In ddi i Anagni, i 2019, we i fff fa f biologics, hi hwhich iis biologics, second quarter d d expected to lclose bby hthe h Maryland ffrom Novavax, Inc. to to acquire two f i southern acquisition l i i i learly-stage d heach isite’s competencies dproduces b hboth fof fi fiscal 2020, l supplement hthe l capabilitiies i bili i f quality assurance, d i iy in particularl l l isuite fof full include hthe f ll validation. lid i dand, iin June 2019, we i capabilitiies fof Paragon, l d closed iin llate d activities, i i i i dand signed an agreement lJuly 2019. Our regulatory, l facilities iin ili i development. hiThis sterile ddose fforms ffor ddrugs signed an agreement to acility iin ili dend fof hthe lrelevant to support addition, iin May manufacturing dand i hin-house including l di Italy hthat acquire loral dand bili l d il li d l i i l We operate our plants in accordance with cGMP or other applicable requirements. All of our facilities are registered with the FDA or other applicable regulatory agencies, such as the EMA. In some cases, our facilities are registered with multiple regulatory agencies. We have invested $534.4 million in our manufacturing facilities since fiscal 2017 through improvements and expansions in our facilities, including $218.1 million on capital expenditures in fiscal 2019. We believe that our facilities and equipment are in good condition, are well maintained, and are able to operate at or above present levels for the foreseeable future, in all material respects. Our manufacturing operations are focused on employee health and safety, regulatory compliance, operational excellence, continuous improvement, and process standardization across the organization. In fiscal 2019, we achieved approximately 97% on-time shipment delivery versus customer request date across our network as a result of this focus. Our manufacturing operations are structured around an enterprise management philosophy and methodology that utilizes principles and tools common to a number of quality management programs, including Lean Six Sigma and Lean Manufacturing. Raw Materials We use a broad and diverse range of raw materials in the design, development, and manufacture of our products. This includes, but is not limited to, key materials such as gelatin, starch, and iota carrageenan for our Softgel Technologies segment; along with resin packaging films for our Clinical Supply Services segment; and glass vials and syringes for injectable fill-finish for our blow-fill-seal business in our Biologics and Specialty Drug Delivery segment. The raw materials that we use are sourced ff 15 externally on a global basis. Globally, our supplier relationships could be interrupted due to natural disasters and international supply disruptions, including those caused by pandemics or geopolitical and other issues. For example, commercially usable gelatin is available from a limited number of sources. In addition, much of the gelatin we use is bovine-derived. Past concerns of contamination from Bovine Spongiform Encephalopathy ( BSE particular types of gelatin. If there were a future can be no assurance that we could obtain an alternative supply from our other suppliers. Any future restriction that were to emerge on the use of bovine-derived gelatin from certain geographic sources due to concerns of contamination from BSE could hinder our ability to timely supply our customers with products and the use of alternative non-bovine-derived gelatin for specific customer products could be subject to lengthy formulation, testing and regulatory approval periods. disruption in the supply of gelatin from any one or more key suppliers, there ”)” have narrowed the number of possible sources of “ ff We work very closely with our suppliers to assure continuity of supply while maintaining excellence in material quality and reliability. We continually evaluate alternate sources of supply, although we do not frequently pursue regulatory qualification of alternative sources for key raw materials dued of our current supplier base, and the time and expense associated with the regulatory process. Although a change in suppliers could require significant effort or investment by us in circumstances where the items supplied are integral to the performance of our products or incorporate specialized material such as gelatin, we do not believe that the loss of any existing supply arrangement would have a material adverse effect on our business. See “Risk Industry—Our future results of operations are subject to fluctuations in the costs, availability,tt and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients,tt purchased components, and raw materials.” to the strength of our existing supplier relationships, the reliability Factors—Risks Relating to Our Business and “ Competition We compete with multiple companies as to each of our offerings and in every region of the globe in which we operate, including with other companies that offer conventional and advanced delivery technologies, clinical trials support, outsourced dose form or biologics manufacturing, or development services to pharmaceutical, biotechnology, and consumer health companies based in North America, South America, Europe, and the Asia-Pacific region. We also compete in some cases with the internal operations of those pharmaceutical, biotechnology, and consumer health customers that also have manufacturing capabilities and choose to source these services internally. Competition is driven by proprietary technologies and know-how (where relevant), capabilities, consistency of operational performance, quality, price, value, responsiveness, and speed. While we do have competitors that compete with us in our individual offerings, and a fewff competition from any directly comparable company. competitors that compete across many of our offerings, we do not believe we have Research and Development Costs Our research activities are primarily directed toward the development of new offerings and manufacturing process improvements. Costs incurred in connection with the development of new offerings and manufacturing process improvements are recorded within selling, general, and administrative expenses. Such research and development costs included in selling, general, and administrative expenses amounted to $3.3 million, $6.3 million, and $7.0 million for fiscal 2019, 2018, and 2017, respectively. Costs incurred in connection with research and development services we provide to customers and services performed in support of the commercial manufacturing process for customers are recorded within cost of sales. Such research and development costs included in cost of sales amounted to $51.2 million, $46.2 million, and $45.8 million for fiscal years ended 2019, 2018, and 2017, respectively. Employees As of June 30, 2019, we had nearly 12,300 employees in thirty-nine facilities on five continents: fifteen facilities are in the United States, with certain employees at one facility being represented by a labor organization with their terms and conditions of employment being subject to a collective bargaining agreement. National works councils and/or labor organizations are active at all thirteen of our European facilities consistent with labor environments/laws in European countries. Similar relationships with labor organizations or national works councils exist at our plants in Argentina, Australia, Brazil, and Canada. Our management believes that our employee relations are satisfactory. Approximate number of employees as of June 30, 2019 North America 6,800 Europe 3,900 South America 900 Asia Pacific Total 700 12,300 16 Corporate Responsibility Responsible business practices are essential to fulfilling our mission of helping people live better, healthier lives. Our corporate values are at the foundation of our culture and everything we do. Our explicit commitment to Patient First means that we put patients at the center of our work to ensure the safety, reliable supply, and optimal performance of our products. We ask employees at every level of our organization to uphold these values and to apply the highest ethical standards in their work. Investing in our people, managing our environmental footprint, and giving back to our communities are part of our long-term growth and sustainability strategy and guide our Corporate Responsibility (CR) program. Governance To manage our CR performance, we maintain a CR Council made up of executive and senior leadership to guide the implementation of our CR strategy and commitments and report to our board of directors or a designated committee on CR matters. Three committees reporting to the CR Council—the Environmental Committee, the Grant-making Committee, and the Community Engagement Ambassador Network—help drive progress in three critical areas of our overall CR commitment and embed CR deeper into our business. Significant initiatives We focus on those aspects within the overall corporate responsibility area that we believe to be most significant to our business. Our view is informed by stakeholder feedback, regulatory developments, and issues that appear to engage our constituencies. From time to time, we assess and prioritize among potential initiatives in order to focus our resources. Relevant issues on which we have focused during fiscal 2019 include: • ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ Community investment and philanthropy Diversity and inclusion Energy use and climate change Occupational health and safety Product innovation Product quality and safety Talent attraction and retention Training and development Waste Business benefits Beyond being the right thing to do, our focus on CR strengthens our business by reducing risks, meeting customer and investor expectations, and attracting top talent to join and stay with us. CR performance is an important contributor to our business success. It informs our risk management process, protects our reputation, and alerts us to regulatory, environmental, and societal threats to our business. Our CR activities also support our customers, some of which have robust CR programs and prefer suppliers with a similar commitment. Our future success depends on our highly skilled and dedicated global team of employees, who are passionate about improving health outcomes. We compete for the top talent in our industry and recognize that our reputation as a responsible company can be a differentiator for prospective job candidates. Progress in 2019 In fiscal 2019, we continued to introduce an expanded set of site-based CR performance metrics to measure the impact of our CR activities across our network. As part of this exercise, we conducted our most comprehensive environmental baseline assessment to date. Our environmental data, and other relevant CR metrics and targets, will be shared as part of our first CR report, which is expected in 2020. Catalent has also achieved global accreditation with respect to the international management standards for environment (ISO14001:2015) and occupational safety (OHSAS18001:2007). In April 2019, our second annual Earth Month campaign, Catalent Unplugged, emphasized our focus on reducing CO₂ emissions linked to energy use. Our employees and sites responded enthusiastically, organizing volunteering, recycling, awareness-raising, and waste elimination initiatives across the network. 17 Our Catalent Month of Service grew to include almost every site in the Catalent network. We expanded our community grant making program, focused on giving back through our diverse network of facilities worldwide. Our grants promote local organizations that support patients and encourage STEM (science, technology, engineering, and mathematics) educational and training initiatives. Catalent’s disaster response program is valued by our employees for helping people affected by natural disasters in the U.S. and beyond. Further information on our CR program is available at https://www.catalent.com/index.php/about-us/Corporate- Responsibility, but this website is not part of our public disclosures and is not incorporated by reference into this Annual Report. Intellectual Property We rely on a combination of know-how, trade secrets, patents, copyrights, trademarks, and other intellectual property laws, nondisclosure and other contractual provisions, and technical measures to protect a number of our offerings, services, and intangible assets. These proprietary rights are important to our ongoing operations. Certain of our operations and products are under intellectual property licenses from third parties, and in certain instances we license our technology to third parties. We also have a long track record of innovation across our lines of business, and, to further encourage active innovation, we have developed incentive compensation systems linked to patent filings and other recognition and reward programs for scientists and non-scientists alike. We have applied in the United States and certain foreign countries for registration of a number of trademarks, service marks, and patents, some of which have been registered and issued, and also hold common law rights in various trademarks and service marks. We hold more than 1,300 patents and patent applications worldwide relating to advanced drug delivery and biologics formulations and technologies, as well as manufacturing and other areas relevant to our business. We hold patents and license rights relating to certain aspects of our formulations, nutritional and pharmaceutical dosage forms, mammalian cell engineering, and sterile manufacturing services. We also hold patents relating to certain processes and products. We have a number of pending patent applications in the United States and certain other countries and intend to pursue additional patents as appropriate. We have enforced and will continue to enforce our intellectual property rights in the United States and worldwide. We do not consider any particular patent, trademark, license, franchise, or concession to be material to our overall business. Regulatory Matters The manufacture, distribution, and marketing of healthcare products and the provision of certain services for development-stage pharmaceutical and biotechnology products are subject to extensive ongoing regulation by the FDA, other U.S. governmental authorities, and foreign regulatory authorities. Certain of our subsidiaries are required to register for permits or licenses with, and must comply with the operating, cGMP, quality, and security standards of, applicable domestic and foreign healthcare regulators, including the FDA, the U.S. Drug Enforcement Agency (the D“ EA”),” the U.S. Department of Health and Human Services (the D“ HHS”),” the equivalent agencies of the European Union (the E.U. ”)” and its member states, and various state boards of pharmacy, state health departments, and comparable foreign agencies, as well as various accrediting bodies, each depending upon the type of operations and the locations of distribution and sale of the products manufactured or services provided by those subsidiaries. “ In addition, certain of our subsidiaries are subject to other healthcare laws, including the U.S. Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, the Controlled Substances Act, and comparable state and foreign laws and regulations in certain of their activities. We are also subject to various federal, state, local, foreign and transnational laws, regulations, and requirements, both in the United States and abroad, relating to safe working conditions, laboratory and distribution practices, and the use, transportation, and disposal of hazardous or potentially hazardous substances. In addition, U.S. and international import and export laws and regulations require us to abide by certain standards relating to the cross-border transit of finished goods, raw materials, and supplies and the handling of information. We are also subject to various other laws and regulations concerning the conduct of our foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Anti-Bribery Act, and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records. The costs associated with complying with the various applicable federal, state, local, foreign, and transnational regulations could be significant, and the failure to comply with such legal requirements could have an adverse effect on our to results of operations and financial condition. See “Risk Factors—Risks Relating to Our Business and Industry—Failure — “ 18 comply with existing and future regulatory requirements could adversely affect our results of operations and financial condition or result in claims from customers,” f” orff regulations. additional discussion of the costs associated with complying with the various In fiscal 2019, we were subject to 75 regulatory audits, and, over the last five fiscal years, we successfully completed approximately 300 regulatory audits. Quality Assurance We are committed to ensuring and maintaining the highest standard of regulatory compliance while providing high quality products to our customers. To meet these commitments, we have developed and implemented a Catalent-wide quality management system. We have more than 1,900 employees around the globe focusing on quality and regulatory compliance. Our senior management team is actively involved in setting quality policies, standards, and internal position papers as well as managing internal and external quality performance. Our quality assurance department provides quality leadership and supervises our quality systems programs. An internal audit program monitors compliance with applicable regulations, standards, and internal policies. In addition, our facilities are subject to periodic inspection by the FDA, the DEA, and other equivalent local, state, and foreign regulatory authorities as well as our customers. All FDA, DEA, and other regulatory inspectional observations have been resolved or are on track to be completed at the prescribed timeframe provided in commitments to the applicable agency in all material respects. We believe that our operations are in compliance in all material respects with the regulations under which our facilities are governed. Environmental Matters Our operations are subject to a variety of environmental, health, and safety laws and regulations, including those of the ”)” and equivalent state, local, and foreign regulatory agencies in each of the U.S. Environmental Protection Agency (the EPA“ jurisdictions in which we operate. These laws and regulations govern, among other things, air emissions, wastewater discharges, the use, handling, and disposal of hazardous substances and wastes, soil and groundwater contamination, and employee health and safety. Our manufacturing facilities use, in varying degrees, hazardous substances in their processes. These substances include, among others, chlorinated solvents, and in the past chlorinated solvents were used at one or more of our facilities, including a number we no longer own or operate. As at our current facilities, contamination at such formerly owned or operated properties can result and has resulted in liability to us, for which we have recorded appropriate reserves as needed. We believe that our operations are in compliance in all material respects with the environment, health, and safety regulations applicable to our facilities. 19 ITEM 1A. RISK FACTORS If any of the following risks actually occur, our business, financial condition, operating results, or cash flow could be materially and adversely affected. Additional risks or uncertainties not presently known to us, or that we currently believe are immaterial, may also impair our business operations. Risks Relating to Our Business and Industry We participate in a highly competitive market, and increased competition may adversely affect our business. We operate in a market that is highly competitive. We compete with multiple companies as to each of our offerings and in every region of the globe in which we operate, including competing with other companies that offer advanced delivery technologies, outsourced dose form or biologics manufacturing, clinical trials support services, or development services to pharmaceutical, biotechnology, and consumer health companies based in North America, South America, Europe, and the Asia- Pacific region. We also compete in some cases with the internal operations of those pharmaceutical, biotechnology, and consumer health customers that also have manufacturing capabilities and choose to source these services internally. We face substantial competition in each of our markets. Competition is driven by proprietary technologies and know- how, capabilities, consistency of operational performance, quality, price, value, responsiveness, and speed. Some competitors may have greater financial, research and development, operational, and marketing resources than we do. Competition may also increase as additional companies enter our markets or use their existing resources to compete directly with ours. Expanded competition from companies in low-cost jurisdictions, such as India and China, may in the future adversely affect our results of operations or limit our growth. Greater financial, research and development, operational, and marketing resources may allow our competitors to respond more quickly with new, alternative, or emerging technologies. Changes in the nature or extent of our customers’ requirements may render our offerings obsolete or non-competitive and could adversely affect our results of operations and financial condition. The demand for our offerings depends in part on our customers’ research and development and the clinical and market success of their products. Our business, financial condition, and results of operations may be harmed if our customers spend less on, or are less successful in, these activities. Our customers are engaged in research, development, production, and marketing of pharmaceutical, biotechnology, and consumer health products. The amount of customer spending on research, development, production, and marketing, as well as the outcomes of such research, development, and marketing activities, have a large impact on our sales and profitability, particularly the amount our customers choose to spend on our offerings. Our customers determine the amounts that they will spend based upon, among other things, available resources and their need to develop new products, which, in turn, is dependent upon a number of factors, including their competitors’ research, development, and production initiatives, and the anticipated market uptake, clinical, and reimbursement scenarios for specific products and therapeutic areas. In addition, consolidation in the industries in which our customers operate may have an impact on such spending as customers integrate acquired operations, including research and development departments and their budgets. Our customers finance their research and development spending from private and public sources. A reduction in spending by our customers could have a material adverse effect on our business, financial condition, and results of operations. If our customers are not successful in attaining or retaining product sales due to market conditions, reimbursement issues, or other factors, our results of operations may be materially adversely affected. We are subject to product and other liability risks that could adversely affect our results of operations, financial condition, liquidity, and cash flows. We are subject to potentially significant product liability and other liability risks that are inherent in the design, development, manufacture, and marketing of our offerings. We may be named as a defendant in product liability lawsuits, which may allege that our offerings have resulted or could result in an unsafe condition or injury to consumers. Such lawsuits could be costly to defend and could result in reduced sales, significant liabilities, and diversion of management’s time, attention, and resources. Even claims without merit could subject us to adverse publicity and require us to incur significant legal fees. Furthermore, product liability claims and lawsuits, regardless of their ultimate outcome, could have a material adverse effect on our business operations, financial condition, and reputation and on our ability to attract and retain customers. We have historically sought to manage this risk through the combination of product liability insurance and contractual indemnities and liability limitations in our agreements with customers and vendors. The availability of product liability insurance for companies in the pharmaceutical industry is generally more limited than insurance available to companies in other industries. Insurance carriers providing product liability insurance to those in the pharmaceutical and biotechnology industries generally limit the amount of available policy limits, require larger self-insured retentions, and exclude coverage for certain products and claims. 20 We maintain product liability insurance with annual aggregate limits in excess of $25.0 million. There can be no assurance that a successful product liability or other claim would be adequately covered by our applicable insurance policies or by any applicable contractual indemnity or liability limitations. Failure to comply with existing and future regulatory requirements could adversely affect our results of operations and financial condition or result in claims from customers. The healthcare industry is highly regulated. We, and our customers, are subject to various local, state, federal, national, and transnational laws and regulations, which include the operating, quality, and security standards of the FDA, the DEA, various state boards of pharmacy, state health departments, the DHHS, similar bodies of the E.U. and its member states, and other comparable agencies around the world, and, in the future, any change to such laws and regulations could adversely affect us. Among other rules affecting us, we are subject to laws and regulations concerning cGMP and drug safety. Our subsidiaries may be required to register for permits or licenses, and may be required to comply, with the laws and regulations of the FDA, the DEA, the DHHS, ex-U.S. agencies including the EMA, and various boards of pharmacy, health departments, or comparable agencies in various jurisdictions around the world, as well as certain accrediting bodies, depending upon the type of operations and locations of distribution and sale of the products manufactured or services provided by those subsidiaries. The manufacture, distribution, and marketing of our offerings are subject to extensive ongoing regulation by the FDA, the DEA, the EMA, and other equivalent local, state, federal, national, and transnational regulatory authorities. Failure by us or by our customers to comply with the requirements of these regulatory authorities could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture or distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, permits or registrations, including those relating to products or facilities. In addition, any such failure relating to the products or services we provide could expose us to contractual or product liability claims as well as claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients, which cost could be significant. Customers may also claim loss of profits due to lost or delayed sales, although our contracts generally place substantial limits on such claims. There can be no assurance that any such contractual limitation will be applicable, sufficient, or fully enforced in any given situation. In addition, any new offering or product classified as a pharmaceutical or medical device must undergo lengthy and rigorous clinical testing and other extensive, costly and time-consuming procedures mandated by the FDA, the EMA and other equivalent local, state, federal, national and transnational regulatory authorities in the jurisdictions that regulate our offerings and products. We or our customers may elect to delay or cancel anticipated regulatory submissions for current or proposed new offerings or products for any number of reasons. Although we believe that we comply in all material respects with applicable laws and regulations, there can be no assurance that a regulatory agency or tribunal would not reach a different conclusion concerning the compliance of our operations with applicable laws and regulations. In addition, there can be no assurance that we will be able to maintain or renew existing permits, licenses, or other regulatory approvals or obtain, without significant delay, future permits, licenses, or other approvals needed for the operation of our businesses. Any noncompliance by us or our customers with applicable law or regulation or the failure to maintain, renew, or obtain necessary permits and licenses could have an adverse effect on our results of operations and financial condition. Furthermore, loss of a permit, license, or other approval in any one portion of our business may have indirect consequences in another portion of our business if regulators or customers adjust their reviews of such other portion as a result or customers cease business with such other portion due to fears that such loss is a sign of broader concerns about our ability to deliver products or services of sufficient quality. Failure to provide quality offerings to our customers could have an adverse effect on our business and subject us to regulatory actions or costly litigation. Our results depend on our ability to execute and improve when necessary our quality management strategy and systems, and effectively train and maintain our employee base with respect to quality management. Quality management plays an essential role in determining and meeting customer requirements, preventing defects, and improving our offerings. While we have a network of quality systems throughout our business units and facilities that relate to the design, formulation, development, manufacturing, packaging, sterilization, handling, distribution, and labeling of the products we supply, quality and safety issues may occur with respect to any of our offerings. A quality or safety issue could have an adverse effect on our business, financial condition, and results of operations and may subject us to regulatory actions, including product recalls, product seizures, injunctions to halt manufacture or distribution, or restrictions on our operations; monetary fines; or other civil or criminal sanctions. In addition, such an issue could subject us to costly litigation, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical ingredients or other related losses, the cost of which could be significant. 21 The services and offerings we provide are highly exacting and complex, and, if we encounter problems providing the services or support required, our business could suffer. The offerings we provide are highly exacting and complex, particularly in our Softgel Technologies, Biologics and Specialty Drug Delivery, and Oral Drug Delivery segments, due in part to strict regulatory requirements. From time to time, problems may arise in connection with facility operations or during preparation or provision of an offering, in both cases for a variety of reasons including, but not limited to, equipment malfunction, sterility variances or failures, failure to follow specific protocols and procedures, problems with raw materials, environmental factors, and damage to, or loss of, manufacturing operations due to fire, flood, or similar causes. Such problems could affect production of a particular batch or series of batches, require the destruction of or otherwise result in the loss of product or materials used in the production of product, or could halt facility production altogether. This could, among other things, lead to increased costs, lost revenue, damage to customer relations, reimbursement to customers for lost active pharmaceutical ingredients or other related losses, time and expense spent investigating the cause, lost production time, and, depending on the cause, similar losses with respect to other batches or products. Production problems in our drug and biologic manufacturing operations could be particularly significant because the cost of raw materials is often higher than in our other businesses. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred. In addition, such risks may be greater at facilities that are new or going through significant expansion or renovation. Our global operations are subject to economic, political, and regulatory risks, including the risks of changing regulatory standards or changing interpretations of existing standards that could affect the profitability of our operations or require costly changes to our procedures. We conduct our operations in various regions of the world, including North America, South America, Europe, and the Asia-Pacific region. Global and regional economic and regulatory developments affect businesses such as ours in many ways. Our operations are subject to the effects of global and regional competition, including potential competition from manufacturers in low-cost jurisdictions such as India and China. Local jurisdiction risks include regulatory risks arising from local laws. Our global operations are also affected by local economic environments, including inflation and recession. Political changes, some of which may be disruptive, and related hostilities can interfere with our supply chain, our customers, and some or all of our activities in a particular location. While some of these risks can be hedged using derivatives or other financial instruments and some are insurable, such mitigating measures may be unavailable, costly, or unsuccessful. The exit of the U.K. from the European Union could have future adverse effects on our operations revenues, and costs, and therefore our profitability. In June 2016, the U.K. held a referendum in which a majority of voters approved the U.K.’s exit from the E.U., and the U.K. government has invoked its right to withdraw, effective in March 2019. This deadline for withdrawal has since been extended by agreement to October 2019. There is no immediate change in either the U.K. or the E.U. as a result of either action, but the U.K. government is now engaged in both internal and external discussions with affected parties and considering additional legislation regarding the changes that will result from the decision to exit. Five of our facilities, employing hundreds of workers, are located in the U.K., and these facilities, as well as others in our network, source goods, manufacture goods, and provide services from or intended for the U.K. These facilities operate within an existing framework of trade and human capital integration with the E.U. and, by extension, the other parts of the world, with which the E.U. has trade and immigration agreements. Furthermore, some of our facilities located in other E.U. member states ship materials to and from or otherwise engage in various business interactions with the U.K., including our U.K. facilities. Due to future changes in the U.K. resulting from an eventual exit, including potentially increased trade barriers, increased tariff rates, or custom duties, or in anticipation of such changes, our suppliers, customers, or employees may change their interactions with us, including changes in imports to or exports from the U.K., changes in the requested utilization of our facilities, both within and without the U.K., and changes in our relationships with our workforce in the U.K. To the extent that our facilities operate as part of a cross-border supply and distribution chain, their operations may also be negatively affected by a decrease in the cross-border mobility of goods and services. We cannot anticipate the nature of these changes, as they largely depend on factors outside our control, but the changes may result in adverse changes in our future operations, revenues, and costs, and therefore our future profitability. If we do not enhance our existing or introduce new technology or service offerings in a timely may become obsolete or uncompetitive over time, customers may not buy our offerings, and our revenue and profitability may decline. tt manner, our offerings The healthcare industry is characterized by rapid technological change. Demand for our offerings may change in ways we may not anticipate because of evolving industry standards as well as a result of evolving customer needs that are increasingly sophisticated and varied and the introduction by others of new offerings and technologies that provide alternatives to our offerings. Several of our higher margin offerings are based on proprietary technologies. To the extent that such technologies are 22 protected by patents, their related offerings may become subject to competition as the patents expire. Without the timely introduction of enhanced or new offerings and technologies, our offerings may become obsolete or uncompetitive over time, in which case our revenue and operating results would suffer. For example, if we are unable to respond to changes in the nature or extent of the technological or other needs of our pharmaceutical customers through enhancing our offerings, our competition may develop offerings that are more competitive than ours and we could find it more difficult to renew or expand existing agreements or obtain new agreements. Potential innovations intended to facilitate enhanced or new offerings generally will require a substantial investment before we can determine their commercial viability, and we may not have financial resources sufficient to fund all desired innovations. The success of enhanced or new offerings will depend on several factors, including our ability to: • • • • • • • properly anticipate and satisfy customer needs, including increasing demand for lower cost products; enhance, innovate, develop, and manufacture new offerings in an economical and timely manner; differentiate our offerings from competitors’ offerings; achieve positive clinical outcomes for our customers’ new products; meet safety requirements and other regulatory requirements of governmental agencies; obtain valid and enforceable intellectual property rights; and avoid infringing the proprietary rights of third parties. Even if we succeed in creating enhanced or new offerings from these innovations, they may still fail to result in commercially successful offerings or may not produce revenue in excess of the costs of development, and they may be rendered obsolete by changing customer preferences or the introduction by our competitors of offerings embodying new technologies or features. Finally, innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice, the need for regulatory clearance, and uncertainty over market access or government or third-party reimbursement. We and our customers depend on patents, copyrights, trademarks, know-how, trade secrets, and other forms of intellectual property protections, but these protections may not be adequate. We rely on a combination of know-how, trade secrets, patents, copyrights, trademarks, and other intellectual property laws, nondisclosure and other contractual provisions, and technical measures to protect many of our offerings and intangible assets. These proprietary rights are important to our ongoing operations. There can be no assurance that these protections will provide uniqueness or meaningful competitive differentiation in our offerings or otherwise be commercially valuable or that we will be successful in obtaining additional intellectual property or enforcing our intellectual property rights against unauthorized users. Our exclusive rights under certain of our offerings are protected by patents, some of which will expire in the near term. When patents covering an offering expire, loss of exclusivity may occur, which may force us to compete with third parties, thereby negatively affecting our revenue and profitability. We do not currently expect any material loss of revenue to occur as a result of the expiration of any patent currently protecting our business. Our proprietary rights may be invalidated, circumvented, or challenged. We may in the future be subject to proceedings seeking to oppose or limit the scope of our patent applications or issued patents. In addition, in the future, we may need to take legal actions to enforce our intellectual property rights, to protect our trade secrets, or to determine the validity or scope of the proprietary rights of others. Legal proceedings are inherently uncertain, and the outcome of such proceedings may be unfavorable to us. Any legal action regardless of outcome might result in substantial costs and diversion of resources and management attention. Although we use reasonable efforts to protect our proprietary and confidential information, there can be no assurance that our confidentiality and non-disclosure agreements will not be breached, our trade secrets will not otherwise become known by competitors, or that we will have adequate remedies in the event of unauthorized use or disclosure of proprietary information. Even if the validity and enforceability of our intellectual property is upheld, an adjudicator might construe our intellectual property not to cover the alleged infringement. In addition, intellectual property enforcement may be unavailable or practically ineffective in some countries. There can be no assurance that our competitors will not independently develop technologies that are substantially equivalent or superior to our technology or that third parties will not design around our intellectual property claims to produce competitive offerings. The use of our technology or similar technology by others could reduce or eliminate any competitive advantage we have developed, cause us to lose sales, or otherwise harm our business. We have applied in the United States and certain other countries for registration of a number of trademarks, service marks, and patents, some of which have been registered or issued, and also claim common law rights in various trademarks and 23 service marks. In the past, third parties have occasionally opposed our applications to register intellectual property, and there can be no assurance that they will not do so in the future. It is possible that in some cases we may be unable to obtain the registrations for trademarks, service marks, and patents for which we have applied, and a failure registrations in the United States or other countries could limit our ability to protect our trademarks and proprietary technologies and impede our marketing efforts in those jurisdictions. to obtain trademark and patent ff License agreements with third parties control our rights to use certain patents, software, and information technology systems and proprietary technologies owned by third parties, some of which are important to our business. Termination of these license agreements for any reason could result in the loss of our rights to this intellectual property, causing an adverse change in our operations or the inability to commercialize certain offerings. In addition, many of our branded pharmaceutical customers rely on patents to protect their products from generic competition. Because incentives exist in some countries, including the United States, for generic pharmaceutical companies to challenge these patents, pharmaceutical and biotechnology companies are under the ongoing threat of challenges to their patents. If the patents on which our customers rely were successfully challenged and, as a result, the affected products become subject to generic competition, the market for our customers’ products could be significantly adversely affected, which could have an adverse effect on our results of operations and financial condition. We attempt to mitigate these risks by making our offerings available to generic as well as branded manufacturers and distributors, but there can be no assurance that we will be successful in marketing these offerings. Our offerings or our customers’ products may infringe on the intellectual property rights of third parties. From time to time, third parties have asserted intellectual property infringement claims against us and our customers, and there can be no assurance that third parties will not assert infringement claims against either us or our customers in the future. While we believe that our offerings do not infringe in any material respect upon proprietary rights of other parties, and that meritorious defenses would exist with respect to any assertion to the contrary, there can be no assurance that we could successfully avoid being found to infringe on the proprietary rights of others. Patent applications in the United States and certain other countries are generally not publicly disclosed until the patent is issued or published, and we and our customers may not be aware of currently filed patent applications that relate to our or their products, offerings, or processes. If patents later issue on these applications, we or they may be found liable for subsequent infringement. There has been substantial litigation in the pharmaceutical and biotechnology industries with respect to the manufacture, use, and sale of products that are the subject of conflicting patent rights. Any claim that our offerings or processes infringe third-party intellectual property rights (including claims arising through our contractual indemnification of our customers), regardless of the claim’s merit or resolution, could be costly and may divert the efforts and attention of our management and technical personnel. We may not prevail against any such claim given the complex technical issues and inherent uncertainties in intellectual property matters. If any such claim results in an adverse outcome, we could, among other things, be required to: • • • • • • pay substantial damages (potentially including treble damages in the United States); cease the manufacture, use, or sale of the infringing offerings or processes; discontinue the use of the infringing technology; expend significant resources to develop non-infringing technology; license technology from the third party claiming infringement, which license may not be available on commercially reasonable terms, or may not be available at all; and lose the opportunity to license our technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual property against others. In addition, our customers’ products may be subject to claims of intellectual property infringement and such claims could materially affect our business if their products cease to be manufactured or they have to discontinue the use of the infringing technology. Any of the foregoing could affect our ability to compete or have a material adverse effect on our business, financial condition, and results of operations. 24 Our future results of operations are subject to fluctuations in the costs, availability, and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients, purchased components, and raw materials. We depend on various active pharmaceutical ingredients, components, compounds, raw materials, and energy supplied primarily by others for our offerings. This includes, but is not limited to, gelatin, starch, iota carrageenan, petroleum-based products and resin. Also, our customers frequently provide to us their active pharmaceutical or biologic ingredient for formulation or incorporation in the finished product. It is possible that any of our or our customers’ supplier relationships could be interrupted due to changing regulatory requirements, import or export restrictions, natural disasters, international supply disruptions caused by pandemics, geopolitical issues, operational or quality issues at the suppliers’ facilities, and other events, or could be terminated in the future. For example, gelatin is a critical component in most of the products produced in our Softgel Technologies segment. Gelatin is available from only a limited number of sources. In addition, much of the gelatin we use is bovine-derived. Past concerns of contamination from bovine spongiform encephalopathy, or BSE, have narrowed the number of possible sources of particular types of gelatin. If there were a future disruption in the supply of gelatin from any one or more key suppliers, we may not be able to obtain an adequate alternative supply from our other suppliers. If future restrictions were to emerge on the use of bovine-derived gelatin due to concerns of contamination from BSE or otherwise, any such restriction could hinder our ability to timely supply our customers with products and the use of alternative non-bovine-derived gelatin could be subject to lengthy formulation, testing, and regulatory approval. ff Any sustained interruption in our receipt of adequate supplies could have an adverse effect on us. In addition, while we have processes intended to reduce volatility in component and material pricing, we may not be able to successfully manage price fluctuations, and future price fluctuations or shortages may have an adverse effect on our results of operations. Changes in market access or healthcare reimbursement for, or public sentiment towards our customers’ products in the United States or internationally, or other changes in applicable policies regarding the healthcare industry, including possible changes to the Affordable Care Act (the ““ACAA““ results of operations and financial condition by affecting demand for our offerings. ii hett United States, could adversely affect our ””) i)”” n t The healthcare industry has changed significantly over time, and we expect the industry to continue to evolve. Some of these changes, such as ongoing healthcare reform, adverse changes in governmental or private funding of healthcare products and services, legislation or regulations governing patient access to care and privacy, or the delivery, pricing, or reimbursement approval of pharmaceuticals and healthcare services or mandated benefits, may cause healthcare industry participants to change the amount of our offerings that they purchase or the price they are willing to pay for these offerings. In particular, there is significant uncertainty about the likelihood of changes to the ACA and healthcare laws in general in the United States, including future legislation that may affect or put a cap on future pricing of pharmaceutical and biotechnology products. While we are unable to predict the likelihood of changes to the ACA, any substantial revision of this or other healthcare legislation could have a material adverse effect on the demand for our customers’ products, which in turn could have a negative impact on our results of operations, financial condition, or business. Changes in the healthcare industry’s pricing, selling, inventory, distribution, or supply policies or practices, or in public or government sentiment for the industry as a whole, could also significantly reduce our revenue and results of operations. In particular, volatility in individual product demand may result from changes in public or private payer reimbursement or coverage. As a global gg currencies could have a material adverse effect on our financial performance and results of operations. enterprise, fluctuations in the exchange rate of the U.S. dollar, our reporting currency, against other As a company with significant operations outside of the United States, certain revenues, costs, assets, and liabilities, including our euro-denominated 4.75% Senior Notes due 2024 and a portion of our senior secured credit facilities, are denominated in currencies other than the U.S. dollar, which is the currency that we use to report our financial results. As a result, changes in the exchange rates of these or any other applicable currencies to the U.S. dollar will affect our revenues, earnings and cash flows. There has been, and may continue to be, volatility in currency exchange rates affecting the various currencies in which we do business, including as a result of the U.K.’s referendum to exit from the E.U. Such volatility and other changes in exchange rates could result in unrealized and realized exchange losses, despite any effort we may undertake to manage or mitigate our exposure to fluctuations in the values of various currencies. Tax legislative or regulatory initiatives, new interpretations or developments concerning existing tax laws, or challenges to our tax positions could adversely affect our results of operations and financial condition. We are a large multinational corporation with operations in the United States and several international jurisdictions, including Canada, South America, Europe, and the Asia-Pacific region. As such, we are subject to the tax laws and regulations 25 of the U.S. federal, state, and local governments and of many jurisdictions outside of the U.S. From time to time, various legislative initiatives may be proposed that could adversely affect our tax positions, and existing legislation, such as the 2017 U.S. Tax Cuts and Jobs Act (the “2017 Tax bj can be no assurance that our effective tax rate or tax payments will not be adversely affected by these initiatives. In addition, U.S. federal, state, local, and foreign tax laws and regulations are extremely complex and subject to varying interpretations. There can be no assurance that relevant tax authorities will not challenge our tax positions or that we would succeed in defending against any such challenge. regulatory hchanges or new iinterpretations subject to ddi i )Act”), may bbe additional l l ions. There Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. l We have in the past sustained net operating losses that we may use to reduce future taxable income. Utilization of our net operating loss carryforwards may be subject to a substantial limitation under Section 382 of the Internal Revenue Code of 1986, “Internal Revenue Code”),” and comparable provisions of state, local, and foreign tax laws due to changes in as amended (the ownership of our company that may occur in the future. Under Section 382 of the Code and comparable provisions of state, local, and foreign tax laws, if a corporation undergoes an ow“ nership change, g” enerally defined as a greater than 50% change by value in its equity ownership over a three-year period, the corporation’s ability to carry forward its pre-change net operating losses to reduce its post-change income may be limited. We may experience ownership changes in the future as a result of future changes in our stock ownership. As a result, our ability to use our pre-change net operating loss carryforwards to reduce U.S. federal and state taxable income we produce in the future years may be subject to limitations, which could result in increased future tax liability to us. Changes to the estimated future profitability of the business may require that we establish an additional valuation allowance against all or some portion of our net U.S. deferred tax assets. We have deferred tax assets for net operating loss carryforwards and other temporary differences. We currently do not maintain a valuation allowance for a portion of our U.S. net deferred tax assets. We may experience, in the future, a decline in U.S. federal taxable income, resulting from a decline in profitability of our U.S. operations, an increased level of debt in the U.S., or other factors. In assessing our ability to realize our U.S. deferred tax assets, we may conclude that it is more likely than not that some portion or all of our U.S. deferred tax assets will not be realized. As a result, we may be required to record an additional valuation allowance against our U.S. deferred tax assets, which could adversely affect our effective income tax rate and therefore our financial results. We depend on key personnel. We depend on our executive officers and other key personnel, including our technical personnel, to operate and grow our business and to develop new and enhanced offerings and technologies. The loss of any of these officers or other key personnel ff or a failure to attract and retain suitably skilled technical personnel could adversely affect our operations. In addition to our executive officers, we rely on approximately 150 senior employees to lead and direct our business. Our senior leadership team ( SLT“ directors who hold critical positions and possess specialized talents and capabilities that give us a competitive advantage in the market. The members of the SLT hold positions such as facility general manager, vice president/general manager of business unit commercial development, vice president of quality and regulatory activities, and vice president-finance. ”)” is comprised of our and our subsidiaries’ executive officers and other vice presidents and With respect to our technical talent, we have more than 2,400 scientists and technicians whose areas of expertise and specialization cover subjects such as advanced delivery, drug and biologics formulation and manufacturing. Many of our sites and laboratories are located in competitive labor markets like those in which our Morrisville, North Carolina; Brussels, Belgium; Woodstock, Illinois; Madison, Wisconsin; Emeryville; California, Bloomington, Indiana; Nottingham, U.K.; and Schorndorf, Germany facilities are located. Global and regional competitors and, in some cases, customers and suppliers compete for the same skills and talent as we do. We use advanced information and communication systems to run our operations, compile and analyze financial and operational data, and communicate among our employees, customers, and counter-parties, and the risks generally associated with information and communications systems could adversely affect our results of operations. We are continuously working to install new, and upgrade existing, systems and provide employee awareness training around phishing, malware, and other cyber security risks to enhance the protections available to us, but such protections may be inadequate to address malicious attacks or inadvertent compromises of data security. We rely on information systems in our business to obtain, process, analyze and manage data to: • ff facilita te the manufacture and distribution of thousands of inventory items in, to and from our facilities; 26 • • • • • • • • receive, process and ship orders on a timely basis; manage the accurate billing and collections for more than one thousand customers; create, compile, and retain testing and other product-, manufacturing-, or facility-related data necessary for meeting our and our customers’ regulatory obligations. manage the accurate accounting and payment for thousands of vendors; schedule and operate our global network of development, manufacturing, and packaging facilities; document various aspects of our activities, including the agreements we make with suppliers and customers; compile financial and other operational data into reports necessary to manage our business and comply with various regulatory or contractual obligations, including obligations under our bank loans and other indebtedness, the federal securities laws, the Code, and other applicable state, local, and ex-U.S. tax laws; and communicate among our nearly 12,300 employees spread across thirty-nine facilities over five continents. We deploy defenses against cyber-attack and work to secure the integrity of our data systems using techniques, hardware, and software typical of companies of our size and scope. Despite our security measures, however, our information technology and infrastructure may be vulnerable to attacks by increasingly sophisticated intruders or others who try to cause harm to or interfere with our normal use of our systems. They are also susceptible to breach due to employee error, malfeasance, or other disruptions. Our results of operations could be adversely affected if these systems are interrupted or damaged or fail for any extended period. We engage from time to time in acquisitions and other transactions that may complement or expand our business or in divestments of non-strategic businesses or assets. We may not be able to complete such transactions, and such transactions, if executed, pose significant risks, including risks relating to our ability to successfully and efficiently integrate acquisitions or execute on dispositions and realize anticipated benefits therefrom. The failure to execute or realize the full benefits from any such transaction could have a negative effect on our operations. Our future success may depend in part on opportunities to buy or otherwise acquire rights to other businesses or technologies, enter into joint ventures or otherwise enter into strategic arrangements with business partners that could complement, enhance, or expand our current business or offerings and services or that might otherwise offer us growth opportunities, or divest assets or an ongoing business. We may face competition from other companies in pursuing acquisitions and similar transactions in the pharmaceutical and biotechnology industry. Our ability to complete transactions may also be limited by applicable antitrust and trade laws and regulations in the U.S. and other jurisdictions in which we or the operations or assets we seek to acquire carry on business. To the extent that we are successful in making acquisitions, we expend substantial amounts of cash, incur debt, or assume loss-making divisions as consideration. We or the purchaser of a divested asset or business may not be able to complete a desired transaction for any number of reasons, including a failure to secure financing. ff Any acquisition that we are able to identify and complete may involve a number of risks, including, but not limited to, the diversion of management’s attention to integrate the acquired businesses or joint ventures, the possible adverse effects on our operating results during the integration process, the potential loss of customers or employees in connection with the acquisition, delays or reduction in realizing expected synergies, unexpected liabilities and our potential inability to achieve our intended objectives for the transaction. In addition, we may be unable to maintain uniform standards, controls, procedures and policies, which may lead to operational inefficiencies. To the extent that we are not successful in completing desired divestitures, as such may be determined by future strategic plans and business performance, we may have to expend substantial amounts of cash, incur debt, or continue to absorb the costs of loss-making or under-performing divisions. Any divestiture, whether we are able to complete it or not, may involve a number of risks, including diversion of management’s attention, a negative impact on our customer relationships, costs associated with maintaining the business of the targeted divestiture during the disposition process, and the costs of closing and disposing of the affected business or transferring remaining portions of the operations of the business to other facilities. ew and still-developing mode of treatment, dependent on cutting-edge technologies, and Gene therapy is a relatively nll our customers’ gene therapies may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion, continuing research, or increased regulatory scrutiny of gene therapy and its financial cost may damage public perception of the safety, utility, or efficacy of gene therapies and harm our customers’ ability to conduct their business or obtain regulatory approvals for their gene therapy products, and thereby have an indirect, adverse effect on our gene therapy offerings. 27 Gene therapy remains a relatively new means for treating disease and other medical conditions, with only a fewff gene therapies approved to date in the U.S., the E.U., or elsewhere. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In addition, ethical, social, legal, and cost-benefit concerns about gene therapy, genetic testing, and genetic research could result in additional regulations or limitations or even outright prohibitions on certain gene therapies or gene-therapy-related products. Various regulatory and legislative bodies have expressed an interest in, or have taken steps towards, further regulation of various biotechnologies, including gene therapies. More restrictive regulations or claims that certain gene therapies are unsafe or pose a hazard could reduce our customers’ use of our services. We can provide no assurance whether legislative changes will be enacted, regulations, policies, or guidance changed, or interpretations of existing strictures by agencies or courts changed, or what the impact of such changes, if any, may be. We are subject to environmental, health, and safety laws and regulations, which could increase our costs and restrict our operations in the future. Our operations are subject to a variety of environmental, health, and safety laws and regulations, including those of the EPA and the U.S. Occupational Safety & Health Administration and equivalent local, state, national, and transnational regulatory agencies in each of the jurisdictions in which we operate. These laws and regulations govern, among other things, air emissions, wastewater discharges, the use, handling, and disposal of hazardous substances and wastes, soil and groundwater contamination, and employee health and safety. Any failure by us to comply with environmental, health, and safety requirements could result in the limitation or suspension of production or subject us to monetary fines, civil or criminal sanctions, or other future liabilities in excess of our reserves. We are also subject to laws and regulations governing the destruction and disposal of raw materials and non-compliant products, the handling of regulated material included in our offerings, and the disposal of our products or their components at the end of their useful lives. In addition, compliance with environmental, health, and safety requirements could restrict our ability to expand our facilities or require us to acquire costly environmental or safety control equipment, incur other significant expenses, or modify our manufacturing processes. Our manufacturing facilities may use, in varying degrees, hazardous substances in their processes. These substances include, among others, chlorinated solvents, and in the past chlorinated solvents were used at one or more of our facilities, including a number we no longer own or operate. As at our current facilities, contamination at such formerly owned or operated properties can result and has resulted in liability to us. In the event of the discovery of new or previously unknown contamination either at our facilities or at third-party locations, including facilities we formerly owned or operated, the issuance of additional requirements with respect to existing contamination, or the imposition of other cleanup obligations for which we are responsible, we may be required to take additional, unplanned remedial measures for which we have not recorded reserves. We are conducting monitoring and cleanup of contamination at certain facilities currently or formerly owned or operated by us, and such activities may result in unanticipated costs or management distraction. We are subject to labor and employment laws and regulations, which could increase our costs and restrict our operations in the future. We employ nearly 12,300 individuals worldwide, including approximately 6,800 employees in North America, 3,900 in Europe, 900 in South America, and 700 in the Asia-Pacific region. Certain employees at one of our North American facilities are represented by a labor organization, and national works councils or labor organizations are active at all of our European facilities and certain of our other facilities consistent with local labor environments and laws. Our management believes that our employee relations are satisfactory. However, further organizing activities, collective bargaining, or changes in the regulatory framework for employment may increase our employment-related costs or may result in work stoppages or other labor disruptions. Moreover, as employers are subject to various employment-related claims, such as individual and class actions relating to alleged employment discrimination and wage-hour and labor standards issues, such actions, if brought against us and successful in whole or in part, may affect our ability to compete or have a material adverse effect on our business, financial condition, and results of operations. Certain of our pension plans are underfunded, and additional cash contributions we may make to increase the funding level will reduce the cash available for our business or to discharge our financial obligations. Certain of our current and former employees in the U.S., the U.K., Germany, France, Japan, Belgium, Switzerland, and Australia are participants in defined benefit pension plans that we sponsor. As of June 30, 2019, the underfunded amount of our pension plans on a worldwide basis was $77.4 million, primarily related to our pension plans in the U.K. and Germany. In addition, we have an estimated obligation of $38.8 million, as of June 30, 2019, related to our withdrawal from a multiemployer pension plan in which we formerly participated. In general, the amount of future contributions to the underfunded plans will depend upon asset returns, applicable actuarial assumptions, prevailing and expected interest rates, and other factors, and, as a result, the amount we may be required to contribute in the future to fund the obligations associated with such plans may vary. 28 Such cash contributions to the plans will reduce the cash available for our business, including the funds available to pursue strategic growth initiatives or the payment of interest expense on our indebtedness. Risks Relating to Our Indebtedness Our substantial leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or in our industry or to deploy capital to grow our business, expose us to interest-rate risk to the extent of our variable-rate debt, or prevent us from meeting our obligations under our indebtedness. We are highly leveraged. As of June 30, 2019, we had $2,959.3 million (U.S. dollar equivalent) of total indebtedness outstanding, consisting of $1,283 million (U.S. dollar equivalent) of secured indebtedness under our senior secured credit facilities; $1,365 million of senior unsecured indebtedness, including $500.0 million aggregate principal amount of Senior Notes due 2027 (the “USD 2027 Notes”), $450.0 million aggregate principal amount of Senior Notes due 2026 (the “USD 2026 Notes” and, together with the USD 2027 Notes, the “USD Notes”), €380.0 million aggregate principal amount of Senior Notes due 2024 (the “Euro Notes” and, together with the USD Notes, the “Senior Notes”); $143.9 million representing the fair value of the remaining deferred purchase consideration related to the acquisition of Catalent Indiana, and $167.3 million of capital lease and other obligations. In addition, we had $543.4 million of unutilized capacity and $6.6 million of outstanding letters of credit under our $550.0 million secured revolving credit facility, which is part of our senior secured credit facilities (the “Revolving Credit Facility”). Our high degree of leverage could have important consequences for us, including: • • • • • • • increasing our vulnerability to adverse economic, industry, or competitive developments; exposing us to the risk of increased interest rates because certain of our borrowings, including borrowings under our senior secured credit facilities, are at variable rates of interest; exposing us to the risk of fluctuations in exchange rates because certain of our borrowings, including the Euro Notes and certain borrowings under our senior secured credit facilities, are denominated in euros; making it more difficult for us to satisfy our obligations with respect to our indebtedness, and any failure to comply with the obligations of any of our debt instruments, including restrictive covenants and borrowing conditions, could result in one or more events of default under the agreements governing such indebtedness; restricting us from making strategic acquisitions or capital investments or causing us to make non-strategic divestitures; limiting our ability to obtain additional financing for working capital, capital expenditures, product development, debt service requirements, acquisitions, and general corporate or other purposes; and limiting our flexibility in planning for, or reacting to, changes in our business or market conditions and placing us at a competitive disadvantage compared to our competitors who are less highly leveraged and who, therefore, may be able to take advantage of opportunities that our leverage prevents us from exploiting. Our total interest expense, net was $110.9 million, $111.4 million, and $90.1 million for fiscal years 2019, 2018, and 2017, respectively. After taking into consideration our ratio of fixed-to-floating-rate debt, and assuming that our revolving credit facility is undrawn and LIBOR is above any applicable minimum floor, each change of 100 basis points in interest rates would result in a change of approximately $9.5 million in annual interest expense on the indebtedness under our senior secured credit facilities. Despite our high indebtedness level, we and our subsidiaries will still be able to incur significant additional debt, which could further exacerbate the risks associated with our substantial indebtedness. We and our subsidiaries may be able to incur substantial additional indebtedness in the future. Although the agreements governing our indebtedness contain restrictions on the incurrence of additional indebtedness, these restrictions are subject to a number of significant qualifications and exceptions, and, under certain circumstances, the amount of indebtedness that we may incur while remaining in compliance with these restrictions could be substantial. As of June 30, 2019, we would have had approximately $543.4 million available to us for borrowing, subject to certain conditions, under our Revolving Credit Facility. If new debt is added to our subsidiaries’ existing debt levels, the risks associated with debt we currently face would increase. 29 Our debt agreements contain restrictions that limit our flexibility i o tt n oii perating our business. The agreements governing our outstanding indebtedness contain various covenants that limit our ability to engage in specified types of transactions. These covenants limit the ability of Operating Company and those of its subsidiaries to which these covenants apply (which Operating Company’s Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended, the “Credit subsidiaries”)” to, among other things: Agreement )”) calls “restricted “ “ • • • • • • • • • • incur additional indebtedness and issue certain preferred stock; pay certain dividends on, repurchase, or make distributions in respect of capital stock or make other restricted payments; pay distributions from restricted subsidiaries; issue or sell capital stock of restricted subsidiaries; guarantee certain indebtedness; make certain investments; sell or exchange certain assets; enter into transactions with affiliates; create certain liens; and consolidate, merge, or transfer all or substantially all of our assets and the assets of our subsidiaries on a consolidated basis. A breach of any of these covenants could result in a default under one or more of these agreements, including as a result of cross-default provisions, and, in the case of our Revolving Credit Facility, permit the lenders to cease making loans to us. Despite the limitations in our debt agreements, we retain the ability to take certain actions that may interfere with our ability timely to pay our substantial indebtedness. The covenants in the Credit Agreement and the indentures governing our Senior Notes contain various exceptions to the limitations they otherwise impose on our ability and the ability of our restricted subsidiaries to take the various actions described in the prior risk factor. For example, if the notes have investment-grade ratings and we are not in default under these agreements, certain of these covenants will not apply, including the covenants restricting certain dividends and other payments, the covenants concerning the incurrence of indebtedness, and the covenants limiting guarantees of indebtedness by our restricted subsidiaries. In addition, the covenants restricting dividends and other distributions by us, purchases or redemption of certain equity securities, and prepayment, redemption, or repurchase of any subordinated indebtedness are subject to various exceptions. We may use derivative financial instruments to reduce our exposure to market risks from changes in interest rates on our variable-rate indebtedness or changes in currency exchange rates, and any such instrument may expose us to risks related to counterparty credit worthiness or non-performance of these instruments. We may enter into interest-rate swap agreements, currency swap agreements, or other hedging transactions in an attempt to limit our exposure to adverse changes in variable interest rates and currency exchange rates. Such instruments may result in economic losses if, for example, prevailing interest rates decline to a point lower than any applicable fixed-rate commitment. Any such swap will expose us to credit-related risks that, if realized, could adversely affect our results of operations or financial condition. Risks Relating to Our Series A Preferred Stock. The issuance of shares of our Series A Preferred Stock, dilutes the ownership of such holders, and may adversely affect the market price of our Common Stock. Stock reduces the relative voting power of holders of our Common PP On May 16, 2019, we filed with the Delaware Secretary of State a certificate of designation of preferences, rights, and limitations (the “Certificate of Designation”) with respect to 1,000,000 shares of our preferred stock, par value $0.01 per share, designating such shares as our Series A Convertible Preferred Stock (the “Series A Preferred Stock”), and, on May 17, 2019, we completed the sale of 650,000 shares of our Series A Preferred Stock to affiliates (the “Preferred Stock Investors”) of Leonard Green & Partners, L.P. pursuant to an equity commitment and investment agreement, dated as of April 14, 2019, between us and certain of the Preferred Stock Investors (the “Investment Agreement”). As of August 22, 2019, these shares represented approximately 8.3% of our outstanding Common Stock, on an as-converted basis. Holders of Series A Preferred 30 Stock are entitled to a cumulative dividend at the rate of 5.0% per annum, subject to adjustment and payable quarterly in arrears. See Note 13 to the Consolidated Financial Statements. The dividends are to be paid in cash or in-kind through an increase in the stated value of each share of Series A Preferred Stock. Such holders are also entitled to receive, on an as- converted basis, whatever holders of each share of Common Stock may be entitled to receive as a result of any declaration of a dividend on the Common Stock. As holders of our Series A Preferred Stock are entitled to vote, on an as-converted basis, together with holders of our Common Stock on all matters submitted to a vote of the holders of our Common Stock, the issuance of the Series A Preferred Stock to the Preferred Stock Investors, and any subsequent increase in the stated value of those shares by a payment-in-kind of the dividends payable thereon, effectively reduces the relative voting power of the holders of our Common Stock. dUnder ivarious icircumstance ds d fi d efined iin hthe Certificate off D i esignation, ( )(a) h ldholders fof hshares fof our ifi i iSeries A P f i k k i l d Stock. Any k entitled to convert Stock, (b)(b) we may hsuch hshares to hshares fof our Common Stock may bbe convert our Common iSeries A P f hshares fof Stock, k our Common fof hthe iSeries A P f Stock Investors customary k Common Stock i facilitate hthe ili f Common Common trading di d issued upon any hsuch resale fof l available ffor il bl public bli iprice fof our Common hsuch hshares to hshares fof our Common k conversion fof hshares fof hthe d referred dand any referred d i Stock ffor hshares fof our Common k public bli lsale iin hthe kmarket ld k adversely ffaffect l could d Stock i i Stock, or ( )(c) we may iSeries A P f referred d Stock k fof hshares fof our Common ili prevailing fof h i i d redemption fof hthe kmarket, public bli lSales bby hthe perception hthat i require llall h ldholders fof election, i l Stock or k Stock to hshares fof our Common i ownership iinterest hi i fof d conversion or i issuable upon bl k Stock i granted hthe Stock. We d k iprices fof our Common dand any hshare fof our referred iSeries A P f Stock k d registration i hrights i k Stock. hThese referred d number b ldwould iincrease hthe number ubstantial b i l aterial dadverse ffeffect on hthe could hhave a m i l d existing h ldholders fof redemption i Preferred f d ldwould fof hshares fof our fof hshares fof our iSeries A P f resale l hsuch Stock Investors fof a s b k conversion or securities iinto hthe i i public trading. di bli kmarket, or hthe Stock. k registration i hrights iin respect i dredeem llall k ldwould dildilute hthe dand any f Preferred d lsales hsuch kmarket their hshares fof k Stock Stock iin hthe k hsuch hshares ffor, at our i hmight occur, ld k i referred d hsuch hshares to hcash or hshares fof redemption fof i The Preferred Stock Investors may exercise significant influence over us, including through their ability to designate, and the ability of the holders of Series A Preferred Stock to elect, a member of our board of directors. PP As of August 22, 2019, the outstanding shares of our Series A Preferred Stock represented approximately 8.3% of our outstanding Common Stock, on an as-converted basis. In addition, the terms of the Series A Preferred Stock grant the Preferred Stock Investors consent rights with respect to certain actions by us, including: • • • amending our organizational documents in a manner that would have an adverse effect on the Series A Preferred Stock; issuing securities that are senior to, or equal in priority with, the Series A Preferred Stock; and incurrence of indebtedness to the extent such incurrence would cause our Total Leverage Ratio for any applicable Test Period to exceed 6:00:1:00, determined on a Pro-Forma Basis (as such terms are defined in our Credit Agreement). As a result, the Preferred Stock Investors have the ability to influence the outcome of certain matters affecting our governance and capitalization. The sponsors of the Preferred Stock Investors are in the business of making or advising on investments in companies, including businesses that may directly or indirectly compete with certain portions of our business, and they may have interests that diverge from, or even conflict with, those of our other shareholders. They may also pursue acquisition opportunities that may be complementary to our business, and, as a result, those acquisition opportunities may not be available to us. In addition, the terms of that certain stockholders’ agreement we entered into with the Preferred Stock Investors (the “Stockholders’ Agreement”) and of the Certificate of Designation grant the Preferred Stock Investors certain rights to designate a director to serve on our board of directors, which director is elected by a separate class vote of the holders of shares of the Series A Preferred Stock. For so long as the Preferred Stock Investors beneficially own shares of Series A Preferred Stock (or shares of our Common Stock issued upon conversion of Series A Preferred Stock) that have an aggregate value of $250.0 million, the Preferred Stock Investors have the right to designate one director for election to our board of directors. In addition, for so long as the Preferred Stock Investors beneficially own shares of Series A Preferred Stock (or shares of our Common Stock issued upon conversion of Series A Preferred Stock) that have an aggregate value of $500.0 million, the Preferred Stock Investors have the right to designate one observer to our board of directors. The director designated by the Preferred Stock Investors is entitled to serve on committees of our board of directors, subject to applicable law and stock exchange rules. Notwithstanding the fact that all directors will be subject to fiduciary duties to us and to applicable law, the interests of the director designated by the Preferred Stock Investors may differ from the interests of our security holders as a whole or of our other directors. 31 PP Our Series A Preferred Stock has rights, preferences, and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock, which could adversely affect our liquidity and financial condition, and may result in the interests of the Preferred Stock Investors differing from holders of our Common Stock. As holders of Series A Preferred Stock, the Preferred Stock Investors have the right under the Certificate of Designation to receive a liquidation preference entitling them to be paid out of our assets available for distribution to stockholders before any payment may be made to holders of any other class or series of capital stock, an amount equal to the greater of (a) the stated value of their preferred shares plus all accrued and unpaid dividends or (b) the amount that such holders would have been entitled to receive upon our liquidation, dissolution, and winding up if all outstanding shares of Series A Preferred Stock had been converted into shares of our Common Stock immediately prior to such liquidation, dissolution, or winding up. In addition, regular dividends on the Series A Preferred Stock accrue and are cumulative at the rate of 5.0% per annum, subject to adjustment and payable quarterly in arrears. The dividend on each share of Series A Preferred Stock is to be paid in cash or in-kind through an increase in the stated value of such share. We are also required to redeem all shares of Series A Preferred Stock upon certain change of control events at a value per share equal to the greater of (a) the sum of (1) the product of (A) the applicable Mandatory Redemption Multiplier (as defined in the Certificate of Designation), multiplied by (B) the stated value of each such share, plus (2) all accrued but unpaid dividends on such share, and (b) the consideration holders would have received if they had converted their shares of Series A Preferred Stock into shares of Common Stock immediately prior to the change of control event. These dividend and share redemption obligations could adversely affect our liquidity and reduce the amount of cash available for working capital, capital expenditures, growth opportunities, acquisitions, and other general corporate purposes. Our obligations to the holders of Series A Preferred Stock could also limit our ability to obtain additional financing or increase our borrowing costs, which could have an adverse effect on our financial condition. The preferential rights could also result in divergent interests between the Preferred Stock Investors and holders of shares of our Common Stock. Risks Relating to Ownership of Our Common Stock Our stock price may change significantly, and a holder of shares of our Common Stock may not be able to resell such shares at or above the price such stockholder paid, or at all, and could lose all or part of such investment as a result. The trading price of our Common Stock has been and continues to be volatile. Since shares of our Common Stock were offered for sale in our initial public offering on July 31, 2014 through June 30, 2019, our Common Stock price as quoted on the NYSE ranged from $18.92 to $54.91. The trading price of our Common Stock may be adversely affected due to a number of factors, such as those listed above in “Risks Relating to Our Business and Our Industry a” nd the following: “ • • • • • • • • • • • • • results of operations that vary from the expectations of securities analysts or investors; results of operations that vary from those of our competitors; changes in expectations as to our future financial performance, including financial estimates and investment recommendations by securities analysts or investors; declines in the market prices of stocks generally, or those of pharmaceutical or other healthcare companies; strategic actions by us or our competitors; announcements by us or our competitors of significant contracts, new products, acquisitions, joint marketing relationships, joint ventures, other strategic relationships, or capital commitments; changes in general economic or market conditions or trends in our industry or markets; changes in business or regulatory conditions or regulatory actions taken with respect to our business or the business of any of our competitors or customers; ff future sales of our Common Stock or other securities; investor perceptions of the investment opportunity associated with our Common Stock relative to other investment alternatives; the public response to press releases or other public announcements by us or third parties, including our filings with or information furnished to the SEC; announcements relating to or developments in litigation; guidance, if any, that we provide to the public, any change in this guidance, or any failure to meet this guidance; 32 • • • the availability of an active trading market for our Common Stock; changes in the accounting principles we use to record our or our application of these principles to our business; and other events or factors, including those resulting from natural disasters, hostilities, acts of terrorism, geopolitical activity, or responses to these events. Broad market and industry fluctuations may adversely affect the market price of our Common Stock, regardless of our actual operating performance. In addition, price volatility may be greater if the public float or trading volume of our Common Stock is low, and the amount of public float on any given day can vary depending on the individual actions of our stockholders. Following periods of market volatility, stockholders have been known to institute securities class action litigation in order to recover their resulting losses. If we become involved in securities litigation, it could have a substantial cost and divert resources and the attention of senior management from our business regardless of the outcome of such litigation. Because we have no plan to pay cash dividends on our Common Stock for the foreseeable future, a stockholder may not receive any return on an investment in our Common Stock unless it is sold for a net price greater than that which was paid for it. We currently i lplan to pay any d intend to hcash di id d retain ffuture dividend on our Common earnings, ifif any, ffor ffuture Stock ffor hthe f operations, i foreseeable ffuture. Our b bl expansion, dand d bdebt repayment board fof didirectors hhas lalso d k l i i i dand hhave no buyback program hthat we may use ffrom itime to itime to fof our Common ividend iin respect d h dand i i d board fof didirectors. Our b hsuch ffactors as hthey may ddeem lrelevant, i available i dand current il bl operations, our requirements, capital l i current ktock b b k authorized a s h i d d i i decision to pay da di id d di discretion fof our b di id d dividend, results fof l i hcash, our ffuture di id d dividends bby us to our h ldholders fof hshares fof our Common di id d dividends iis li fof any ffuture i d b d any return on applicable li bl limited bby covenants iin hthe agreements indebtedness we or our hsuch iinvestment commission or i acquisition or i i i hother costs fof lunless iit iis b idi hcash i d dand i i lsale. i Stock, k including l di timing fof any dand hthe amount board fof didirectors may ktake iinto account, hwhen d idi i economic di i l general dand conditions, our fi possible ffuture l ibl hcash dneeds, anticipat ded i i li dand i restrictions i i regulatory l dand egal, tax, l subsidiaries to us. In ddi i b idi indebtedness outstanding i d b d di esult, ha h ldolder governing our i l dand contractual l, l l Stock or bby our fof a shhare fof our Common k i dividend, hsuch di id d deciding h hwhether or hhow to pay a financial dand i l i condition di i alternative d ldeployments fof our fof implicatiions on hthe payment dand may bbe li ability to pay addition, our bili limited bby covenants i d receive i Stock may not k taking iinto account any ldsold ffor a p irice greater hthan hthat hi hwhich was idpaid ffor iit, ki subsidiaries iincur. As a r purchase hshares fof our Common k Stock. Any ffuture illwill bbe at hthe lsole If securities analysts do not publish research or reports about our business or if they downgrade our stock or our sector, our stock price and trading volume could decline. The trading market for our Common Stock has been affected in part by the research and reports that industry and financial analysts publish about us or our business. We do not control these analysts. Furthermore, if one or more of the analysts who cover us downgrade our stock or our industry, change their views regarding the stock of any of our competitors or other healthcare sector companies, or publish inaccurate or unfavorable research about our business, the market price of our Common Stock could decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline. Future sales, or the perception of future the market price for our Common Stock to decline. ff sales, of our Common Stock, by us or our existing stockholders could cause The sale of shares of our Common Stock in the public market, or the perception that such sales could occur, could harm the prevailing market price of shares of our Common Stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. As of August 22, 2019, 13,926,458 shares of our Common Stock (including (a) the 13,213,408 shares of Common Stock into which outstanding shares of Series A Preferred Stock can be converted at any time after May 17, 2020 (the “As-Converted Shares”) and (b) 699,503 shares of restricted stock and performance-based restricted stock issued pursuant to the equity incentive plans we have established for our employees and non-employee directors), representing approximately 8.7% of the sum of our total outstanding shares of Common Stock and the As-Converted Shares, are “restricted securities” within the meaning of the SEC’s Rule 144 under the Securities Act (“Rule 144”) and subject to certain restrictions on resale. Restricted securities may be sold in the public market only if they are registered under the Securities Act or are sold pursuant to an exemption from registration such as Rule 144. We are obliged to use our reasonable best efforts to prepare, file, and obtain the effectiveness of a registration statement in respect of the offer and sale of the shares of Series A Preferred Stock and As- Converted Shares by the holders of the Series A Preferred Stock by September 14, 2019. 33 In addition, as of August 22, 2019, 2,537,207 shares of our Common Stock may become eligible for sale upon exercise of vested options. A total of 15,600,000 shares of our Common Stock were reserved for issuance under our 2018 Omnibus Incentive Plan, subject to adjustment for retired and post-June 30, 2018 awards under the prior 2014 Omnibus Incentive Plan. As of August 22, 2019, 11,159,256 shares of our Common Stock remain available for future issuance under the 2018 Omnibus Incentive Plan. These shares can be sold in the public market upon issuance, subject to restrictions under the securities laws applicable to resales by affiliates. i ld Stock k llsell hthem. hThese ffactors equity i iprice fof hshares fof our Common intending to di kmarket as i offerings fof hshares fof our i i i acquisitions. hThe i could ld i hwithout kmarket hThe perceived perceived bby hthe h h through ffuture ff connection i hwith iinvestments or i an iinvestment or limitatiions on iissuance fof new hshares li agreements i ddi i additional l our Common securities iin i i Stock. k governing our i d b d indebtedness, hthe i i number b aterial constitute a m i l kh ld stockholder Certificate off D i connection i hwith iinvestments, difficult ffor us to kmake iit more diffi i hwish to iissue. In hthe ffuture, we may lalso iissue our significantly ifif hthe h ldholders fof hthese hshares could ddrop i ifi could lalso ld llsell hthem or are l funds d additional f securities iin i i connection i hwith i subject to bj Stock, k forth iin hthe h restrictions set f i i Stockholders’ Agreement. Any iissuance fof fof hshares fof our Common issuable iin bl Stock i then-outstanding hshares fof our Common d l dand hthe esignation, otherwise may i h portion fof h approval i imposed bby hthe NYSE or to i acquisitions, or i i i kh ld result iin dil l dilution to hthe h ldholders fof hshares fof securities hthat we iraise ddi i acquisition i i i issued or i d ifi di k i i l i l i Anti-takeover provisions in our organizational documents could delay or prevent a change of control. Certain provisions of our current certificate of incorporation and bylaws may have an anti-takeover effect and may delay, defer, or prevent a merger, acquisition, tender offer, takeover attempt, or other change of control transaction that may otherwise be in the best interests of our stockholders, including transactions that might otherwise result in the payment of a premium over the market price for the shares held by our stockholders. These provisions provide for, among other things: • • • • • • until the provision completely sunsets at our annual meeting in respect of fiscal 2021, a classified board of directors with staggered three-year terms; the ability of our board of directors to issue one or more series of preferred stock; advance notice for nominations of directors by stockholders and for stockholders to include matters to be considered at our annual meetings (though our board of directors has implemented shareholder proxy access); certain limitations on convening special stockholder meetings; the removal of directors serving multi-year terms only for cause; and any amendment of certain provisions of our certificate of incorporation only by the affirmative vote of at least 66-2/3% of the shares of Common Stock entitled to vote generally in the election of directors. Provisions such as those just described, to the extent that they remain in effect, could make it more difficult for a third party to acquire us, even if the third-party’s offer may be considered beneficial by many of our stockholders. As a result, our stockholders may be limited in their ability to obtain a premium for their shares. ITEM 1B. UNRESOLVED STAFF COMMENTS None. 34 ITEM 2. PROPERTIES Our principal executive offices are located at 14 Schoolhouse Road, Somerset, New Jersey. We have thirty-nine facilities (four geographical locations operate as multiple facilities because they support more than one reporting segment), comprising manufacturing operations, development centers, and sales offices contained in approximately 6.4 million square feet of manufacturing, laboratory and related space. Our manufacturing capabilities include all required regulatory, quality assurance and in-house validation space. The following table sets forth our manufacturing and laboratory facilities as of June 30, 2019: Facility Sites Country Region Segment Total Square Footage Leased/Owned 1 Eberbach Germany Europe 2 St. Petersburg, FL USA 3 Buenos Aires 4 Braeside 5 Windsor 6 Sorocaba 7 Strathroy 8 Kakegawa (1) 9 Aprilia 10 Beinheim 11 Indaiatuba 12 Bloomington, IN Argentina Australia Canada Brazil Canada Japan Italy France Brazil USA North America South America Asia-Pacific North America South America North America Asia-Pacific Europe Europe South America North America 13 Woodstock, IL USA North America 14 Brussels Belgium Europe 15 Morrisville, NC (1) USA North America 16 Limoges France Europe 17 Madison, WI 18 Emeryville, CA 19 Baltimore, MD 20 Harmans, MD USA USA USA USA North America North America North America North America 21 Kansas City, MO (1) USA North America 22 Somerset, NJ USA North America Softgel Softgel Softgel Softgel Softgel Softgel Softgel Softgel Softgel Softgel Softgel Biologics and Specialty Drug Delivery Biologics and Specialty Drug Delivery Biologics and Specialty Drug Delivery Biologics and Specialty Drug Delivery Biologics and Specialty Drug Delivery Biologics and Specialty Drug Delivery Biologics and Specialty Drug Delivery Biologics and Specialty Drug Delivery Biologics and Specialty Drug Delivery Oral Drug Delivery / Biologics and Specialty Drug Delivery Oral Drug Delivery / Corporate HQ 23 Swindon United Kingdom Europe Oral Drug Delivery 24 Winchester, KY 25 Schorndorf (1) 26 Malvern, PA 27 San Diego, CA USA Germany USA USA North America Oral Drug Delivery Europe Oral Drug Delivery North America Oral Drug Delivery North America Oral Drug Delivery 28 Dartford United Kingdom Europe 29 Nottingham United Kingdom Europe 30 Paris France Europe Oral Drug Delivery Oral Drug Delivery Oral Drug Delivery 370,580 Leased 328,073 Owned 265,000 Owned 163,100 Owned 125,892 Owned 124,685 Owned 118,009 Owned 104,500 Owned 156,020 Leased/Owned 78,100 Owned 53,800 Owned 876,561 Owned 352,260 Owned 265,287 Owned 186,406 Leased 179,000 Owned 157,955 Leased 10,323 Leased 96,072 Leased 289,560 Leased 329,394 Owned 265,000 Owned 253,314 Owned 180,000 Owned 166,027 Owned 84,000 Leased 66,244 Leased 20,250 Leased 37,428 Owned 150 Leased 35 Facility Sites 31 Philadelphia, PA 32 Bathgate 33 Kansas City, MO (1) 34 Bolton 35 Schorndorf (1) 36 Shanghai 37 Shanghai 38 Singapore 39 Kakegawa (1) Country Region Segment USA North America Clinical Supply Services Total Square Footage Leased/Owned 212,833 Leased/Owned United Kingdom Europe Clinical Supply Services 191,000 Owned USA North America Clinical Supply Services United Kingdom Europe Clinical Supply Services Germany Europe Clinical Supply Services China China Asia-Pacific Clinical Supply Services Asia-Pacific Clinical Supply Services Singapore Asia-Pacific Clinical Supply Services Japan Asia-Pacific Clinical Supply Services 80,606 Owned 60,830 Owned 54,693 Owned 30,052 Leased 27,562 Leased 26,023 Leased 2,800 Owned 6,389,389 Total (1) Represents sites where multiple segments operate. 36 ITEM 3. LEGAL PROCEEDINGS From time to time, we may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. We intend to vigorously defend ourselves against any such litigation and do not currently believe that the outcome of any such litigation will have a material adverse effect on our financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise. From time to time, we receive subpoenas or requests for information relating to the business practices and activities of customers or suppliers from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties engaged in patent infringement, antitrust, tort, and other litigation. We generally respond to such subpoenas and requests in a timely and thorough manner, and responses sometimes require considerable time and effort and can result in considerable costs being incurred. We expect to incur costs in future periods in connection with future requests. ITEM 4. MINE SAFETY DISCLOSURES Not Applicable. 37 PART II ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES The principal market for trading of our Common Stock is the NYSE. Our Common Stock trades under the symbol ” CTLT. “ As of August 22, 2019 we had 17 holders of record and 4 holders of record of outstanding shares of our Common Stock and Preferred Stock, respectively. This number does not include beneficial owners whose shares were held in street name. We did not declare or pay any dividend on our Common Stock in fiscal 2019 or fiscal 2018. We have no current plan to pay any dividend on our Common Stock. Any decision to declare and pay dividends in the future will be made at the sole discretion of our board of directors and will depend on, among other things, our results of operations, cash requirements, financial condition, contractual restriction, and other factors that our board of directors may deem relevant. Because we are a holding company and have no direct operations, we will only be able to pay dividends from funds we receive from our subsidiaries. In addition, our ability to pay dividends will be limited by covenants in our existing indebtedness and the Certificate of Designation and may be limited by the agreements governing other indebtedness we or our subsidiaries incur in anagement’s Discussion and Analysis of Financial Condition and Results of Operations—Debt Covenants.” the future. See M“ Recent Sales of Unregistered Equity Securities On May 17, 2019, we i iprice fof $$650.0 issued to hthe d Preferred f d Stock Investors 650,000 hshares fof k iSeries A P f referred d i registration pursuant to “accredit ded iinvestor” as d fi d acquired ffor iinvestment purposes legends hhave bbeen ffi d affixed to our b illimillion, or $$1,000 per hshare, pursuant to hthe Investment Agreement. hiThis iissuance i i dunder hthe Section ( )( ) 4(a)(2) i defined iin Securities Act. hThe lRule 501 fof hthe Securities Act i i lsale iin i hwith a viiew to or ffor records iin respect llall fof available iin hthe Current Report on Form 8-K hthat we fil dfiled on May 22, f Stock Investors Preferred d dand hthat hthe hshares fof connection i hwith any di hsuch hshares fof iSeries A P f d il bl k i dand not k book-entry lsale iis dand k dand Stock ffor an aggregate lsale were represented to us hthat d referred d iSeries A P f thereof, ib i f distribution h Stock. k referred d dand concerning hithis iissuance i purchase purchase exempt ffrom i heach was an Stock were k appropriate l hFurther i f 2019 . di i d i d information i Purchases of Equity Securities In October 2015, our Board of Directors authorized a share repurchase program to use up to $100.0 million to repurchase outstanding shares of our Common Stock. We may repurchase shares under the program through open market purchases, privately negotiated transactions, or otherwise as permitted by applicable federal securities laws. There was no purchase by us, on our behalf, or on behalf of any affiliate of our registered equity securities during the period covered by this Annual Report. 38 Performance Graph Set forth below is a line graph comparing the cumulative total shareholder return on our Common Stock since July 31, 2014 (the date our Common Stock commenced trading on the NYSE) through June 30, 2019, based on the market price of our Common Stock and assuming reinvestment of dividends, with the cumulative total shareholder return of companies on the S&P Composite 1500 Index and S&P Composite 1500 Healthcare Index. The graph assumes that $100 was invested in our Common Stock and in each index at the market close on July 31, 2014. The stock price performance of the following graph is not necessarily indicative of future stock performance. Comparison of Cumulative Total Return $300 $250 $200 $150 $100 $50 7/31/14 6/30/15 6/30/16 6/30/17 6/30/18 6/30/19 Catalent, Inc. S&P Composite 1500 Index S&P Composite 1500 Health Care Index 39 ITEM 6. SELECTED FINANCIAL DATA The following table sets forth our selected historical financial and operating data for, or as of the end of, each of the five years ended June 30, 2019. The selected financial data as of June 30, 2019 and 2018, and for the fiscal years ended June 30, 2019, 2018, and 2017, have been derived from our audited Consolidated Financial Statements. The financial data as of June 30, 2017, 2016, and 2015 and for the fiscal years ended June 30, 2016 and 2015 have been derived from our audited consolidated financial statements not included in this Annual Report. This table should be read in conjunction with the Consolidated Financial Statements and the notes thereto. (Dollars in millions, except per share data) Statement of Operations Data: Net revenue Cost of sales Gross margin Selling, general, and administrative expenses Impairment charges loss on sale of assets Restructuring and other Operating earnings Interest expense, net Other (income)/expense, net Earnings from continuing operations before income taxes Income tax expense/(benefit) Earnings from continuing operations Earnings from discontinued operations, net of tax Net earnings Less: Net (loss)/earnings attributable to non-controlling interest, net of tax 2019 2018 2017 2016 2015 Year Ended June 30, $ 2,518.0 $ 2,463.4 $ 2,075.4 $ 1,848.1 $ 1,830.8 1,712.9 1,710.8 1,420.8 1,260.5 1,215.5 805.1 512.0 5.1 14.1 273.9 110.9 2.7 160.3 22.9 137.4 — 137.4 — 752.6 464.8 8.7 10.2 268.9 111.4 5.5 152.0 68.4 83.6 — 83.6 — 654.6 402.6 9.8 8.0 234.2 90.1 8.5 135.6 25.8 109.8 — 109.8 587.6 358.1 2.7 9.0 217.8 88.5 (15.6) 144.9 33.7 111.2 — 111.2 615.3 337.3 4.7 13.4 259.9 105.0 42.4 112.5 (97.7) 210.2 0.1 210.3 — (0.3) (1.9) Net earnings attributable to Catalent $ 137.4 $ 83.6 $ 109.8 $ 111.5 $ 212.2 Basic earnings per share attributable to Catalent common shareholders: Earnings from continuing operations Net earnings Diluted earnings per share attributable to Catalent common shareholders: Earnings from continuing operations Net earnings $ $ $ $ 0.92 0.92 0.90 0.90 $ $ 0.64 0.64 0.63 0.63 $ $ 0.88 0.88 0.87 0.87 $ $ 0.89 0.89 0.89 0.89 1.77 1.77 1.75 1.75 40 (Dollars in millions) Balance Sheet Data (at period end): Cash and cash equivalents Goodwill Total assets Long-term debt, including current portion and other short-term borrowing Total liabilities 2019 2018 2017 2016 2015 Year Ended June 30, $ 345.4 $ 410.2 $ 288.3 $ 131.6 $ 151.3 2,220.9 6,184.0 2,959.3 3,895.8 1,397.2 4,531.1 2,721.3 3,444.4 1,044.1 3,454.3 2,079.7 2,730.8 996.5 3,091.1 1,860.5 2,455.2 1,061.5 3,138.3 1,880.8 2,498.5 Total shareholders’ equity/(deficit) $ 1,681.6 $ 1,086.7 $ 723.5 $ 635.9 $ 634.0 (Dollars in millions) Other Financial Data: Capital expenditures 2019 2018 2017 2016 2015 $ 218.1 $ 176.5 $ 139.8 $ 139.6 $ 141.0 Net cash provided by/(used in) continuing operations: Operating activities Investing activities Financing activities Net cash provided by/(used in) discontinued operations: 247.7 (1,510.4) 1,201.4 374.5 (919.3) 669.1 — Effect of foreign currency on cash $ (3.5) $ (2.4) $ 299.5 (309.0) 161.3 — 4.9 155.3 (137.7) (30.8) — 171.7 (271.8) 196.5 0.1 $ (6.5) $ (19.6) 41 ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read in conjunction 6. Selected Financial Data a” nd our Consolidated Financial Statements and related notes, which appear elsewhere with “Item“I in this Annual Report. In addition to historical consolidated financial information, the following discussion contains forward- looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. You should carefully read Annual Annual Report. Factors Annual Report, particularly in “Item“I that could cause or contribute to these differences include those discussed below and elsewhere in this Forward-Looking Statements” in hthis 1A. Risk Factors.” “Special Note Regarding F d d k l Overview We are the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. Our oral, injectable, and respiratory delivery technologies provide delivery solutions across the full diversity of the pharmaceutical industry, including small molecules, protein and gene therapy biologics, and consumer health products. Through our extensive capabilities and deep expertise in product development, we help our customers take products to market faster, including nearly half of new drug products approved by the FDA in the last decade. Our advanced delivery technology platforms, which include those in our Softgel Technologies, Biologics and Specialty Drug Delivery, and Oral Drug Delivery segments, our proven formulation, manufacturing, and regulatory expertise, and our broad and deep intellectual property enable our customers to develop more products and better treatments forff development and delivery, our commitment to reliably supply our customers’ and their patients’ needs is the foundation for the value we provide; annually, we produce approximately 73 billion doses for nearly 7,000 customer products, or approximately 1 in every 20 doses of such products taken each year by patients and consumers around the world. We believe that, through our investments in growth-enabling capacity and capabilities, our ongoing focus on operational and quality excellence, the sales of existing customer products, the introduction of new customer products, our innovation activities and patents, and our entry into new markets, we will continue to benefit from attractive and differentiated margins and realize the growth potential from these areas. patients and consumers. Across both Our Reportable Segments We Technologies, h l currently operate iin ffour i i Biologics l i l operating segments, hi hwhich lalso liDelivery, i l lOral Drug Specialty Drug dand constitute our ffour dand li i reporting segments: Services. i Clinical l i Supply l liDelivery, i i Softgel f l Each of our segments reports through a separate management team. Our offerings and services are summarized below by reporting segment. Softgel Technologies Through our Softgel Technologies segment, we provide formulation, development, and manufacturing services for soft capsules, or s“ oftgels, w” hich our predecessor first commercialized in the 1930s and which we have continually enhanced. We are the market leader in overall softgel development and manufacturing and hold the leading market position in the prescription arena. Our principal softgel technologies include traditional softgel capsules, in which the shell is made of animal-derived gelatin, and Vegicaps and OptiShell capsules, in which the shell is made from plant-derived materials. Softgel capsules are used in a broad range of customer products, including prescription drugs, over-the-counter medications, dietary supplements, unit- dose cosmetics, and animal health medicinal preparations. Softgel capsules encapsulate liquid, paste, or oil-based active compounds in solution or suspension within an outer shell. In the manufacturing process, the capsules are formed, filled, and sealed simultaneously. We typically perform encapsulation for a product within one of our softgel facilities, with active ingredients provided by customers or sourced directly by us. Softgels have historically been used to solve formulation challenges or technical issues for a specific drug, to help improve the clinical performance of compounds, to provide important market differentiation, particularly forff over-the-counter medications, and to provide safe handling of hormonal, potent, and cytotoxic drugs. We also participate in the softgel vitamin, mineral, and supplement business in selected regions around the world. With the 2001 introduction of our plant-derived softgel shell, Vegicaps capsules, consumer health customers have been able to extend the softgel dose form to a broader range of active ingredients and serve patient/consumer populations that were previously inaccessible due to religious, dietary, or cultural preferences. In recent years, we have extended this platform to pharmaceutical products via our OptiShell capsule offering. Our Vegicaps and OptiShell capsules are protected by patents in most major global markets. Physician and patient studies we have conducted have demonstrated a preference for softgels versus traditional tablet and hard capsule dose forms in terms of ease of swallowing, real or perceived speed of delivery, ability to remove or eliminate unpleasant odor or taste, and, for physicians, perceived improved patient adherence with dosing regimens. Representative customers of Softgel Technologies include Pfizer, Novartis, Bayer, GlaxoSmithKline, Teva, Johnson & Johnson, Procter & Gamble, and Allergan. 42 As of June 30, 2019, we had eleven Softgel Technologies manufacturing facilities in nine countries, including three in North America, three in Europe, three in South America, and two in the Asia-Pacific region, as well as additional sales offices. Our Softgel Technologies segment represents 34% of our aggregate revenue for fiscal 2019 before inter-segment eliminations. Biologics and Specialty Drug Delivery Our dand i l Specialty Drug i i l Biologics commerciall m f i dand clinical l li i product product i specialty i l htherapy bi l biologics, advanced d lidelivery traditional dand d di i i d l Representative customers fof manufacturing. i f lalong i hwith Novartis, Sarepta, Novartis, i Genentech, h ll small h dand dand i liDelivery segment integrated li i d administered ivia i j anufacturing, i l molecules d i i l d l technologies. hThe b ibusiness hhas i l i Biologics multiple i l i l dand i l innovative i id provides ddrug bsubstance d i dand clinical l commerciall s inhalation, injection, i h l i i expertise iin d i extensive i liDelivery i Specialty Drug l dand f development l protein i solutions ffor i upply l i dand ophthalmic routes, h h l development, scale up, l l include liEli illLilly, Teva, l d pharmaceuti i i manufacturing, ddrug dand gene iusing b hboth dand lMylan, i dand bi l lcal id imid-tier h small ll dand biologics customers. commerciall hRoche, i l i l d bili Our lCatalent biologics based on our d llcell lilines ffor b hboth iinnovator cell-line d development b ll li mammalian li growing bi l i dused to d develop l l technology can h dand technology, l h i biologic compounds. ili versatility. Our dand quality li dproduce cGMP flexibility. ibili dand fl includes i offering i l d i biologics ff high-yielding stable, hi h i ldi bl id cell-line d provide ll li rapid id facility iin ili manufacturing f i f bsubstance ffrom 250L to 4000L acquisition fof i i i hi hwhich iis GPEx development l d biologics ddrug biologics Our fi l fiscal 2018 organization i hwith i i formulation, fi i h d d i l f capacity iin b hboth i dproduct dand new ddrug technology l conjugate h j manufacturabilility. In fi bi f dand fsafety, seamlessly iintegrate ddrug l l upply across b hboth ddrug bsubstance d commerciall s i integrated supporting hthe d services h development i i i commerciali i gene to d dand patented GPEx d advanced il biosimilar bi l i dand bi flexibility, ibili production i ldyields, fl d i development, hi hhigh bi l capacity to i capability a dnd bili Wisconsin hhas hthe i i diMadison, efficiency imaximum ffi i id provide single-use h l scale iusing i l manufacturing dand iologics-focused contract d i added ba bi l i f development l d f di Indiana dd d manufacturing, f bsubstance commercial dl drug clinical, a dnd development, biologics d i l li i i l d expand d continued to d i fiscal 2019, we packaging. In fi k i dand manufacturing, f i l bsubstance i starting di isuites iin fourth h construction on f i Indiana, i ib d d Bloomington. Our SMARTag capacity iin l k i antibody-drug next-generation i i packaging improved ffiefficacy, conjugates ib d d d j hother j antibody-drug potential to i l OneBio i launched our h d dand ffor l clinical supply management ffor l dand li i dproduct. We dand dand entities, bi i i biologic i protein i id dproducts iin d l broadest range fof dand bi bbiobetters to b ibring a p droduct ffrom capabilitiies across bi l dproduct finished-dose ddrug i dand l Bloomington, manufacturing dand f enables d bl i hwith i conjugates provides customers hthe development, technologies l fiscal 2019, we l dproduct, id provide hthe b biosimilars, il launch fof new bi l bsubstance, ddrug lization, ffaster. dand fif hfifth ddrug technology to l development iSuite, hi hwhich production diMadison diMadison dand l dand l l fof d h d l i l i i i i i acquired Paragon, hi hwhich iis f viral vectors biotech h therapies b i dand CAR-T llcell h i d On May 17, 2019, we l di l including i icals, i l biopharmaceut biopharmaceuti dand hpharma ldworld’s l di leading bi based on AAV dand d including gene h l di i therapies), h iviruses ) i AAV vectors, hthe most commonly l iusing cGMP. By ddi vectors tailwinds iin hthe i d capitalize on strong i dindustry il li i l dand ifi i manufacturing i f development, scientific, d h biopharmaceuti integrated bi dand d end-to-end i d l blaboratory facilities l ili i manufacturing f i f llate d dand lJuly 2019. manufactured f d dand focused on hthe d d development l i therapies. For over 25 years, Paragon hhas fmanufacture next-generation i dused iin gene h develop l i dand companies to d modalities, d li i hother therapeutic dand i dused d lidelivery system ffor gene htherapy, as i d l technologies, transformative i i h (oncolytic i l immunotherapies ( i h specializedd e i li xpertise iin i biologics. Paragon b ibrings dand l plasmids id capabilitiies iin l xpertise iin AAV vectors, we b libelieve we are dproducts b vaccines, i i llwell as cutting-edge partnered i hwith some fof hthe f based on d oncology i l adding Paragon’s fmanufacture fof complex bi l l proteins, i hother bili d d i i li specializedd e therapies. Paragon lalso b ibrings to illwill f kmarket ffor gene h capabilitiies, hi hwhich we b libelieve l ical l located iin ll solutions ffor customers. In June 2019, Paragon d agreed to Maryland ffrom Novavax, Inc. hThe Novavax bili i southern h lCatalent iits diff fundamentally e hnhance our bi l l d d d i i i lentivirus i i positioned to differentiat ded i biologics b ibusiness i additional acquire two ddi i l i closed iin d transaction l i Our range of injectable manufacturing offerings includes filling small molecules or biologics into pre-filled syringes, cartridges, and vials, with flexibility to accommodate other formats within our existing network, increasingly focused on complex pharmaceuticals and biologics. With our range of technologies, we are able to meet a wide range of specifications, timelines, and budgets. We believe that the complexity of the manufacturing process, the importance of experience and know- how, regulatory compliance, and high start-up capital requirements provide us with a substantial competitive advantage in the market. For example, blow-fill-seal is an advanced aseptic processing technology, which uses a continuous process to form, fill with drug or biologic, and seal a plastic container in a sterile environment. Blow-fill-seal units are currently used for a variety of pharmaceuticals in liquid form, such as respiratory, ophthalmic, and otic products. Our sterile blow-fill-seal manufacturing has significant capacity and flexibility in manufacturing configurations. This business provides flexible and scalable solutions for unit-dose delivery of complex formulations such as suspensions and emulsions. Further, the business provides engineering and manufacturing solutions related to complex containers. Our regulatory expertise can lead to decreased time to commercialization, and our dedicated development production lines support feasibility, stability, and clinical runs. We plan to continue to expand our product line in existing and new markets, and in higher margin specialty products with additional respiratory, ophthalmic, injectable, and nasal applications. We also offer bioanalytical development and testing services for large molecules, including cGMP release and stability testing. Our respiratory product capabilities include development and manufacturing services for inhaled products for delivery 43 via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. Across multiple complex dosage forms, the segment provides drug and biologic solutions from early-stage development and clinical support all the way through to scale up and commercialization. As of June 30, 2019, we had ten BSDD manufacturing facilities, including eight in North America and two in Europe. Our BSDD segment represents 29% of our aggregate revenue for fiscal 2019 before inter-segment eliminations. Oral Drug Delivery Our Oral Drug Delivery segment provides various advanced formulation development and manufacturing technologies, and related integrated solutions including: clinical development and commercial manufacturing of a broad range of oral dose forms, including our proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled-release tablets, capsules, and sachet products. Representative customers of Oral Drug Delivery include Pfizer, Johnson & Johnson, Bayer, Novartis, and Perrigo. We provide comprehensive pre-formulation, development, and cGMP manufacturing at both clinical and commercial scales for traditional and advanced complex oral solid-dose formats, including coated and uncoated tablets, pellet/bead/powder- filled two-piece hard capsules, granulated powders, and other forms of immediate and modified release branded prescription, generic, and consumer products. We have substantial experience developing and scaling up products requiring accelerated development timelines, solubility enhancement, specialized handling (e.g., potent or DEA-regulated materials), complex technology transfers, and specialized manufacturing processes. We also provide micronization and particle engineering services, which may enhance a drug’s manufacturability or clinical performance. We offer comprehensive analytical testing and scientific services and stability testing for small molecules, both to support integrated development programs and on a fee-for- service basis. We provide global regulatory and support services for our customers’ clinical strategies during all stages of development. In recent years, we have expanded our network of development sites focused on earlier phase compounds, to engage with more customer molecules, earlier, with the intent to provide later stage manufacturing and supporting services as those molecules progress towards commercial approval scientific expertise and depth and breadth of services offered, as well as by the reliability of our supply, including quality, execution, and performance. and beyond. Demand for our offerings is driven by the need for a ff We launched our orally dissolving tablet business in 1986 with the introduction of Zydis tablets, a unique proprietary freeze-dried tablet that typically dissolves in the mouth, without water, in less than three seconds. Most often used for drugs and patient groups that can benefit from rapid oral disintegration, we can adapt the Zydis technology to a wide range of products and indications, including treatments forff disease, and schizophrenia, and consumer healthcare products targeting indications such as pain and allergy relief. We continue to develop Zydis tablets in different formats with our customers as we extend the application of the technology to new therapeutic categories, including immunotherapy, vaccines, and biologic molecule delivery. a variety of central nervous system-related conditions such as migraines, Parkinson’s As of June 30, 2019, we had nine ODD manufacturing facilities, including four in North America and five in Europe. Our ODD segment represents 24% of our aggregate revenue for fiscal 2019 before inter-segment eliminations. Clinical Supply Services Our Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, project management, and inventory management for drugs and biologics in clinical trials. We offer customers flexible solutions for clinical supplies production and provide distribution and inventory management support for both simple and complex clinical trials. This includes over-encapsulation where needed; supplying placebos, comparator drug procurement, and clinical packages and kits for physicians and patients; inventory management; investigator kit ordering and fulfillment; and return supply reconciliation and reporting. We support trials in all regions of the world through our facilities and distribution network. In fiscal 2018, we completed the second phase of our expansion program in our Kansas City, Missouri facility. Further, in fiscal 2016 and again in fiscal 2018, we expanded our Singapore facility by building additional flexible cGMP space, and we introduced clinical supply services at our existing 100,000 square foot facility in Japan, expanding our Asia-Pacific capabilities. Additionally, in fiscal 2013, we established our first clinical supply services facility in China as a joint venture, assumed full ownership in fiscal 2015, and opened a second facility in China in fiscal 2019. We are the leading provider of integrated development solutions and one of the leading providers of clinical trial supplies. Representative customers of Clinical Supply Services include Merck KGaA, IQVIA, Eli Lilly, AbbVie, and Incyte Corporation. As of June 30, 2019, we had nine Clinical Supply Service facilities, including two in North America, three in Europe, and four in the Asia-Pacific region. Our Clinical Supply Services segment represents 13% of our aggregate revenue for fiscal 2019 before inter-segment eliminations. 44 Critical Accounting Policies and Recent Accounting Pronouncements The following disclosure supplements the descriptions of our accounting policies contained in Note 1 to our Consolidated Financial Statements in regard to significant areas of judgment. Management made certain estimates and assumptions during the preparation of the Consolidated Financial Statements in accordance with generally accepted accounting principles. These estimates and assumptions affect the reported amount of assets and liabilities and disclosures of contingent assets and liabilities in the Consolidated Financial Statements. These estimates also affect the reported amount of net earnings during the reporting periods. Actual results could differ from those estimates. Because of the size of the financial statement elements to which they relate, some of our accounting policies and estimates have a more significant impact on the Consolidated Financial Statements than others. Management has discussed the development and selection of these critical accounting policies and estimates with the audit committee of our board of directors. A discussion of some of our more significant accounting policies and estimates follows. Revenue We sell products and services directly to our pharmaceutical, biotechnology, and consumer health customers. The majority of our business is conducted through manufacturing and commercial product supply, development services, and clinical supply services. On July 1, 2018, we adopted Accounting Standards Update (ASU) No. 2014-09, Revenue from ”) 6)”) 606 u, sing the modified Contracts with Customers (Topic 606), codified as Accounting Standards Codification (“ASCA“ retrospective method of adoption. Prior period amounts have not been restated and continue to be reported in accordance with our historical accounting policies. For discussion on the impact of adopting ASC 606 on our accounting, refer to Note 1 to our Consolidated Financial Statements. Our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. For our manufacturing and commercial product supply revenue, the contract generally includes the terms of the manufacturing services and related product quality assurance procedures to comply with regulatory requirements. Due to the regulated nature of our business, these contract terms are highly interdependent and, therefore, are considered to be a single combined performance obligation. For our development services and clinical supply services revenue, our performance obligations vary per contract and are accounted for as separate performance obligations. If a contract contains a single performance obligation, we allocate the entire transaction price to the single performance obligation. If a contract contains multiple performance obligations, we allocate consideration to each performance obligation using the “relative standalone selling price” as defined under ASC 606. Generally, we utilize observable standalone selling prices in our allocations of consideration. If observable standalone selling prices are not available, we estimate the applicable standalone selling price using an adjusted market assessment approach, representing the amount that we believe the market is willing to pay for the applicable service. Revenue is recognized over time using an appropriate method of measuring progress towards fulfilling our performance obligation for the respective arrangement. Determining the measure of progress that consistently depicts our satisfaction of performance obligations within each of our revenue streams across similar arrangements requires judgment. LLicensing revenue occasionally enter iinto arrangements i hwith customers hthat i i ll We i formulae, or l including ddrug f l di contains more hthan one i d bl royalties. l i customer’s use benefit, ppayments ffrom hthe Nonrefundable, f dand b id d fi hsuch arrangements are obligation to hi hwhich fperformance bli i hother i fperformance bli intangible property ( obligation. Our i ibl fup-front lilicense ffees are provided hthere iis no i d recognized hwhen lrelates iis royalty l bsubsequent satisfied. i fi d licensing fof f i include li l d (“out-licensing”)). We ddo not hhave any li i ll out-licensing li i d recognized as revenue hwhen hthe li obligation i fperformance bli entitles us to intellec ll i l d bl licensed property iis included iin hthe arrangement. l subject to hthe nonrefundable, d l d d lsale or usage fof an iitem bj generally dmade i l f i i unsatisfied i fi d i l functional i material lilicense arrangement hthat tual property, l il bl available ffor hthe Royalty l royalty occurs dand fup-front ffees or Long-lived and Other Definite-Lived Intangible II Assets We allocate the cost of an acquired company to the tangible and identifiable intangible assets and liabilities acquired, with ntangible assets ibl the remaining amount being recorded as goodwill. I Valuing the identifiable intangible assets requires judgment. We applied a discounted cash flow model in measuring the customer relationships in relation to the Paragon acquisition, which included certain assumptions such as revenue growth, forecasted revenue and related margin, and customer contract attrition and renewal rates. amortized on a s i d their estimated useful lives. Intangibles assets are ibl dand are consumed, d reflecting hthe pattern iin hi hwhich hthe traight-line b ibasis, include customer relationships economic b benefits are fi primarily i i h li generally ll amortized over i d trademarks. dand l d hi fl il k d i i i l i 45 We assess the impairment of identifiable intangibles if events or changes in circumstances indicate that the carrying values of the assets may not be recoverable. Factors that we consider important that could trigger an impairment review include the following: • • • • significant under-performance relative to historical or projected future operating results; significant changes in the manner of use of the acquired assets or the strategy of the overall business; significant negative industry or economic trends; and recognition of goodwill impairment charges. If we determine that the carrying value of intangibles and/or long-lived assets may not be recoverable based on the existence of one or more of the above indicators of impairment, we measure recoverability of assets by comparing the respective carrying values of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, we measure any impairment based on the amount in which the net carrying amounts of the assets exceed the fair values of the assets. See Notes 5 and 18 to the Consolidated Financial Statements. Goodwill and Indefinite-Lived Intangible Assets d ill goodwill goodwill d ill We account ffor purchased h d dand i intangible assets ibl i hwith i d fi i indefinite lilives iin accordance d indefinite lilives are not bl II ntangible i hwith AASC 350,, I tested d instead are amortized, bbut i i d d h annually d iduring hthe f fourth quarter fof our ll i i hOther Assets. U dnder ASC 350, impairment at lleast l li dand ffor i annually. We ll fiscal year or hwhen icircumstances o h fi qualitative assessment ffor i carrying i iunit iis lless hthan iits d assessment iis performed, a q f hcash flflows, to iestimate ffuture i i immediat lely to hthe di impairment. Thhe 2018 fi dfind no i i hwith i d fi i intangible assets ibl dand i impairment l i fperform an i indicate an l i therwise i di iunit to d determine h hwhether iit iis i qualitative assessment ddoes not generate a p i iositive response, or ifif no i li d discounted di i i evaluation fof ld d should bbe evaluation h i more-likely-thhan-not hthat hthe f ifair d ill goodwill f performed. hThe lik l based upon di dand reporting lvalue. fIf hthe uantitative assessment, b i i growth rates, h quantitative assessment, bbut iin fi dand 2017 d i economic l evaluations lalso i kmarket fiscal 2019 we bbegan i hwith hthe resulted iin no i hcash flflows, iis performed d l conditions. In fi fiscal 2017 li i charge. impairment charge heach l d dand f i i l l i i lvalue fof hthe reporting i qualitative li i dand requires management d d proceeded dand 2018, we sufficient to ffi i qualitative assessment, hi hwhich was evaluation may b ibegin i hwith a i See Note 4 to the Consolidated Financial Statements. Series AA P f Series referred d PP Stock i id S k Dividend AdjAdjustment d Feature e ividend djadjustment ffeature to k Stock. Because hithis djadjustment ffeature d control, hithis ffeature iis l lvalue, as fof hthe accounted ffor valuation ddate, i d lmodel, hi hwhich iincorporates hthe terms dand l k iSeries A P f hThe terms fof hthe i external l include da di id d referred d trading di against da d liecline iin hthe referred d lCarlo i dand iis b Stock i l d iprice fof our Common protections protections imetrics at ffuture ddates, over hi hwhich we hhave no lvalue fof derivative iinstrument iis i measured at f ifair d Stock. hThe d i k A P f lattice simulation l i dand (ii)(ii) ba bi i Monte based on hchanges iin hthe iprices fof hshares fof our Common d Stock k d lmodels i include hthe current l d dused iin b hboth dand hthe risk-neutral iinterest rates, i k l volatility, ili considered management j djudgment id d lvalue consolidated b lbalance hsheets at iits f ifair l d lid consolidated statements fof d lid recognized iin hthe i d lvalue are i i l Level i3 inputs. We revalue iit as fof hthe dand operations. i inomial l i l kmarket dand are kmarket l iprice fof one hshare fof hthe Common remaining term fof hthe djadjustment ffeature. hThese k Stock over Stock k id provide hthe h ldholder d iusing a c di i conditions fof hthe i i d successive historical i l dand iits hi assumptions i certain i depends iin part on hthe iSeries i hwith d l separately ffrom hthe ombination fof (i)(i) a i bi iSeries A P f i assumptions referred d periods. Key d dand expected significant ifi require i i liability iin hthe i recognize hthe d i dend fof derivative as i heither an asset or li bili i i quarterly l reporting heach period; hchanges iin hthe f ifair i d IIncome Taxes In liabilitiies are d accordance ethod liability m h d dand li bili diffdifferences hthat dand li bili provided on hthe provided bebe permanently relation to i l hthe remaining i i operations fof hthose f deferred tax assets d financial i l dand fi i hwith AASC 740 Income Taxes, we account ffor iincome taxes i recognition fof d f i i requires iexist bbetween tax bbases currently l measured iusing d ib undistributed d di d reinvested. In fi i repatriations as a r i d ib earnings fof f undistributed subsidiaries iin fi i foreign i i i fof hthe 2017 Tax Act, bbut we hhave not b idi foreign earnings are i fiscal 2019. l enacted tax rates iin hthe d i earnings fof i subsidiaries b idi recorded a p d d fiscal 2018, we l i expected d di subsidiaries as hthose i i b idi esult l i l i iusing hthe asset dand li bili liability m h d ethod. hThe asset d expected ffuture tax consequences fof temporary liabilitiies ffor dand li bili reporting bbases fof our assets i i di respective j id i d outside fof hthe rovision ffor U.S. iincome taxes i jurisdictions iin hi hwhich we operate. d earnings i United States hwhen iit iis withholding taxes iin f d expected hthat hthese foreign i hh ldi Deferred tax assets Deferred taxes are not illwill liabilities. f dand li bili i dand f d i provision ffor U.S. iincome taxes on dmade any i permanently l considered id d reinvested iin hthe d i i i imposed taxes hThe 2017 Tax Act i d subsidiaries fof a U.S. company. In i foreign i certain f i inclusions iin i taxes ddue on ffuture U.S. i b idi taxable iincome i hwith respect to so-called ll d accordance d d l bl l “global i l b l ibl i hwith ASC 740, we intangible l low-taxed iincome” ( d accounting i dmade an i d related to GILTI as a c urrent-period expense hwhen i (“GILTI”) ) lipolicy l earned bby d election to treat i incurred. d 46 We had valuation allowances of $76.3 million and $86.2 million as of June 30, 2019 and 2018, respectively, against our deferred tax assets. We considered all available evidence, both positive and negative, in assessing the need for a valuation allowance for deferred tax assets. We evaluated four possible sources of taxable income when assessing the realization of deferred tax assets: carrybacks of existing net operating losses (if permitted by tax law); ff future reversals of existing taxable temporary differences; tax planning strategies; and ff future taxable income exclusive of reversing temporary differences and carryforwards. • • • • We i i id considered hthe h hwhether iit iis more lik l temporary diffdifferences applicable tax llaw. U.S. hi hwhich diffdifferences hthat combined states. expire over a n bi d i maintain a v l i dneed to d realize hthose d f li likely hthan not hthat we ldwould bl sufficient ffi i ability to generate dand hthe bili d d iDuring hthe year ended June 30, 2019 we released, $$0.5 d l illimillion fOf hthe $$12.1 bumber beginning iin 2028, i fof years b i dreduce iincome ffor state tax purposes iin hthe ffuture. illimillion dand $$11.6 li bl illwill l taxable iincome released $$12.1 d i hiwithin hthe illimillion fof hthe d based on management’s assessment fof i existing i taxable reversals fof l d bl dunder hthe il bl available carryforward period i d d f related to certain valuation llallowance i l d l carryforwards, d f (“NOLs”) ) operating lloss ( i d hother state d f deferred tax temporary i lrelates to state net lrelates to illimillion deferred tax assets b aluation llallowance on d f d deferred tax assets b d based on ffuture While the valuation allowance related to certain U.S. combined states was partially released in the year ended June 30, 2019, a state valuation allowance of $35.1 million is maintained on state NOLs and deductible temporary differences for the separate and remaining combined states. The remaining state valuation allowance is due to our history of tax losses and anticipated loss utilization rates in separate filing status states as well as the difference in the rules related to allocated and apportioned income for separate filing status states versus combined filing status states. generated hwhen hthere are diffdifferences bbetween tax d Unrecognized tax b i d recognized iin hthe i d benefits are fi d Consolidated i lid likely hthan not hthat a tax i l Financial Statements. Tax b position illwill bbe amounts Statements hwhen iit iis more lik l matters ffor hi hwhich li bili established or are bli h d liabilitiies hhave bbeen iincome tax rate iin a giiven ld could bbe bl materiallly ff i l l hcash result iin an iincrease iin our effective iincome tax rate iin hthe year iit iis i ff eduction iin hthe ff bebe i d recognized as a r d effective iincome tax rate iin hthe year related iinterest d l unrecognized tax b i d dand fy forff liabilit material djadjustment iin hthe li bili penalties fof $$5.2 unrecognized iincome tax b i d affected. An d i benefits period i d i d dand dand i l l i fi f i i i positions ktaken iin a tax return i d recognized iin hthe i Consolidated i lid d i examination. To hthe extent we il effective ff liabilitiies, our i require hthe use fof settlement l iincome tax dand i l Financial prevail iin i unfavorable iincome tax l settlement may fff avorable bl fA f resolution. At June 30, 2019 l illimillion, dand $$4.1 fiscal 2019. l fof illimillion fi l d resolved. i benefits d iduring fi respectively. We i recognized no dand 2018, we l ldwould recorded d d i d i i required to pay amounts iin excess fof our li bili benefits are fi sustained upon i d i i i k li bj dand iin accounting ffor iincome taxes i l determinatiion fof iincome jurisdictions iin hi hwhich we operate. hThe d application fof Our US j i di i review us to i addition, hthe ddi i hthose entities i i hi hwhich we operate affiliates whhen byby ffili Additionally, ffor taxes i ll ddi i Act dand regulations l Certain fof hthe i particularly as thhey particularl idguidance hthat ddoes not judgment. considerable judgment bl ipaying j jurisdiction iin hi hwhich we operate. In heach tax i regulations iin hthe U.S. l complex tax involves hthe i subject to occurring d iduring hthe year iin liabilitiies l i taxation iin heach j illwill hhave an ffeffect on hthe tax expense iin i i pricing l transfer apply bl reasonable dand assumptions i deductions bbetween dand d d i i l d entitled, foreign tax i dunder hthe di kmake i deferred tax assets dand hthe events book iincome d i dand li bili i hwith ffili affiliates, we dand informed d d reported b application fof d f i li i transactions i engaging iin i dand certain i f allocation fof iincome assessing hthe ll incurred outside hthe U.S., we are d d l d promulgated h i allocations dused iin hthe d dand ll assumptions calculatiion fof U.S. iincome taxes l il l necessarily ddaddress llall thereunder, to l iclaim U.S. f lrelate to hthe i di i di lvalue fof jurisdiction. For i i jurisdictions iin contributions ib i jurisdictions. guidelines id li iestimates babout hthe consolidated d lid Internal Revenue l liabilitiies i i certain tax li bili i foreign tax underlying hthe f d l i i issued d recently i l based on d bj therefore f dand iis h heach j lrelevant iin many j l relative i entities iin diffdifferent j d d arising iin hthe U.S. credits, di regulatory l subject to i di amended bby hthe 2017 Tax i i dCode as calculatiions l credits to ffoffset determinatiion fof hthe kkey iinputs d owed on GILTI, are b heach fof hthe jurisdiction i di i needed to prepare hthe - non- requires i lelements i di d d id id f i i i i l i Factors Affecting our Performance Fluctuations in Operating Results Our annual financial reporting periods end on June 30. Our revenue and net earnings are generally higher in the third and fourth quarters of each fiscal year, with our first fiscal quarter typically generating our lowest revenue of any quarter, and our last fiscal quarter typically generating our highest revenue. These fluctuations are primarily the result of the timing of our, and our customers’, annual operational maintenance periods at locations in continental Europe and the U.K., the seasonality associated with pharmaceutical and biotechnology budgetary spending decisions, clinical trial and research and development schedules, the timing of new product launches and length of time needed to obtain full market penetration, and, to a lesser extent, the time of the year some of our customers’ products are in higher demand. 47 Acquisition and Related Integration Efforts Our growth and profitability are affected by the acquisitions we complete and the speed at which we integrate those acquisitions into our existing operating platforms. In fiscal 2018, we acquired Catalent Indiana in order to enhance our biologics capabilities, and it has been integrated into our Biologics and Specialty Drug Delivery segment. In fiscal 2019, we completed the acquisitions of Juniper, based in the U.K., in August 2018 and Paragon, based in the U.S., in May 2019, which have been integrated into our Oral Drug Delivery and Biologics and Specialty Drug Delivery segments, respectively. Foreign Exchange Rates Our operating network is global, and, as a result, we have substantial revenues and operating expenses that are denominated in currencies other than the U.S. dollar, the currency in which we report our financial results, and are therefore influenced by changes in currency exchange rates. In fiscal 2019, approximately 48% of our revenue was generated from our operations outside the United States. Significant foreign currencies for our operations include the British pound, the euro, the Brazilian real, the Argentine peso, the Japanese yen, the Canadian dollar, and the Australian dollar. Trends Affecting Our Business Industry We participate in nearly every sector of the global pharmaceutical and biotechnology industry, which has been estimated to generate $1 trillion in annual revenue, including, but not limited to, the prescription drug and biologic sectors as well as consumer health, which includes the over-the-counter and vitamins and nutritional supplement sectors. Innovative pharmaceuticals continue to play a critical role in the global market, while the share of revenue due to generic drugs and biosimilars is increasing in both developed and developing markets. Sustained developed market demand and rapid growth in emerging economies is driving the consumer health product growth rate to more than double that for pharmaceuticals. Payors, both public and private, have sought to limit the economic impact of pharmaceutical and biologics product demand through greater use of generic and biosimilar drugs, access and spending controls, and health technology assessment techniques, favoring products that deliver truly differentiated outcomes. New Molecule Development and R&D Sourcing Continued strengthening in early-stage development pipelines for drugs and biologics, compounded by increasing clinical trial breadth and complexity, support our belief in the attractive growth prospects for development solutions. Large companies are in many cases reconfiguring their R&D resources, increasingly involving the use of strategic partners for important outsourced functions. Additionally, an increasing portion of compounds in development are from companies that do not have a full research and development infrastructure, and thus are more likely to need strategic development solutions partners. Demographics Aging population demographics in developed countries, combined with health care reforms in many global markets that are expanding access to treatments to a greater proportion of their populations, will continue to drive increases in demand for pharmaceuticals, biologics, and consumer health products. Increasing economic affluence in developing regions will further increase demand for healthcare treatments, and we are taking active steps to allow us to participate effectively in these growth regions and product categories. Finally, we believe the market access and payor pressures our customers face, global supply chain complexity, and the increasing demand for improved treatments will continue to escalate the need for product differentiation, improved outcomes, and treatment cost reduction, all of which can often be addressed using our advanced delivery technologies. Non-GAAP Performance Metrics As described in this section, management uses various financial metrics, including certain metrics that are not based on concepts defined in U.S. GAAP, to measure and assess the performance of our business and to make critical business decisions. We therefore, believe that presentation of certain of these non-GAAP metrics in this Annual Report will aid investors in understanding our business performance. Use of EBITDA from operations Management measures operating performance based on consolidated earnings from operations before interest expense, expense/(benefit) forff controlling interests ( EBITDA income taxes and depreciation and amortization, adjusted for the income or loss attributable to non- “ from operations”).” EBITDA from operations is not defined under U.S. GAAP, is not a measure 48 of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations. We believe that the presentation of EBITDA from operations enhances an investor’s understanding of our financial performance. We believe this measure is a useful financial metric to assess our operating performance across periods and use this measure for business planning purposes. In addition, given the significant investments that we have made in the past in property, plant and equipment, depreciation and amortization expenses represent a meaningful portion of our cost structure. We believe that disclosing EBITDA from operations will provide investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations sufficient to pay taxes, to service debt, and to undertake capital expenditures without consideration of non-cash depreciation and amortization expense. We present EBITDA from operations in order to provide supplemental information that we consider relevant for the readers of the Consolidated Financial Statements, and such information is not meant to replace or supersede U.S. GAAP measures. Our definition of EBITDA from operations may not be the same as similarly titled measures used by other companies. The most directly comparable measure to EBITDA from operations defined under U.S. GAAP is earnings/(loss) from operations. Included in this Management's Discussion and Analysis is a reconciliation of earnings/(loss) from operations to EBITDA from operations. In addition, we evaluate the performance of our segments based on segment earnings before non-controlling interest, other (income)/expense, impairments, restructuring costs, interest expense, income tax expense/(benefit), and depreciation and amortization ( S“ egment EBITDA”).” Use of Constant Currency As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a constant currency basis as one measure to evaluate our performance. In this Annual Report, we calculate constant currency by calculating current-year results using prior-year foreign currency exchange rates. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP. 49 Summary Two-Year Key Financial Performance Metrics The below tables summarize our results in fiscal 2019 and 2018 on several financial metrics we use to measure performance. Refer to the discussions below regarding performance and the use of key financial metrics and “—Non-GAAP Performance Metrics c” oncerning the measurement of revenue at constant currency.” “ Revenue and revenue at constant currency (in millions) Gross margin (in millions) and gross margin percentage Actual Constant Currency FY19 FY18 $2,518.0 $2,575.0 $2,463.4 FY19 FY18 $805.1 31% $752.6 29% $0 $500 $1,000 $1,500 $2,000 $2,500 $0 $250 $500 $750 Fiscal Year Ended June 30, 2019 compared to the Fiscal Year Ended June 30, 2018 Results for the fiscal year ended June 30, 2019 compared to the fiscal year ended June 30, 2018 were as follows: (Dollars in millions) Net revenue Cost of sales Gross margin Selling, general and administrative expenses Impairment charges and (gain)/loss on sale of assets Restructuring and other Operating earnings Interest expense, net Other (income)/expense, net Earnings from operations, before income taxes Income tax expense/(benefit) Net earnings *Percentage not meaningful Net Revenue Fiscal Year Ended June 30, 2019 2018 FX Impact Constant Currency Increase/(Decrease) Change $ Change % $ 2,518.0 $ 2,463.4 $ (57.0) $ 111.6 1,712.9 1,710.8 805.1 512.0 5.1 14.1 273.9 110.9 2.7 160.3 22.9 752.6 464.8 8.7 10.2 268.9 111.4 5.5 152.0 68.4 (41.1) (15.9) (5.1) (0.1) (0.4) (10.3) (0.7) (2.9) (6.7) (1.4) $ 137.4 $ 83.6 $ (5.4) $ 43.2 68.4 52.3 (3.5) 4.3 15.3 0.2 0.1 15.0 (44.1) 59.2 5 % 3 % 9 % 11 % (40)% 42 % 6 % * 2 % 10 % (64)% 71 % Net revenue increased by $111.6 million, or 5%, in fiscal 2019 compared to fiscal 2018, excluding the impact of foreign exchange, primarily due to acquisitions. We acquired Paragon in May 2019, Juniper in August 2018, and Catalent Indiana in October 2017, which increased revenue by 7%, but the increase was partially offset by a reduction in revenue from comparator sourcing arrangements within our Clinical Supply Services segment of 4%. As a result of the adoption of ASC 606, we recorded comparator sourcing arrangements on a net basis versus a gross basis, resulting in a decrease in net revenue with no corresponding decrease to EBITDA. Excluding the impact of acquisitions, divestitures, and the change in accounting for comparator sourcing arrangements, revenue increased 2% primarily driven by increased net revenue within our Biologics and Specialty Drug Delivery segment. 50 Gross Margin Gross margin increased by $68.4 million, or 9%, in fiscal 2019 compared to fiscal 2018, excluding the impact of foreign exchange, primarily due to increased sales volumes as a result of acquisitions discussed above. On a constant currency basis, gross margin, as a percentage of revenue, was 31.9% in the twelve months ended June 30, 2019, an increase from the prior year of 133 basis points, primarily as a result of the adoption of ASC 606, pursuant to which we record comparator sourcing arrangements on a net basis versus the former gross basis, which increased gross margin percentage by 127 basis points. Selling, General, and Administrative Expense Selling, general, and administrative expense increased by $52.3 million, or 11%, in fiscal 2019 compared to fiscal 2018, excluding the impact of foreign exchange, primarily driven by acquisition-related expenses during the year, including transaction fees of $19.7 million related to the acquisitions of Paragon, Juniper, and the two advanced biologics clinical development and manufacturing sites in southern Maryland from Novavax, Inc. and the expected acquisition of the oral solids, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Additionally, there were incremental selling, general, and additional administrative expenses from the acquired companies of $28.4 million, primarily driven by $19.9 million of incremental depreciation and amortization expense and $3.0 million of employee-related costs. Selling, general, and administrative expenses further increased approximately $4.4 million for non-cash equity-based compensation driven by the achievement of certain performance-based metrics during the fiscal year. Impairment Charges and Loss on Sale of Assets Impairment charges for the twelve months ended June 30, 2019 and June 30, 2018 were $5.1 million and $8.7 million, respectively. Impairment charges in the current year were driven by a software related intangible asset in our Clinical Supply Services segment that was not implemented and whose value therefore was not fully recoverable. The prior year included losses on the sales of two Asia-Pacific manufacturing sites in the Softgel Technologies segment. The site divestitures were not material, either individually or in the aggregate, to the segment or our business as a whole. Restructuring and Other Restructuring and other charges of $14.1 million in fiscal 2019 increased by $4.3 million, excluding the impact of foreign exchange, compared to the amounts in fiscal 2018 and were driven by increases in employee-related actions. Restructuring expenses varies period-to-period based on site consolidation efforts and other efforts to further streamline the business. Interest Expense, net Interest expense, net, of $110.9 million in fiscal 2019 was in line with interest expense incurred during fiscal 2018. The interest expense during fiscal 2019 was primarily driven by outstanding debt associated with the financing of the Catalent Indiana acquisition in October 2017, the financing of the Paragon acquisition in May 2019, and the offering of the USD 2027 Notes in June 2019. The principal balance of our debt obligation increased during the fiscal year; however, our interest expense remained in line with the prior fiscal year since we were able to reduce the higher interest rates applicable to certain of our debt and pay down some of our debt with the net proceeds of a July 2018 public offering of our Common Stock (the “2018 Equity Offering”). For ddi i additional i f i l l i equity iin our Consolidated i d lid capital structure, see Financial Statements i i l information i concerning our d bdebt i i “—Liquidity idi included l l d d dand h elsewhere iin hithis b Resources—Debt Report. t Annual l financing arrangements, i dand fi dand i Capital l i including hthe h l di Financing Arrangements” i changing i i imix fof d bdebt dand dand Note 7 to thhe A component of the purchase price for the Catalent Indiana acquisition consisted of $200.0 million in deferred purchase consideration payable in four annual $50.0 million installments, the first of which was paid in October 2018. The present value of the unpaid portion of the deferred consideration is accounted for as debt, with the difference between the nominal value of such portion and such present value considered imputed interest expense. 51 Other Expense, net Other expense, net of $2.7 million for fiscal 2019 was primarily driven by financing charges of $15.8 million related to the offering of the USD 2027 Notes and was partially offset by a gain of $12.9 million related to the change in the fair value of the derivative liability arising from the dividend adjustment mechanism of the Series A Preferred Stock and $0.5 million of unrealized foreign currency gains in the year. See Notes 9 and 13 to the Consolidated Financial Statement for more details on the Series A Preferred Stock dividend adjustment. Other expense, net for fiscal 2018 of $5.5 million was primarily driven by financing charges of $11.8 million related to the offering of the USD 2026 Notes and an amendment to the Credit Agreement, which included a $6.1 million charge for commitment fees paid during the first quarter of fiscal 2018, partially offset by $4.6 million of foreign currency gains in the fiscal year. Provision/(Benefit) ffor Income Taxes Provision/(Benefit) Our provision for income taxes for the twelve months ended June 30, 2019 was $22.9 million relative to earnings from operations before income taxes of $160.3 million. Our provision for income taxes for the twelve months ended June 30, 2018 was $68.4 million relative to earnings from operations before income taxes of $152.0 million. The income tax provision for the current period is not comparable to the same period of the prior year primarily due to the impact of the 2017 Tax Act, changes in pretax income over many jurisdictions, and the impact of discrete items, including equity compensation. Generally, fluctuations in our effective tax rate are due to changes in the geographic distribution of our pretax income resulting from our business mix and changes in the tax impact of permanent differences, restructuring, other special items, and other discrete tax items, including the reversal portion of the state valuation allowance, which may have unique tax implications depending on the nature of the item. 52 Segment Review The below charts depict the percentage of revenue from each of our four reporting segments for the previous two years. Refer below for discussions regarding the segments r’ evenue and EBITDA performance and to N“Non-GAAP Performance Metrics .” Softgel Technologies FY18 vs. FY19 Biologics & Specialty Drug Delivery FY18 vs. FY19 Oral Drug Delivery FY18 vs. FY19 Clinical Supply Services FY18 vs. FY19 34% 36% FY 2018 FY 2019 29% 24% FY 2018 FY 2019 24% 23% FY 2018 FY 2019 13% 17% FY 2018 FY 2019 Our results on a segment basis for the twelve months ended June 30, 2019 compared to the twelve months ended June 30, 2018 were as follows: (Dollars in millions) Softgel Technologies Net revenue Segment EBITDA Biologics and Specialty Drug Delivery Net revenue Segment EBITDA Oral Drug Delivery Net revenue Segment EBITDA Clinical Supply Services Net revenue Segment EBITDA Inter-segment revenue elimination Unallocated Costs(1) Combined totals Net revenue EBITDA from operations Fiscal Year Ended June 30, 2019 2018 FX Impact Constant Currency Increase/(Decrease) Change $ Change % $ 872.1 $ 917.3 $ (34.9) $ (10.3) 191.2 196.4 742.1 180.4 619.9 186.7 321.4 84.4 (37.5) (142.9) 601.9 146.8 573.9 172.9 430.4 76.2 (60.1) (138.8) (7.3) (6.5) (1.4) (10.7) (3.7) (6.3) (2.7) 1.4 4.3 2.1 146.7 35.0 56.7 17.5 (102.7) 10.9 21.2 (8.4) $ 2,518.0 $ 2,463.4 $ 499.8 $ 453.5 $ $ (57.0) $ 111.6 (10.8) $ 57.1 (1)% 1 % 24 % 24 % 10 % 10 % (24)% 14 % 35 % (6)% 5 % 13 % (1) Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate-directed costs, and other costs that are not allocated to the segments as follows: (Dollars in millions) Impairment charges and gain/(loss) on sale of assets Equity compensation Restructuring and other special items (a) Other (expense), net (b) Non-allocated corporate costs, net Total unallocated costs 53 Fiscal Year Ended June 30, 2019 2018 $ (5.1) $ (33.3) (57.7) (2.7) (44.1) (8.7) (27.2) (54.4) (5.5) (43.0) $ (142.9) $ (138.8) (a) Restructuring and other special items include fiscal 2019 transaction and integration costs associated with the acquisition of Paragon. (b) Other (expense), net of $2.7 million for the twelve months ended June 30, 2019 was primarily driven by financing charges of $15.8 million related to the offering of the USD 2027 Notes, partially offset by (i) a gain of $12.9 million related to the fair value of the derivative liability arising from the dividend adjustment mechanism of the Series A Preferred Stock and (ii) $0.5 million of unrealized foreign currency gains in the year. See Notes 9 and 13 to the Consolidated Financial Statement for more details on the Series A Preferred Stock dividend adjustment. Provided below is a reconciliation of earnings from operations to EBITDA from operations: (Dollars in millions) Earnings from operations Depreciation and amortization Interest expense, net Income tax expense EBITDA from operations Softgel Technologies segment Factors Contributing to Year-Over-Year Change Revenue / Segment EBITDA without acquisitions/dispositions Impact of divestitures Constant currency change Foreign exchange fluctuation Total % change Fiscal Year Ended June 30, 2019 2018 137.4 $ 228.6 110.9 22.9 499.8 $ 83.6 190.1 111.4 68.4 453.5 $ $ 2019 vs. 2018 Fiscal Year Ended June 30, Net Revenue Segment EBITDA — % (1)% (1)% (4)% (5)% 1 % — % 1 % (4)% (3)% Softgel Technologies’ net revenue decreased $10.3 million, or 1%, excluding the impact of foreign exchange, as compared to the twelve months ended June 30, 2018. Net revenue remained consistent to the twelve months ended June 30, 2018, excluding the impact of divestitures. Volume increases across our consumer health portfolio within Europe were offset by strong price competition across the generic portion of our prescription product business in North America. Revenue in our consumer health business also decreased by 1%, across North America and Latin America, resulting from a shortage in our ibuprofen active pharmaceutical ingredient supply during the first 9 months of 2019, which was partially resolved in the fourth fiscal quarter. Softgel Technologies’ Segment EBITDA increased by $2.1 million, or 1%, compared to the twelve months ended June 30, 2018, excluding the impact of foreign exchange. Excluding the reduction of licensing revenue profit of 2%, segment EBITDA without divestitures increased 3%. The increase was primarily related to increased volume in the consumer health portfolio across Europe, offset by a shortage in our supply of ibuprofen active pharmaceutical ingredient during the first 9 months of 2019, which was partially resolved in the fourth fiscal quarter, which reduced Segment EBITDA by 3%. In December 2017, we divested two manufacturing sites in Asia-Pacific in the Softgel Technologies segment in order to better streamline our global operations. The site divestitures resulted in a decrease to net revenue of 1% with no impact to segment EBITDA in the twelve months ended June 30, 2019 compared to the twelve months ended June 30, 2018. 54 Biologics and Specialty Drug Delivery segment Revenue / Segment EBITDA without acquisitions Impact of acquisitions Constant currency change Foreign exchange fluctuation Total % change 2019 vs. 2018 Fiscal Year Ended June 30, Net Revenue Segment EBITDA 7 % 17 % 24 % (1)% 23 % — % 24 % 24 % (1)% 23 % Net revenue in our Biologics and Specialty Drug Delivery segment increased by $146.7 million, or 24%, compared to the twelve months ended June 30, 2018, excluding the impact of foreign exchange. Net revenue without acquisitions increased by 7%, driven primarily by increased end-market demand for our drug product offerings offset slightly by decreased volume demand related to our U.S. drug substance product offering due to the fiscal 2019 completion of a limited duration customer contract for non-cell line clinical manufacturing services. Biologics and Specialty Drug Delivery segment EBITDA increased by $35.0 million, or 24%, excluding the impact of foreign exchange. Segment EBITDA without acquisitions was in line with prior year, primarily due to strong U.S drug product and drug-substance end-market demand offset by the fiscal 2019 completion of a limited duration customer contract for non- cell line clinical manufacturing services in our U.S. drug substance platform as well as unfavorable product mix in our European specialty drug product platform. On October 23, 2017, we acquired Catalent Indiana, which increased net revenue and Segment EBITDA on an inorganic basis in our Biologics and Specialty Drug Delivery segment by 12% and 17%, respectively, in the twelve months ended June 30, 2019 compared to the corresponding prior-year period. On May 17, 2019, we acquired Paragon, which increased net revenue and Segment EBITDA on an inorganic basis in our Biologics and Specialty Drug Delivery segment by 5% and 7%, respectively, in the twelve months ended June 30, 2019 compared to the corresponding prior-year period. Oral Drug Delivery segment Revenue / Segment EBITDA without acquisitions Impact of acquisitions Constant currency change Foreign exchange fluctuation Total % Change 2019 vs. 2018 Fiscal Year Ended June 30, Net Revenue Segment EBITDA (1)% 11 % 10 % (2)% 8 % (5)% 15 % 10 % (2)% 8 % Net revenue in our Oral Drug Delivery segment increased by $67.7 million, or 10%, compared to the twelve months ended June 30, 2018, excluding the impact of foreign exchange, primarily resulting from our Juniper acquisition. Revenue without acquisitions decreased 1%, primarily driven by decreased end-market demand for a key product within our U.S.-based commercial oral delivery solutions platform, partially offset by an increase related to the intake of new molecules within our development and analytical services platform, the completion of a commercially ready process for a key product within our impact from licensing revenue recorded during the third quarter. U.S.-based oral delivery solutions platform and a favorable The favorable impact of licensing revenue in the third quarter was attributable to a single transaction, which consisted of a grant to a third party of the Company’s right to participate in an arrangement that resulted in a stream of revenue over time in exchange for a one-time up-front license fee. ff Oral Drug Delivery’s Segment EBITDA increased by $2.3 million, or 10%, compared to the twelve months ended June 30, 2018, excluding the impact of foreign exchange. Segment EBITDA without acquisitions decreased 5%, primarily driven by decreased end-market demand for a key product within our U.S.-based commercial oral delivery solutions platform, partially offset by an increase in volume related to the intake of new molecules within our development and analytical services platform, the completion of a commercially ready process for a key product within our U.S.-based oral delivery solutions platform and a 55 favorable impact from licensing profit recorded during the third quarter. The favorable impact of licensing revenue in the third quarter was attributable to a single transaction, which consisted of a grant to a third party of the Company’s right to participate in an arrangement that resulted in a stream of revenue over time in exchange for a one-time up-front license fee. On August 14, 2018, we acquired Juniper, which increased inorganic net revenue and Segment EBITDA in our Oral Drug Delivery segment for the twelve months ended June 30, 2019 by 11% and 15%, respectively, compared to the prior-year period. Clinical Supply Services segment Revenue / Segment EBITDA without acquisitions Comparator revenue recognition adoption impact Constant currency change Foreign exchange fluctuation Total % Change 2019 vs. 2018 Fiscal Year Ended June 30, Net Revenue Segment EBITDA 1 % (25)% (24)% (2)% (26)% 14 % — % 14 % (3)% 11 % Clinical Supply Services’ net revenue decreased by $102.7 million, or 24%, compared to the twelve months ended June 30, 2018, excluding the impact of foreign exchange. As a result of the adoption of ASC 606, the Company recorded comparator sourcing arrangements on a net basis versus a gross basis resulting in a decrease to net revenue of 25%, partially iincrease iin revenue dand manufacturing primarily ddue to hi hhigher comparator packaging b ibusiness partially ffoffset bby an distribution ib i profitability as w llell as storage il k i sourcing lvolume. lvolume fi bili dand di dand dand f i i i Clinical Supply Services’ Segment EBITDA increased by $10.9 million, or 14%, excluding the impact of foreign i hiwithin hthe storage exchange, as compared to the twelve months ended June 30, 2018, primarily dand i h increased d distribution b ibusiness, i ib i di strategic iinvestments. i iprior based on based jproject management revenue, primarily ddue to fa f fff improved d growth iin avorable bl capacity i hif shift iliutilizatiion across hthe dand network k iFiscal Year Ended June 3030, 2012018 CCompared to the iFiscal Year Ended June 3030, 2012017 Management’s di d d fi fiscal year l lResults fof Annual Report on Form 10-K ffor hthe fi i l discussion found iin hthe “Management’s ended June 30, 2017 may bbe f i d d Compared to hthe i d Operations—Fiscal Year i fiscal year l i Ended June 30, 2017” ended June 30, 2018, fil dfiled i hwith hthe SEC on August 28, 2018. d d fiscal year l l dand Analysis fof i d d Fiscal Year l operations ffor hthe fi Discussion i ended June 30, 2018 Financial i l Ended June 30, 2018 analysis fof our i results fof l dand d d d i l i l compared to hthe d di i dand Condition i section fof our Liquidity and Capital Resources Sources and use of Cash Our principal source of liquidity has been cash flow generated from operations and the net proceeds of financing activities. The principal uses of cash are to fund operating and capital expenditures, business or asset acquisitions, interest payments on debt, the payment of deferred purchase consideration from the Catalent Indiana acquisition, the payment of the quarterly dividend on the Series A Preferred Stock, and any mandatory or discretionary principal payment on our debt. At the current stated value of the Series A Preferred Stock outstanding as of June 30, 2019, the aggregate amount of each regular quarterly dividend, if paid in cash, is $8.125 million. Because the shares of Series A Preferred Stock were first issued on May 17, 2019, the aggregate amount of the first regular dividend payment for the period ended June 30, 2019, which was paid in cash, was $4.0 million. As of June 30, 2019, Operating Company had available a $550.0 million revolving credit facility that matures in May 2024 (following the execution of the fourth amendment (the Four Operating Company’s diCredit the senior secured credit facilities and those short-term borrowings referred to as swing-line borrowings. At June 30, 2019, we had $6.6 million of outstanding letters of credit and no outstanding borrowing under our revolving credit facility. Agreement in May 2019), the capacity of which is reduced by the amount of all outstanding letters of credit issued under th Amendment )”) to “ t i We believe that our cash on hand, cash from operations, and available borrowings under our revolving credit facility will be adequate to meet our future liquidity needs for at least the next twelve months, including with respect to payment of our quarterly regular dividend on the Series A Preferred Stock, if paid in cash, and the amounts expected to become due with respect to our pending capital projects. We have no significant maturity under any of our bank or note debt until the euro- denominated term loans in our senior secured credit facility mature in May 2024. We have three remaining annual payments of 56 $50.0 million each with respect to the previously described deferred purchase consideration, the first of which is due in October 2019. Cash Flows Fiscal Year Ended June 30, 2019 Compared to the Fiscal Year Ended June 30, 2018 The following table summarizes our consolidated statements of cash flows from operations for the fiscal year ended June 30, 2019 compared with the fiscal year ended June 30, 2018: (Dollars in millions) Net cash provided by/(used in): Operating activities Investing activities Financing activities Operating Activities Fiscal Year Ended June 30, 2019 2018 Change $ $ $ $ 247.7 $ (1,510.4) $ 1,201.4 $ 374.5 $ (919.3) $ 669.1 $ (126.8) (591.1) 532.3 For the fiscal year ended June 30, 2019, cash provided by operating activities was $247.7 million, a decrease of $126.8 d million compared to $374.5 million for the comparable prior-year period. The decrease was due to a higher collection of receivables during the corresponding prior-year period and higher inventory levels during fiscal 2019 compared to the prior- year period. Also, we had a higher accounts receivable balance at the end of the current-year period as a result of higher days sales outstanding during fiscal 2019 compared to fiscal 2018. The increase in day sales outstanding is primarily driven by the adoption of ASC 606. Upon adoption of ASC 606, the time for recognizing revenue for commercial product supply arrangements changed from delivery to when control is transferred to the customer, which occurs over time as units of product successfully complete the contractually required quality assurance process; however, we continued to invoice upon shipment of the product, which generally added one to two weeks to our days sales outstanding. In addition, certain customers adopted digital payment processing systems, which resulted in further delays in receiving payments and ultimately led to increased days sales outstanding. Investing Activities For the fiscal year ended June 30, 2019, cash used in investing activities was $1,510.4 million compared to $919.3 million during fiscal 2018. Fiscal 2019 cash used in investing activities primarily consists of $1,291.0 million of payments for business acquisition, net of cash acquired. Of this amount, $1,163.5 million was paid for the acquisition of Paragon in the fourth quarter and the remaining $127.5 million was paid for the acquisition of Juniper in the first quarter. In fiscal 2018, $748.0 million of cash was paid for the acquisition of Catalent Indiana. Other uses of cash in investing activities included cash used in acquisitions of property, plant, and equipment, which totaled $218.1 million in fiscal 2019 compared to $176.5 million in fiscal 2018. Financing Activities For the fiscal year ended June 30, 2019, cash provided by financing activities was $1,201.4 million compared to cash provided by financing activities of $669.1 million during the fiscal year ended June 30, 2018. The fiscal 2019 cash provided by financing activities consists of net proceeds of $1,447.6 million from borrowings, $646.3 million of net proceeds from the issuance of shares of our Series A Preferred Stock, and $445.5 million of net proceeds from the issuance of shares of our Common Stock, partially offset by $1,290.3 million of payments against long-term obligations. The fiscal 2018 balance primarily consists of $442.6 million of net proceeds from borrowing and $227.8 million of net proceeds from the issuance of shares of our Common Stock. In the fourth quarter of fiscal 2019, pursuant to the Fourth Amendment, we borrowed $950.0 million aggregate principal amount through new incremental term B loans under our existing senior secured credit facilities, the net proceeds of which were used to pay a portion of the fees and expenses related to the Fourth Amendment, a voluntary prepayment of $300.0 million on the outstanding principal amount of existing U.S. dollar-denominated term loans under the Credit Agreement, and a portion of the consideration for the Paragon acquisition. In addition, the Company raised $500.0 million, before fees and expenses, through the offering of the USD 2027 Notes, and the net proceeds were primarily used to repay in full the remaining outstanding borrowings under the U.S. dollar-denominated term loans that mature in May 2024 under the Credit Agreement. In connection with the USD 2027 Notes offering and the Fourth Amendment, we incurred $27.0 million of debt discount and third-party financing costs, of which $5.4 million was expensed and recorded in other expense, net in the consolidated statements of operations. In hthe f ldsold 650,000 hshares fof our fiscal 2019, we fourth quarter iSeries A fof fi h l 57 k purchase h iprice fof $$650.0 Stock ffor an aggregate illimillion, or $$1,000 per hshare. In hthe fifirst quarter Preferred d f raised net proceeds of $445.3 million as part of the 2018 Equity Offering. In the 2018 Equity Offering, we sold 11.4 i d million shares, including the underwriters' over-allotment, of our Common Stock at a price to the public of $40.24 per share, before underwriting discounts and commissions. The net proceeds of $445.3 million include the effect of discounts and commissions and other offering expenses. We used the net proceeds in addition to cash on hand to repay $450.0 million of outstanding borrowings under the U.S. dollar-denominated term loans outstanding under our senior secured credit facilities. During the second quarter of fiscal 2019, we paid the first installment on the deferred purchase consideration for the acquisition of Catalent Indiana, of which $44.0 million represents the deemed principal portion of the debt. fiscal 2019, we fof fi l Fiscal Year Ended June 30, 2018 Compared to the Fiscal Year Ended June 30, 2017 discussion Management’s di ended June 30, 2017 may bbe f l d year Operations—Cash l Ended June 30, 2018 Flows—Fiscal Year i Annual Report on Form 10-K ffor hthe fi d d fiscal year l found iin hthe “Management’s analysis fof our i l l hcash flflows ffor hthe fi fiscal year dand i Compared to hthe i d d d i l Discussion dand h i i ended June 30, 2018 i d d Analysis fof i l Fiscal Year l Financial i l Ended June 30, 2017” d d Condition di i d compared to hthe fi dand l fiscal lResults fof section fof our i ended June 30, 2018, fil dfiled i hwith hthe SEC on August 28, 2018. d d Debt and Financing Arrangements Senior Secured Credit Facilities and Fourth Amendment In May 2019, Operating Company completed the Fourth Amendment. As part of the Fourth Amendment, Operating “ “ Dollar Term Company borrowed $950.0 million aggregate principal amount through incremental term B loans (“Incremental B-2 Loans”)” and replaced the existing revolving credit commitments of $200.0 million in its senior secured credit facilities with new revolving credit commitments of $550.0 million (“Incremental Revolving Credit Commitments”).” The Incremental Dollar Term B-2 Loans constitute a new class of U.S. dollar-denominated term loans under the Credit Agreement with the same principal terms as the then existing U.S. dollar-denominated term loans. The proceeds of the Incremental Dollar Term B-2 Loans were used to pay a portion of the fees and expenses related to the Fourth Amendment, a voluntary prepayment of $300.0 million on the outstanding principal amount of existing U.S. dollar-denominated term loans under the Credit Agreement, and a portion was used to fund a portion of the consideration for the Paragon acquisition. The Incremental Dollar Term B-2 Loans will mature at the earlier of (1) May 17, 2026 and (2) the 91st day prior to the maturity of the Euro Notes or a permitted refinancing thereof, if on such 91st day any of the Euro Notes remains outstanding. The Incremental Revolving Credit Commitments constitute revolving credit commitments under the Credit Agreement with the same principal terms as the previously existing revolving credit commitments under the Credit Agreement. The maturity date for the Revolving Credit Facility is now the earlier of (1) May 17, 2024 and (2) the 91st day prior to the maturity of any dollar term loans or euro term loans under the Credit Agreement, or any permitted refinancing thereof, if on such 91st day any of such dollar term loans or euro term loans remain outstanding. Under the Credit Agreement, the applicable rate for U.S. dollar-denominated term loans, including the Incremental Dollar Term B-2 Loans is LIBOR (the London Interbank Offered Rate, subject to a floor of 1.00%) plus 2.25%, and the applicable rate for euro-denominated term loans is Euribor (the Euro Interbank Offered Rate published by the European Money Markets Institute, subject to a floor Revolving Credit Commitments is initially LIBOR plus 2.25%, and such rate can additionally be reduced to LIBOR plus 2.00% in future periods based on a measure of Operating Company's total leverage ratio. The euro-denominated term loans will mature in May 2024. of 1.00%) plus 1.75%. The applicable rate for the Incremental ff ff In July 2018, we completed the 2018 Equity Offering and used the net proceeds of $445.2 million and cash on hand to repay $450.0 million of the then-outstanding borrowings under our U.S. dollar-denominated term loans. Euro-denominated 4.75% Senior Notes due 2024 In December 2016, Operating Company completed a private offering of the Euro Notes. The Euro Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The Euro Notes were offered in the United States to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. The Euro Notes will mature on December 15, 2024, bear interest at the rate of 4.75% per annum and are payable semi-annually in arrears on June 15 and December 15 of each year. 58 U.S. dollar-denominated 4.875% Senior Notes due 2026 In October 2017, Operating Company completed a private offering of the USD 2026 Notes. The USD 2026 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The USD 2026 Notes were offered in the United States to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. The USD 2026 Notes will mature on January 15, 2026, bear interest at the rate of 4.875% per annum, and are payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The net proceeds of the USD 2026 Notes, after payment of the initial purchasers’ d’ expenses, were used to fund a portion of the consideration for the Catalent Indiana acquisition due at its closing. iscount and related fees and U.S. dollar-denominated 5.00% Senior Notes due 2027 In June 2019, Operating Company completed a private offering of the USD 2027 Notes. The USD 2027 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The USD 2027 Notes were offered in the United States to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. The USD 2027 Notes will mature on July 15, 2027, bear interest at the rate of 5.00% per annum, and are payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The net proceeds of the USD 2027 Notes, after payment of the initial purchasers' discount and related fees and expenses, were used to repay in full the outstandin bg b hthat mature iin May 2024 on iits b lbalance hsheet ffor orrowings i senior i general corporate purposes. then-outstanding U.S. d ll di dand Operating Company's h i lplus any facilities, ili i credit f di dollar-denomina dted term lloans unpaid iinterest hthereon dunder iits l dunder secured d accrued d provide id dand id d i hcash Deferred Deferred Purchase C h Consideration id i In connection i hwith hthe i acquisition fof i i i lCatalent Indiana in October 2017, $200.0 million of the $950.0 million aggregate nominal purchase price was payable in four annual $50.0 million installments. We paid the first annual installment in October 2018. The remainder of the deferred purchase consideration is recorded at fair value, with the difference between the remaining nominal amount and the fair value balance deemed to be imputed interest. Bridge Loan Facility In September 2017, contemporaneous with execution of the agreement to acquire Catalent Indiana, Operating Company entered into a debt commitment letter with several financial institutions as commitment parties. Pursuant to the debt commitment letter and subject to its terms and conditions, the commitment parties agreed to provide a senior unsecured bridge loan facility of up to $700.0 million in the aggregate for the purpose of providing any back-up financing necessary to fund a portion of the consideration to be paid in the acquisition and related fees, costs, and expenses (the “Bridge In connection with entering into the Bridge Loan Commitment, Operating Company incurred $6.1 million of associated fees, which was recorded in prepaid expenses and other in the consolidated balance sheet as of the end of first quarter of fiscal 2018. Operating Company did not draw on the facility contemplated by the Bridge Loan Commitment to fund the acquisition, and the facility was closed. We expensed the $6.1 million in the second quarter of fiscal 2018 as part of other income, net. Loan Commitment”).” “ Debt Covenants Senior Secured Credit Facilities The Credit Agreement contains a number of covenants that, among other things, restrict, subject to certain exceptions, Operating Company’s (and Operating Company’s restricted subsidiaries’) ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans, or advances; make certain acquisitions; enter into sale and leaseback transactions; amend material agreements governing Operating Company’s subordinated indebtedness; and change Operating Company’s lines of business. The Credit Agreement also contains change-of-control provisions and certain customary affirmative covenants and events of default. The Revolving Credit Facility requires compliance with a net leverage covenant when there is a 30% or more draw outstanding at a period end. As of June 30, 2019, Operating Company was in compliance with all material covenants under the Credit Agreement. Subject to certain exceptions, the Credit Agreement permits Operating Company and its restricted subsidiaries to incur certain additional indebtedness, including secured indebtedness. None of Operating Company’s non-U.S. subsidiaries or Puerto Rico subsidiaries is a guarantor of the loans. 59 Under the Credit Agreement, Operating Company’s ability to engage in certain activities such as incurring certain additional indebtedness, making certain investments, and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as “Consolidated EBITDA” in the Credit Agreement). Adjusted EBITDA is based on the definitions in the Credit Agreement, is not defined under U.S. GAAP, and is subject to important limitations. The Euro Notes and the USD Notes The several indentures governing each of the Euro Notes, the USD 2026 Notes and the USD 2027 Notes (collectively, the ”)” contain certain covenants that, among other things, limit the ability of Operating Company and its restricted “Indentures “ subsidiaries to incur or guarantee more debt or issue certain preferred shares; pay dividends on, repurchase, or make distributions in respect of their capital stock or make other restricted payments; make certain investments; sell certain assets; create liens; consolidate, merge, sell; or otherwise dispose of all or substantially all of their assets; enter into certain transactions with their affiliates, and designate their subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions, limitations, and qualifications as set forth in the Indentures. The Indentures also contain customary events of default including, but not limited to, nonpayment, breach of covenants, and payment or acceleration defaults in certain other indebtedness of Operating Company or certain of its subsidiaries. Upon an event of default, either the holders of at least 30% in principal amount of each of the then-outstanding Euro Notes, USD 2026 Notes, and the USD 2027 Notes, or the applicable Trustee under the Indentures, may declare the applicable Senior Notes immediately due and payable; or in certain circumstances, the applicable Senior Notes will become automatically immediately due and payable. As of June 30, 2019, Operating Company was in compliance with all material covenants under the Indentures. Liquidity in Foreign Subsidiaries As of June 30, 2019 and June 30, 2018, the amounts of cash and cash equivalents held by foreign subsidiaries were $203.9 million and $124.7 million, respectively, out of the total consolidated cash and cash equivalents of $345.4 million and $410.2 million, respectively. These balances are dispersed across many international locations around the world. Adjusted EBITDA and Adjusted Net Income per share The below tables summarize our fiscal 2019 and 2018 results on several financial metrics we use to measure performance. Refer to the discussions below regarding performance and use of key financial metrics and to N“Non-GAAP Performance Metrics.” EBITDA and Adjusted EBITDA (in millions) Basic, Diluted and Adjusted Net Income per share EBITDA Adjusted EBITDA $499.8 $599.6 $453.5 $550.7 2019 2018 $0.92 $0.90 $0.64 $0.63 $1.91 $1.75 $0 $200 $400 $600 ANI Per Share EPS - Basic EPS - Diluted $0.0 $0.5 $1.0 $1.5 $2.0 Adjusted EBITDA Under the Credit Agreement, the ability of Operating Company to engage in certain activities such as incurring certain additional indebtedness, making certain investments and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as “Consolidated EBITDA” i” n the Credit Agreement). Adjusted EBITDA is a covenant compliance measure in our Credit Agreement, particularly those covenants governing debt incurrence and restricted payments. Adjusted EBITDA is not defined under U.S. GAAP and is subject to important limitations. Because not all companies use identical calculations, our presentation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies. “ The measure under U.S. GAAP most directly comparable to EBITDA from operations and Adjusted EBITDA is earnings/ (loss) from operations. In calculating Adjusted EBITDA, we add back certain non-cash, non-recurring and other items that are 60 included in the definitions of EBITDA from operations and consolidated net income, as required in the Credit Agreement. Adjusted EBITDA, among other things: • • • • does not include non-cash stock-based employee compensation expense and certain other non-cash charges; does not include cash and non-cash restructuring, severance and relocation costs incurred to realize future cost savings and enhance our operations; adds back non-controlling interest expense, which represents minority investors’ ownership of certain of our consolidated subsidiaries and is, therefore, not available to us; and includes estimated cost savings that have not yet been fully reflected in our results. A reconciliation between net earnings and Adjusted EBITDA, which also shows the adjustments from EBITDA from operations, follows: (In millions) Net earnings Interest expense, net Income tax expense (1) Depreciation and amortization EBITDA from operations Equity compensation Impairment charges and (gain)/loss on sale of assets Financing-related expenses and other U.S. GAAP restructuring and other Acquisition, integration, and other special items Foreign exchange loss/(gain) (included in other, net) (2) Other adjustments (3) Adjusted EBITDA (4) FX impact (unfavorable) Adjusted EBITDA - constant currency Twelve Months Ended June 30, 2019 June 30, 2018 $ 137.4 $ 110.9 22.9 228.6 499.8 33.3 5.1 15.9 14.1 43.6 0.5 (12.7) 83.6 111.4 68.4 190.1 453.5 27.2 8.7 11.8 10.2 44.1 (5.0) 0.2 $ $ $ 599.6 $ 550.7 (10.2) 609.8 (1) Represents the amount of income tax-related expense recorded within our net earnings/(loss) that may not result in cash payment or receipt. (2) Foreign exchange loss of $0.5 million for the twelve months ended June 30, 2019 includes: (a) $5.4 million of unrealized losses related to foreign trade receivables and payables, (b) $3.4 million of unrealized losses on the unhedged portion of the euro-denominated debt, and (c) $17.9 million of unrealized losses on inter-company loans. The foreign exchange adjustment was also affected by the exclusion of realized foreign currency exchange rate gains from the settlement of inter-company loans of $21.5 million. Inter-company loans are between our subsidiaries and do not reflect the ongoing results of our trade operations. Foreign exchange gain of $5.0 million for the twelve months ended June 30, 2018 includes: (a) $2.9 million of unrealized gains related to foreign trade receivables and payables, (b) $11.9 million of unrealized losses on the unhedged portion of the euro-denominated debt, and (c) $10.7 million of unrealized losses on inter-company loans. The foreign exchange adjustment was also affected by the exclusion of realized foreign currency exchange rate gains from the settlement of inter-company loans of $24.7 million. Inter-company loans are between our subsidiaries and do not reflect the ongoing results of our trade operations. (3) Represents primarily the $12.9 million gain recorded on the change in the estimated fair value of the derivative liability from issuance through June 30, 2019. (4) In our earnings releases for the quarters ended September 30, 2018, December 31, 2018, and March 31, 2019, we included an adjustment in the three months ended September 30, 2018 relating to a cumulative effect of change in accounting for ASC 606. We are no longer making this adjustment in our presentation of Adjusted EBITDA. 61 Adjusted Net Income and Adjusted Net Income per share We use Adjusted Net Income and Adjusted Net Income per share (which we sometimes refer to as A“ djusted EPS )”) as performance metrics. Adjusted Net Income is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP and is subject to important limitations. We believe that the presentations of Adjusted Net Income and Adjusted Net Income per share enhance an investor’s understanding of our financial performance. We believe this measure is a useful financial metric to assess our operating performance from period to period by excluding certain items that we believe are not representative of our core business, and we use this measure for business planning and executive compensation purposes. We define Adjusted Net Income as net earnings/(loss) adjusted for (1) earnings or loss from discontinued operations, net of tax, (2) amortization attributable to purchase accounting, and (3) income or loss from non-controlling interest in majority-owned operations. We also make adjustments for other cash and non-cash items included in the table below, partially offset by our estimate of the tax effects as a result of such cash and non-cash items. Our definition of Adjusted Net Income may not be the same as similarly titled measures used by other companies. Adjusted Net Income per share is computed by dividing Adjusted Net Income by the weighted average diluted shares outstanding. (In millions, except per share data) Net earnings Amortization (1) Equity compensation Impairment charges and (gain)/loss on sale of assets Financing-related expenses U.S. GAAP restructuring and other Acquisition, integration, and other special items Foreign exchange loss/(gain) (included in other, net) (2) Other adjustments Estimated tax effect of adjustments (3) Discrete income tax (benefit)/expense items (4) Tax law changes provision (5) Adjusted net income (ANI) (6) Weighted average shares outstanding Weighted average diluted shares outstanding ANI per share: ANI per basic share ANI per diluted share Twelve Months Ended June 30, 2019 June 30, 2018 $ $ 137.4 88.2 33.3 5.1 15.9 14.1 43.6 0.5 (12.7) (42.5) (14.5) (3.5) $ 264.9 $ 144.2 146.0 $ $ 1.84 1.81 $ $ 83.6 62.6 27.2 8.7 11.8 10.2 44.1 (5.0) 0.2 (43.5) (9.4) 42.5 233.0 131.2 133.2 1.78 1.75 (1) Represents the amortization attributable to purchase accounting for previously completed business combinations. (2) Foreign exchange gain of $0.5 million for the twelve months ended June 30, 2019 includes: (a) $5.4 million of unrealized losses related to foreign trade receivables and payables, (b) $3.4 million of unrealized losses on the unhedged portion of the euro-denominated debt, and (c) $17.9 million of unrealized losses on inter-company loans. The foreign exchange adjustment was also affected by the exclusion of realized foreign currency exchange rate gains from the settlement of inter-company loans of $21.5 million. Inter-company loans are between our subsidiaries and do not reflect the ongoing results of our trade operations. Foreign exchange loss for the twelve months ended June 30, 2018 includes: (a) $2.9 million of unrealized gains related to foreign trade receivables and payables, (b) $11.9 million of unrealized losses on the unhedged portion of the euro-denominated debt, and (c) $10.7 million of unrealized gains on inter-company loans. The foreign exchange adjustment was also affected by the exclusion of realized foreign currency exchange rate losses from the settlement of inter-company loans of $1.8 million. Inter-company loans are between our subsidiaries and do not reflect the ongoing results of our trade operations. 62 (3) We computed the tax effect of adjustments to Adjusted Net Income by applying the statutory tax rate in the jurisdictions to the income or expense items that are adjusted in the period presented; if a valuation allowance exists, the rate applied is zero. (4) Discrete period income tax expense/(benefit) items are unusual or infrequently occurring items primarily including: changes in judgment related to the realizability of deferred tax assets in future years, changes in measurement of a prior year tax position, deferred tax impact of changes in tax law, and purchase accounting. (5) ( )(6) l iDuring fi iimpact NNo. 118, fiscal 2018, we d d fof hthe 2017 Tax Act. In fi recorded a r d d d dand fiscal 2019, we i eduction fof $$3.5 l recorded a net tax hcharge fof $$42.5 d completed our illimillion as a p l analysis, as i i i l rovisional permitted bby i d l illimillion. iestimate fof hthe net ffStaff Accounting i accounting Bulletin i ll i earnings i lreleases ffor hthe quarters In our i hmonths included an djadjustment iin hthe hthree accounting ffor ASC 606. We are no llonger l d d i September 30, 2018, ended d d ended l b d d kimaking hithis djadjustment iin our September 30, 2018 December 31, 2018, dand l relating to a c umulative ffeffect i Adjusted Net Income. presentation fof dj i hMarch 31, 2019, we fof hchange iin b i d b Interest Rate Risk Management A portion of the debt used to finance our operations is exposed to interest-rate fluctuations. We may use various hedging strategies and derivative financial instruments to create an appropriate mix of fixed-and floating-rate assets and liabilities. Historically, we have used interest-rate swaps to manage the economic effect of variable rate interest obligations associated with our floating-rate term loans so that the interest payable on the term loans effectively becomes fixed at a certain rate, thereby reducing the impact of future interest-rate changes on our future interest expense. As of June 30, 2019, we did not have any interest-rate swap agreement in place that would have the economic effect of modifying the variable interest obligations associated with our floating-rate term loans. Currency Risk Management We are exposed to fluctuations in the euro-U.S. dollar exchange rate on our investments in our foreign operations in Europe. While we do not actively hedge against changes in foreign currency, we have mitigated the exposure of our investments in our European operations by denominating a portion of our debt in euros. At June 30, 2019, we had $775.1 million of euro-denominated debt outstanding that qualifies as a hedge of a net investment in foreign operations. Refer to Note 9 to our Consolidated Financial Statements for further discussion of net investment hedge activity in the period. From time to time, we may use forward currency exchange contracts to manage our exposure to the variability of cash flows primarily related to the foreign exchange rate changes of future foreign currency transaction costs. In addition, we may use foreign currency forward contracts to protect the value of existing foreign currency assets and liabilities. Currently, we do not use foreign currency exchange contracts. We expect to continue to evaluate hedging opportunities for foreign currency in the future. Contractual Obligations The following table summarizes our significant contractual obligations as of June 30, 2019: in millions)(1) Long-term debt obligations (2) Interest on long-term obligations (3) Capital lease obligations (4) Operating lease obligations (5) Purchase obligations (6) Other long-term liabilities (7) Total (1) Total Fiscal 2020 Fiscal 2021 - Fiscal 2022 Fiscal 2023 - Fiscal 2024 Thereafter $ 2,823.6 $ 59.7 $ 123.9 $ 357.2 $ 2,282.8 897.8 167.3 58.2 79.4 64.2 133.4 252.6 246.8 5.3 12.2 67.1 5.7 10.4 19.2 10.0 8.7 13.4 15.9 2.3 7.7 265.0 138.2 10.9 — 42.1 $ 4,,090.5 $ 283.4 $ 424.8 $ 643.3 $ 2,,739.0 i Estimated ffuture payments d calculat ded l hthe U.S. d lldollar were i hwith respect to our bli iusing hthe currency l obligations i dand hother li bili liabilitiies d denominated iin a currency d i hother hthan hexchange rates iin ffeffect as fof June 30, 2019. (2) Represents gross maturities of our long-term debt obligations, excluding capital lease obligations as of June 30, 2019. 63 (3) Represents estimated interest payments relating to our long-term obligations, including our capital lease obligations. Estimated future interest payments on our variable-rate debt obligations were calculated using the interest rates in effect as of June 30, 2019. (4) Represents maturities of our capital lease obligations included within long-term debt as of June 30, 2019. (5) Represents minimum rental payments for operating leases having initial or remaining non-cancelable lease terms. (6) Purchase obligations includes agreements to purchase goods or services that are enforceable and specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and approximate timing of the transaction. Purchase obligations disclosed above may include estimates of the period in which cash outflows will occur. Purchase orders entered into in the normal course of business and authorizations to purchase that involve no firm commitment from either party are excluded from the above table. In addition, contracts that can be unilaterally canceled with no termination fee or with proper notice are excluded from our total purchase obligations except for the amount of the termination fee or the minimum amount of goods that must be purchased during the requisite notice period. (7) Primarily relates to certain long-term employee-related liabilities for operations under programs that we have discontinued. The table excludes our retirement and other post-employment benefits ( O“ PEB”)” obligations. The timing and amount of payments for these obligations may be affected by a number of factors, including the funded status of the plans. In fiscal 2020, we are not required to make contributions to our plans to satisfy regulatory funding standards. Beyond fiscal 2020, the actual amounts required to be contributed are dependent upon, among other things, interest rates, underlying asset returns, and the impact of legislative or regulatory actions related to pension funding obligations. Payments due under our OPEB plans are not required to be funded in advance but are generally paid as medical costs are incurred by covered retiree populations and principally depend on the future cost of retiree medical benefits under our plans. Refer to Note 11 to the Consolidated Financial Statements for further discussion. The table also excludes $22.6 million of funded deferred compensation payments owed as of June 30, 2019 to certain employees participating in our deferred compensation plan. The timing and amount of payments for these obligations depend on participant-directed distributions, withdrawals, and status. As part of the deferred compensation plan, we have a corresponding $21.9 million of deferred compensation investments as of June 30, 2019, which will be used to fund future obligations to the participants. Off-Balance Sheet Arrangements Other than operating leases and outstanding letters of credit as discussed above, we do not have any material off-balance sheet arrangement as of June 30, 2019. See Note 7 to the Consolidated Financial Statements for further detail. 64 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are exposed to cash flow and earnings fluctuations as a result of certain market risks. These market risks primarily relate to changes in interest rates associated with our long-term debt obligations and foreign exchange rate changes. Interest Rate Risk We have historically used interest-rate swaps to manage the economic effect of variable-rate interest obligations associated with our floating-rate term loans so that the interest payable on the term loans effectively becomes fixed at a certain rate, thereby reducing the impact of future interest-rate changes on our future interest expense. As of June 30, 2019, we did not have any interest-rate swap agreement in place that would either have the economic effect of modifying the variable interest obligations associated with our floating-rate term loans or would be considered effective cash flow hedges for financial reporting purposes. Foreign Currency Exchange Risk By the nature of our global operations, we are exposed to cash flow and earnings fluctuations resulting from foreign exchange-rate variation. These exposures are transactional and translational in nature. Since we manufacture and sell our products throughout the world, our foreign-currency risk is diversified. Principal drivers of this diversified foreign-exchange exposure include the European euro, British pound, Argentinean peso, Brazilian real, and Australian dollar. Our transactional exposure arises from the purchase and sale of goods and services in currencies other than the functional currency of our operational units. We also have exposure related to the translation of financial statements of our foreign divisions into U.S. dollars, our functional currency. The financial statements of our operations outside the U.S. are measured using the local currency as the functional currency, except in Argentina, a hyper-inflationary economy, where our results are measured in U.S. dollars. Adjustments to translate the assets and liabilities of these foreign operations in U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. Foreign-currency transaction gains and losses calculated by utilizing weighted average exchange rates for the period are included in the statements of operations in other (income)/expense, net. Such foreign currency transaction gains and losses include inter-company loans denominated in non-U.S. dollar currencies. 65 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA INDEX TO FINANCIAL STATEMENTS Consolidated Financial Statements as of June 30, 2019 and 2018 and for the years ended June 30, 2019, 2018 and 2017 Reports of Independent Registered Public Accounting Firm Consolidated Balance Sheets Consolidated Statements of Operations Consolidated Statements of Comprehensive Income Consolidated Statement of Changes in Shareholders’ Equity/(Deficit) Consolidated Statements of Cash Flows Notes to Consolidated Financial Statements 67 71 72 73 74 75 76 66 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Catalent, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Catalent, Inc. and subsidiaries (the Company) as of June 30, 2019 and 2018, the related consolidated statements of operations, comprehensive income, changes in shareholders’ equity/ (deficit), and cash flows for each of the three years in the period ended June 30, 2019, and the related notes and financial statement schedule listed in the Index at Item 15(a)(2) (collectively referred to as the “Consolidated Financial Statements”).” In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2019, in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of June 30, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated August 27, 2019 expressed an unqualified opinion thereon. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Adoption of ASU No. 2014-09 As discussed in Note 1 to the Consolidated Financial Statements, effective July 1, 2018, the Company changed its method of accounting for revenue due to the adoption of Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), and the related amendments. See below for discussion of our related critical audit matter. Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee of the Company’s board of directors and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. Description of the Matter of uncertain tax positions and foreign tax credits As discussed in Note 10 to the Consolidated Financial Statements, the Company recorded income tax expense related to US and non-US tax paying jurisdictions totaling $22.9 million for the year ended June 30, 2019 and a liability for unrecognized tax benefits totaling $3.8 million at June 30, 2019. The Company’s accounting for income taxes involves the application of complex tax regulations in each of the international tax paying jurisdictions in which it operates. The determination of income subject to income tax in each tax paying jurisdiction requires management to apply transfer pricing guidelines for certain intercompany transactions and make assumptions and estimates about the value of transactions when allocating income and deductions between consolidated entities in different tax paying jurisdictions. The estimates and assumptions used in these allocations can result in uncertainty in the measured tax benefit. Additionally, the Company is entitled to claim US foreign tax credits for taxes paid at tax paying jurisdictions. Certain of the assumptions and allocations used in the determination of the key inputs underlying the foreign tax credits are highly subjective and can also materiallyyy affect the calculation of US income taxes owed on ggglobal intangggible low tax income. international 67 Auditing the completeness and measurement of the liability forff recognized tax benefits related to certain intercompany transactions was complex because the assumptions are based on the interpretation of tax laws and legal rulings in multiple tax paying jurisdictions and require significant judgment in determining whether a tax position’s technical merits are more-likely-than-not to be sustained and measuring the amount of tax benefit that qualifies for recognition. Additionally, auditing the calculation of the foreign tax credits was complex because the estimates and assumptions about apportionment and allocation methodologies are highly judgmental. How We Addressed the Matter in Our Audit We tested controls over the process to assess the technical merits of tax positions related to certain intercompany transactions, as well as management’s process to measure the benefit of those tax positions, including controls over the completeness and accuracy of the underlying data. For example, we tested controls over management’s review of the evaluation of matters identified by and discussed with various tax authorities. We also tested controls over including management’s review of such calculations and the completeness and accuracy of the data underlying the calculations. foreign tax credits, the calculation of Our audit procedures with respect to the calculation of the liability for unrecognized tax benefits and the benefit for foreign tax credits involved an assessment of the technical merits of the Company’s tax positions performed with the assistance of tax subject matter professionals with knowledge of and experience with the application of international and local income tax laws by the relevant income tax authorities. These procedures also included, among others, evaluating third-party advice obtained by the Company and making inquiries of its external tax advisers. We also evaluated the Company’s significant assumptions and the completeness and accuracy of the data used to determine the amount of tax benefits recognized and tested the accuracy of such calculations. For foreign tax credits, we also performed sensitivity analyses on the significant assumptions related to allocations and apportionment to evaluate how changes in assumptions affected the measurement of tax credits, and verified the completeness and accuracy of the computations. Valuation of customer relationship intangible assets in the Paragon acquisition Description of the Matter During fiscal 2019, the Company completed its acquisition of Paragon Bioservices, Inc. (Paragon) for an aggregate nominal purchase price of $1,192.1 million. As discussed in Note 3 to the Consolidated Financial Statements, the transaction was accounted for using the acquisition method of accounting for business combinations. Auditing the Company’s accounting for the Paragon acquisition was complex and required the involvement of specialists due to the significant estimation uncertainty involved in determining the $389.0 million fair value of the acquired customer relationship intangible assets recorded. Estimating the fair value of the customer relationship intangible assets involved the application of a valuation methodology and models using assumptions including a discount rate, revenue growth rates and appropriate profit margins on such revenues, customer contract renewal rates and a customer attrition rate. These significant assumptions are forward-looking and could be affected by future economic and market conditions. How We Addressed the Matter in Our Audit We tested controls over the risks of material misstatement relating to the measurement and valuation of the acquired customer relationship intangible assets. For example, we tested controls over management’s review of the valuation models and the underlying assumptions used to develop such estimates. To test the estimated fair value of the acquired customer relationship intangible assets, our audit procedures included, among others, evaluating the Company’s selection of a valuation method and testing the models and significant assumptions used in the models, including the completeness and accuracy of the underlying data. For example, we compared the significant assumptions to current industry and market trends and to the historical results of the acquired business. We also performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the acquired customer relationship intangible assets that would result from changes in the assumptions. In addition, we involved internal valuation specialists to assist in our evaluation of the significant assumptions and methodologies used by the Company. 68 Description of the Matter Fair value of derivative liabilitytt During May 2019, the Company entered into an equity commitment and investment agreement for the issuance and sale of 650,000 shares of Catalent’s Series A Preferred Stock for an aggregate purchase price of $650.0 million. As discussed in Note 9 to the Consolidated Financial Statements, the Series A Preferred Stock included a dividend adjustment feature that met the definition of a derivative for accounting purposes. The dividend adjustment feature was bifurcated from the Series A Preferred Stock and recorded separately as a derivative liability at its estimated fair value on the date of issuance and as of June 30, 2019 of $39.7 million and $26.8 million, resppectivelyy. Auditing the Company’s valuations of this derivative was challenging as the Company uses complex valuation methodologies that incorporate significant assumptions which include the discount rate and forecasted volatility of the Company’s common stock price. The valuations include assumptions about economic and market conditions with uncertain future outcomes. How We Addressed the Matter in Our Audit We tested controls over the risks of material misstatement relating to the valuations of the derivative liability. For example, we tested controls over management’s review of the valuation models, the underlying assumptions used in the models and the related accounting conclusions. Description of the Matter To test the valuations of the derivative liability, our audit procedures included, among others, evaluating the methodologies used in the valuation model and testing the significant assumptions. For example, we compared the discount rate that was adjusted for the credit risk of the Company to the interest rates on comparable debt instruments, and we compared the forecasted volatility of the Company’s common stock price to its historical volatility. We also assessed the completeness and accuracy of the underlying data. In addition, we involved our internal valuation specialists to assist in our evaluation of the significant assumptions and methodologies used by the Company. We have also evaluated the Company’s financial statement disclosures related to these matters included in Note 9 to the Consolidated Financial Statements. Revenue from contracts with customers As discussed above and in Note 1 to the Consolidated Financial Statements, the Company adopted Accounting Standards Codification 606 ( A“ SC 606”): Revenue from Contracts with Customers as of July 1, 2018. As discussed in Note 1 and Note 2 to the Consolidated Financial Statements, the Company earns its revenue by providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. For performance obligations related to services that are required to be recognized over-time, there is judgment involved in determining the most appropriate measure of progress towards satisfaction of each performance obligation. Auditing the Company’s assessment of measure of progress required a high degree of auditor judgment due to the subjectivity in determining the measure that most faithfully depicts the entity’s performance in satisfying performance obligations within each of the Company’s revenue streams and consistently applying the selected measure across similar arrangements. How We Addressed the Matter in Our Audit We tested controls over the risks of material misstatement relating to the determination of the most appropriate measure of progress towards satisfaction of performance obligations for each of its revenue streams. To test the measures of progress used for performance obligations related to services that are required to be recognized over-time, our audit procedures included, among others, evaluating the appropriateness of the Company’s accounting policy for each type of arrangement. We also tested the identified measure of performance for a sample of arrangements by reading the contracts with the customers and reviewing the contract analyses prepared by management. We evaluated whether the selected measures of progress towards satisfaction of performance obligations were applied consistently across similar arrangements. We also tested the completeness and accuracy of the underlying data used for the measure of progress. /s/ Ernst & Young LLP We have served as the Company’s auditor since 2007. Iselin, New Jersey August 27, 2019 69 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Catalent, Inc. Opinion on Internal Control over Financial Reporting We have audited Catalent, Inc. and subsidiaries’ internal control over financial reporting as of June 30, 2019 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Catalent, Inc. and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of June 30, 2019, based on the COSO criteria. As indicated in the accompanying Management’s Annual Report on Internal control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Paragon Bioservices, Inc. (“Paragon”), which is included in the fiscal 2019 consolidated financial statements of the Company and, excluding intangible assets and goodwill arising from the acquisition (which were included in the scope of management's assessment), constituted 4% of total assets as of June 30, 2019 and 1% of revenues for the fiscal year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Paragon. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of June 30, 2019 and 2018, the related consolidated statements of operations, comprehensive income, changes in shareholders’ equity/(deficit), and cash flows for each of the three years in the period ended June 30, 2019, and the related notes and financial statement schedules listed in the Index at Item 15(a) and our report dated August 27, 2019 expressed an unqualified opinion thereon. Basis for Opinion The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Definition and Limitations of Internal Control over Financial Reporting A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. /s/ Ernst & Young LLP Iselin, New Jersey August 27, 2019 70 Catalent, Inc. and Subsidiaries Consolidated Balance Sheets (Dollars in millions, except share and per share data) ASSETS Current assets: Cash and cash equivalents Trade receivables, net Inventories Prepaid expenses and other Total current assets Property, plant, and equipment, net Other assets: Goodwill Other intangibles, net Deferred income taxes Other Total assets June 30, 2019 June 30, 2018 $ 345.4 $ 716.4 257.2 76.8 1,395.8 1,536.7 410.2 555.8 209.1 65.2 1,240.3 1,270.6 2,220.9 1,397.2 930.8 38.6 61.2 544.9 32.9 45.2 $ 6,184.0 $ 4,531.1 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current portion of long-term obligations and other short-term borrowings $ 76.5 $ Accounts payable Other accrued liabilities Total current liabilities Long-term obligations, less current portion Pension liability Deferred income taxes Other liabilities Commitment and contingencies (see Note 16) Total liabilities 255.8 338.4 670.7 2,882.8 143.6 74.4 124.3 — 71.9 192.1 312.9 576.9 2,649.4 131.6 32.5 54.0 — 3,895.8 3,444.4 Redeemable preferred stock, $0.01 par value; 1.0 million and 0 shares authorized at June 30, 2019 and 2018, respectively; 650,000 and 0 shares issued and outstanding at June 30, 2019 and 2018, respectively Shareholders’ equity/(deficit): Common stock, $0.01 par value; 1.0 billion shares authorized in 2019 and 2018; 145.7 million and 133.4 million shares issued and outstanding at June 30, 2019 and 2018, respectively Preferred stock, $0.01 par value, other than redeemable preferred stock; 99.0 million and 100.0 million shares authorized at June 30, 2019 and 2018, respectively; 0 shares issued and outstanding at June 30, 2019 and 2018 Additional paid in capital Accumulated deficit Accumulated other comprehensive income/(loss) Total shareholders’ equity 606.6 1.5 — 2,757.4 (723.4) (353.9) 1,681.6 Total liabilities, redeemable preferred stock, and shareholders’ equity $ 6,184.0 $ The accompanying notes are an integral part of these consolidated financial statements. — 1.3 — 2,283.3 (872.1) (325.8) 1,086.7 4,531.1 71 Catalent, Inc. and Subsidiaries Consolidated Statements of Operations (Dollars in millions, except per share data) Net revenue Cost of sales Gross margin Selling, general, and administrative expenses Impairment charges and loss on sale of assets Restructuring and other Operating earnings Interest expense, net Other expense, net Earnings from operations before income taxes Income tax expense Net earnings Earnings per share: Basic Net earnings Diluted Net earnings Year ended June 30, 2019 2018 2017 $ 2,518.0 $ 2,463.4 $ 1,712.9 1,710.8 805.1 512.0 5.1 14.1 273.9 110.9 2.7 160.3 22.9 137.4 0.92 0.90 $ $ $ 752.6 464.8 8.7 10.2 268.9 111.4 5.5 152.0 68.4 83.6 0.64 0.63 $ $ $ $ $ $ 2,075.4 1,420.8 654.6 402.6 9.8 8.0 234.2 90.1 8.5 135.6 25.8 109.8 0.88 0.87 The accompanying notes are an integral part of these consolidated financial statements. 72 Catalent, Inc. and Subsidiaries Consolidated Statements of Comprehensive Income (Dollars in millions) Net earnings Other comprehensive income, net of tax Foreign currency translation adjustments Defined benefit pension plan Available for sale investment adjustments Other comprehensive income, net of tax Comprehensive income Year Ended June 30, 2019 2018 2017 $ 137.4 $ 83.6 $ 109.8 (18.6) (9.5) — (28.1) (4.4) 4.3 (11.6) (11.7) $ 109.3 $ 71.9 $ (31.9) 13.0 10.5 (8.4) 101.4 The accompanying notes are an integral part of these consolidated financial statements. 73 Catalent, Inc. and Subsidiaries Consolidated Statement of Changes in Shareholders’ Equity/(Deficit) (Dollars in millions, except share data in thousands) Shares of Common Stock Common Stock Additional Paid in Capital Accumulated Deficit Accumulated Other Comprehensive Income/(Loss) Total Shareholders’ Equity/ (Deficit) 124,712.2 $ 1.2 $ 1,976.5 $ (1,036.1) $ (305.7) $ 635.9 337.7 0.1 (29.4) 109.8 20.9 (5.4) 125,049.9 1.3 1,992.0 (955.7) (314.1) (8.4) 7,354.2 1,019.5 277.8 27.2 (13.7) 83.6 (11.7) (29.4) 0.1 20.9 (5.4) 109.8 (8.4) 723.5 277.8 — 27.2 (13.7) 83.6 (11.7) 133,423.6 1.3 2,283.3 (872.1) (325.8) 1,086.7 11,431.4 883.3 0.1 0.1 445.4 33.3 (14.6) 10.0 15.1 (3.8) 137.4 15.1 445.5 0.1 33.3 (14.6) 10.0 (3.8) 137.4 (28.1) (28.1) Balance at June 30, 2016 Cumulative effect of stock compensation standard adoption Share issuances related to stock- based compensation Equity compensation Cash paid, in lieu of equity, for tax withholding Net earnings Other comprehensive income / (loss), net of tax Balance at June 30, 2017 Equity offering, sale of common stock Share issuances related to stock- based compensation Equity compensation Cash paid, in lieu of equity, for tax withholding Net earnings Other comprehensive income / (loss), net of tax Balance at June 30, 2018 Cumulative effect of change in accounting for ASC 606, net of tax Equity offering, sale of common stock Share issuances related to stock- based compensation Equity compensation Cash paid, in lieu of equity, for tax withholding Equity issued in lieu of cash consideration for acquisition Preferred dividend Net earnings Other comprehensive income / (loss), net of tax Balance at June 30, 2019 145,738.3 $ 1.5 $ 2,757.4 $ (723.4) $ (353.9) $ 1,681.6 The accompanying notes are an integral part of these consolidated financial statements. 74 Catalent, Inc. and Subsidiaries Consolidated Statements of Cash Flows (Dollars in millions) CASH FLOWS FROM OPERATING ACTIVITIES: Net earnings Adjustments to reconcile earnings from operations to net cash from operations: Depreciation and amortization Non-cash foreign currency transaction (gains)/losses, net Amortization and write-off of debt financing costs Asset impairments charges and (gain)/loss on sale of assets Reclassification of financing fees paid (Gain)/loss on derivative instrument Equity compensation Provision/(benefit) for deferred income taxes Provision for bad debts and inventory Change in operating assets and liabilities: (Increase) in trade receivables (Increase) in inventories Increase in accounts payable Other assets/accrued liabilities, net - current and non-current Net cash provided by operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Year ended June 30, 2019 2018 2017 $ 137.4 $ 83.6 $ 228.6 (0.5) 14.2 5.1 5.4 (12.9) 33.3 (15.1) 12.5 (118.9) (34.0) 36.2 (43.6) 247.7 190.1 (2.7) 4.7 8.7 11.8 — 27.2 35.4 6.9 (33.6) (1.8) 32.3 11.9 374.5 109.8 146.5 7.8 6.8 9.8 — — 20.9 (1.3) 11.0 (54.9) (13.5) 9.9 46.7 299.5 Acquisition of property and equipment and other productive assets (218.1) (176.5) (139.8) Proceeds from sale of property and equipment Proceeds from sale of subsidiaries Payment for acquisitions, net of cash acquired Payment made for investments Net cash (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Net change in other borrowings Proceeds from borrowing, net Payments related to long-term obligations Financing fees paid Proceeds from sale of common stock, net Proceeds from sale of preferred stock, net Cash paid, in lieu of equity, for tax withholding obligation Net cash provided by financing activities Effect of foreign currency on cash NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS CASH AND EQUIVALENTS AT BEGINNING OF PERIOD CASH AND EQUIVALENTS AT END OF PERIOD SUPPLEMENTARY CASH FLOW INFORMATION: Interest paid Income taxes paid, net 0.5 — (1,291.0) (1.8) (1,510.4) (8.4) 1,447.6 (1,290.3) (24.7) 445.5 646.3 (14.6) 1,201.4 (3.5) (64.8) 410.2 345.4 102.5 42.2 $ $ $ $ $ $ 1.8 3.4 (748.0) — (919.3) (3.1) 442.6 (18.9) (15.6) 277.8 — (13.7) 669.1 (2.4) 121.9 288.3 410.2 83.2 23.9 $ $ $ 0.7 — (169.9) — (309.0) (5.8) 397.4 (218.5) (6.4) — — (5.4) 161.3 4.9 156.7 131.6 288.3 80.8 39.8 The accompanying notes are an integral part of these consolidated financial statements. 75 Catalent, Inc. and Subsidiaries Notes to Consolidated Financial Statements 1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Catalent, Inc. (“Catalent “ “ o” r the Company ”)” directly and wholly owns PTS Intermediate Holdings LLC (“Intermediate “ Holdings”).” Intermediate Holdings directly and wholly owns Catalent Pharma Solutions, Inc. ( O“ perating Company”).” The financial results of Catalent are primarily comprised of the financial results of Operating Company and its subsidiaries on a consolidated basis. On July 31, 2014, the Company commenced an initial public offering (the IP“ O”)” of its common stock, par value $0.01 “ Stock”),” in which it sold a total of 48.9 million shares at a price of $20.50 per share, before underwriting (the Common discounts and commissions. The Common Stock began trading on the New York Stock Exchange (the N“NYSE”)” under the “ symbol CTLT a” s of the IPO. The Company is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. Its oral, injectable, gene therapy, and respiratory delivery technologies address the full diversity of the pharmaceutical industry, including small molecules, protein and gene therapy biologics and consumer health products. Through its extensive capabilities and deep expertise in product development, it helps its customers take products to market faster, including nearly half of new drug products approved by the U.S. Food and Drug Administration (the FD“ A”)” in the last decade. Its advanced delivery technology platforms, its proven formulation, manufacturing, and regulatory expertise, and its broad and deep intellectual property enable its customers to develop more products and better treatments forff patients and consumers. Across both development and delivery, its commitment to reliably supply its customers’ and their patients’ needs is the foundation for the value it provides; annually, it produces approximately 73 billion doses for nearly 7,000 customer products, or approximately 1 in every 20 doses of such products taken each year by patients and consumers around the world. The Company believes that through its investments in growth-enabling capacity and capabilities, its ongoing focus on operational and quality excellence, the sales of existing customer products, the introduction of new customer products, its innovation activities and patents, and its entry into new markets, it will continue to benefit from attractive and differentiated margins and realize the growth potential from these areas. Reportable Segments In fiscal 2018, the Company engaged in a business reorganization to better align its internal business unit structure with its F“ ollow the Molecule s” trategy and the increased focus on its biologics-related offerings. Under the revised structure, the Company created two operating segments from the former Drug Delivery Solutions segment: • • Biologics and Specialty Drug Delivery, which encompasses biologic cell-line development and manufacturing, development and manufacturing services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; and development and manufacturing for inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays; and Oral Drug Delivery, which encompasses comprehensive formulation, development, manufacturing, and analytical development capabilities using advanced processing technologies such as bioavailability enhancement, controlled release, particle size engineering, and taste-masking for solid oral-dose forms. Each of these two segments reports through a separate management team and ultimately reports to the Company's Chief Executive Officer who is designated as the Chief Operating Decision Maker ( CO“ DM”)” for segment reporting purposes. The Company's operating segments are the same as its reporting segments. All prior-period comparative segment information has been restated to reflect the current reportable segments in accordance with Accounting Standards Codification (“ASCA“ 80 Segment Reporting, promulgated by the Financial Accounting Standards Board (the F“ ASB”).” The Company's offerings and services are summarized below by reporting segment. ”) 2)” Softgel Technologies Through its Softgel Technologies segment, the Company provides formulation, development and manufacturing services for soft capsules, or s“ oftgels, w” hich the Company’s predecessor first commercialized in the 1930s and which have continually been enhanced. The Company is the market leader in overall softgel development and manufacturing and holds the leading market position in the prescription arena. The Company’s principal softgel technologies include traditional softgel capsules, in which the shell is made of animal-derived gelatin, and Vegicaps and OptiShell capsules, in which the shell is made from plant- derived materials. Softgel capsules are used in a broad range of customer products, including prescription drugs, over-the- 76 counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. Softgel capsules encapsulate liquid, paste or oil-based active compounds in solution or suspension within an outer shell. In the manufacturing process, the capsules are formed, filled, and sealed simultaneously. The Company typically performs encapsulation for a product within one of its softgel facilities, with active ingredients provided by customers or sourced directly by the Company. Softgels have historically been used to solve formulation challenges or technical issues for a specific drug, to help improve the clinical performance of compounds, to provide important market differentiation, particularly forff over-the-counter medications, and to provide safe handling of hormonal, potent and cytotoxic drugs. The Company also participates in the softgel vitamin, mineral and supplement business in selected regions around the world. With the 2001 introduction of the Company’s plant- derived softgel shell, Vegicaps capsules, consumer health customers have been able to extend the softgel dose form to a broader range of active ingredients and serve patient/consumer populations that were previously inaccessible due to religious, dietary or cultural preferences. In recent years, the Company has extended this platform to pharmaceutical products via its OptiShell capsule offering. The Company’s Vegicaps and OptiShell capsules are protected by patents in most major global markets. Physician and patient studies the Company has conducted have demonstrated a preference for softgels versus traditional tablet and hard capsule dose forms in terms of ease of swallowing, real or perceived speed of delivery, ability to remove or eliminate unpleasant odor or taste and, for physicians, perceived improved patient adherence with dosing regimens. Representative customers of Softgel Technologies include Pfizer, Novartis, Bayer, GlaxoSmithKline, Teva, Johnson & Johnson, Procter & Gamble, and Allergan. Biologics and Specialty Drug Delivery The Company’s Biologics and Specialty Drug Delivery segment provides drug substance development and manufacturing, drug product clinical and commercial manufacturing, integrated clinical and commercial supply solutions for protein and gene therapy biologics and specialty small molecules administered via injection, inhalation and ophthalmic routes, using both traditional and advanced delivery technologies. The business has expertise in development as well as scale up and commercial manufacturing. Representative customers of Biologics and Specialty Drug Delivery include Eli Lilly, Teva, Mylan, Roche, Novartis, Sarepta, and Genentech, along with multiple innovative small and mid-tier pharmaceutical and biologics customers. P”)” as defined by the FDA and other health regulatory agencies to provide maximum efficiency and flexibility. The Indiana”)” added a biologics-focused The Company’s growing biologics offering includes cell-line development based on its advanced and patented GPEx technology, which is used to develop stable, high-yielding mammalian cell lines for both innovator and biosimilar biologic compounds. GPEx technology can provide rapid cell-line development, high biologics production yields, flexibility, and versatility. The Company’s development and manufacturing facility in Madison, Wisconsin has the capability and capacity to produce biologics drug substance from 250L to 4000L scale in single-use reactors, using current good manufacturing practices ( cGM“ fiscal 2018 acquisition of Cook Pharmica LLC (now Catalent Indiana LLC, “Catalent contract development and manufacturing organization with capabilities across biologics development, clinical, and commercial drug substance manufacturing, formulation, finished-dose manufacturing, and packaging. In fiscal 2019, the Company continued to expand production capacity in both Madison and Bloomington, starting construction on a fourth suite at its facility in Madison, Wisconsin and new drug product manufacturing and packaging capacity at its facility in Bloomington, Indiana. The Company’s SMARTag next-generation antibody-drug conjugate technology enables development of antibody-drug conjugates and other protein conjugates with improved efficacy, safety, and manufacturability. In fiscal 2019, the Company launched its OneBio Suite, which provides customers the potential to seamlessly integrate drug substance, drug product, and clinical supply management for products in development, and for integrated commercial supply across both drug substance and product. Combined with offerings from the Company’s other businesses, the Company provides the broadest range of technologies and services supporting the development and launch of new biologic entities, biosimilars, and biobetters to bring a product from gene to commercialization, faster. drug substance “ ff The Company’s range of injectable manufacturing offerings includes filling drugs or biologics into pre-filled syringes, cartridges, and vials, with flexibility to accommodate other formats within our existing network, increasingly focused on complex pharmaceuticals and biologics. With the Company’s range of technologies, the segment is able to meet a wide range of specifications, timelines, and budgets. The Company believes that the complexity of the manufacturing process, the importance of experience and know-how, regulatory compliance, and high start-up capital requirements provide it with a substantial competitive advantage in the market. For example, blow-fill-seal is an advanced aseptic processing technology, which uses a continuous process to form, fill with drug or biologic, and seal a plastic container in a sterile environment. Blow-fill-seal units are currently used for a variety of pharmaceuticals in liquid form, such as respiratory, ophthalmic, and otic products. The Company’s sterile blow-fill-seal manufacturing has significant capacity and flexibility in manufacturing configurations. This business provides flexible and scalable solutions for unit-dose delivery of complex formulations such as suspensions and emulsions. Further, the business provides formulation, engineering and manufacturing solutions related to complex containers. The Company’s regulatory expertise can lead to decreased time to commercialization, and its dedicated development production lines support feasibility, stability, and clinical runs. The Company plans to continue to expand its product line in 77 existing and new markets, and in higher margin specialty products with additional respiratory, ophthalmic, injectable, and nasal applications. The segment also offers analytical development and testing services for large molecules, including cGMP release and stability testing. The Company’s respiratory product capabilities include development and manufacturing services for inhaled products for delivery via metered dose inhalers, dry powder inhalers and intra-nasal sprays. Across multiple complex dosage forms, the segment provides drug and biologic solutions from early-stage development and clinical support all the way through to scale up and commercialization. ib d described b lbelow iin Note 3, BBusiness On May 17, 2019, as d focused on hthe d (“Paragon”), hi hwhich iis f l d ) Inc. ( therapies. Paragon partners i dused iin gene h vectors technologies, i i l h transformative i f based on based vaccines, i i modalities, d li i biologics. Paragon b ibrings proteins, proteins, llwell as bili system ffor gene htherapy, as manufacturing i f development, l dand scientific, d ifi i ical solutions ffor customers. In June 2019, Paragon h i integrated bi l biopharmaceuti southern h located iin d facilities l ili i manufacturing f i f immunotherapies ( h i li specializedd e dand l illwill development i hwith bi including gene h l di oncology i l i capabilitiies iin l bili bCombinations, thhe Company i acquired Paragon i fmanufacture fof dand biopharmaceuti h cutting-edge bi dand hpharma h biotech companies to d dand develop l i adeno-associated iviruses ( based on d d therapies b i d i dand CAR-T llcell h (oncolytic iviruses i xpertise iin AAV vectors, hthe most i i icals, i l fmanufacture (“AAV”) ) therapies), h i commonly l i lentivirus vectors henhance hthe Company’s bi l i iusing cGMP biologics b ibusiness i acquire two ddi i transaction l i Maryland ffrom Novavax, Inc. hThe Novavax plasmids id capabilitiies hthat dand diff d dand additional l blaboratory l closed iin llate d next-generation manufactured f d complex bi l l agreed to dand ) i Bioservices, including i viral l l di dproducts dused d lidelivery differentiat ded i end-to-end d dand lJuly 2019. hother therapeutic i hother l d i d dand d d d i l l i Oral Drug Delivery The Company’s Oral Drug Delivery segment provides various advanced formulation development and manufacturing technologies, and related integrated solutions including: clinical development and commercial manufacturing of a broad range of oral dose forms, including our proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. Representative customers of Oral Drug Delivery include Pfizer, Johnson & Johnson, Bayer, Novartis, and Perrigo. The segment provides comprehensive pre-formulation, development, and cGMP manufacturing at both clinical and commercial scales for traditional and advanced complex oral solid-dose formats, including coated and uncoated tablets, pellet/ bead/powder-filled two-piece hard capsules, granulated powders, and other forms of immediate and modified release branded prescription, generic, and consumer products. The Company has substantial experience developing and scaling up products requiring accelerated development timelines, bioavailability or solubility enhancement, specialized handling (e.g., potent or DEA-regulated materials), complex technology transfers, and specialized manufacturing processes. The Company also provides micronization and particle engineering services, which may enhance a drug’s manufacturability or clinical performance. The Company offers comprehensive analytical testing and scientific services and stability testing for small molecules, both to support integrated development programs and on a fee-for-service services for its customers’ clinical strategies during all stages of development. In recent years, the Company has expanded its network of development sites focused on earlier phase compounds, to engage with more customer molecules, earlier, with the intent to provide later stage manufacturing and supporting services as those molecules progress towards commercial approval and beyond. Demand for the segment’s offerings is driven by the need for scientific expertise and depth and breadth of services offered, as well as by the reliability of its supply, including quality, execution, and performance. basis. The Company provides global regulatory and support a ff (( The Company launched its orally dissolving tablet business in 1986 with the introduction of Zydis tablets, a unique proprietary freeze-dried tablet that typically dissolves in the mouth, without water, in less than three seconds. Most often used for drugs and patient groups that can benefit from rapid oral disintegration, the Company can adapt the Zydis technology to a wide range of products and indications, including treatments forff a variety of central nervous system-related conditions such as migraines, Parkinson’s disease, and schizophrenia, and consumer healthcare products targeting indications such as pain and allergy relief. The Company continues to develop Zydis tablets in different ways with its customers as it extends the application of the technology to new therapeutic categories, including immunotherapy, vaccines, and biologic molecule delivery. In August 2018, hthe Company l Laboratories, Inc. ( i early-development Pharmatek k geographic reach fof hthe h hi acquisition fof h i i i l d b acquired i d Juniper h Pharmaceutic lals, Inc. ( i i dand spray-dry di capabilitiies iit bili i d (“Pharmatek”). k ) h dispersion i (“Juniper”), hi hwhich ) gained h i d extends to hthe U.K. hthe d September 2016 b through iits h Clinical Supply Services The Company’s Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics in clinical trials. The segment offers customers flexible solutions for clinical supplies production and provides distribution and inventory management support for both simple and complex clinical trials. This includes over-encapsulation where needed; supplying placebos, comparator drug procurement, and clinical packages and kits for physicians and patients; inventory management; investigator kit ordering and fulfillment; and return supply 78 reconciliation and reporting. The segment supports trials in all regions of the world through its facilities and distribution network. In fiscal 2018, the Company completed the second phase of its expansion program in our Kansas City, Missouri facility. Further, in fiscal 2016 and again in fiscal 2018, the Company expanded its Singapore facility by building additional flexible cGMP space, and the Company introduced clinical supply services at its existing 100,000 square foot facility in Japan, expanding its Asia Pacific capabilities. Additionally, in fiscal 2013, the Company established its first clinical supply services facility in China as a joint venture and assumed full ownership in fiscal 2015. The Company opened a second Clinical Supply Services facility in China in fiscal 2019. The Company is the leading provider of integrated development solutions and one of the leading providers of clinical trial supplies. Representative customers of Clinical Supply Services include Merck KGaA, IQVIA, Eli Lilly, AbbVie, and Incyte Corporation. Basis of Presentation These financial statements include all of the Company’s subsidiaries, including those operating outside the United States ( U“ .S.”)” and are prepared in accordance with U.S. GAAP. All significant transactions among the Company’s businesses have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, inventory and long-lived asset valuation, goodwill and other intangible asset valuation and impairment, equity-based compensation, income taxes, derivative valuation, and pension plan asset and liability valuation. Actual amounts may differ from these estimated amounts. Foreign Currency Translation The financial statements of the Company’s operations outside the U.S. are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of the foreign operations into U.S. dollars are accumulated as a component of other comprehensive income/(loss) utilizing period-end exchange rates. In June 2018, as a result of the three-year cumulative consumer price index exceeding 100%, Argentina was classified as a highly inflationary economy. Beginning on July 1, 2018, the Company accounts for its Argentine operations as highly inflationary, but this change has not had a material effect on the consolidated financial statements. The currency fluctuation related to certain long-term inter-company loans deemed to not be repayable in the foreseeable future have been recorded within the cumulative translation adjustment, a component of other comprehensive income/(loss). In addition, the currency fluctuation associated with the portion of the Company’s euro-denominated debt designated as a net investment hedge is included as a component of other comprehensive income/(loss). Foreign currency transaction gains and losses calculated by utilizing weighted average exchange rates for the period are included in the statements of operations in “ “other repayable in the foreseeable future. (income)/expense, net. S” uch foreign currency transaction gains and losses include inter-company loans that are Cash and Cash Equivalents All liquid investments purchased with original maturities of three months or less are considered to be cash and equivalents. The carrying value of these cash equivalents approximates fair value. Receivables and Allowance for Doubtful Accounts Trade receivables are primarily comprised of amounts owed to the Company through its operating activities and are presented net of an allowance for doubtful accounts. The Company monitors past due accounts on an ongoing basis and establishes appropriate reserves to cover probable losses. An account is considered past due on the first day after its due date. The Company makes judgments as to its ability to collect outstanding receivables and provides allowances when it concludes that all or a portion of the receivable will not be collected. The Company determines its allowance by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history, the specific customer’s ability to pay its obligation to the Company, and the condition of the general economy and the customer’s industry. 79 Concentrations of Credit Risk and Major Customers Concentration of credit risk, with respect to accounts receivable, is limited due to the large number of customers and their dispersion across different geographic areas. The customers are primarily concentrated in the pharmaceutical and healthcare industry. The Company normally does not require collateral or any other security to support credit sales. The Company performs ongoing credit evaluations of its customers’ financial conditions and maintains reserves for credit losses. Such losses historically have been within the Company’s expectations. No single customer exceeded 10% of revenue during the fiscal years ended 2019, 2018, and 2017 or 10% of accounts receivable as of the years ended 2019 and 2018. Inventories Inventory is stated at the lower of cost or net realizable value, using the first-in, first-out ( F“ IFO”)” method. The Company provides for cost adjustments for excess, obsolete, or slow-moving inventory based on changes in customer demand, technology developments or other economic factors. Inventory consists of costs associated with raw material, labor, and overhead. Goodwill hThe Company accounts ffor dand Intangible d ll Goodwill, bl d tested ffor i butbut i d instead are fourth quarter h d iduring hthe f hOther Assets. U dnder ASC 350, impairment at lleast fof iits fi annually. hThe Company fiscal year or hwhen icircumstances o h ll l i ibl intangible assets goodwill d ill dand i i hwith i d fi i intangible assets ibl fperforms an i indefinite lilives iin accordance d indefinite lilives are not i hwith i d fi i l i evaluation fof i impairment should bbe ld evaluation h i l i d amortized, d ill annually ll goodwill performed. d f i hwith AASC 350 therwise i di i indicate an purchased h d goodwill d ill dand i i l i hThe evaluation may b ibegin i hwith a q li lvalue fof hthe reporting macroeconomic c lrelevant hother reporting hother hithings, dand iunit i hthan-not hthat hthe f ifair include, among l d i respective i not generate a p i iositive response, or ifif no dand performed f hcash flflows, iis d fiscal 2017 l conditions. In fi di i kmarket dand fiscal 2019 hthe Company bbegan iits i fi l impairment i i i iunit to d di i dand onditions, i dindustry ualitative assessment ffor iunit iis lless hthan iits i ientity i li i considered iin a q li d i reporting heach lvalue. Factors i carrying id kmarket dand considerations, fi i id i specific ifi reporting-unit i considerations. fIf hthe i i f uantitative assessment, b performed, a q d hcash flflows, growth rates, h di d d determine h hwhether iit iis more-likely- more-likely- ualitative assessment fperformance fof hthe financial i l qualitative assessment ddoes li discounted d based upon di macroeconomic, i dindustry, quantitative assessment, bbut iin qualitative assessment iis iestimate ffuture proceeded i id d i i i i i dand 2018, hthe Company ilApril 1, 2019 i hwith hthe immediat lely to hthe li dand i qualitative assessment. i requires management to evaluation as fof i l dBased on iits goodwill hthat iit was more lik l impairment. For more i f i d ill i information i regarding di li qualitative assessments i d likely hthan not hthat iits d conducted as fof i d ilApril 1, 2019, hthe Company d determined ffor lvalue, i di i Goodwill. goodwill b lbalances at June 30, 2019, see Note 4, Goodwill respective f ifair i d ill exceeded iits carrying lvalue d d iunit indicating hthere was no heach i reporting i i hwith Property and Equipment and Other Definite-Lived Intangible II Assets Property and equipment are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including leasehold improvements and capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following range of useful lives for its property and equipment categories: buildings and improvements—5 to 50 years; machinery and equipment—3 to 10 years; and furniture and fixtures—3 to 7 years. Depreciation expense was $140.4 million for the fiscal year ended June 30, 2019, $127.5 million for the fiscal year ended June 30, 2018, and $102.2 million for the fiscal year ended June 30, 2017. Depreciation expense includes amortization of assets related to capital leases. The Company charges repairs and maintenance costs to expense as incurred. The amount of capitalized interest was immaterial for all periods presented. Intangible assets with finite lives, including customer relationships, patents, and trademarks, are amortized over their useful lives. The Company also capitalizes certain computer software and development costs in other intangibles, net, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 5 years. The Company evaluates the recoverability of its other long-lived assets, including amortizing intangible assets, if circumstances indicate impairment may have occurred pursuant to ASC 360 Property, Plant and Equipment. This analysis is performed by comparing the respective carrying values of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, the carrying value of such assets is reduced to fair value through a charge to the consolidated statements of operations. Fair value is determined based on assumptions the Company believes marketplace participants would utilize and comparable marketplace information in similar arm’s length transactions. The Company recorded impairment charges related to definite-lived intangible assets and property, plant, and equipment of $5.1 million, $8.7 million, and $9.8 million, forff the fiscal years ended June 30, 2019, 2018, and 2017, respectively. 80 Post-Retirement and Pension Plans The Company sponsors various retirement and pension plans, including defined benefit retirement plans and defined contribution retirement plans. The measurement of the related benefit obligations and the net periodic benefit costs recorded each year are based upon actuarial computations, which require management’s judgment as to certain assumptions. These assumptions include the discount rates used in computing the present value of the benefit obligations and the net periodic benefit costs, the expected future rate of salary increases (for pay-related plans) and the expected long-term rate of return on plan assets (for funded plans). The Company uses the corridor approach to amortize actuarial gains and losses. Effective June 30, 2016, the approach used to estimate the service and interest components of net periodic benefit cost for benefit plans was changed to provide a more precise measurement of such costs. Historically, the Company estimated these service and interest components utilizing a single weighted-average discount rate derived from the yield curve used to measure the benefit obligation at the beginning of the period. Going forward, the Company has elected to utilize an approach that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period. The Company has accounted for this change as a change in accounting estimate that is inseparable from a change in accounting principle and accordingly has accounted for it prospectively. The expected long-term rate of return on plan assets is based on the target asset allocation and the average expected rate of growth for the asset classes invested. The average expected rate of growth is derived from a combination of historic returns, current market indicators, and the expected risk premium for each asset class. The Company uses a measurement date of June 30 for all its retirement and postretirement benefit plans. Derivative Instruments, Hedging Activities, and Fair Value Derivative Instruments and Hedging Activities The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest-rate, liquidity, and credit risk primarily by managing the amount, sources and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings. The Company does not net any of its derivative positions under master netting arrangements. Specifically, the Company is exposed to fluctuations in the euro-U.S. dollar exchange rate on its investments in foreign operations in Europe. While the Company does not actively hedge against changes in foreign currency, it has mitigated the exposure of investments in its European operations through a net-investment hedge by denominating a portion of its debt in euros. In addition, as discussed in Note 9, Derivative Instruments and Hedging Activities, the Company has determined that an aspect of the dividend-rate adjustment feature of the Company’s convertible Series A Preferred Stock (as defined below, see Note 13, Redeemable Preferred Stock—Series A Preferred) sdd hould be accounted for as a derivative liability. Fair Value The Company is required to measure certain assets and liabilities at fair value, either upon initial measurement or for subsequent accounting or reporting. The Company uses fair value extensively in the initial measurement of net assets acquired in a business combination and when accounting for and reporting on certain financial instruments. The Company estimates fair value using an exit price approach, which requires, among other things, that it determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of assets and, for liabilities, assuming the risk of non-performance will be the same before and after the transfer. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. When estimating fair value, depending on the nature and complexity of the assets or liability, the Company may use one or all of the following approaches: • • • Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. Cost approach, which is based on the cost to acquire or construct comparable assets less an allowance for functional and/or economic obsolescence. Income approach, which is based on the present value of the future stream of net cash flows. 81 These fair value methodologies depend on the following types of inputs: • • • Quoted prices for identical assets or liabilities in active markets (called Level 1 inputs). Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are directly or indirectly observable (called Level 2 inputs). Unobservable inputs that reflect estimates and assumptions (called Level 3 inputs). Certain investments that are measured at fair value using the net asset value ( N“NAV”)” per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. • Self-Insurance The Company is partially self-insured for certain employee health benefits and partially self-insured for property losses and casualty claims. The Company accrues for losses based upon experience and actuarial assumptions, including provisions for losses incurred but not reported. Accumulated Other Comprehensive Income/(Loss) Accumulated other comprehensive income, which is reported in the accompanying consolidated statements of changes in shareholders’ equity, consists of net earnings, foreign currency translation, and defined benefit pension plan changes. Research and Development Costs The Company expenses research and development costs as incurred. It records costs incurred in connection with the development of new offerings and manufacturing process improvements within selling, general, and administrative expenses. Such research and development costs amounted to $3.3 million, $6.3 million, and $7.0 million for the fiscal years ended June 30, 2019, June 30, 2018, and June 30, 2017, respectively. The Company records within cost of sales the costs it incurred in connection with the research and development services that it provided to customers and services it performed for customers in support of the commercial manufacturing process. This second type of research and development costs amounted to $51.2 million, $46.2 million, and $45.8 million for the fiscal years ended June 30, 2019, June 30, 2018, and June 30, 2017, respectively. Earnings/(Loss) Per Share The Company reports net earnings per share in accordance with ASC 260 Earnings per Share. The Company computes iusing hthe basic earnings per share for the Common Stock two-class l stockholders by the weighted average number of common shares outstanding during the period. The Series A Preferred Stock, due to its convertible feature, is participating in nature; accordingly, the outstanding shares of Series A Preferred Stock are included in the two-class method. Diluted earnings per common share measures the performance of the Company over the reporting period while giving effect to all potential common shares that were dilutive and outstanding during the period. The denominator includes the weighted average number of basic shares and the number of additional common shares that would have been outstanding if the potential common shares that were dilutive had been issued, and is calculated using either the two- class, treasury stock or if-converted method, whichever is more dilutive. method bby did viding net income attributable to common h d Income Taxes In accordance with ASC 740 Income Taxes, the Company accounts for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities. The Company measures deferred tax assets and liabilities using enacted tax rates in the respective jurisdictions in which it operates. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that the Company will be able to realize some or all of the deferred tax assets. The calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax regulations in each of its tax jurisdictions. The number of years with open tax audits varies by tax jurisdiction. A number of years may lapse before a particular matter is audited and finally resolved. The Company applies ASC 740 to determine the accounting for uncertain tax positions. This standard clarifies the accounting for income taxes by prescribing a minimum recognition threshold a tax position is required to meet before the Company may recognize the position in its financial statements. The standard also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure, and transition. 82 Equity-Based Compensation The Company accounts for its equity-based compensation in accordance with ASC 718 Compensation—Stock Compensation. Under ASC 718, companies recognize compensation expense using a fair-value-based to share-based payments, including stock options and restricted stock units. The expense is measured based on the grant date fair value of the awards, and the expense is recorded over the applicable requisite service period. Forfeitures are recognized as and when they occur. In the absence of an observable market price for a share-based award, the fair value is based upon a valuation methodology that takes into consideration various factors, including the exercise price of the award, the expected term of the award, the current price of the underlying shares, the expected volatility of the underlying share price based on peer companies, the expected dividends on the underlying shares and the risk-free interest rate. method for costs related ff The terms of the Company’s equity-based compensation plans permit an employee holding vested stock options or restricted stock units to elect to have the Company withhold a portion of the shares otherwise issuable upon the employee’s exercise of the option or grant, a so-called net settlement transaction, a” s a means of paying the exercise price, meeting tax withholding requirements, or both. “ Marketable Securities Marketable securities consist of investments that have a readily determinable fair ff value based on quoted market price of value measurement. Under ASC 321, Investments—Equity Securities, these the investment, which is considered a Level 1 fair investments are classified as available-for-sale and are reported at fair value in other assets on the Company’s consolidated balance sheets. Unrealized holding gains and losses are reported within other expense, net on the Company’s consolidated statements of operations. ff Recent Financial Accounting Standards Recently Adopted Accounting Standards ”) 2)” In May 2014, the FASB issued Accounting Standards Update (“ASUA“ model that requires a company to exercise judgment when considering the terms of the contracts and all 014-09, Revenue from Contracts with Customers, which was codified as ASC 606 and superseded nearly all existing revenue-recognition guidance. The guidance’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, the guidance creates a five-step ff relevant facts and circumstances. The five steps require a company to identify customer contracts, identify the separate performance obligations, determine the transaction price, allocate the transaction price to the separate performance obligations, and recognize revenue when or as each performance obligation is satisfied. The guidance allows for either full retrospective adoption, where the standard is applied to all periods presented, or modified retrospective adoption, where the standard is applied only to the most current period presented in the financial statements. The Company adopted the guidance as of July 1, 2018 using the modified retrospective approach applied to contracts that were not completed as of that date. The Company recorded a cumulative effect adjustment to the fiscal 2019 opening balance of its accumulated deficit upon adoption of this guidance, which decreased beginning accumulated deficit by $15.1 million. The following table provides the impact of adopting the guidance on the Company’s financial statements: Year Ended June 30, 2019 (Dollars in millions) Net revenue Cost of sales Gross margin Earnings from operations before income taxes Income tax expense Net earnings/(loss) As Reported $ 2,518.0 $ 1,712.9 805.1 160.3 22.9 Effects of Change Amount without Adoption of ASC 606 $ 79.9 91.3 (11.4) (11.4) (5.9) 2,597.9 1,804.2 793.7 148.9 17.0 131.9 $ 137.4 $ (5.5) $ The principal impact of ASC 606 on the Company’s consolidated balance sheets is the decrease in accumulated deficit described above. The adoption of ASC 606 resulted in three primary changes as compared to the previous revenue recognition guidance: (a) revenue from commercial product supply is recognized following successful completion of the required quality assurance process where it was previously recognized upon shipment of the product to the customer; (b) earlier recognition of revenue 83 from certain commercial supply contract cancellations is recognized as variable consideration as the Company’s performance obligations are satisfied rather than only upon agreement of the amount with the customer; and (c) revenue from sourcing comparator drug product for clinical supply services is recorded net of the cost of procuring it rather than at full value with a corresponding expense. Refer to Note 2, Revenue Recognition for further discussion of the Company’s revenue recognition policy. In March 2017, the FASB issued ASU 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the hich requires entities to report the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, wtt service cost component of the net periodic benefit cost in the same income statement line as other compensation costs arising from services rendered by employees during the reporting period. The other components of the net benefit costs will be presented in the income statement separately from the service cost and below the income from operations subtotal. The Company adopted this guidance as of July 1, 2018, on a retrospective basis, which had an effect on the consolidated statement of operations for fiscal 2018. The following table summarizes the Company’s As Previously Reported and As Adjusted changes to the consolidated statement of operations for fiscal 2018: (Dollars in millions) Selling, general, and administrative expenses Operating earnings Other expense, net Year Ended June 30, 2018 As Previously Reported As Adjusted $ $ 462.6 271.1 7.7 $ $ 464.8 268.9 5.5 In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (AOCI), which permits an entity to Tax Act”)” on reclassify to retained earnings the stranded tax effects caused by the Tax Cuts and Jobs Act of 2017 (the 2017 items within accumulated other comprehensive income/(loss). The ASU will be effective for fiscal years beginning after December 15, 2018 and interim periods within those years. Early adoption is permitted. The Company adopted this guidance and elected not to reclassify the income tax effects stranded in accumulated other comprehensive income to retained earnings and, as a result, there was no impact on the Company’s consolidated financial statements. “ In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which reduces the complexity of and simplifies the application of hedge accounting by issuers. The ASU is effective for fiscal years beginning after December 15, 2018 and interim periods within those years. Early adoption is permitted. The Company early adopted this guidance as of July 1, 2018 on a prospective basis. The adoption of this guidance was not material to the Company’s consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when an entity will apply modification accounting for changes to stock-based compensation arrangements. Modification accounting applies if the value, vesting conditions, or classification of an award changes. The Company adopted this guidance prospectively at the beginning of fiscal 2019. The adoption of this guidance was not material to the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which provides additional guidance on the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The Company adopted this guidance prospectively at the beginning of fiscal 2019. The adoption of this guidance was not material to the Company’s consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which changes the accounting for equity investments and financial liabilities under the fair value option, and presentation and disclosure requirements for financial instruments. The ASU requires equity investments with readily determinable fair values to be measured at fair value and to recognize change in fair value in net earnings. The ASU is not applicable to equity investments accounted for under the equity method of accounting or those that result in consolidation of the investee. The Company adopted this guidance at the beginning of fiscal 2019. The adoption of this guidance was not material to the Company’s consolidated financial statements. ff New Accounting Standards Not Adopted as of June 30, 2019 In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging and Topic 825, Financial Instruments, which clarifies certain hedge accounting 84 guidance. The ASU will be effective for the Company in fiscal 2020. The Company does not expect the adoption of the guidance to have a material impact on its consolidated financial statements. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies that certain transaction between participants in a collaboration arrangement should be accounted for under ASC 606 when the counterparty is a customer. The guidance also precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The ASU will be effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years and should be applied retrospectively. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The ASU will be effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years and allow for either a retrospective or prospective application. The Company does not expect the adoption of the guidance to have a material impact on its consolidated financial statements. SS In August 2018, the FASB issued ASU 2018-14, Compensation—Retirement Benefits—Defined Benefit Plans—General (Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plan, which removes certain disclosures and added additional disclosures around weighted-average interest crediting rates for cash balance plans and explanation for significant gains and losses related to change in the benefit obligation for the period. The ASU will be effective for fiscal years beginning after December 15, 2020 with a retrospective application for all periods presented. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit ”).” CECL requires earlier recognition of credit losses, while also providing additional transparency about credit risk. Losses on Financial Instruments, which introduces a new accounting model known as Credit Expected Credit Losses ( CECL “ The CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses for receivables at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. This model replaces the multiple existing impairment models in current GAAP, which generally require that a loss be incurred before it is recognized. The new standard will also apply to receivables arising from revenue transactions such as contract assets and accounts receivables. The ASU will be effective for fiscal years beginning after December 15, 2019. The Company does not expect the adoption of the guidance to have a material impact to its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which will supersede ASC 840 Leases. The new guidance requires lessees to recognize most leases on their balance sheets for the rights and obligations created by those leases. The guidance requires enhanced disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases and will be effective for public reporting entities in annual reporting periods beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The guidance is required to be adopted using the modified retrospective approach. The Company adopted the guidance on July 1, 2019, and anticipates that most of its operating leases will result in the recognition of additional assets and corresponding liabilities on its consolidated balance sheets. The Company elected the transition method that allows for the application of the standard at the adoption date rather than at the beginning of the earliest comparative period presented in the financial statements. The Company has selected a lease accounting tool and made progress in validating lease data for contracts that are in the Company’s current lease portfolio and continues to assess the impact. The Company expects the additional assets and liabilities it will recognize on its balance sheet as a result of the adoption of this standard to be approximately 1% of total assets and liabilities, respectively. 2. REVENUE RECOGNITION The Company recognizes revenue in accordance with ASC 606. The Company generally earns its revenue by supplying goods or providing services under contracts with its customers in three primary revenue streams: manufacturing and commercial product supply, development services, and clinical supply services. The Company measures the revenue from customers based on the consideration specified in its contracts, excluding any sales incentive or amount collected on behalf of a third party. The Company’s customer contracts generally include provisions entitling the Company to a termination penalty when the customer invokes its contractual right to terminate prior to the contract’s nominal end date. The termination penalties in the customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and 85 obligations throughout the stated duration of the contract. The Company accounts for a contract cancellation as a contract modification in the period in which the customer invokes the termination provision. The determination of the contract termination penalty is based on the terms stated in the related customer agreement. As of the modification date, the Company updates its estimate of the transaction price using the expected value method, subject to constraints, and recognizes the amount over the remaining performance period. The Company generally expenses sales commissions as incurred because either the amortization period is one year or less, or the balance with an amortization period greater than one year is not material. The following table reflects revenue for the twelve months ended June 30, 2019 by type of activity and reporting segment (in millions): Manufacturing & commercial product supply Development services Clinical supply services Total $ $ Softgel Technologies Biologics & Specialty Drug Delivery Oral Drug Delivery Clinical Supply Services Total 806.1 $ 379.5 $ 403.0 $ — $ 1,588.6 66.0 — 872.1 $ 362.6 — 742.1 216.9 — — 321.4 619.9 $ 321.4 Inter-segment revenue elimination $ $ 645.5 321.4 2,555.5 (37.5) 2,518.0 The following table allocates revenue by the location where the goods were made or the service performed: Combined net revenue $ (Dollars in millions) United States Europe Other international locations Elimination of revenue attributable to multiple locations Total Development Services Revenue Twelve Months Ended June 30, 2019 $ $ 1,317.3 842.1 433.8 (75.2) 2,518.0 i ll related to generally ktake hthe fform fof hshort-term, f services contracts i cell-line d include bi l frequently i ll li biologic l d l providing idi dand l transaction lDevelopment obligations vary, bbut f bli i dproduct d d l services i d d otherwise not i intended ffor i iin hthe contracts ffor heach i Company enforceable i hright to payment ffor Company hhas an l development, manufacturing i service iis i recognizes revenue over itime bbecause hthere iis no l fperformance development, commerciall s lale. hThe i service, i f performing f services ffor i i fee-for-service arrangements. formulation, l dproducts hthat are f iprices ffor hthese arrangements are fi d fixed considered to bbe a separate d alternative use to hthe Company ffor hthe asset fPerformance tability, or analyticall s bili l i development or l dunder d include amounts dand i l d stated d obligation. hThe fperformance bli i dand hthe created d generally i completed as fof hthat ddate. promised i d hother heach dand f i bl id ll h d f i i l hThe Company measures progress performed. For f measured d obligation. For i expended. d d dand services to bbe satisfy a p ferformance bli based on ffeffort i i d nature fof hthe recognized over itime i f to iinput method b h d toward f lfilli d require a p i ppayment iis i i i ll d fulfilling iits iortion fof hthe contract initially r llall hEach fof hthese obligations ffor iits i consideration to bbe i liability. id ecorded as a contract li bili d d fperformance bli toward hthe d completion fof iits i l certain types fof arrangements based on hthe d method b h d d iusing an output i i hother types fof arrangements, revenue iis fperformance bli l i related to bi l d completion fof l i fi d satisfied over itime b ll li cell-line d dand based on hthe d obligations development, revenue iis i biologic performed d i i i ktasks i d recognized over itime appropriate d i i i l certain d i l activities hthat are dand depiction fof hthe Company’s progress services arrangements hthat development measured d f iusing an i provides an id h d methods i i d respective arrangement. In received iin dadvance at hthe commencement fof hthe contract, hsuch dadvance i id dunder ASC 606. hThe Company llallocates c onsideration to Generally, hthe Company ll standalone d l observable bl adjusted d kmarket assessment applicable li bl d fi d defined consideration. fIf b i id price iusing an dj price to pay ffor hthe following hthe i customer, based on the payment terms set forth in the applicable customer agreement. d l selling l lli standalone “relative i allocations fof iprices iin iits ll applicable li bl representing hthe amount hthat hthe Company b libelieves hthe services i obligation fperformance bli observable standalone d l bl il bl iusing hthe selling lli available, thhe Company selling lli h approach, ll i typically ddue 30 to 90 ddays f ll iliutilizes b iprices are not service. Payment iis completion fof l iestimates hthe heach i i i i i iprice” as selling lli standalone d l kmarket iis illiwilling provided to hthe id d 86 Manufacturing & Commercial CC Product Supply Revenue i i i l l f dand related l d dproduct dproducts earned bby d dused iin hthe supply revenue di services i consists fof revenue commerciall p droduct i l commerciall s ingredient, or API, hthat iis dand regulated nature fof hthe Company’s b ibusiness, hthese contract terms are hi hl f Manufacturing i dunder llong-term customers lcal i pharmaceuti i hthe iactive h manufacturing i terms fof hthe d Due to hthe fperformance bli combined bi d ingle l considered to bbe a si d id l i i i hwith no price provision ffor a r f contractual iunit, price per recognize hthe orresponding i hright to creating a c l i di i enforceable i hright to payment ffor created dand hthe Company hhas an d completed hthe l f ll based on hthe based generally d fidefines hthe itime hwhen hthe hthe i permit i i permit hthe customer to shipping i hi f manufacturing dand typically owns ll upply arrangements. In hthese arrangements, hthe customer i l d includes hthe generally i f requirements. i l regulatory therefore, are f dand, h stated iin hthe agreement as transferred to hthe customer over itime, d generally ll l f alternative use to hthe Company ffor hthe asset related revenue, bbecause hthere iis no l d l measured d quality assurance process, as dproduct required i d requirements dand hthe related l d arranging hthe i typically ll i manufacturing process. hThe contract i comply i hwith d l procedures to interdependent highly i fperformance contractuallly l applicable contract li bl disposition. hThe customer iis iunits fof conclusion fof hthat process i li regulatory l responsible ffor ibl dproduct hthat hhave ll completed as fof hthat ddate. Progress iis l control over hthe following i obligation. hThe i iprice efund or d dproduct’s di li transaction concession. iprice iis Control iis quality assurance. quality assurance li d supplied to supplies li successfully dproduct f ll handling fof dand h dli exercise fa fi dixed d d i i bl ll li d d d fff f l i i Payment iis terms set f forth iin hthe h typically ddue 30 to 90 ddays fafter hthe i applicable customer agreement. ll li bl goods are hi shipped as d d requested bby hthe customer, b based on hthe payment d d Clinical Supply Services Revenue Clinical supply services contracts generally take the form of fee-for-service arrangements. Performance obligations for clinical supply services revenue typically include a combination of the following services: the manufacturing, packaging, storage, distribution, destruction, and inventory management of customer clinical trials materials. Performance obligations can also include the sourcing of comparator drug products on behalf of customers to be used in clinical trials to compare performance with the drug under clinical investigation. In certain arrangements, the Company recognizes revenue over time when the Company satisfies performance obligations. Satisfaction of the performance obligations is measured using an input method measure of progress based on effort expended by the Company. In other arrangements, revenue is recognized at the point in time when control transfers, which occurs upon either the delivery of the related output of the service to the customer or the completion of quality testing with respect to the product, and the Company has an enforceable right to payment based on the terms of the arrangement. Payment is typically due 30 to 90 days following the completion of services provided to the customer based on the payment terms set forth in the applicable customer agreement. The Company records revenue for comparator sourcing arrangements on a net basis because it is acting as an agent that does not control the product or service before it is transferred to the customer. Payment for comparator sourcing activity is typically received in advance at the commencement of the contract and is initially recorded as a contract liability. Licensing Revenue The Company occasionally enters into arrangements with its customers that include licenses of functional intellectual property, including patents, or other intangible property (“out-licensing”). Revenue from such arrangements are within the scope of ASC 606. The Company does not have any material license arrangement that contains more than one performance obligation. The terms of such out-licensing arrangements include the license of functional intellectual or intangible property (primarily drug formulae) and typically provide for payment by the licensee of one or more of the following: non-refundable, up-front license fees or royalties on net sales of licensed products. The Company recognizes revenue from nonrefundable, up- front license fees when the licensed intellectual property is made available for the customer’s use and benefit, which is generally at the inception of the arrangement. Royalty payments from such arrangements are recognized when subsequent sale or usage of an item subject to the royalty occurs and the performance obligation to which royalty relates is satisfied. Contract Liabilities Contract liabilities relate to cash consideration that the Company receives in advance of satisfying the related performance obligations. Changes in the contractual liabilities balance during the twelve months ended June 30, 2019 are as follows: (Dollars in millions) Balance at June 30, 2018 Balance at June 30, 2019 Revenue recognized in the period from: Amounts included in contracts liability at the beginning of the period 87 $ $ $ 100.9 177.4 55.6 3. BUSINESS COMBINATIONS Paragon Bioservices, Inc. Acquisition Transaction Overview On May 17, 2019, the Company acquired 100% of the equity interest in Paragon for an aggregate nominal purchase price of $1,192.1 million, subject to adjustment, in order to enhance the Company’s solutions. Paragon is l i manufacturing fof f dand development eading contract d h d end-to-end i organization ( i dused iin gene h viral vectors la l di cutting-edge bi d h focused on hthe d d (“CDMO”) f i integrated bi ) therapies. biopharmaceuti dand icals, i l manufacturing including i l di biopharmaceuti d i d f i i l l i ical l development l The Company accounted for the transaction using the acquisition method of accounting for business combinations, in accordance with ASC 805 Business Combinations. The total consideration was (in millions): Cash paid at closing Non-cash consideration Total consideration $ $ 1,182.1 10.0 1,192.1 The operating results of Paragon have been included in the Company’s consolidated financial statements for the period following the acquisition date. For the period from the acquisition date through June 30, 2019, Paragon’s net revenue was $28.9 million and pre-tax earnings were $1.1 million. Transaction costs incurred as a result of the acquisition of $10.0 million are included in selling, general, and administrative expenses for the fiscal year ended June 30, 2019. Paragon Valuation Assumptions and Preliminary Purchase Price Allocation The Company estimated fair values at the date of acquisition for the preliminary allocation of consideration to the net tangible and intangible assets acquired and liabilities assumed. During the measurement period ending no later than one year after the acquisition date, the Company will continue to obtain information to assist in finalizing the fair values of the net assets acquired, which may differ materially from these preliminary estimates. Amounts subject to finalization include working capital adjustments and income taxes. If any measurement period adjustment is material, the Company will record such adjustment, including any related impact on net income, in the reporting period in which the adjustment is determined. The preliminary purchase price allocation to assets acquired and liabilities assumed in the transaction is (in millions): Property, plant, and equipment Identifiable intangible assets Other net assets Deferred revenue Deferred income taxes Total identifiable net assets Goodwill $ 163.2 392.3 (63.0) (73.2) (42.5) 376.8 815.3 Total assets acquired and liabilities assumed $ 1,192.1 The carrying value of trade receivables, raw materials inventory, and trade payables, as well as certain other current and non-current assets and liabilities, generally represented the fair value at the date of acquisition. Property, plant, and equipment was valued using the cost approach, which is based on current replacement and/or reproduction cost of the asset as new, less depreciation attributable to physical, functional, and economic factors. The Company then determined the remaining useful life based on the anticipated life of the asset and Company policy for similar assets. Customer-relationship intangible assets of $389.0 million were valued using the multi-period, excess-earnings method, a method that values the intangible asset using the present value of the after-tax cash flows attributable to the intangible asset only. The significant assumptions used in developing the valuation included the estimated annual net cash flows (including application of an appropriate margin to forecasted revenue, selling and marketing costs, return on working capital, contributory asset charges, and other factors), the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and an assessment of the asset’s life cycle, as well as other factors. The assumptions used in the financial forecasts were based on historical data, supplemented by current and anticipated growth rates, management plans, and market-comparable information. Fair-value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors. Preliminary assumptions may change and may result in significant changes to the final valuation. The customer relationship intangible asset has a weighted average useful life of 13 years. 88 Goodwill has preliminarily been allocated to our Biologics and Specialty Drug Delivery segment as shown in Note 4, Goodwill. Goodwill is mainly comprised of the following: growth from an expected increase in capacity utilization, potential new customers, and advanced gene therapy development and manufacturing capabilities. Goodwill is not deductible for tax purposes. Paragon Pro Forma Results The following table provides pro forma results for the Company, prepared in accordance with ASC 805, for the fiscal years ended June 30, 2019 and June 30, 2018, as if the Company had acquired Paragon as of July 1, 2017 (in millions): Revenue Net earnings the Year Ended June 30, 2019 June 30, 2018 $ 2,638.8 $ 2,535.1 116.0 28.0 The pro forma financial information was prepared based on the historical information of Catalent and Paragon. In order to reflect the acquisition on July 1, 2017, the pro forma financial information includes the impact of incremental stock-based compensation expenses attributable to the acquisition, incremental amortization expense to be incurred based on the fair values of the intangible assets acquired, the incremental depreciation expense related to the fair-value adjustments associated with Paragon's property, plant, and equipment, the additional interest expense associated with the issuance of debt to finance the acquisition, the shares issued to finance the acquisition, the acquisition, integration, and financing-related costs incurred, and income tax-related adjustments for the fiscal years ended June 30, 2019 and 2018, respectively. The results do not include any anticipated cost savings or other effects associated with integrating Paragon into the rest of the Company. Pro forma amounts are not necessarily indicative of results had the acquisition occurred on July 1, 2017 or of future results. Juniper Pharmaceuticals Acquisition On August 14, 2018, Operating Company acquired Juniper through a tender offer and back-end merger, pursuant to the terms of an agreement and plan of merger (the J“ uniper Merger Agreement”),” and Juniper became a wholly owned subsidiary of Operating Company. Under the terms of the Juniper Merger Agreement, all outstanding options to purchase Juniper shares were canceled in exchange for cash equal to the product of the number of Juniper shares subject to the option and the difference between the price per share paid in the tender offer and the exercise price. Similarly, all outstanding restricted stock units in respect of Juniper shares were canceled in exchange for cash equal to the product of the number of units and the price per share paid in the tender offer. Juniper has expertise in formulation development and supply and augments the Company's pre-existing portfolio of solid-state screening, pre-formulation, formulation, analytical, and bioavailability enhancement solutions, including the development of drug products produced using spray-dried dispersion, with integrated development, analytical, and clinical manufacturing. Juniper also owns the ex-U.S. rights to and supplies for sale to its licensee of such rights CRINONE®, a reproductive therapy. The primary operations of the acquired business are located in an owned facility aggregating 38,000 square feet in Nottingham, U.K., and isince hthe included iin hthe l d d acquisition. acquisition Juniper hhas bbeen i liDelivery segment results fof hthe lOral Drug i l The aggregate purchase consideration, net of cash acquired, of $127.5 million was funded by cash on hand. As a result of the preliminary fair value allocations, the Company recognized intangible assets of $69.0 million and $11.0 million for product relationships and customer relationships, respectively. The remainder of the fair value was allocated to tangible assets acquired and goodwill. Pending Acquisitions as of June 30, 2019 i On June 15, 2019, Operating Company acquisition fof BMS’s i i i loral Agreement ffor hthe consideration fof €€45.0 i Italy ( Anagni, i (“Anagni”) ffor i ) l hi transition ffrom BMS to Company i i idaid hthe continuing i i hwith respect to hthe agreement id i dand solid, bi l lid Bristol-Myers l i biologics, i illimillion, ownership. At hthe l supply bby hthe Company fof l lS.r.l. ( dproduct d manufacturing ) (“BMS”), f lplus hthe ibb Squibb sterile il subject to djadjustment, acquisition, BMS illwill enter iinto fa fiive-year i i i closing fof hithis Anagni f i dproducts certain i Purchase h ili facility iin certain i fff produced at hthe d entered iinto a S lale i dand lvalue fof i i i packaging f k i initiating i dand bj i currently l dand d services to i facility. ili ddiAdding i bl illwill Company expects existing European fill/finish sterile fill/fi i h to augment hthe Company's current Anagni to hthe Company’s l b l global enable iit to b hboth capture il bili bili capabilitiies. hThe capabilitiies iin Europe. i i network illwill k la larger segment expand iits bi l d fof hthe bi l acquisition illwill i i i lalso ddadd biologics ddrug i biologics i loral dproduct kmarket iin hthat f solid lid ff offering iin Europe, hi hwhich hthe i region i manufacturing i complement iits l packaging k i dand dand capacity i hThe Anagni i acquisition iis i i i expected to lclose d iduring hthe d second quarter d fof fi fiscal 2020. l 89 On June 26, 2019, Paragon i acquire, ffor $18.0 million lplus hthe i d d equipment needed to operate hthose f hthe i hright to Maryland, l d i hright to assume hthe quality, dand li ffrom hthese f f facility ili biologics biologics employment development, among l dproduct d ili i facilities to Novavax. hThe i i i acquisition illwill i operatives to support iits expand Paragon’s growth. h i transactions l d d l (“Novavax”) ) dand Novavax Inc. ( lvalue fof facilities, ili i d i certain iinventory, Novavax’s i hrights related d l fof more hthan 100 Novavax entered iinto agreements pursuant to hi hwhich Paragon b i d obtained h dunder two f southern dand hthe certain raw i operations, i facilities iin hthe areas fof ili i entered iinto an agreement ffor Paragon to provide id closed iin llate d services i lJuly 2019. hThe Novavax facility lleases iin material iinventory, including l di located at hthose f d hother assets, i l hother hithings. Novavax lalso employees l ili i l d contemplat ded bby hthese agreements l capabilitiies bili dand early-development l l l supplement Paragon’s pool l fof experienced i d 4. GOODWILL The following table summarizes the changes from June 30, 2017, to June 30, 2018 and then to June 30, 2019 in the carrying amount of goodwill in total and by reporting segment: (Dollars in millions) Softgel Technologies Drug Delivery Solutions Biologics and Specialty Drug Delivery Oral Drug Delivery Clinical Supply Services Total Balance at June 30, 2017 $ 415.2 $ 477.2 $ — $ — $ 151.7 $ 1,044.1 Additions Reallocation Divestitures Foreign currency translation adjustments Balance at June 30, 2018 Additions Foreign currency translation adjustments 0.4 — (0.9) 0.5 415.2 — (6.0) — (477.2) — — — — — 341.9 163.8 — — 505.7 815.3 (1.0) — 313.4 — 6.56.5 319.9 25.3 (4.9) — — — 4.7 342.3 — (0.9) 11.7 156.4 1,397.2 — (5.0) 840.6 (16.9) Balance at June 30, 2019 $ 409.2 $ — $ 1,320.0 $ 340.3 $ 151.4 $ 2,220.9 hThe iincrease iin lrelates to hthe Paragon AAccounting lPolicies goodwill iin fi d ill Juniper i dand dand Note 3, BBusiness bCombinations. l fiscal 2019 iin hthe acquisitions, i i i Biologics dand respectively. See Note 1, BBasis fof Presentation Specialty Drug liDelivery i l i dand i l i l lOral Drug dand Summary fof liDelivery segments Significant f 5. DEFINITE-LIVED LONG-LIVED ASSETS The Company’s definite-lived long-lived assets include property, plant, and equipment as well as certain categories of intangible assets with definite lives. Refer to Note 18, Supplemental Balance Sheet Information for details related to property, plant, and equipment. The details of other intangible assets subject to amortization as of June 30, 2019 and June 30, 2018 are as follows (in millions): June 30, 2019 Amortized intangibles: Core technology Customer relationships Product relationships Other Total intangible assets Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value 18 years $ 168.2 $ (105.6) $ 14 years 11 years 4 years 981.1 275.5 9.3 (182.5) (213.9) (1.3) $ 1,434.1 $ (503.3) $ 62.6 798.6 61.6 8.0 930.8 90 June 30, 2018 Amortized intangibles: Core technology Customer relationships Product relationships Total intangible assets Weighted Average Life Gross Carrying Value Accumulated Amortization Net Carrying Value 18 years $ 170.8 $ (85.3) $ 14 years 12 years 587.0 210.5 (140.9) (197.2) $ 968.3 $ (423.4) $ 85.5 446.1 13.3 544.9 Amortization expense was $88.2 million, $62.6 million, and $44.3 million for the fiscal years ended June 30, 2019, 2018, and 2017, respectively. Future amortization expense for the next five fiscal years is estimated to be: (Dollars in millions) Amortization expense 2020 2021 2022 2023 2024 $ 86.8 $ 86.7 $ 85.9 $ 85.6 $ 85.3 The Company impaired definite-lived intangible assets of $0.0 million, $0.6 million and $3.4 million in the fiscal years ended June 30, 2019, 2018 and 2017, respectively. During the fiscal year ended June 30, 2019, the Company recorded $12.3 million of accelerated amortization related to an intangible property licensing right. 6. RESTRUCTURING AND OTHER COSTS Restructuring Costs The Company has implemented plans to restructure certain operations, both domestically and internationally. The restructuring plans focused on various aspects of operations, including closing and consolidating certain manufacturing operations, rationalizing headcount and aligning operations in a strategic and more cost-efficient structure. In addition, the Company may incur restructuring charges in the future in cases where a material change in the scope of operation with its business occurs. Employee-related costs consist primarily of severance costs and also include outplacement services provided to employees who have been involuntarily terminated. Facility exit and other costs consist of accelerated depreciation, equipment relocation costs and costs associated with planned changes to the Company's facilities to streamline its operations. Other Costs/(Income) Other costs include settlement charges for claim amounts that the Company deemed to be both probable and reasonably estimable, but where the Company is not currently in a position to record under U.S. GAAP any insurance recovery with temporary suspension of operations at a softgel manufacturing facility. respect to such costs. The claims relate to a former ff The following table summarizes the costs recorded within restructuring and other costs: (Dollars in millions) Restructuring costs: Employee-related reorganization Facility exit and other costs Total restructuring costs Other - Temporary suspension customer claims (recoveries) Total restructuring and other costs Year ended June 30, 2019 2018 2017 $ $ $ $ 14.1 — 14.1 $ $ — $ 14.1 $ 11.9 0.4 12.3 $ $ (2.1) $ 10.2 $ 7.9 (1.7) 6.2 1.8 8.0 91 7. LONG-TERM OBLIGATIONS AND SHORT-TERM BORROWINGS Long-term obligations and short-term borrowings consist of the following at June 30, 2019 and June 30, 2018: (Dollars in millions) Senior Secured Credit Facilities Term loan facility incremental dollar term B-2 Term loan facility U.S. dollar-denominated Term loan facility euro-denominated Revolving credit facility Euro-denominated 4.75% Senior Notes due 2024 U.S. dollar-denominated 4.875% Senior Notes due 2026 U.S. dollar-denominated 5.00% Senior Notes due 2027 Deferred purchase consideration Capital lease obligations Other obligations Total Less: Current portion of long-term obligations and other short-term borrowings Long-term obligations, less current portion Senior Secured Credit Facilities and Fourth Amendment Maturity as of June 30, 2019 June 30, 2019 June 30, 2018 May 2026 $ 936.2 $ May 2024 May 2024 May 2024 December 2024 January 2026 July 2027 October 2021 2020 to 2044 2019 to 2020 — 346.8 — 428.3 444.6 492.1 143.9 167.3 0.1 2,959.3 — 1,228.4 358.9 — 438.4 443.8 — 188.9 60.8 2.1 2,721.3 76.5 71.9 $ 2,882.8 $ 2,649.4 l i i i i ) h d d i i fof dand d d Fourth h revolving l i Commitment i fff completed fa f l Incremental l i hwith hthe same amendment ( h(the d d d d d fof iincrementall term dused to pay hthe ffees d dunder hthe outstanding U.S. d ll acquisition ddue at iits l h ourth amended h In May 2019, Operating Company i dollar-denomina dted term lloans. hThe d d Amended dand Agreement”). ) “Credit di i then-existing U.S. d ll dand expenses d di credit constitute a new lclass fof U.S. d ll i principal amount l credit di diCredit dunder hthe d related to hthe d l dollar-denomina dted term lloans through hthe borrowed $950 million aggregate existing i i replaced hthe Loans”) ) commitments fof $550 million ( h(the “Incrementall R Amendment”) to iits h “Fourth Amendment, hthe Fourth h i commitments fof $200 million revolving l i )s”). hThe evolving l i diCredit Agreement dollar-denomina dted term lloans proceeds fof hthe Incremental l d i Amendment, a v loluntary prepayment dand a p dated as fof May 20, 2014 ((as diCredit Agreement, d Restated d d As part Operating Company b i Amendment, d Fourth h fof hthe lB loans ( h(the “Incrementall D llollar Term B-2 i hwith new llDollar Term B-2 Loans principal principal terms as hthe h Loans were principal di principal amount consideration ffor hthe Paragon id ( )(1) May 17, 2026 ( h(the “Euro pprepayment h six-month i event d iduring hthe fifirst revolving l i onstitute i Commitments c i existing previously credit di revolving l i i previously hthe fof ( )(1) May 17, 2024 earlier li diCredit Agreement, or any outstanding. remain i Incremental l applicable rate ffor li bl kMarkets Institute, i 2.25%, and such rate can additionally be reduced to LIBOR plus 2.00% in future periods based on a measure of Operating Company's total leverage ratio. The euro-denominated term loans will mature in May 2024. i i i dand ( )(2) hthe 91st dday refinancing h thereof, ifif on f ) fi Notes”) or a p principal amount l i premium fof 1.00% to any i Fourth i d period fafter hthe h commitments i credit di commitments i f hsuch 91st dday any fof thereof, ifif on dollar-denomina dted term lloans, i d applicable rate ffor U.S. d ll li bl bj subject to fa flloor d Interbank ff b k Offered Rate, Offered Rate d Interbank ff b k ibEuribor ( h(the Euro earlier li unsecured notes ddue 2024 di subject to a r l i l l fof hthe Incremental i Amendment d diCredit Agreement dunder hthe diCredit Agreement. hThe dand ( )(2) hthe 91st dday i d refinancing h permitted diCredit Agreement, hthe dLondon bj Revolving i i hwith hthe same i imaturity ddate ffor hthe llDollar Term B-2 fof $300 million iortion fof hthe illwill mature at hthe fof 1.00%) plus 1.75%. The applicable rate for the revolving loans is initially LIBOR plus Operating Company’s 4.75% i hsuch 91st dday any fof hthe Euro Notes l Incremental principal terms as hthe euro-denominatedd term lloans iis subject to fa flloor imaturity fof any d lldollar term lloans or euro term lloans diCredit Agreement, llDollar Term B-2 Loans i closing. hThe i imaturity fof hsuch d lldollar term lloans or euro term lloans llDollar Term B-2 iis LIBOR ( h(the llDollar Term B-2 Loans hthat iis Incremental l i l di lplus 2.25%, outstanding. hThere iis a epricing i i published bby hthe European Money effective ddate. hThe ff fof bli h d revolving lloans iis now including hthe iprior to hthe iprior to hthe dUnder hthe dunder hthe dunder hthe ermitted i d 1.00%) ) dand hthe remain i diCredit senior i fff l i di bj fi d d fff i i i i i fof In July 2018, the Company completed the 2018 Equity Offering (as defined in Note 12, Equity and Accumulated Other Comprehensive Income/(Loss)) and used the net proceeds of $445.5 million and cash on hand to repay $450.0 million of the borrowings then-outstanding under the U.S. dollar-denominated term loans. As of June 30, 2019, the Company has $543.4 million of un-utilized capacity and $6.6 million of outstanding letters of credit under the $550 million revolving credit facility. 92 Euro-denominated 4.75% Senior Notes due 2024 In December 2016, Operating Company completed a private offering of €380.0 million aggregate principal amount of the Euro Notes. The Euro Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The Euro Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”)” and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The Euro Notes will mature on December 15, 2024, bear interest at the rate of 4.75% per annum and are payable semi-annually in arrears on June 15 and December 15 of each year. “ U.S. dollar-denominated 4.875% Senior Notes due 2026 In October 2017, Operating Company completed a private offering of $450.0 million aggregate principal amount of 4.875% Senior Notes due 2026 (the U“ SD 2026 Notes”).” The USD 2026 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The USD 2026 Notes were offered in the U.S to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S only to non-U.S. investors pursuant to Regulation S under the Securities Act. The USD 2026 Notes will mature on January 15, 2026, bear interest at the rate of 4.875% per annum, and are payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The net proceeds of the USD 2026 Notes offering, after payment of the initial purchasers' discount and related fees and expenses, were used to fund a portion of the consideration for the Catalent Indiana acquisition due at its closing. U.S. dollar-denominated 5.00% Senior Notes due 2027 In June 2019, Operating Company completed a private offering of $500.0 million aggregate principal amount of 5.00% h h together i hwith hthe USD 2026 Notes, hthe U“ SD Notes”; “Senior Notes”).” The USD 2027 Notes are fully and unconditionally guaranteed, jointly and Senior Notes due 2027 (the U“ SD 2027 Notes” a dnd, dand Euro Notes together, hthe “Senior severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The USD 2027 Notes were offered in the U.S to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S only to non-U.S. investors pursuant to Regulation S under the Securities Act. The USD 2027 Notes will mature on July 15, 2027, bear interest at the rate of 5.00% per annum, and are payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The net proceeds of the USD 2027 Notes, after payment of the initial purchasers' discount and related fees and expenses, were used to repay in full the outstanding borrowings under Operating Company's U.S. dollar-denominated term loans that mature in May 2024 under its senior secured credit facilities, plus any accrued and unpaid interest thereon, and provide cash on its balance sheet for general corporate purposes. dand hthe USD Notes Bridge Loan Facility In September 2017, contemporaneous with the Company entering into the agreement to acquire Catalent Indiana, Operating Company entered into a debt commitment letter with several financial institutions, as commitment parties. Pursuant to the debt commitment letter and subject to its terms and conditions, the commitment parties agreed to provide a senior unsecured bridge loan facility (the “Bridge back-up financing necessary to fund a portion of the consideration to be paid in the acquisition and related fees, costs, and expenses (the “Bridge Loan Commitment”).” In connection with entering into the Bridge Facility, Operating Company incurred $6.1 million of associated fees. Operating Company did not draw on the Bridge Facility to fund the acquisition, and the Bridge Facility was closed. The Company expensed the $6.1 million in the second quarter of fiscal 2018. Facility”)” of up to $700.0 million in the aggregate for the purpose of providing any “ “ Deferred Purchase Consideration In connection with the acquisition of Catalent Indiana in October 2017, $200.0 million of the $950.0 million aggregate nominal purchase price is payable in $50.0 million installments, on each of the first four anniversaries of the closing date. The Company paid the first installment in October 2018. The balance of the deferred purchase consideration is recorded at fair value as of the date of acquisition, with the difference between the remaining nominal amount and the fair value treated as imputed interest. 93 Long-Term and Other Obligations Other obligations consist primarily of capital leases for buildings and other loans for business and working capital needs. Maturities of long-term obligations, including capital leases of $167.3 million, and other short-term borrowings for future fiscal years are: (Dollars in millions) 2020 2021 2022 2023 2024 Thereafter Total Maturities of long-term and other obligations $ 65.0 66.4 67.9 18.8 351.8 2,421.1 $ 2,991.0 Debt Issuance Costs Debt issuance costs associated with the Credit Agreement (other than its revolving credit facility component) and the Senior Notes are presented as a reduction to the carrying value of the related debt, while debt issuance costs associated with the revolving credit facility are capitalized within prepaid expenses and other assets on the balance sheet. All debt issuance costs are amortized over the life of the related obligation through charges to interest expense in the consolidated statements of operations. The unamortized total of debt issuance costs were $34.6 million and $16.0 million as of June 30, 2019 and 2018, respectively. Amortization of debt issuance costs totaled $3.8 million and $2.5 million for the fiscal years ended June 30, 2019 and 2018, respectively. Guarantees and Security Senior Secured Credit Facilities All obligations under the Credit Agreement, and the guarantees of those obligations, are secured by substantially all of the following assets of Operating Company and each guarantor (Operating Company's parent entity, PTS Intermediate Holdings Intermediate”),” and each of Operating Company's material domestic subsidiaries), subject to certain exceptions: “ LLC ( PTS • • a pledge of 100% of the capital stock of Operating Company and 100% of the equity interests directly held by Operating Company and each guarantor in any wholly owned material subsidiary of Operating Company or any guarantor (which pledge, in the case of any non-U.S. subsidiary of a U.S. subsidiary, will not include more than 65% of the voting stock of such non-U.S. subsidiary); and a security interest in, and mortgages on, substantially all tangible and intangible assets of Operating Company and of each guarantor, subject to certain limited exceptions. The Senior Notes All obligations under the Senior Notes are general, unsecured and subordinated to all existing and future secured indebtedness of the guarantors to the extent of the value of the assets securing such indebtedness. Each of the Senior Notes is separately guaranteed by all of Operating Company's wholly owned U.S. subsidiaries that guarantee the senior secured credit facilities. None of the Senior Notes is guaranteed by either PTS Intermediate or Catalent, Inc. Debt Covenants Senior Secured Credit Facilities The Credit Agreement contains a number of covenants that, among other things, restrict, subject to certain exceptions, Operating Company’s (and Operating Company’s restricted subsidiaries’) ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans or advances; make certain acquisitions; enter into sale and leaseback transactions; amend material agreements governing Operating Company's subordinated indebtedness and change Operating Company's lines of business. The Credit Agreement also contains change of control provisions and certain customary affirmative covenants and events of default. The revolving credit facility requires compliance with a net leverage covenant when there is a 30% or more draw outstanding at a period end. As of June 30, 2019, the Company was in compliance with all material covenants related to the Credit Agreement. Subject to certain exceptions, the Credit Agreement permits Operating Company and its restricted subsidiaries to incur certain additional indebtedness, including secured indebtedness. None of Operating Company’s non-U.S. subsidiaries nor its dormant Puerto Rico subsidiary is a guarantor of the loans. 94 Under the Credit Agreement, Operating Company’s ability to engage in certain activities such as incurring certain additional indebtedness, making certain investments and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as “Consolidated Credit Agreement, is not defined under U.S. GAAP, and is subject to important limitations. EBITDA” i” n the Credit Agreement). Adjusted EBITDA is based on the definitions in the “ The Senior Notes The various indentures governing the Senior Notes (collectively, the “Indentures “ ”)” contain covenants that, among other things, limit the ability of Operating Company and its restricted subsidiaries to incur or guarantee more debt or issue certain preferred shares; pay dividends on, repurchase, or make distributions in respect of their capital stock or make other restricted payments; make certain investments; sell certain assets; create liens; consolidate, merge, sell; or otherwise dispose of all or substantially all of their assets; enter into certain transactions with their affiliates, and designate their subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions, limitations, and qualifications as set forth in the Indentures. The Indentures also contain customary events of default, including, but not limited to, nonpayment, breach of covenants, and payment or acceleration defaults in certain other indebtedness of Operating Company or certain of its subsidiaries. Upon an event of default, either the holders of at least 30% in principal amount of each of the then-outstanding Senior Notes or the applicable Trustee under the Indentures may declare the applicable notes immediately due and payable; or in certain circumstances, the applicable notes will become automatically immediately due and payable. As of June 30, 2019, Operating Company was in compliance with all material covenants under the Indentures. Fair Value of Debt Measurements The estimated fair value of the senior secured credit facilities and Senior Notes, is classified as Level 2 in the fair value hierarchy and is calculated by using a discounted cash flow model with market interest rate as a significant input. The carrying amounts and the estimated fair values of financial instruments as of June 30, 2019 and June 30, 2018 are as follows: (Dollars in millions) Euro-denominated 4.75% Senior Notes U.S. Dollar-denominated 4.875% Senior Notes U.S. Dollar-denominated 5.00% Senior Notes Senior Secured Credit Facilities & Other Total 8. EARNINGS PER SHARE June 30, 2019 June 30, 2018 Fair Value Measurement Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value Level 2 Level 2 Level 2 Level 2 $ 428.3 $ 454.2 $ 438.4 $ 444.6 492.1 457.0 509.0 443.8 — 1,594.3 1,526.0 1,839.1 $ 2,959.3 $ 2,946.2 $ 2,721.3 $ 457.6 428.3 — 1,768.0 2,653.9 The Company computes earnings per share ( EPS “ Stock ((as k ”)” of the Common Stock noted iin Note 12, Equity iusing hthe dand iSeries A P f Diluted net iincome per hshare iis issued d ldwould bbe i referred d d participat participatiing nature fof hthe Income/(Loss) Income/(Loss))). number b securities h ihaving an i i hthe i i reflected iin dil d fl il fof common hshares hthat i dil i issuable bl securities hthat are i diluted d anti-dilutive ffeffect on dil diluted net iincome per hshare are dunder hthe Company’s equity i i earnings per hshare bby i application fof hthe treasury li i d iusing hthe exercise or i i h d weighted-average llall conversion fof i excluded ffrom hthe l d d incentive lplans ((see Note 14, Equity-Based dilutive ffeffect method. hThe dil h d stock k i i required ddue to hthe two-class h d i d method h Comprehensive outstanding lplus hthe di l Accumulated d l hOther number b fof hshares ilutive iinstruments. i potentiall dy dil i ll calculatiion. hThe dil l l dilutive ffeffect il iDilutive fof i EEquity-Based Compensation)) are iSeries A P f fof hthe referred d computed d assuming d i 95 computed bby Stock iis k attributable to C l i d atalent common shareholders for the fiscal years ended June 30, 2019, 2018, and 2017 are as follows: applying hthe if t reconcilia itions bbetween b ibasic method. hThe h d if-converted d earnings per hshare diluted d dand dil ili i (Dollars in millions, except per share data) 2019 2018 2017 Year ended June 30, Net earnings Less: Net earnings attributable to participating securities Net earnings attributable to common shareholders Weighted average shares outstanding Weighted average dilutive securities issuable-stock plans Total weighted average diluted shares outstanding Earnings per share: Basic Diluted $ $ $ $ 137.4 5.4 132.0 $ $ 83.6 — 83.6 $ $ 109.8 — 109.8 144,245,956 131,226,110 124,954,248 1,708,519 1,975,106 1,783,537 145,954,475 133,201,216 126,737,785 0.92 0.90 $ $ 0.64 0.63 $ $ 0.88 0.87 The computations of diluted earnings per share for the fiscal years ended June 30, 2019, 2018, and 2017 exclude the effect of shares potentially issuable under pre-IPO employee stock options totaling 0.0 million, 0.4 million, and 0.4 million options, respectively, because the vesting provisions of those awards specify performance or market-based conditions that had not been met as of the period end. Further, the computation of diluted earnings per share for the year ended June 30, 2019 excludes the effect of approximately 1.6 million “if-converted potentially issuable on the conversion of Series A Preferred Stock, as those shares would be anti-dilutive. s” hares of Common Stock, on a weighted average basis, “ 9. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES Risk Management Objective of Using Derivatives The Companym is exposed to fluctuations in the currency exchange rates applicable to its investments in foreign operations. While the Company does not actively hedge against changes in foreign currency, the Company has mitigated the exposure arising from its investments in its European operations by denominating a portion of its debt in euros. At June 30, 2019, the Company had euro-denominated debt outstanding of $775.1 million, which qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of the translation gains or losses are reported in accumulated other comprehensive income/(loss) as part of the cumulative translation adjustment. The unhedged portions of the translation gains or losses are reported in the consolidated statements of operations. The following table includes net investment hedge activity during the fiscal years ended June 30, 2019 and 2018, respectively: (Dollars in millions) Unrealized foreign exchange gain/(loss) within Other Comprehensive Income Unrealized foreign exchange gain/(loss) within the Consolidated Statements of Operations June 30, 2019 June 30, 2018 $ $ 12.2 7.6 $ $ (12.5) (11.8) The net accumulated gain of this net investment as of June 30, 2019 within accumulated other comprehensive income/ (loss) was $59.8 million. Amounts are reclassified out of accumulated other comprehensive income/(loss) into earnings when the entity in which the gains and losses reside is either sold or substantially liquidated. 2019 2019 Derivative i bili i Liability i As di discussed iin Note 13, Redeemable d RRedeemable hexchange ffor net referred d Stock iin k Preferred Stock d d proceeds fof $646.3 million fafter ki d Stockkk—Series A P f f iSeries A P f referred, iin May 2019, hthe Company i issued hshares fof d taking iinto account hthe $3.7 million iissuance cost. dividend rate hThe di id d Stock iis bj k d li decline iin hthe d i derivative li bili i hthe S&P 500 iSeries A P f trading di liability, k referred d stock i dindex. Stock k subject to djadjustment so as to dused to d determine hthe amount id i provide h ldholders fof hshares fof dividend quarterly di id d l iSeries A P f fof hthe iprice fof hshares fof Common isince hthe ffeature flfluctuates i di k l bifurcated hthe dj d accounted ffor hithis ffeature as da d i Accordingly, hthe Company bif dand Stock. hThe Company d inversely to hchanges iin hthe di trading iprice adjustable di id d bl liability at f ifair erivative li bili d l i determined hthat hithis ffeature h bl referred d i d payable on hshares fof hthe certain i Stock i hwith k iSeries A P f protections i should bbe ld dand iis lalso li k d linked to hthe dividend ffeature ffrom hthe remainder i d referred d against a i accounted ffor as a d fperformance fof fof hthe lvalue fof hthe lvalue. hChanges iin hthe f ifair 96 pricing i i recognized iin hthe i d ifi methodology h d l derivative li bili d i liability willill bbe i based based on ioption methodology iincorporates hthe terms h d l redit ffree iinterest rate, a c di Stock. hThe k iinputs, consolidated statements fof lid lCarlo i specificall by b hoth a Monte preferred f d operations ffor i dand ba bi simulation i l stock arrangement, hi k bonds d high-yield b based on hthe i ldyield i dindexes fof hi h i ld spread b dand hthe iy i hs hi hl derivative li bili liabilit i ighly lvalue fof hthe d i i spread. d credit di specific ifi estimated f ifair volatility a dnd hthe Company's calculatiion fof hthe expected d l l hsuch as hthe conditions fof hthe dand d d ll di i ili d d l heach lvalue was i d period. hThe f ifair d lmodel. hThe ili iprice i reporting i lattice inomial l i l l historical l stock k i iprice fof hshares fof hthe Common trading di i i unobservable bl risk- volatility, hthe risk- sensitive to hchanges iin hthe b hThe Company recorded a g iain fof $12.9 million on hthe hchange iin hthe d d iissuance h f ifair h through June 30, 2019, hi hwhich iis derivative li bili i reflected as a n d liability as off June 30, 2019 was $26.8 million. lvalue fof hthe d i fl i d on-operating expense iin hthe estimated f ifair lvalue fof hthe d i d consolidated statements fof derivative li bili i liability ffrom operations. hThe i lid i hThe f ifair assumptions hthe lvalue fof hthe d i lvalue iis l d l i i derivative li bili i classified as ifi d l underlying hthe liability: Level l calculatiion fof l i3 in thhe f ifair lvalue hi hierarchy ddue to hthe i significant management j djudgment h forth a summary fof hchanges iin hthe h table sets f following bl i i d required ffor d i estimated f ifair ifi lvalue. hThe f ll (Dollars in millions) Balance at July 1, 2018 Series A Preferred Stock at issuance Change in estimated fair value of Series A Preferred Stock derivative liabilit y Balance at June 30, 2019 10. INCOME TAXES Fair Value Measurements of Series A Preferred Stock Derivative Liability Using Significant Unobservable Inputs (Level 3) $ $ $ — 39.7 12.9) ( 26.86.8 2 Earnings from operations before income taxes are as follows for fiscal 2019, 2018, and 2017: (Dollars in millions) U.S. operations Non-U.S. operations Fiscal Year Ended June 30, 2019 2018 2017 $ $ 36.1 124.2 160.3 $ $ 13.3 138.7 152.0 $ $ 5.0 130.6 135.6 The provision /(benefit) for income taxes consists of the following for fiscal 2019, 2018, and 2017: (Dollars in millions) Current: Federal State and local Non-U.S. Total current Deferred: Federal State and local Non-U.S. Total deferred Total provision $ $ $ $ $ 97 Fiscal Year Ended June 30, 2019 2018 2017 $ $ $ 2.4 0.3 25.8 28.5 3.6 (11.6) 2.4 (5.6) $ 14.1 $ 0.1 24.9 39.1 24.2 (1.0) 6.1 29.3 $ $ $ $ 2.1 (0.4) 22.7 24.4 1.9 1.4 (1.9) 1.4 25.8 22.9 $ 68.4 A reconciliation of the provision/(benefit) starting from the tax computed at the federal statutory income tax rate to the tax computed at the Company’s effective income tax rate is as follows for the fiscal years ended 2019, 2018, and 2017: (Dollars in millions) 2019 2018 2017 Fiscal Year Ended June 30, Provision at U.S. federal statutory tax rate $ 33.7 $ 42.7 $ State and local income taxes Foreign tax rate differential Global intangible low tax income Other permanent items Unrecognized tax positions Tax valuation allowance Foreign tax credit Withholding tax and other foreign taxes Change in tax rate R&D tax credit Impact of U.S. tax reform Other (0.3) (3.0) 3.4 4.9 1.1 (11.3) (4.2) 1.1 0.8 (2.3) — (1.0) (2.5) (15.4) — 2.7 (2.4) 7.2 — 1.3 (3.6) (2.4) 42.5 (1.7) $ 22.9 $ 68.4 $ 47.4 (1.7) (25.7) — 2.9 (0.3) 5.6 — (0.2) (0.3) (1.2) — (0.7) 25.8 fiscal year l i jurisdictions i di geographic hi ended June 30, 2019 iis not d d dand hthe iimpact fof didiscrete iitems. bl comparable to hthe Generally, fl ll i i hThe iincome tax primarily ddue to hchanges iin hthe provision ffor hthe fi to hchanges iin pretax iincome over many j il rate are i diffdifferences dand effective tax rate ffor hthe fi i ff ppermanent diffdifferences, i f foreign earnings i i reflects hthe iimpact fl benefit fi hthe b fof U.S. tax fof an iincrease iin f fiscal year l including l di foreign i hother didiscrete tax iitems, hi hwhich may hhave ended June 30, 2019 d d “global i l b l dand hchanges iin hthe tax iimpact imix fof pretax iincome di iunique tax i li valuation llallowance, eduction to hthe state i reflects a r d fl (“GILTI”), ) low-taxed iincome” ( d effective tax rate ffor hthe fi taxed at rates llower hthan hthe U.S. statutory rate. hThe ff l ffoffset bby hthe b implicatiions d intangible l ibl d i i depending on hthe nature fof hthe iitem. hThe dand hthe iimpact fof benefit fi fiscal year l fof permanent diffdifferences, fof an iincrease iin ended June 30, 2018 d d ffoffset bby freform, an iincrease iin hthe valuation llallowance, taxed at rates llower hthan hthe U.S. statutory dand hthe iimpact erate. d l i earnings i i i provision iin hthe i fluctuations iin hthe ff fof permanent iprior year ddue effective tax i As fof June 30, 2019, ffor purposes fof ASC 740-10-25-3, hthe Company h dhad $$62.9 b idi subsidiaries hthat are i i earnings are non-U.S. 740-10-25-3 hthe amount earnings i fof hithis i fof tax hthat i previously l repatriation iin fi i d d intended to bbe considered d id i hmight bbe taxed as a r d fiscal 2018. l payable on hthe esult l permanently l bl eventual l fof hthe hchanges permanently l i illimillion fof reinvested iin hthe Company's non-U.S. d provision hhas bbeen i d reinvested, no tax d i i i i remittance off s huch wrought bby hthe 2017 Tax Act earnings ffrom undistributed d operations. As hthese ASC i iestimate feasible to ibl accrued. It iis not f foreign i repatriate f i intends to d recorded hthe iincome tax consequences earnings. hThe Company i dand iit d d ib di h i i Deferred income taxes arise from temporary differences between the financial reporting and tax reporting bases of assets and liabilities, and operating loss and tax credit carryforwards for tax purposes. The components of the Company's deferred income tax assets and liabilities are as follows at June 30, 2019 and 2018: 98 (Dollars in millions) Deferred income tax assets: Accrued liabilities Equity compensation Loss and tax credit carryforwards Foreign currency Pension Property-related Intangibles Other Euro-denominated debt Total deferred income tax assets Valuation allowance Net deferred income tax assets (Dollars in millions) Deferred income tax liabilities: Accrued liabilities Foreign currency Property-related Goodwill and other intangibles Other Total deferred income tax liabilities Net deferred tax asset/(liability) Fiscal Year Ended June 30, 2019 2018 $ 23.3 35.9 150.0 10.8 30.7 9.7 16.6 7.3 6.0 290.3 (76.3) 214.0 $ $ 19.9 12.9 118.9 9.5 29.4 9.7 22.5 1.9 11.5 236.2 (86.2) 150.0 Fiscal Year Ended June 30, 2019 2018 (1.2) $ (0.8) (47.4) (194.6) (5.8) (0.8) (0.9) (50.2) (95.6) (2.1) (249.8) $ (149.6) (35.8) $ 0.4 $ $ $ $ $ $ Deferred tax assets and liabilities in the preceding table are in the following captions in the consolidated balance sheets at June 30, 2019 and 2018: (Dollars in millions) Non-current deferred tax asset Non-current deferred tax liability Net deferred tax asset/(liability) Fiscal Year Ended June 30, 2019 2018 $ $ $ 38.6 74.4 (35.8) $ 32.9 32.5 0.4 At June 30, 2019, the Company had federal net operating loss ( N“NOL”)” carryforwards of $240.9 million, all of which are Revenue Code”).” Of subject to limitations under Section 382 of the Internal Revenue Code of 1986, as amended (the “Internal this amount, $0.3 million of NOL carryforwards were generated in years prior to April 10, 2007, when the Company was ”).” The remaining carryforwards are limited as a result of the Company's acquisition owned by Cardinal Health, Inc. (“Cardinal of Pharmatek, Juniper, and Paragon. The Company's federal NOL carryforwards will expire in fiscal years 2023 through 2037. “ “ At June 30, 2019, the Company has state tax NOL carryforwards of $459.1 million. Approximately $49.4 million of these losses are state tax losses generated in periods ending on or before April 10, 2007. Substantially all state carryforwards have a twenty-year carryforward period. At June 30, 2019, the Company had international tax NOL carryforwards of $119.7 million. Substantially all of these carryforwards are available for at least three years or have an indefinite carryforward period. The Company had valuation allowances of $76.3 million and $86.2 million as of June 30, 2019 and 2018, respectively, against its deferred tax assets. The Company considered all available evidence, both positive and negative, in assessing the need 99 for a valuation allowance for deferred tax assets. Four possible sources of taxable income were evaluated when assessing the realization of deferred tax assets: • • • • carrybacks of existing NOLs (if permitted under the tax law); ff future reversals of existing taxable temporary differences; tax planning strategies; and ff future taxable income exclusive of reversing temporary differences and carryforwards. The Company considered the need to maintain a valuation allowance on deferred tax assets based on management’s assessment of whether it is more likely than not that the Company would realize the value of its deferred tax assets based on future reversals of existing taxable temporary differences and the ability to generate sufficient taxable income within the carryforward period available under the applicable tax law. During the year ended June 30, 2019, the Company released $12.1 million of its valuation allowance related to certain U.S. combined states, primarily as a result of the deferred tax liability recorded related to the Paragon acquisition. Of the $12.1 million released, $0.5 million relates to state NOL carryforwards, which expire over a number of years beginning in 2028, and the remaining $11.6 million related to other state deferred taxes. While the valuation allowance related to certain U.S. combined states was partially released in year end June 30, 2019, a state valuation allowance of $35.1 million was maintained on state NOLs and temporary differences for the separate and remaining combined states. The Company retained the remaining state valuation allowance due to its separate state history of tax losses, anticipated loss utilization rates and the difference in application of allocated and apportioned income rules for separate states versus combined states. In the normal course of business, the Company's income taxes are subject to audits by federal, state, and foreign tax authorities, some of which are ongoing and may result in proposed assessments. Among the foreign jurisdictions where the Company has substantial tax positions are Germany, the U.K., and France. The Company is no longer subject to examinations by the relevant tax authorities for years prior to fiscal 2009. The Company’s estimate for the potential outcome for any uncertain tax issue is highly judgmental. The Company assesses its income tax positions and recorded benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available at the reporting date. For those tax positions for which it is more likely than not that a tax benefit will be sustained, the Company records the amount that has a greater than 50% likelihood of being realized upon resolution with a taxing authority that has full knowledge of all relevant information based on the technical merits. Interest and penalties are accrued, where applicable. As of June 30, 2019, the Company had a total of $3.8 million of unrecognized tax benefits. A reconciliation of unrecognized tax benefits, excluding accrued interest, for June 30, 2019, 2018, and 2017 is as follows: (Dollars in millions) Balance at June 30, 2016 Additions based on tax positions related to the current year Additions for tax positions of prior years Reductions for tax positions of prior years Settlements Lapse of the applicable statute of limitations Balance at June 30, 2017 Additions based on tax positions related to the current year Additions for tax positions of prior years Reductions for tax positions of prior years Settlements Lapse of the applicable statute of limitations Balance at June 30, 2018 Additions based on tax positions related to the current year Additions for tax positions of prior years Reductions for tax positions of prior years Settlements Lapse of the applicable statute of limitations Balance at June 30, 2019 100 $ $ $ $ 61.5 3.3 0.1 (6.8) (5.4) (0.2) 52.5 0.1 — (2.7) (47.5) (0.2) 2.2 — 3.0 (0.1) — (1.3) 3.8 Of this amount, $3.8 million and $2.2 million represent the amounts of unrecognized tax benefits that, if recognized, would favorably affect the effective income tax rate as of June 30, 2019 and 2018, respectively. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of June 30, 2019, the Company has $1.4 million of accrued interest related to uncertain tax positions, a decrease of $0.6 million from the prior year, the majority of which relates to lapses of the applicable statute of limitations with respect to the imposition of such interest. The Company had $2.0 million and $5.0 million of accrued interest related to uncertain tax positions as of June 30, 2018 and 2017, respectively. The portion of such interest and penalties subject to indemnification by Cardinal is $1.3 million as of June 30, 2019, a decrease of $0.2 million from the prior year. 11. EMPLOYEE RETIREMENT BENEFIT PLANS The Company sponsors various retirement plans, including defined benefit pension plans and defined contribution plans. Substantially all of the Company’s domestic non-union employees are eligible to participate in employer-sponsored retirement savings plans, which include plans created under Section 401(k) of the Internal Revenue Code that provide for the Company to match a portion of employee contributions. The Company’s contributions to the plans are discretionary but are subject to certain minimum requirements as specified in the plans. The Company uses a measurement date of June 30 for all of its retirement and postretirement benefit plans. The Company recorded obligations related to its withdrawal from one multi-employer pension plan related to three former sites. Its withdrawal has been classified as a mass withdrawal under the Multiemployer Pension Plan Amendments Act of 1980, as amended, and the Pension Protection Act of 2006 and resulted in the recognition of liabilities associated with the Company’s long-term obligations in prior-year periods not presented, which were primarily recorded as an expense within discontinued operations. The estimated discounted value of the projected contributions related to these plans is $38.8 million and $39.0 million as of June 30, 2019 and 2018, respectively. The annual cash impact associated with the Company’s long-term obligation arising from this plan is $1.7 million per year. 101 The following table provides a reconciliation of the change in projected benefit obligation and fair value of plan assets for the defined benefit retirement and other retirement plans, excluding the multi-employer pension plan liability: (Dollars in millions) Retirement Benefits Other Post-Retirement Benefits June 30, June 30, 2019 2018 2019 2018 Accumulated Benefit Obligation $ 341.7 $ 322.7 $ 2.9 $ Change in Benefit Obligation Benefit obligation at beginning of year 331.1 330.6 Company service cost Interest cost Employee contributions Plan amendments Curtailments Settlements Special termination benefits Divestitures Other Benefits paid Actual expenses Actuarial (gain)/loss Exchange rate gain/(loss) 3.6 7.5 0.3 — — — — — — (11.5) (0.1) 27.5 (8.7) 3.5 7.3 0.3 — — (0.2) — — — (14.8) — (4.5) 8.9 Benefit obligation at end of year $ 349.7 $ 331.1 $ Change in Plan Assets Fair value of plan assets at beginning of year Actual return on plan assets Company contributions Employee contributions Settlements Special company contributions to fund termination benefits Divestitures Other Benefits paid Actual expenses Exchange rate gain/(loss) 258.1 23.2 9.7 0.3 — — — — (11.5) (0.1) (7.4) 244.6 10.6 11.2 0.3 (0.2) — — — (14.8) — 6.4 Fair value of plan assets at end of year $ 272.3 $ 258.1 $ — $ Funded Status Funded status at end of year Employer contributions between measurement date and reporting date (77.4) (73.0) (2.9) — — Net pension asset (liability) $ (77.4) $ (73.0) $ 102 (0.2) (0.2) 2.8 2.8 — — — — — — — — — — 0.2 — 2.8 — — 0.2 — — — — — (0.2) — — — (2.8) — (2.8) 2.8 — 0.1 — — — — — — — $ — 0.2 — 2.9 — — 0.2 — — — — — (0.2) — — — (2.9) $ The following table provides a reconciliation of the net amount recognized in the consolidated balance sheets: Retirement Benefits Other Post-Retirement Benefits June 30, June 30, 2019 2018 2019 2018 $ 25.8 $ 18.0 $ — $ (Dollars in millions) Amounts Recognized in Statement of Financial Position Noncurrent assets Current liabilities Noncurrent liabilities Total asset/(liability) Amounts Recognized in Accumulated Other Comprehensive Income Transition (asset)/obligation Prior service cost Net (gain)/loss Total accumulated other comprehensive income at the end of the year Additional Information for Plan with ABO in Excess of Plan Assets Projected benefit obligation Accumulated benefit obligation Fair value of plan assets Additional Information for Plan with PBO in Excess of Plan Assets Projected benefit obligation Accumulated benefit obligation Fair value of plan assets Components of Net Periodic Benefit Cost Service cost Interest cost Expected return on plan assets Amortization of unrecognized: Transition (asset)/obligation Prior service cost Net (gain)/loss Net periodic benefit cost (0.3) (2.6) (2.9) — — (0.8) (0.8) 2.9 2.9 — 2.9 2.9 — — 0.1 — — — — (0.3) (2.5) (2.8) — — (1.1) (1.1) 2.8 2.8 — 2.8 2.8 — — — — — — (0.1) — $ (0.1) (0.1) (0.8) (102.4) (77.4) — (0.5) 65.7 65.2 174.6 168.4 71.5 174.6 168.4 71.5 3.6 7.5 (11.5) (0.8) (90.2) (73.0) — (0.5) 53.0 52.5 157.8 152.1 66.7 157.8 152.1 66.7 3.5 7.3 (11.9) — — 2.5 2.1 $ — — 2.4 1.3 $ $ 103 (Dollars in millions) Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income Net (gain)/loss arising during the year Prior service cost (credit) during the year Transition asset/(obligation) recognized during the year Prior service cost recognized during the year Net gain/(loss) recognized during the year Exchange rate gain/(loss) recognized during the year Total recognized in other comprehensive income Total Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Total recognized in net periodic benefit cost and other comprehensive income Estimated Amounts to be Amortized from Accumulated Other Comprehensive Income into Net Periodic Benefit Cost Amortization of: Transition (asset)/obligation Prior service cost/(credit) Net (gain)/loss Financial Assumptions Used to Determine Benefit Obligations at the Balance Sheet Date Discount rate (%) Rate of compensation increases (%) Financial Assumptions Used to Determine Net Periodic Benefit Cost for Financial Year Discount rate (%) Rate of compensation increases (%) Expected long-term rate of return (%) Expected Future Contributions Fiscal year 2020 $ $ $ Retirement Benefits Other Post-Retirement Benefits June 30, June 30, 2019 2018 2019 2018 $ 15.8 $ (3.1) $ 0.2 $ — — — (2.5) (0.6) — — — (2.4) 0.3 12.7 $ (5.2) $ — — — 0.1 — 0.3 $ 14.8 $ (3.9) $ 0.3 $ 0.3 — $ — $ — $ — 4.5 1.90 % 2.03 % 2.50 % 2.03 % 4.70 % — 2.6 2.50 % 2.03 % 2.49 % 2.04 % 5.09 % — (0.1) n/a n/a 2.96 % n/a 3.79 % n/a 3.79 % 3.28 % 0.2 — — — 0.1 — 0.3 — — (0.1) n/a n/a 0.3 $ 11.3 $ 9.4 $ 0.3 $ 104 (Dollars in millions) Expected Future Benefit Payments Financial year 2020 2021 2022 2023 2024 2025-2029 Actual Asset Allocation (%) Equities Government bonds Corporate bonds Property Insurance contracts Other Total Actual Asset Allocation (Amount) Equities Government bonds Corporate bonds Property Insurance contracts Other Total Target Asset Allocation (%) Equities Government bonds Corporate bonds Property Insurance contracts Other Total Retirement Benefits Other Post-Retirement Benefits June 30, June 30, 2019 2018 2019 2018 $ $ $ 12.8 12.1 12.4 13.3 14.1 77.5 17.6 % 29.8 % 15.2 % 2.6 % 11.0 % 23.8 % $ 11.0 12.2 11.8 12.3 13.2 77.7 22.7 % 28.9 % 14.1 % 2.4 % 9.3 % 22.6 % 100.0 % 100.0 % $ 47.9 80.8 41.4 7.2 30.0 65.0 58.7 74.5 36.4 6.2 24.0 58.3 $ 0.3 0.3 0.3 0.3 0.2 1.0 — % — % — % — % — % — % — % $ — $ — — — — — $ 272.3 $ 258.1 $ — $ 21.4 % 30.2 % 13.8 % 2.9 % 11.2 % 20.5 % 22.8 % 29.7 % 13.6 % 2.9 % 10.1 % 20.9 % 100.0 % 100.0 % — % — % — % — % — % — % — % 0.3 0.3 0.3 0.3 0.2 1.0 — % — % — % — % — % — % — % — — — — — — — — % — % — % — % — % — % — % The Company employs a building-block approach in determining the long-term rate of return for plan assets, with proper consideration of diversification and rebalancing. Historical markets are studied and long-term historical relationships between equities and fixed income are preserved consistent with the widely accepted capital market principle that assets with higher volatility generate a greater return over the long run. Current market factors such as inflation and interest rates are evaluated before long-term capital market assumptions are determined. Peer data are reviewed to check for reasonability and appropriateness. Plan assets are recognized and measured at fair value in accordance with the accounting standards regarding fair value measurements. The following are valuation techniques used to determine the fair value of each major category of assets: • Short-term investments, equity securities, fixed-income securities, and real estate are valued using quoted market prices or other valuation methods, and thus are classified within Level 1 or Level 2. 105 • • Insurance contracts and other types of investments include investments with some observable and unobservable prices that are adjusted by cash contributions and distributions, and thus are classified within Level 2 or Level 3. Other assets as of June 30, 2019 and June 30, 2018, including $24.3 million and $26.9 million of investments in hedge funds related to the Company's U.K. pension plan, are classified as Level 2. The following table provides a summary of plan assets that are measured in fair value as of June 30, 2019, aggregated by the level in the fair value hierarchy within which those measurements fall: (Dollars in millions) Equity securities Debt securities Real estate Other Total Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total Assets $ $ 1.8 0.1 0.4 0.6 2.9 $ $ 46.0 $ — $ — $ 122.2 4.9 73.4 246.5 $ — — 21.0 21.0 $ — 1.9 — 1.9 $ 47.8 122.3 7.2 95.0 272.3 Level 3 other assets consist of an insurance contract in the U.K. to fulfill the benefit obligations for a portion of the participant benefits. The value of this commitment is determined using the same assumptions and methods used to value the U.K. Retirement & Death Benefit Plan pension liability. Level 3 other assets also include the partial funding of a pension liability relating to current and former employees of the Company’s Eberbach, Germany facility through a Company promissory note or loan with an annual rate of interest of 5%. The value of this commitment fluctuates due to contributions and benefit payments in addition to loan interest. The following table provides a summary of plan assets that are measured in fair value as of June 30, 2018, aggregated by the level in the fair value hierarchy within which those measurements fall: (Dollars in millions) Equity securities Debt securities Real estate Other Total Level 1 Level 2 Level 3 Investments Measured at Net Asset Value Total Assets $ $ 1.8 0.1 0.4 0.7 3.0 $ $ 56.9 $ — $ — $ 110.8 3.9 60.7 232.3 $ — — 20.9 20.9 $ — 1.9 — 1.9 $ 58.7 110.9 6.2 82.3 258.1 Level 3 other assets consist of an insurance contract in the U.K. to fulfill the benefit obligations for a portion of the participant benefits. The value of this commitment is determined using the same assumptions and methods used to value the U.K. Retirement & Death Benefit Plan pension liability. Level 3 other assets also include the partial funding of a pension liability relating to current and former employees of the Company’s Eberbach, Germany facility through a Company promissory note or loan with an annual rate of interest of 5%. The value of this commitment fluctuates due to contributions and benefit payments in addition to loan interest. 106 The following table provides a reconciliation of the beginning and ending balances of level 3 assets as well as the changes during the period attributable to assets held and those purchases, sales, settlements, contributions and benefits that were paid: Asset Category Allocations - June 30, 2019 Total (Level 3) (Dollars in millions) Fair Value Measurement Using Significant Unobservable Inputs Total (Level 3) Fair Value Measurement Using Significant Unobservable Inputs Insurance Contracts Fair Value Measurement Using Significant Unobservable Inputs Other Beginning Balance at June 30, 2018 Actual return on plan assets: Relating to assets still held at the reporting date Relating to assets sold during the period Purchases, sales, settlements, contributions and benefits paid Transfers in and/or out of Level 3 Ending Balance at June 30, 2019 $ $ 20.9 $ 2.9 $ 0.8 — (1.8) 1.1 21.0 $ 0.4 — (0.2) — 3.1 $ 18.0 0.4 — (1.6) 1.1 17.9 The investment policy reflects the long-term nature of the plans’ funding obligations. The assets are invested to provide the opportunity for both income and growth of principal. This objective is pursued as a long-term goal designed to provide required benefits for participants without undue risk. It is expected that this objective can be achieved through a well-diversified asset portfolio. All equity investments are made within the guidelines of quality, marketability, and diversification mandated by the Employee Retirement Income Security Act of 1974, as amended ( ERISA ”)” (for plans subject to ERISA) and other relevant legal requirements. Investment managers are directed to maintain equity portfolios at a risk level approximately equivalent to that of the specific benchmark established for that portfolio. Assets invested in fixed income securities and pooled fixed-income portfolios are managed actively to pursue opportunities presented by changes in interest rates, credit ratings, or maturity premiums. “ Assumed Healthcare Cost Trend Rates at the Balance Sheet Date Healthcare cost trend rate – initial (%) Pre-65 Post-65 Healthcare cost trend rate – ultimate (%) Pre-65 Post-65 Year in which ultimate rates are reached Pre-65 Post-65 Effect of 1% Change in Healthcare Cost Trend Rate Healthcare cost trend rate up 1% on APBO at balance sheet date on total service and interest cost Effect of 1% Change in Healthcare Cost Trend Rate Healthcare cost trend rate down 1% on APBO at balance sheet date on total service and interest cost Expected Future Contributions Fiscal year 2020 107 Other Post-Retirement Benefits 2019 2018 n/a n/a 19.86 % (1.42)% n/a 4.83 % n/a 2026 n/a 4.83 % n/a 2026 $ 117,555 $ 120,821 3,640 3,118 $ (106,088) $ (108,873) (3,284) (2,804) $ 319,469 $ 311,318 12. EQUITY AND ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) Description of Capital Stock The Company is authorized to issue 1,000,000,000 shares of its Common Stock and 100,000,000 shares of preferred stock, par value $0.01 per share. In accordance with the Company’s amended and restated certificate of incorporation, each share of Common Stock has one vote, and the Common Stock votes together as a single class. Recent Public Offerings of its Common Stock On July 27, 2018, the Company completed a public offering of its Common Stock (the 2018 “ Equity Offering )”) pursuant to which the Company sold 11.4 million shares, including shares sold pursuant to an exercise of the underwriters' over- allotment option, at a price of $40.24 per share, before underwriting discounts and commissions. Net of these discounts and commissions and other offering expenses, the Company's proceeds from the 2018 Equity Offering, including the over-allotment exercise, totaled $445.5 million. The net proceeds of the 2018 Equity Offering were used to repay a corresponding portion of the outstanding borrowings under Operating Company's U.S. dollar-denominated term loans. On September 29, 2017, the Company completed a public offering of its Common Stock (the 2017 “ Equity Offering”),” pursuant to which the Company sold 7.4 million shares, including shares sold pursuant to an exercise of the underwriters' over- allotment option, at a price of $39.10 per share, before underwriting discounts and commissions. Net of these discounts and commissions and other offering expenses, the Company's proceeds from the 2017 Equity Offering, including the over-allotment exercise, totaled $277.8 million. The net proceeds of the 2017 Equity Offering were used to fund a portion of the consideration for the Catalent Indiana acquisition due at its closing. Outstanding Common Stock Shares outstanding of Common Stock include shares of unvested restricted stock. Unvested restricted stock included in reportable shares outstanding was 0.7 million shares as of June 30, 2019. Shares of unvested restricted stock are excluded from the calculation of basic weighted average shares outstanding, but their dilutive impact is added back in the calculation of diluted weighted average shares outstanding. Stock Repurchase Program On October 29, 2015, the Company’s board of directors authorized a share repurchase program to use up to $100.0 million to repurchase shares of outstanding Common Stock. Under the program, the Company is authorized to repurchase shares through open market purchases, privately negotiated transactions, or otherwise as permitted by applicable federal securities laws. There has been no purchase pursuant to this program as of June 30, 2019. Accumulated Other Comprehensive Income/(Loss) Accumulated other comprehensive income/(loss) by component and changes for the fiscal years ended June 30, 2019, 2018, and 2017 consist of: (Dollars in millions) Balance at June 30, 2016 Activity, net of tax Balance at June 30, 2017 Activity, net of tax Balance at June 30, 2018 Activity, net of tax Balance at June 30, 2019 Foreign Curren cy Translation Adjustment Available for Sale Investment Adjustments Pension Liability Adjustments Other Comprehensive Income/(Loss) $ (248.8) $ — $ (56.9) $ (305.7) (31.9) (280.7) (4.4) (285.1) (18.6) 10.5 10.5 (11.6) (1.1) — 13.0 (43.9) 4.3 (39.6) (9.5) $ (303.7) $ (1.1) $ (49.1) $ (8.4) (314.1) (11.7) (325.8) (28.1) (353.9) The Company held an investment in a specialty pharmaceutical company, which was treated as a cost method investment prior to the second quarter of fiscal 2017. In the second quarter of fiscal 2017, the specialty pharmaceutical company became publicly traded after an initial public offering, and, as a result, the Company recognized an initial unrealized gain on the investment of $15.3 million, net of tax. The Company recorded an other-than-temporary impairment in the fourth quarter of fiscal 2018, and the investment has been fully impaired. This amount is reflected in accumulated other comprehensive income. 108 The components of the changes in the cumulative translation adjustment, minimum pension liability, and available for sale investment for the fiscal years ended June 30, 2019, 2018, and 2017 consists of: (Dollars in millions) Foreign currency translation adjustments: Net investment hedge Long term inter-company loans Translation adjustments Total foreign currency translation adjustments, pretax Tax expense/(benefit) Total foreign currency translation adjustments, net of tax Net change in minimum pension liability Net gain/(loss) arising during the year Net (gain)/loss recognized during the year Foreign exchange translation and other Total minimum pension liability, pretax Tax expense/(benefit) Net change in minimum pension liability, net of tax Net change in available for sale investment: Net gain/(loss) arising during the year Net (gain)/loss recognized during the year Foreign exchange translation and other Total change in available for sale investment, pretax Tax expense/(benefit) Net change in available for sale investment, net of tax Year Ended June 30, 2019 2018 2017 $ $ $ $ $ $ $ $ $ 12.2 $ (12.5) $ (12.8) (15.8) (16.4) $ 2.2 (18.6) $ 16.0 $ (2.4) (0.6) 13.0 3.5 9.5 $ $ 9.3 (10.1) (13.3) $ (8.9) (4.4) $ 2.9 2.3 (0.3) 4.9 0.6 4.3 $ $ $ — $ (16.2) $ — — — — — $ (16.2) $ (4.6) — $ (11.6) $ (21.3) (14.3) (3.8) (39.4) (7.5) (31.9) 13.9 4.3 0.5 18.7 5.7 13.0 16.2 — — 16.2 5.7 10.5 13. REDEEMABLE PREFERRED STOCK — SERIES A PREFERRED iDuring May 2019, hthe Company d i ibl Convertible i dand li limitatiions ( h(the iSeries A P f fof hthe L.P. ( h(the “Series A I i i hwith hthe terms fof hthe Company’s Common or d k Stock” ( h(the Preferred f ifi “Certificate fof Stock ffor an aggregate d preferred f ifi Stock”), pursuant to a c designated 1,000,000 hshares fof iits i i d “Series A P f k ) referred d ) Designation”) fil dfiled i hwith hthe purchase h k stated lvalue fof $$1,000 ((as d heach hshare h ihaving an i i i l initial nvestors”), ) d i Certificate off D i ifi Value”). hThe ) l “Stated esignation, hthe Stock i hwith respect to di id d dand i hrights upon hthe dividend i hrights k affairs fof hthe Company. i diwinding up fof hthe ff i ffiliates fof iprice fof $650.0 million, to affili hsuch lvalue may bbe dj d Stock referred kranks k involuntary li l lvoluntary or i lvalue $$0.01, a is its ldsold 650,000 hshares “Series A i fpreferences, designation fof dand issued d Leonard Green & Partners, d adjusted iin accordance d senior to hthe i liquidation, di id i stock, par k ertificate fof d i lDelaware Secretary fof State, iSeries A P f dissolution, l referred d i hrights, dand i d i i i i referred d iSeries A P f dand, ffor so llong as hthe hThe h ldholders fof “as-converted” b ibasis d d election to hthe b l ivoting as a separate lclass. hThey lalso hhave veto i hrights over ldwould hhave an dadverse ffeffect on hthe i hrights fof hthe certain lleverage indebtedness babove iincurrence fof i d b d their board pursuant to h i kh ld i i hwith hthe h ldholders fof hthe Common Stock as a si k their successors hhave hthe i hright to d idesignate a n i hwith hthe Company, hhave hthe i hright to lelect one b amendments to hthe Company’s i certain i d senior or referred esignation. h k forth iin hthe Certificate off D i Stock; iissuance fof ifi d i board d organizational dl documents hthat i i ipari passu i securities; or hthe i iominee ffor bmember ingle lclass on an l k entitled to vote i l d Stock are iSeries A Investors or h i iSeries A P f ratios, as set f i stockholders’ agreement Holders of Series A Preferred Stock have the right under the Certificate of Designation to receive a liquidation preference entitling them to be paid out of our assets available for distribution to stockholders before any payment may be made to holders of any other class or series of capital stock, the value of which preference is equal to the greater of (a) the Stated Value plus all accrued and unpaid dividends or (b) the amount that such holders would have been entitled to receive upon the Company’s liquidation, dissolution, and winding up if all outstanding shares of Series A Preferred Stock had been converted into shares of Common Stock immediately prior to such liquidation, dissolution, or winding up. 109 referred d iSeries A P f l ldHolders fof lValue, Stated d payable bl hsuch rate l i i hwith election, i fifth) certain cases fif h) i distribution fof any di ib i i receive a c Stated d subject to an iincrease to 6.5% or 8.0% d depending on hthe di forth iin hthe h calculat ded on an l initial iissuance, as set f Stock k i l d increasing hthe i anniversary fof hthe i i i l diordinary di id d dividend on hthe Common quarterly iin arrears iin Stock are lalso entitled ( )(a) to hcash, bby i bj k l umulative l i lValue, or iin a c dividend annual di id d ombination h i bi l iprice fof hthe Common equal to 5.0% fof hthe l f thereof at lCatalent’s Stock at hthe f k participat i i dand (b)(b) to h fourth ((or iin ie in thhe ifi Certificate off D i d as-converted b ibasis. esignation, i i i hThe iSeries A P f Price”) ) i i i anniversary fof hthe i i i l outstanding hshares fof h ldholders to convert some or “Conversion hthe hi d third dredeem llall pper hshare hthese. hThe A P f i hrights, iits di equal to hthe l Conversion d k referred i il privileges, lid i Stock are li ibl dand consolidated b lbalance hsheets. d d bj subject to conversion or referred d llall initial iissuance ifif hthe dand hthe Company’s i hright to ( )(x) convert k Stock iis their hshares iinto hshares fof Common fof h i ivarious icircumstances, i dunder redemption fa fi dixed hmonths at twelve l Stock fafter k outstanding hshares fof di iSeries A P f d exceeds 150% fof hthe i Stock k Stock at any itime fafter hthe fif hfifth anniversary fof hthe i i i l i hcash, hshares fof Common dividends, ffor unpaid di id d id i dil dand anti-dilution i their hshares iin hthe event redemption fof h i i iSeries A P f iprice fof hthe Common d referred dand accrued d lValue, Stated d bj subject to customary iPrice iis eligible to d demand d fpreferences, hthe Company hhas l fff k referred d Conversion hother djadjustments. In ddi i Stock as temporary ( fof a chhange fof iSeries A P f classified hthe ifi d referred d lplus llall d k k initial iissuance at a p irice ombination fof i iSeries Stock, or a c k addition, h ldholders fof hshares fof control. Due to hthese ivarious bi l (mezzanine)) e i iquity on l di including hthe i hright fof iprice fof $$49.54 ( h(the Stock at any itime fafter iPrice or ( )(y) d i referred d Proceeds ffrom hthe ff iortion fof hthe consideration ffor hthe Paragon dividend djadjustment ffeature at iits iissuance offering fof hthe iSeries A P f i dused to f fund a p d llallocatedd to thhe di id d NNote 9, DDerivative Instruments dand id dHedging Activities; hthus, hthe k Stock, net k fof i i i acquisition ddue at iits l l separately dand d stock iissuance costs, were $646.3 million, hi hwhich were proceeds, $39.7 million was disclosed iin i closing. i accounted ffor as da d i d liability, as di proceeds fof hthe iissuance were llallocatedd a fs f llollows: erivative li bili fff fOf hthe net d d l (Dollars in millions) Balance at July 1, 2018 Issuance of Series A Preferred Stock Stock issuance costs Net of stock issuance costs Derivative liability (see Note 9) Net proceeds from Series A Preferred Stock issuance at June 30, 2019 14. EQUITY-BASED COMPENSATION $ $ — 650.0 (3.7) 646.3 (39.7) 606.6 The Company’s stock-based compensation is comprised of stock options, restricted stock units, and restricted stock. 2007 Stock Incentive Plan Awards issued under the Company’s pre-IPO incentive compensation plan, known as the 2007 PTS Holdings Corp. Stock Plan”),” were generally issued for the purpose of retaining key employees and directors. Incentive Plan, as amended (the 2007 Certain awards remain outstanding under the 2007 Plan, but it is no longer possible to issue new awards. “ 2014 and 2018 Omnibus Incentive Plans i l di adopted, d effective Omnibus iDirectors d Incentive lPlan ff dBoard fof i lJuly 31, 2014 ( h(the “2014 l i lmployees, stock ioptions, k approved hthe 2018 d In connection i hwith hthe IPO, hthe Company’s dand hthe h ldholder fof a m j approved, hthe 2014 ib d ) Plan”). hThe 2014 lPlan bmembers fof management, e subsidiaries i b idi dand iits dand didirectors fof hthe Company i incentives, i i ) dand d iunits (d fi d i below), (defined b l stock k restricted Company’s h Incentive lPlan ( h(the “2018 l ib Omnibus Plan”), ) i llonger bbe i previously l i remains iin ffeffect as to any i h similar to hthe 2014 lPlan, except hthat ( )(a) a t substantially i i ll d issued may bbe i d stock i or award illwill d iunit k restricted awards hthat may bbe d lvalue hthe ajority fof hthe hshares certain id d i provided ivarious obtain opportunity to b i i hwith hthe i bOctober 2018, hthe k stock. In restricted d i l dand as a r awards may no esult, new d d award. hThe 2018 lPlan iis granted (subject to dj Stock ( bj k dunder hthe 2018 lPlan pursuant to a r including grants fof h ld shareholders dunder hthe 2014 lPlan, il adjustment) ) d stock k estricted i imit on i la li dand ( )(c) hthe 2018 lPlan iimposes fof 15,600,000 hshares fof Common issuable bl reserved hshares bby 2.25 hshares, on-employee didirector. heach hshare fof Common b number ingle year to a n dunder hthe 2018 lPlan, (b)(b) dreduce hthe l Stock i d dmade iin a si although iit l h issued d lotal fof d b k i l Stock Compensation Expense Stock compensation expense recognized in the consolidated statements of operations was $33.3 million, $27.2 million, and $20.9 million in fiscal 2019, 2018, and 2017, respectively. Stock compensation expense is classified in selling, general, and administrative expenses as well as cost of sales. The Company has elected to account for forfeitures as they occur. 110 Stock Options The Company adopted two forms of non-qualified stock option agreement (each, a F“ orm Option Agreement”)” for ff awards granted under the 2007 Plan. Under the Company’s Form Option Agreement adopted in 2009, a portion of the stock option awards vest in equal annual installments over a five-year period contingent solely upon the participant’s continued employment with the Company, or one of its subsidiaries, another portion of the stock option awards vest over a specified performance period upon achievement of pre-determined operating performance targets over time, and the remaining portion of the stock option awards vest upon realization of certain internal rates of return or multiple of investment goals. Under the Company’s other Form Option Agreement, adopted in 2013, a portion of the stock option awards vest over a specified performance period upon achievement of pre-determined operating performance targets over time while the other portion of the stock option awards vest upon realization of a specified multiple of investment goal. The Form Option Agreements include certain forfeiture provisions upon a participant’s separation from service with the Company. Following the IPO, the Company decided not to grant any further award under the 2007 Plan; however, all outstanding awards granted prior to the IPO remained outstanding in accordance with the terms of the 2007 Plan. Stock options granted under the 2014 Plan or 2018 Plan, as applicable, during fiscal 2019, 2018, and 2017 had an intrinsic value of $24.0 million, $2.3 million, and $5.3 million, respectively, which represents approximately 1,179,000, 442,000, and 516,000 shares of Common Stock, respectively. Each stock option granted under the 2014 Plan or 2018 Plan vests in equal annual installments over a four-year employment with the Company, except for a small number of grants that vest based on the achievement of operating performance targets set forth in the award documents. period from the date of grant, contingent upon the participant’s continued d ff Methodology and Assumptions All outstanding stock options have an exercise price per share equal to the fair market value of one share of Common Stock on the date of grant. All outstanding stock options have a contractual term of 10 years, subject to forfeiture under certain conditions upon separation of employment. The grant-date fair value, adjusted for estimated forfeitures, is recognized as expense on a graded-vesting basis over the vesting period. The fair value of stock options is determined using the Black- Scholes-Merton option pricing model for service and performance-based awards, and an adaptation of the Black-Scholes- Merton option valuation model, which takes into consideration the internal rate of return thresholds, for market-based awards. This model adaptation is essentially equivalent to the use of a path dependent-lattice model. The weighted average of assumptions used in estimating the fair value of stock options granted during each year were as follows: Expected volatility Expected life (in years) Risk-free interest rates Dividend yield Year Ended June 30, 2019 22% - 24% 6.25 2.2% - 2.8% None 2018 24% - 27% 6.25 1.9% - 2.1% None 2017 25% - 27% 6.25 1.2% - 1.3% None Public trading of the Common Stock commenced only in July 2014, and, as a result, there is only available limited relevant historical volatility experience; therefore, the expected volatility assumption is based on the historical volatility of the closing share prices of a comparable peer group. The Company selected peer companies from the pharmaceutical industry with similar characteristics, including market capitalization, number of employees and product focus. In addition, since the Company does not have a pattern of exercise behavior of option holders, the Company used the simplified method to determine the expected life of each option, which is the mid-point between the vesting date and the end of the contractual term. The risk-free interest-rate for the expected life of the option is based on the comparable U.S. Treasury yield curve in effect at the time of grant. The weighted-average grant-date fair value of stock options in fiscal 2019, 2018, and 2017 was $9.49 per share, $10.39 per share and $7.13 per share, respectively. 111 The following table summarizes stock option activity and shares subject to outstanding options for the year ended June 30, 2019: Weighted Average Exercise Price Number of Shares Time Weighted Average Contractual Term Aggregate Intrinsic Value Number of Shares Performance Weighted Average Contractual Term Aggregate Intrinsic Value Number of Shares Market Weighted Average Contractual Term Aggregate Intrinsic Value Outstanding as of June 30, 2018 Granted Exercised Forfeited Expired / Canceled Outstanding as of June 30, 2019 Vest and expected to vest as of June 30, 2019 Vested and exercisable as of June 30, 2019 $ $ $ $ $ $ $ $ 23.57 1,712,836 7.01 $27,418,051 550,623 4.79 $13,052,439 117,467 3.35 $ 3,154,413 33.38 1,096,501 — — 82,990 — — — — — 19.14 21.03 — (576,259) (53,264) — — 13,210,249 (205,621) — 5,533,365 (80,065) — 2,301,861 — — — (300,258) — — — — — — — — — — — — 30.55 2,179,814 7.56 51,739,617 127,734 7.68 2,369,291 37,402 3.52 1,373,525 30.37 2,179,814 7.56 22,851,430 127,734 7.68 2,369,291 37,402 3.52 1,373,525 18.63 780,875 5.61 $27,741,047 44,744 1.26 $ 1,635,659 37,402 3.52 $ 1,373,525 In fiscal 2019, participants exercised options to purchase approximately 283,000 net settled shares, resulting in $8.9 million of cash paid on behalf of participants forff withholding taxes. The intrinsic value of the options exercised in fiscal 2019 was $21.0 million. The total fair value of options vested during the period was $3.6 million. As part of the time-based options granted, there were 230,093 shares granted in consideration for the acquisition of Paragon. Excluding this grant, the Weighted Average Exercise Price for fiscal 2019 would have been $41.47. In fiscal 2018, participants exercised options to purchase approximately 240,000 net settled shares, resulting in $5.5 million of cash paid on behalf of participants forff withholding taxes. The intrinsic value of the options exercised in fiscal 2018 was $15.3 million. The total fair value of options vested during the period was $3.6 million. As of June 30, 2019, $6.5 million of unrecognized compensation cost related to granted and not forfeited stock options is expected to be recognized as expense over a weighted-average period of approximately 2.6 years. Restricted Stock and Restricted Stock Units i i d d dand iunits iunits” llwell as stock k f Plan) hshares fof board fof didirectors dunder hthe 2018 lPlan ( d(and f employees l restricted i d k respectively). hThe i restricted d stock hthat hhave l ) hThe Company may grant to ) i d (“performance hshare l dand stock k iSince hthe IPO, hthe Company hhas specified ifi d requirements ( l d granted formerly bmembers fof iits b dand iunits i Stock ( (“restricted d k representing hthe i hright to one hshare fof Common heach k iunits stock stock hthat dand dand didirectors d granted to l k restricted d i employees dated performance-rel certain i l f restricted d i iunits restricted d i restricted i d dand stock k restricted i d “performance hshares,” dand periods fof itime as f i fiscal 2019 and 2018 had grant date fair values aggregating $47.6 million and $44.6 million, granted d iduring fi dunder hthe 2014 l stock units”). ) i k vest over vesting i stock k respectively, which represent approximately 1,066,000 and 1,275,000 shares of Common Stock, respectively. Under the 2014 Plan or 2018 Plan, as appropriate, the performance shares and performance share units vest upon achieving Company financial performance metrics established at the outset of the three-year performance period associated with each grant. The metrics for the fiscal 2016 performance share unit grant were based on performance against a mix of cumulative revenue and cumulative Adjusted EBITDA targets, and these grants vested in fiscal 2018 based on achievement against those targets. Note that EBITDA” i” n the Credit Agreement) is calculated based on the definition in Adjusted EBITDA (which is called “Consolidated the Credit Agreement, is not defined under U.S. GAAP, and is subject to important limitations. The metrics for the fiscal 2017, 2018, and 2019 performance share and performance share unit grants were based on performance against a mix of adjusted EPS targets and relative total shareholder return ( RTSR ”)” targets. Note that adjusted EPS is calculated as a quotient of tax-effected Adjusted EBITDA by the weighted average number of fully diluted shares, is not defined under U.S. GAAP, and is subject to important limitations. The performance shares and performance share units vest following the end of their respective three-year performance periods upon a determination of achievement relative to the targets. Each quarter during the period in which the performance shares and performance share units are outstanding, the Company estimates the likelihood of such achievement by the end of the performance period in order to determine the probability of vesting. The number of shares actually earned at the end of the three-year period for the fiscal 2017, 2018 and 2019 grants will vary, based only on actual performance, from 0% to 200%, or from 0% to 150%, of the target number of performance shares or performance share units specified on the date of grant, in the case of adjusted EPS and RTSR grants, respectively. Time-based restricted stock units and restricted stock generally vest on the second or third anniversary of the date of grant, subject to the participant’s continued employment with the Company. “ “ 112 Methodology and Assumptions - Expense EE Recognition and Grant Date Fair Value The fair values of (a) time-based restricted stock units and restricted stock are recognized as expense on a cliff-vesting schedule over the applicable vesting period and (b) performance shares and performance share units are re-assessed quarterly as discussed above. The grant date fair values of both time-based and performance-based shares and units are determined based on the number of shares subject to the grants and the fair value of the Common Stock on the dates of the grants, as determined by the closing market prices. Time-Based Restricted Stock Units and Restricted Stock The following table summarizes activity in unvested time-based restricted stock units and restricted stock for the year ended June 30, 2019: Unvested as of June 30, 2018 Granted Vested Forfeited Unvested as of June 30, 2019 Time-Based Units and Shares Weighted Average Grant-Date Fair Value 1,004,236 $ 681,702 196,973 94,115 1,394,850 $ 31.81 44.16 31.90 36.32 37.53 Adjusted EPS and Other Performance Share Units and Performance Shares The following table summarizes activity in unvested performance share units and performance shares for the year ended June 30, 2019: Unvested as of June 30, 2018 Granted Vested Forfeited Unvested as of June 30, 2019 Performance-Based Units and Shares Peerfoormanccee Basseedddd sed e o Performance Based Performance-Based 577,856 ce $ Weighted Average Grant-Date Fair Value 213,730 93,082 54,049 644,455 $ 30.30 43.81 31.77 40.68 33.70 RTSR Performance Shares and Performance Share Units The fair value of the RTSR performance share units and performance shares is determined using the Monte Carlo pricing model because the number of shares to be awarded is subject to a market condition. The Monte Carlo simulation is a generally accepted statistical technique used to simulate a range of possible future outcomes. Because the valuation model considers a range of possible outcomes, compensation cost is recognized regardless of whether the market condition is actually satisfied. The assumptions used in estimating the fair value of the RTSR performance share units and performance shares granted during each year were as follows: Expected volatility Exppected life ((in yyears)) Risk-free interest rates Dividend yield Year Ended June 30, 2019 30% - 33% 2.4 - 3.0 2.5% - 3.0% None 2018 32% - 33% 2.4 - 2.9 1.4% - 2.1% None 113 The following table summarizes activity in unvested RTSR performance share units and performance shares for the year ended June 30, 2019: Unvested as of June 30, 2018 Granted Vested Forfeited Unvested as of June 30, 2019 RTSR Units and Shares Weighted Average Grant-Date Fair Value 483,097 $ 170,969 98,373 30,437 525,256 $ 32.47 47.64 40.01 36.76 35.75 In fiscal 2019, participants vested and settled 262,000 net settled shares, resulting in $5.4 million of cash paid on behalf of participants forff withholding taxes. In fiscal 2018, participants vested and settled 420,000 net settled shares, resulting in $8.2 million of cash paid on behalf of participants forff withholding taxes. As of June 30, 2019, $39.1 million of unrecognized compensation cost related to restricted stock and restricted stock units is expected to be recognized as expense over a weighted-average period of approximately 1.8 years. The weighted-average grant-date fair value of restricted stock and restricted stock units in fiscal 2019, 2018, and 2017 was $44.65, $34.99, and $25.20, respectively. The fair value of restricted stock units vested in fiscal 2019, 2018, and 2017 was $13.2 million, $13.6 million, and $1.1 million, respectively. 15. OTHER (INCOME)/EXPENSE, NET The components of other (income)/expense, net for the twelve months ended June 30, 2019, 2018, and 2017 are as follows: (Dollars in millions) Other (income)/expense, net Debt refinancing costs (1) Foreign currency (gains) and losses (2) Other (3) Total other (income)/expense Twelve Months Ended June 30, 2019 2018 2017 $ $ 15.8 $ 11.8 $ (0.5) (12.6) (4.6) (1.7) 2.7 $ 5.5 $ 4.3 4.2 — 8.5 (1) The expense in the twelve months ended June 30, 2019 includes $15.8 million of financing charges related to the offering of the USD 2027 Notes. The expense in the twelve months ended June 30, 2018 includes $11.8 million of financing charges related to the offering of the USD 2026 Notes and an amendment to the Credit Agreement, which included a $6.1 million charge for commitment fees paid during the first quarter of fiscal 2018 on the Bridge Facility. The twelve months ended June 30, 2017 include financing charges of $4.3 million related to the December 2016 offering of the Euro Notes and repricing and partial paydown of the Company's term loans under its senior secured credit facilities. (2) Foreign currency (gains) and losses include both cash and non-cash transactions. (3) Included within Other are realized derivative instrument gains of $12.9 million during the fiscal year ended June 30, 2019. 16. COMMITMENTS AND CONTINGENCIES Contingent Losses From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. The Company intends to vigorously defend itself against any such litigation and does not currently believe that the outcome of any such litigation will 114 have a material adverse effect on the Company’s financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise. From time to time, the Company receives subpoenas or requests for information relating to the business practices and activities of customers or suppliers from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties engaged in patent infringement, antitrust, tort, and other litigation. The Company generally responds to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred. The Company expects to incur costs in future periods in connection with future requests. Rental Payments and Expense The future minimum rental payments for operating leases having initial or remaining non-cancelable lease terms in excess of one year at June 30, 2019 are: (Dollars in millions) Minimum rental payments 2020 2021 2022 2023 2024 Thereafter Total $ 12.2 $ 10.0 $ 9.2 $ 8.5 $ 7.4 $ 10.9 $ 58.2 Rental expense relating to operating leases was $18.0 million, $16.4 million, and $13.2 million for the fiscal years ended June 30, 2019, 2018, and 2017, respectively. Sublease rental income was not material for any period presented. 17. SEGMENT AND GEOGRAPHIC INFORMATION As discussed in Note 1, Basis of Presentation and Summary of Significant Accounting Policies, the Company conducts its business within the following segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Company evaluates the performance of its segments based on segment revenue and segment earnings before non-controlling interest, other (income)/expense, impairments, restructuring costs, interest expense, income tax (benefit)/expense, and depreciation and amortization ( S“ egment EBITDA”).” The Company considers its reporting segments' results in the context of a similar Company-wide measure: EBITDA from operations, which the Company defines as consolidated earnings from operations before interest expense, income tax (benefit)/expense, depreciation and amortization, adjusted for the income or loss attributable to non-controlling interest. Neither Segment EBITDA nor EBITDA from operations is defined under U.S. GAAP, and neither is a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP. Each of these non-GAAP measures is subject to important limitations. This Note to the consolidated financial statements includes information concerning Segment EBITDA and EBITDA from operations (a) because Segment EBITDA and EBITDA from operations are operational measures used by management in the assessment of the operating segments, the allocation of resources to the segments, and the setting of strategic goals and annual goals for the segments, and (b) in order to provide supplemental information that the Company considers relevant for the readers of the consolidated financial statements, but such information is not meant to replace or supersede U.S. GAAP measures. The Company’s presentation of Segment EBITDA and EBITDA from operations may not be comparable to similarly titled measures used by other companies. The most directly comparable U.S. GAAP measure to EBITDA from operations is earnings/ (loss) from operations. Included in this Note is a reconciliation of earnings/(loss) from operations to EBITDA from operations. The following tables include net revenue and Segment EBITDA for each of the Company's current reporting segments during the fiscal years ended June 30, 2019, 2018, and 2017 (restated in accordance with ASC 280): (Dollars in millions) Net revenue: Softgel Technologies Biologics and Specialty Drug Delivery Oral Drug Delivery Clinical Supply Services Inter-segment revenue elimination Net revenue Fiscal Year Ended June 30, 2019 2018 2017 $ 872.1 $ 917.3 $ 742.1 619.9 321.4 (37.5) 601.9 573.9 430.4 (60.1) 855.3 350.8 561.6 348.8 (41.1) $ 2,518.0 $ 2,463.4 $ 2,075.4 115 (Dollars in millions) Segment EBITDA reconciled to earnings from operations: Softgel Technologies Biologics and Specialty Drug Delivery Oral Drug Delivery Clinical Supply Services Sub-Total Reconciling items to earnings from operations Unallocated costs (1) Depreciation and amortization Interest expense, net Income tax expense Earnings from operations Fiscal Year Ended June 30, 2019 2018 2017 $ $ $ $ 191.2 180.4 186.7 84.4 $ 196.4 146.8 172.9 76.2 642.7 $ 592.3 $ (142.9) (228.6) (110.9) (22.9) 137.4 $ (138.8) (190.1) (111.4) (68.4) 83.6 $ 190.5 63.4 179.0 54.9 487.8 (115.6) (146.5) (90.1) (25.8) 109.8 (1) Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: (Dollars in millions) 2019 2018 2017 Fiscal Year Ended June 30, Impairment charges and gain/(loss) on sale of assets $ (5.1) $ (8.7) $ Equity compensation Restructuring and other special items (a) Other income/(expense), net (b) Non-allocated corporate costs, net Total unallocated costs (33.3) (57.7) (2.7) (44.1) (27.2) (54.4) (5.5) (43.0) (9.8) (20.9) (33.5) (8.5) (42.9) $ (142.9) $ (138.8) $ (115.6) (a) Restructuring and other special items during fiscal 2019 include transaction and integration costs associated with the acquisitions of Juniper and Paragon. Restructuring and other special items during fiscal 2018 include transaction and integration costs associated with the acquisitions of Catalent Indiana. Restructuring and other special items during fiscal 2017 include transaction and integration costs associated with the acquisitions of Pharmatek and Accucaps Industries Limited. (b) Refer to Note 15, Other (income)/expense, net, for details of financing charges and foreign currency translation adjustments recorded within other income/(expense), net. The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated balance sheets. Total Assets (Dollars in millions) Softgel Technologies Biologics and Specialty Drug Delivery Oral Drug Delivery Clinical Supply Services Corporate and eliminations Total assets June 30, 2019 June 30, 2018 $ 1,196.1 $ 3,104.8 1,210.0 463.2 209.9 1,139.8 1,615.4 999.5 452.7 323.7 $ 6,184.0 $ 4,531.1 116 The following tables include depreciation and amortization expense and capital expenditures for the fiscal years ended June 30, 2019, 2018, and 2017 for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated statements of operations: Depreciation and Amortization Expense (Dollars in millions) Softgel Technologies Biologics and Specialty Drug Delivery Oral Drug Delivery Clinical Supply Services Corporate $ Fiscal Year Ended June 30, 2019 2018 2017 $ 39.0 76.7 73.5 18.8 20.6 $ 43.9 54.7 54.4 19.5 17.6 38.4 25.2 50.1 18.7 14.1 Total depreciation and amortization expense $ 228.6 $ 190.1 $ 146.5 Capital Expenditures (Dollars in millions) Softgel Technologies Biologics and Specialty Drug Delivery Oral Drug Delivery Clinical Supply Services Corporate Total capital expenditures The following table presents long-lived assets(1) by geographic area: (Dollars in millions) United States Europe International Other Total $ Fiscal Year Ended June 30, 2019 2018 2017 $ 50.6 88.9 51.5 2.9 24.2 $ 41.3 55.2 40.2 11.5 28.3 27.6 40.8 42.7 7.2 21.5 $ 218.1 $ 176.5 $ 139.8 June 30, 2019 June 30, 2018 $ $ 1,066.0 $ 344.4 126.3 849.9 304.9 115.8 1,536.7 $ 1,270.6 (1) Long-lived assets include property, plant, and equipment, net of accumulated depreciation. 18. SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental balance sheet information at June 30, 2019 and June 30, 2018 is detailed in the following tables. Inventories Work-in-process and finished goods inventories include raw materials, labor, and overhead. Total inventories consist of the following: (Dollars in millions) Raw materials and supplies Work-in-process & finished ff goods Total inventory, gross Inventory cost adjustment Inventories June 30, 2019 June 30, 2018 $ $ 161.6 $ 115.0 276.6 (19.4) 257.2 $ 137.1 90.6 227.7 (18.6) 209.1 117 Prepaid expenses and other Prepaid expenses and other current assets consist of the following: (Dollars in millions) Prepaid expenses Spare parts supplies Prepaid income tax Non-U.S. value-added tax Other current assets Prepaid expenses and other Property, plant, and equipment, net Property, plant, and equipment, net consist of the following: (Dollars in millions) Land, buildings, and improvements Machinery, equipment, and capitalized software Furniture and fixtures Construction in progress Property and equipment, at cost Accumulated depreciation Property, plant, and equipment, net Other assets Other assets consist of the following: (Dollars in millions) Deferred compensation investments Pension asset Deferred long-term debt financing costs Other Total other assets Other accrued liabilitiestt Other accrued liabilities consist of the following: (Dollars in millions) Accrued employee-related expenses Restructuring accrual Accrued interest Deferred revenue and fees Accrued income tax Other accrued liabilities and expenses Other accrued liabilities 118 June 30, 2019 June 30, 2018 18.7 $ 8.1 10.0 16.4 23.6 76.8 $ 19.2 11.1 7.2 12.5 15.2 65.2 $ $ June 30, 2019 June 30, 2018 $ 1,049.4 $ 1,104.9 16.9 278.9 2,450.1 (913.4) 928.1 988.1 14.9 166.8 2,097.9 (827.3) $ 1,536.7 $ 1,270.6 June 30, 2019 June 30, 2018 $ $ 21.9 25.8 3.0 10.5 61.2 $ $ 20.1 18.0 1.1 6.0 45.2 June 30, 2019 June 30, 2018 $ 103.9 $ 8.2 11.7 155.2 8.5 50.9 $ 338.4 $ 104.3 9.4 16.5 100.9 25.9 55.9 312.9 Allowance for doubtful accounts Trade receivables allowance for doubtful accounts activity is as follows: (Dollars in millions) Beginning balance Charged to cost and expenses (recoveries) Deductions Impact of foreign exchange Closing balance June 30, 2019 June 30, 2018 June 30, 2017 $ $ 6.0 3.1 (3.0) — 6.1 $ $ 4.0 1.7 0.3 — 6.0 $ $ 3.9 1.0 (0.9) 4.0 19. QUARTERLY FINANCIAL DATA (UNAUDITED) The following table summarizes the Company’s unaudited quarterly results of operation. (Dollars in millions, except per share data) Net revenue Gross margin Net earnings/(loss) Earnings per share: Basic Net earnings/(loss) Diluted Net earnings/(loss) (Dollars in millions, except per share data) Net revenue Gross margin Net earnings Earnings per share: Basic Net earnings Diluted Net earnings Fiscal 2019, By Quarters First Second Third Fourth 551.8 $ 148.5 (14.4) $ 623.0 201.4 49.0 (0.10) $ 0.34 (0.10) $ 0.33 $ $ $ $ 617.5 198.7 31.7 0.22 0.22 $ $ $ $ 725.7 256.5 71.1 0.45 0.44 Fiscal 2018, By Quarters First Second Third Fourth 543.9 140.1 3.8 0.03 0.03 $ $ $ $ 606.3 $ 187.4 (21.9) $ 627.9 191.7 19.0 (0.16) $ 0.14 (0.16) $ 0.14 $ $ $ $ 685.3 233.4 82.7 0.62 0.61 $ $ $ $ $ $ $ $ ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None. ITEM 9A. CONTROLS AND PROCEDURES Disclosure Controls and Procedures We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, and our Senior Vice President and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only 119 reasonable assurance of achieving the desired control objectives. Our management, with the participation of our Chief Executive Officer, and our Senior Vice President and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Annual Report. Based upon that evaluation, our Chief Executive Officer and our Senior Vice President and Chief Financial Officer concluded that, as of June 30, 2019, our disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level, other than with respect to Paragon, which we acquired in May 2019, and are permitted to exclude from this conclusion. Management’s Annual Report on Internal Control Over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Our internal control over financial reporting is designed to provide reasonable assurances regarding the reliability of financial reporting and the preparation of our consolidated financial statements in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that: • • • pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because either conditions change or the degree of compliance with our policies and procedures may deteriorate. Our management has assessed the effectiveness of our internal control over financial reporting as of June 30, 2019. In making this assessment, management used the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on this assessment, our management concluded that our internal control over financial reporting was effective as of June 30, 2019. In May 2019, we acquired Paragon, which has total assets, excluding intangible assets and goodwill arising from the acquisition, and total revenue of approximately 4% and 1%, respectively, of the amounts reported as total assets and net revenue in our consolidated financial statements as of and for the period ended June 30, 2019. Our management assessment of the effectiveness of our internal control over financial reporting as of June 30, 2019 excluded the Paragon acquisition, as permitted under applicable SEC guidance, because we are in the process of aligning and integrating various processes, systems and internal controls related to the business and operations of this subsidiary, excluding intangible assets and goodwill, which are included within the scope of our assessment. The effectiveness of our internal control over financial reporting as of June 30, 2019 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in its report, which is included in Item 8. Financial Statements and Supplementary Data in this Annual Report. Changes in Internal Control over Financial Reporting Other than as noted above in connection with the acquisition of Paragon, there was no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. ITEM 9B. OTHER INFORMATION None. 120 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Information concerning our Directors and Executive Officers, “Section “ 16(a) Beneficial Ownership Reporting Compliance,” d” efinitive shareholder communications with our Board of Directors, and corporate governance may be found in our Proxy Statement for the 2019 Annual Meeting of Shareholders (the P“ roxy Statement”),”) which will be filed within 120 days after June 30, 2019, the close of our fiscal year covered by this Annual Report. Such information is incorporated by reference. ITEM 11. EXECUTIVE COMPENSATION Information concerning executive compensation may be found in the Proxy Statement, which will be filed within 120 days after June 30, 2019, the close of our fiscal year covered by this Annual Report. Such information is incorporated herein by reference. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS Information regarding security ownership of certain beneficial owners and management may be found in the Proxy Statement, which will be filed within 120 days after June 30, 2019, the close of our fiscal year covered by this Annual Report. Such information is incorporated herein by reference. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE Information regarding certain relationships and related-party transactions and director independence may be found in the Proxy Statement, which will be filed within 120 days after June 30, 2019, the close of our fiscal year covered by this Annual Report. Such information is incorporated herein by reference. ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES Information regarding the fees paid to and services performed by our independent accountants may be found in the Proxy Statement, which will be filed within 120 days after June 30, 2019, the close of our fiscal year covered by this Annual Report. Such information is incorporated herein by reference. 121 PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES Financial Statements. The Financial Statements listed in the Index to Financial Statements are filed under Item 8. (a)(1) Financial Statements and Supplementary Data of this Annual Report. (a)(2) Financial Statements Schedule. Deferred Tax Assets - Valuation Allowance (Dollars in millions) Year ended June 30, 2017 Tax valuation allowance Year ended June 30, 2018 Tax valuation allowance Year ended June 30, 2019 Tax valuation allowance Beginning Balance Current Period (Charge) / Benefit Deductions and Other Ending Balance $ $ $ (69.9) $ (9.4) $ 0.5 $ (78.8) (78.8) $ (13.8) $ 6.4 $ (86.2) (86.2) $ 11.3 $ (1.4) $ (76.3) The schedule for the allowance for doubtful accounts is not included as the required information is included in Note 18 to the Consolidated Financial Statements. The remaining schedules are not applicable. (b) Exhibits. The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves and you should not rely on them for that purpose. In particular, any representation or warranty made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time. Exhibit No. 2.1 Descriptionp Interest Purchase Agreement, dated September 18, 2017, by and among Catalent Pharma Solutions, Inc., Cook Pharmica LLC, and Cook Group Incorporated. Disclosure schedules and exhibits have been omitted. The Interest Purchase Agreement as filed identifies such schedules and exhibits, including the general nature of their contents. Catalent, Inc. agrees to furnish a copy of any omitted attachment to the Securities and Exchange Commission on a confidential basis upon request (incorporated by reference to exhibit 2.1 to the Company's Current Report on Form 8-K filed on September 19, 2017). 2.2 Agreement and Plan of Merger, dated as of July 2, 2018, among Catalent Pharma Solutions, Inc., Catalent Boston, Inc., and Juniper Pharmaceuticals, Inc. (incorporated by reference to exhibit 2.1 to the Company's Current Report on Form 8-K filed on July 3, 2018). 2.3 Agreement and Plan of Merger, dated April 14, 2019, by and among Catalent Pharma Solutions, Inc., Paragon Bioservices, Inc., solely for purposes of Section 4.12 (solely with respect to the Equity Financing (as defined therein)) and Section 8.19, Catalent, Inc., and Pearl Shareholder Representative, LLC. Disclosure schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S- K. The Merger Agreement as filed identifies such schedules and exhibits, including the general nature of their contents. The Company agrees to furnish a copy of any omitted attachment to the Securities and Exchange Commission on a confidential basis upon request (incorporated by reference to exhibit 2.1 to the Company's Current Report on Form 8-K filed on April 17, 2019). 2.4 3.1 3.2 iFirst hPharma d l Amendment to Agreement Solutions, Inc. i dand Paragon i dand lPlan fof Merger, d Bioservices, Inc. * i dated as fof May 9, 2019, bby d dand bbetween lCatalent Third Amended and Restated Certificate of Incorporation of Catalent, Inc., as filed with the Secretary of State of the State of Delaware on October 31, 2018 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on November 6, 2018). Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, Par Value $0.01 Per Share, of Catalent, Inc. (incorporated by reference to exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 22, 2019). 122 3.3 4.1 4.2 4.3 4.4 4.5 Bylaws of Catalent, Inc., effective October 31, 2018 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Commission on November 6, 2018). Indenture dated December 9, 2016, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, Deutsche Trustee Company Limited, as trustee, Deutsche Bank AG, London Branch, as principal paying agent, and Deutsche Bank Luxembourg S.A., as transfer agent and registrar (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on December 12, 2016). Form of 4.750% Senior Notes due 2024 (included as part of Exhibit 4.1 above). Indenture, dated October 18, 2017, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein and Deutsche Bank Trust Company Americas, as trustee (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on October 18, 2017). Form of 4.875% Senior Notes due 2026 (included as part of Exhibit 4.3 above). Indenture, dated June 27, 2019, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, and Deutsche Bank Trust Company Americas, as trustee (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on June 27, 2019). 4.6 Form of 5.00% Senior Notes due 2027 (included as part of Exhibit 4.5 above). 4.7 Description of the Company’s Common Stock, par value $0.01. * 10.1 10.2 10.3 Form of Severance Agreement between named executive officers and Catalent Pharma Solutions, Inc. (incorporated by reference to Exhibit 10.3 to Catalent Pharma Solutions, Inc.’s Annual Report on Form 10-K filed on September 17, 2010). † Form of Unit Subscription Agreement (incorporated by reference to Exhibit 10.12 to Catalent Pharma Solutions, Inc.’s Amendment No. 1 to the Registration Statement on Form S-4/A filed on March 3, 2008). † Form of Management Equity Subscription Agreement (incorporated by reference to Exhibit 10.13 to Catalent Pharma Solutions, Inc.’s Amendment No. 1 to the Registration Statement on Form S-4/A filed on March 3, 2008). † 10.4 2007 PTS Holdings Corp. Stock Incentive Plan (incorporated by reference to Exhibit 10.16 to Catalent Pharma Solutions, Inc.’s Registration Statement on Form S-4 filed on December 6, 2007). † 10.5 Amendment No. 1 to the 2007 PTS Holdings Corp. Stock Incentive Plan, dated September 8, 2010 (incorporated by reference to Exhibit 10.16 to Catalent Pharma Solutions, Inc.’s Annual Report on Form 10-K filed on September 17, 2010). † 10.6 Amendment No. 2 to the 2007 PTS Holdings Corp. Stock Incentive Plan, dated June 25, 2013 (incorporated by reference to Exhibit 10.45 to Catalent, Inc.’s Amendment No. 1 to the Registration Statement on Form S-1/A as filed on September 28, 2014). † 10.7 10.8 10.9 10.10 10.11 10.12 10.13 Form of Nonqualified Stock Option Agreement (executives) approved June 25, 2013 (incorporated by reference to Exhibit 10.45 of Catalent Pharma Solutions, Inc.’s Annual Report on Form 10-K filed on September 10, 2013). † Form of Nonqualified Stock Option Agreement (Chief Executive Officer) approved June 25, 2013 (incorporated by reference to Exhibit 10.46 of Catalent Pharma Solutions Inc.’s Annual Report on Form 10-K filed on September 10, 2013). † Catalent, Inc. 2014 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on August 5, 2014). † Form of Stock Option Agreement for U.S. Employees (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on August 5, 2014). † Form of Stock Option Agreement for Non-U.S. Employees (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed on August 5, 2014). † Form of Restricted Stock Unit Agreement for U.S. Employees (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed on August 5, 2014). † Form of Restricted Stock Unit Agreement for Non-U.S. Employees (incorporated by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on August 5, 2014). † 123 10.14 Form of Restricted Stock Unit Agreement for Non-Employee Directors (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed on August 5, 2014). † 10.15 Amended and Restated Credit Agreement, dated as of May 20, 2014, relating to the Credit Agreement, dated as of April 10, 2007, as amended, among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc., as the administrative agent, collateral agent and swing line lender and other lenders as parties thereto (incorporated by reference to Exhibit 10.1 to Catalent Pharma Solutions, Inc.’s Current Report on Form 8-K filed on May 27, 2014). 10.16 10.17 Intellectual Property Security Agreement, dated as of April 10, 2007, among PTS Acquisition Corp., Cardinal Health 409, Inc., PTS Intermediate Holdings LLC, Certain Subsidiaries of Holdings Identified Therein and Morgan Stanley Senior Funding, Inc. (incorporated by reference to Exhibit 10.21 to Catalent Pharma Solutions, Inc.’s Registration Statement on Form S-4 filed on December 6, 2007). Intellectual Property Security Agreement Supplement, dated as of July 1, 2008, to the Intellectual Property Security Agreement, dated as of April 10, 2007, among PTS Acquisition Corp., Cardinal Health 409, Inc., PTS Intermediate Holdings LLC, Certain Subsidiaries of Holdings Identified Therein and Morgan Stanley Senior Funding, Inc. (incorporated by reference to Exhibit 10.28 to Catalent Pharma Solutions, Inc.’s Annual Report on Form 10-K filed on September 29, 2008). 10.18 Amendment No. 1, dated December 1, 2014 to Amended and Restated Credit Agreement, dated as of May 20, 2014 among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc., as the administrative agent, collateral agent and swing line lender and other lenders as parties thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 2, 2014). 10.19 10.20 Employment Agreement, dated October 22, 2014 by and among Catalent, Inc. and John R. Chiminski (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 24, 2014). † Catalent Pharma Solutions, Inc. Deferred Compensation Plan as amended and restated effective January 1, 2016 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on November 6, 2017). † 10.21 Amendment to the Catalent Pharma Solutions, Inc. Deferred Compensation Plan effective January 1, 2017 (incorporated by reference to Exhibit 10.41 to the Company’s Annual Report on Form 10-K filed on August 28, 2017). † 10.22 Amendment No. 2 to Amended and Restated Credit Agreement, dated as of December 9, 2016, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc. as administrative agent, collateral agent and swing line lender and the lenders party thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc. PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc. and JP Morgan Chase Bank, N.A. as L/C Issuers, the other lenders party thereto and the other agents party thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on December 12, 2016). 10.23 10.24 Form of Performance Share Unit Agreement for U.S. Employees for the performance period July 1, 2016 through June 30, 2019 (incorporated by reference to Exhibit 10.45 to the Company’s Annual Report on Form 10-K filed on August 28, 2017). † Form of Performance Share Unit Agreement for Non-U.S. Employees for the performance period July 1, 2016 through June 30, 2019 (incorporated by reference to Exhibit 10.46 to the Company’s Annual Report on Form 10-K filed on August 28, 2017). † 10.25 Amendment to Employment Agreement, dated August 23, 2017, by and between Catalent, Inc. and John R. Chiminski (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 28, 2017). † 10.26 Form of Restricted Stock Agreement for U.S. Employees (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on August 28, 2017). † 10.27 Amendment No. 2 to the Catalent Pharma Solutions, Inc. Deferred Compensation Plan effective October 16, 2017 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on November 6, 2017). † 124 10.28 Amendment No. 3 to Amended and Restated Credit Agreement, dated as of October 18, 2017, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc., as administrative agent, collateral agent and swing line lender and the lenders party thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, Morgan Stanley Senior Funding, Inc. and JPMorgan Chase Bank, N.A., as L/C Issuers, the other lenders party thereto and the other agents party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 18, 2017). 10.29 10.30 Form of the Performance Share Unit Agreement for U.S. Employees for the performance period July 1, 2017 through June 30, 2020 (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q filed on November 6, 2017). † Form of the Performance Share Unit Agreement for Non-U.S. Employees for the performance period July 1, 2017 through June 30, 2020 (incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q filed on November 6, 2017). † 10.31 Offer letter, dated January 31, 2018, between Wetteny Joseph and Catalent Pharma Solutions, LLC (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed on February 5, 2018). † 10.32 10.33 10.34 10.35 10.36 10.37 10.38 10.39 Form of Performance Restricted Stock Agreement for U.S. Employees (for the performance period July 1, 2016 through June 30, 2019) (incorporated by reference to Exhibit 10.40 to the Company's annual report on Form 10-K filed on August 28, 2018). † Form of Performance Restricted Stock Agreement for Non-U.S. Employees (for the performance period July 1, 2016 through June 30, 2019) (incorporated by reference to Exhibit 10.41 to the Company's annual report on Form 10-K filed on August 28, 2018). † Form of Performance Restricted Stock Agreement for U.S. Employees (for the performance period July 1, 2017 through June 30, 2020) (incorporated by reference to Exhibit 10.42 to the Company's annual report on Form 10-K filed on August 28, 2018). † Form of Performance Restricted Stock Agreement for Non-U.S. Employees (for the performance period July 1, 2017 through June 30, 2020) (incorporated by reference to Exhibit 10.43 to the Company's annual report on Form 10-K filed on August 28, 2018). † Form of the Performance Share Unit Agreement for U.S. Employees (for the performance period July 1, 2018 through June 30, 2021) (incorporated by reference to Exhibit 10.44 to the Company's annual report on Form 10-K filed on August 28, 2018). † Form of the Performance Share Unit Agreement for Non-U.S. Employees (for the performance period July 1, 2018 through June 30, 2021) (incorporated by reference to Exhibit 10.45 to the Company's annual report on Form 10-K filed on August 28, 2018). † Form of Performance Restricted Stock Agreement for U.S. Employees (for the performance period July 1, 2018 through June 30, 2021) (incorporated by reference to Exhibit 10.46 to the Company's annual report on Form 10-K filed on August 28, 2018). † Form of Performance Restricted Stock Agreement for Non-U.S. Employees (for the performance period July 1, 2018 through June 30, 2021) (incorporated by reference to Exhibit 10.47 to the Company's annual report on Form 10-K filed on August 28, 2018). † 10.40 Offer letter, dated January 31, 2019, between Alessandro Maselli and Catalent Pharma Solutions. † * 10.41 10.42 Terms and Conditions of Employment Statement, dated February 1, 2018, between Alessandro Maselli and Catalent Pharma Solutions. † * Equity Commitment and Investment Agreement, dated as of April 14, 2019, by and among Catalent, Inc., Green Equity Investors VII, L.P. and Green Equity Investors Side VII, L.P. Disclosure schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Investment Agreement as filed identifies such schedules, including the general nature of their contents. The Company agrees to furnish a copy of any omitted attachment to the Securities and Exchange Commission on a confidential basis upon request (incorporated by reference to exhibit 10.1 to the Company's Current Report on Form 8-K filed on April 17, 2019). 10.43 Stockholders’ Agreement, dated as of May 17, 2019, by and among Catalent, Inc., Green Equity Investors VII, L.P., Green Equity Investors Side VII, L.P., LGP Associates VII-A LLC and LGP Associates VII-B LLC (incorporated by reference to exhibit 10.1 to the Company's Current Report on Form 8-K filed on May 22, 2019). 125 10.44 Registration Rights Agreement, dated as of May 17, 2019, by and among Catalent, Inc., Green Equity Investors VII, L.P., Green Equity Investors Side VII, L.P., LGP Associates VII-A LLC and LGP Associates VII-B LLC (incorporated by reference to exhibit 10.2 to the Company's Current Report on Form 8-K fiff led on May 22, 2019). 10.45 Amendment No. 4 to Amended and Restated Credit Agreement by and among /Catalent Pharma Solutions, Inc., as Borrower, PTS Intermediate Holdings LLC, as Holdings, the subsidiaries of Holdings party thereto, JP Morgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto (incorporated by refeff rence to exhibit 10 4 to the Company's Current Report on Form 8-K fiff led on May 22 2019) Form of 2018 Omnibus Incentive Plan Restricted Stock Unit Agreement for U.S. Employees (incorporated by reference to exhibit 10.40 to the Company's Quarterly Report on Form 10-Q filed on Mayy 7,, 2019)). †† Form of 2018 Omnibus Incentive Plan Restricted Stock Unit Agreement for non-U.S. Employees (incorporated by reference to exhibit 10.41 to the Company's Quarterly Report on Form 10-Q filed on Mayy 7,, 2019)). †† Form of 2018 Omnibus Incentive Plan Performance Share Unit Agreement for U.S. Employees (three- year performance period) (incorporated by reference to exhibit 10.42 to the Company's Quarterly Report on Form 10-Q filed on May 7, 2019). † Form of 2018 Omnibus Incentive Plan Performance Share Unit Agreement for non-U.S. Employees (three-year performance period) (incorporated by reference to exhibit 10.43 to the Company's QQQuarterlyyy Reppport on Form 10-QQQ filed on Mayyy 7,,, 2019))). ††† Form of 2018 Omnibus Incentive Plan Option Agreement for U.S. Employees (incorporated by reference to exhibit 10.44 to the Company's Quarterly Report on Form 10-Q filed on May 7, 2019). † Form of 2018 Omnibus Incentive Plan Option Agreement for non-U.S. Employees (incorporated by reference to exhibit 10.45 to the Company's Quarterly Report on Form 10-Q filed on May 7, 2019). † 10.46 10.47 10.48 10.49 10.50 10.51 10.52 Offer letter, dated March 13, 2018, between Steven Fasman and Catalent Pharma Solutions Inc. † * 10.53 Rollover Agreement, dated as of May 9, 2019, between Pete Buzy and Catalent, Inc. † * 10.54 Offer letter, dated May 14, 2019, between Pete Buzy and Catalent Pharma Solutions Inc. † * 10.55 Option Grant Notice, dated May 17, 2019, to Pete Buzy (retention grant) † * 10.56 Substitute Option Grant Notice and Agreement, dated May 17, 2019, between Pete Buzy and Catalent, Inc. † * 10.57 Summary of Management Incentive Plan for the fiscal year ended June 30, 2019. † * 21.1 Subsidiaries of the Registrant. * 23.1 Consent of Ernst & Young LLP. * 31.1 31.2 32.1 32.2 101.1 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. * Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. * Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ** Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ** The following materials are formatted in inline XBRL (inline eXtensible Business Reporting Language): (i) the Consolidated Statements of Operations, (ii) the Consolidated Statements of Comprehensive Income (Loss), (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statement of Changes in Shareholders’ Equity (Deficit), (v) the Consolidated Statements of Cash Flows and (vi) Notes to Consolidated Financial Statements. * * Filed herewith ** Furnished herewith † Represents a management contract, compensatory plan or arrangement in which directors and/or executive officers are eligible to participate. 126 ITEM 16. FORM 10-K SUMMARY Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. We elect not to include such summary information. 127 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 27, 2019 By: /s/ STEVEN L. FASMAN CATALENT, INC. Steven L. Fasman Senior Vice President, General Counsel and Secretary 128 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Signature /s/ JOHN R. CHIMINSKI John R. Chiminski Title Chief Executive Officer (Principal Executive Officer) and Director Date 8/27/2019 /s/ MADHAVAN BAA ALACHANDRAN Director 8/27/2019 Madhavan Balachandran /s/ J. MARTIN CARROLL J. Martin Carroll /s/ ROLF CLASSON Rolf Classon /s/ ROSEMARY A. CRANE Rosemary A. Crane /s/ JOHN J. GREISCH John J. Greisch /s/ CHRISTA KREUZBURG Christa Kreuzburg /s/ GREGORY T. LUCIER Gregory T. Lucier /s/ DONALD E. MOREL, JR. Donald E. Morel, Jr. /s/ JACK STAHL Jack Stahl /s/ PETER ZIPPELIUS Peter Zippelius /s/ WETTENY JOSEPH Wetteny Joseph 8/27/2019 8/27/2019 8/27/2019 8/27/2019 8/27/2019 8/27/2019 8/27/2019 8/27/2019 8/27/2019 8/27/2019 Director Director Director Director Director Director Director Director Director Senior Vice President & Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) 129 [THIS PAGE INTENTIONALLY LEFT BLANK] [THIS PAGE INTENTIONALLY LEFT BLANK] Corporate Information board of directors company executives John Chiminski chief executive off icer Alessandro Maselli president & chief operating off icer Wetteny Joseph senior vice president & chief f inancial off icer Jonathan Arnold president, oral drug delivery Peter Buzy president, gene therapy Steven Fasman senior vice president, general counsel & secretary Aristippos Gennadios, Ph.D. president, softgel technologies Scott Gunther senior vice president, quality & regulatory affairs Paul Hegwood, Jr. president, clinical supply services Barry Littlejohns president, biologics & specialty drug delivery Ricardo Pravda senior vice president & chief human resources off icer Kay Schmidt senior vice president, technical operations John Chiminski chair of the board Madhavan Balachandran1 2 J. Martin Carroll1 2 3 Rolf Classon4 5 Rosemary A. Crane4 John J. Greisch3 4 Christa Kreuzburg, Ph.D.1 2 Gregory T. Lucier3 5 Donald E. Morel, Jr., Ph.D.2 3 4 Jack Stahl1 5 6 Peter Zippelius 1 Indicates Nominating and Corporate Governance Committee member 2 Indicates Quality and Regulatory Compliance Committee member 3 Indicates Compensation and Leadership Committee member 4 Indicates Audit Committee member 5 Indicates Mergers and Acquisitions Committee member 6 Indicates Lead Director investor relations Catalent encourages those seeking additional information to visit the Company’s website, http://investor.catalent.com. Prospective and current investors may also contact: Thomas Castellano vice president, investor relations & treasurer phone +1 732 537 6325 email investors@catalent.com global headquarters 14 Schoolhouse Road Somerset NJ 08873 USA global +1 866 720 3148 eu 00800 88 55 6178 www.catalent.com solutions@catalent.com transfer agent & registrar: For information or assistance regarding individual stock records, contact your broker or the Company’s transfer agent, Computershare. You may reach Computershare at +1 (877) 373-6374. stock exchange listing: The Company’s common stock is listed on the New York Stock Exchange under the ticker symbol CTLT. forward-looking statements: This annual report contains certain forward-looking statements that are based largely on the Company’s current expectations. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For more information about these forward-looking statements and risks, please refer to pages 3-4 of our Annual Report on Form 10-K that is part of this Annual Report, in the section “Special Note Regarding Forward-Looking Statements.” corporate governance: Information and documents concerning our corporate governance practices, including copies of our Standards of Business Conduct, Committee Charters and Corporate Governance Guidelines, are available on our Investor Relations website at http://investor.catalent.com. more products. better treatments. reliably supplied.™ © 2019 Catalent, Inc. All rights reserved. 39 facilities on 5 continents More than 1,000 customers in 80+ countries 73 billion doses branded, generic, consumer health 21 23 83 of top 25 generics of top 25 biotechs of top 100 branded drug marketers 1,100+ new development programs